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VALIDATION OF NOVEL COLORECTAL CANCER BIOMARKERS 
DERIVED FROM ANIMAL MODELS OF Apc INACTIVATION: ANALYSIS 
OF COHORTS FROM THE UK AND BRAZIL. 
 
ABSTRACT 
Colorectal cancer (CRC) is the third and second most common cause 
of cancer death in men and women, respectively, worldwide. Most deaths 
result from late diagnosis and the lack of effective treatments for patients with 
advanced disease. Better biomarkers for early diagnosis, prediction of 
response to treatment and prognostic determination are therefore urgently 
needed. In this research, we have assessed several CRC candidate 
biomarkers that had previously been identified during studies involving 
animal models of adenomatous polyposis coli (Apc) inactivation (the most 
common genetic alteration in colorectal carcinogenesis). Our hypothesis was 
that these candidate proteins would translate into valid biomarkers of human 
colorectal neoplasia. Therefore, we tested the expression of these candidate 
biomarkers in tissue and blood samples obtained from patients with 
colorectal neoplasia as well as healthy controls. Patient cohorts from the UK 
and Brazil were analysed in this research. 
Using electronic scoring tools, we assessed the immunohistochemical 
expression of the candidate proteins in normal colonic mucosa, adjacent non-
neoplastic colonic mucosa, colonic adenomas and colorectal cancer 
samples. Clear differential patterns of expression were observed for 
nucleosome assembly protein 1 – like 1 (NAP1L1), ribosomal protein L6 
(RPL6) and prohibitin (PHB) when comparing cancers and non-malignant 
tissues. Additionally, NAP1L1 and RPL6 exhibited different expression 
patterns in low-grade versus high-grade adenomas, thus suggesting that they 
may play roles in the transition from low-risk to high-risk premalignant 
lesions. 
Gene expression studies showed that NAP1L1 and RPL6 were highly 
expressed in the tumour and the adjacent mucosa from patients with CRC 
when compared to colonic biopsies obtained from normal control subjects. 
These results support a role for these genes not only in colorectal 
carcinogenesis but also in colonic “field cancerisation”. RPL6 silencing 
resulted in strong inhibition of proliferation in HCT116 colorectal cancer cells. 
PCR-array studies demonstrated that RPL6 silencing caused up-regulation of 
BCL2 associated X (BAX) and mutS homolog 2 (MSH2) - protectors against 
cancer development, and down-regulation of matrix metalloproteases 12 and 
13 (MMP-12 and MMP-13) - promoters of cancer progression, supporting the 
importance of RPL6 in colorectal carcinogenesis.  
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The blood concentrations of NAP1L1 (assessed using a novel in-
house electrochemiluminescence immunoassay), RPL6 and PHB (measured 
using commercial enzyme-linked immunosorbent assay kits) did not show 
any significant differences in cancer individuals when compared with normal 
controls and adenoma-bearing individuals. However, several new findings 
related to the measurement of the concentrations of these proteins in blood-
derived fluids were made. 
A study of a retrospective cohort of CRC patients clearly demonstrated 
that the immunohistochemical expression of NAP1L1 was related to 
prognosis. High nuclear expression of NAP1L1 was independently 
associated with a marked increase in overall survival and 5-year survival 
estimates. Mortality in this group was 61 to 72% lower when compared with 
the low-expression group. This difference was however only observed in 
patients who had late stage disease (stages III and IV). 
The original contribution of this thesis is the confirmation that the 
candidate biomarkers derived from animal models of Apc inactivation are 
also differentially expressed in human CRC samples. The results produced 
by the various methodologies described suggest that NAP1L1, RPL6 and 
PHB may be potential novel biomarkers for the early diagnosis of CRC and 
the identification of high-risk premalignant lesions. Additionally, the 
association of NAP1L1 expression with the prognosis of CRC patients has 
not been previously reported and may have a clinical application. Further 
prospective research assessing larger sample cohorts is now highly 
recommended in order to confirm these findings. 
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1. CHAPTER 1 – INTRODUCTION 
 
1.1. Epidemiology 
 
1.1.1. Cancer - general aspects  
 
Cancer is a major health problem worldwide. In 2012, 14.1 million new 
cases were estimated causing 8.2 million deaths (Ferlay et al., 2015). These 
figures established cancer as the second leading cause of death, but it 
becomes the leading cause when only high-income countries are taken into 
account (Mathers et al., 2008). Although it highlights the importance of 
cancer for developed countries, it should be noted that 64% of those deaths 
occurred in developing nations (Jemal et al., 2011). It has been predicted that 
cancer deaths will increase steadily in the next decades, as shown in figure 
1.1 (World Health Organization, 2008). 
 
Figure 1.1. Projected global deaths for selected causes, 2004-2030. From (World 
Health Organization, 2008).  
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Cancer incidence and mortality vary widely in different regions. In a 
report of data from all continents, the overall cancer incidence ranged from 
126/100,000 in African men to 398.4/100,000 in North American men (world 
average 209.6/100,000 men) (Kamangar et al., 2006). In most developed 
countries, although cancer incidence is increasing, overall mortality is 
decreasing. In the European Union, evaluating the period between 1990 and 
2004, the cancer mortality rate diminished from 185.2 to 168/100,000 in men 
and from 104.8 to 96.4/100,000 in women (La Vecchia et al., 2010). The 
same trend was seen in North America (Kamangar et al., 2006) and Japan 
(Katanoda et al., 2013). Another noteworthy indicator demonstrating the 
contrast between regions is the mortality-to-incidence ratio (mortality ratio 
divided by incidence ratio, MR:IR). MR:IR approaching 1.0 suggests a limited 
survival and can reflect disease aggressiveness, late diagnosis or inadequate 
access to proper treatment. MR:IR was shown to range from 0.38 and 0.43 
for North American and Oceanic men to 0.83 for African men. Europe and 
Central/South America have remained at an intermediate position (0.63 for 
both) (Kamangar et al., 2006).  
 
1.1.2. Colorectal cancer in the world 
 
Colorectal cancer (CRC) is the third most common type of cancer in 
both sexes, and the third and second most common cause of cancer death in 
men and women, respectively (Ferlay et al., 2015). Worldwide, new cases 
totalled 1.36 million in 2012, and 694,000 deaths occurred in the same year 
translating into an incidence rate of 17.2/100,000 and a mortality rate of 
8.4/100,000 (Ferlay et al., 2015). Incidence of CRC varied 10-fold when 
comparing North America/Western Europe/Australasia (30.1 to 44.8/100,000 
for men and 22.7 to 32.2/100,000 for women) to Western Africa (4.5 and 
3.8/100,000 for men and women, respectively). Again, the mortality-to-
incidence ratio was higher in less developed regions. MR:IR ranged from 
0.34 in North America to 0.89 in Africa (Kamangar et al., 2006).  
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Besides these static figures, it is important to assess the trends in 
CRC epidemiology. With the globalisation of habits and westernisation of 
many cultures, changes in CRC incidence are occurring in some countries 
(Center et al., 2009). While most developed countries are experiencing a 
plateau or even a decrease in CRC incidence, developing areas are 
experiencing an increase. From 51 international cancer registries evaluated 
in one study, 27 showed an increase in CRC incidence, while only one (USA) 
showed a decrease for both males and females (Center et al., 2009). 
Selected Eastern Europe countries (such as Czech Republic, Slovakia, 
Slovenia, Poland and Estonia) exhibited a striking increase exceeding USA 
rates for men (see figure 1.2a-d). Further studies have shown increases in 
CRC incidence in Hong Kong (Xie et al., 2012), Spain (Bernal et al., 2009) 
and Serbia (Mihajlović et al., 2013). Other areas of increasing incidence 
include most parts of Asia and selected South American countries (Center et 
al., 2009). On the other hand, recent reports have demonstrated a reduced 
incidence in Japan (Katanoda et al., 2013) and Italy (Crocetti et al., 2010). 
Historically exhibiting a very high incidence of CRC, the reduction seen in the 
USA has also been demonstrated by other reports (Edwards et al., 2010, 
Siegel et al., 2012). 
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Figure 1.2. Colorectal cancer incidence in selected countries, according to gender. 
From (Center et al., 2009). 
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Focusing on CRC mortality, a similar pattern has been seen with the 
highest rates in Central/Eastern Europe (20.3 and 11.7/100,000 for men and 
women, respectively) and the lowest rates in Western Africa (3.5 and 
3.0/100,000 for men and women, respectively) (Ferlay et al., 2015). Most 
developed countries have exhibited a decreasing trend in CRC mortality in 
recent decades (La Vecchia et al., 2010, Katanoda et al., 2013, Arfè et al., 
2011, Edwards et al., 2010). Important exceptions in Europe include some 
Eastern countries such as Hungary and Czech Republic (La Vecchia et al., 
2010) which demonstrated increasing mortality rates.  
Striking differences in CRC epidemiology can be seen even when 
comparing European countries. Table 1.1 shows the incidence and mortality 
by CRC in selected countries. Spain has shown a transitional pattern in 
recent years. From 1975 to 2004, it exhibited a steady increase in CRC 
mortality (Bernal et al., 2009). After 2006, new figures and estimates 
indicated a trend to stabilisation or even a slight decrease both in incidence 
and mortality in males and females (Sanchez et al., 2010). In France, the 
incidence of CRC has increased by 0.99% in males and 0.83% in females 
annually since 1978 (Chevreul, 2010). In the same period, the mortality rate 
decreased by 0.76% in males and 1.07% in females every year. The overall 
5 year-survival rate in France was 56%, ranging from 94% in stage I (early 
disease) to 5% in stage IV (advanced disease) (Chevreul, 2010). Recently, 
Rollot et al. analysed net survival (survival that might occur if cancer was the 
only cause of death) due to CRC in France since 1976. They reported an 
improvement in 5 year-net survival from 39% during 1976-1985 to 56% 
during 1996-2005 (Rollot et al., 2013). In the case of Germany, CRC 
incidence and mortality have decreased both for males and females (GEKID, 
2013). The overall age-adjusted 5 year survival rate in Germany has 
improved from 60.6% in 2002 to 65% in 2006 (Majek et al., 2012). That 
improvement in survival was limited to local or regional disease stages, 
excluding advanced disease (stage IV). When sex differences were 
evaluated in patients with CRC in Germany, it was found that women had a 
higher 5 year survival rate compared to men (64.5% vs 61.9%) (Majek et al., 
2013). That difference was most pronounced for patients less than 65 years 
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of age, which led the authors to hypothesise that sex hormones could play a 
role in that survival advantage via the regulation of immune or inflammatory 
responses.  
 
Table 1.1. Incidence and mortality caused by CRC in selected European countries 
(per 100,000 age-adjusted population). 
Incidence Males Females Reference 
Hungary - - - 
Czech Republic 59.1 30.6 (Center et al., 2009) 
Spain 65.0 36.0 (Sanchez et al., 2010) 
France      31.6          
(combined) 
- (Chevreul, 2010) 
Germany 58.7 36.9 (GEKID, 2013) 
Italy (Parma Province) 42.6 27.1 (Center et al., 2009) 
    
Mortality    
Hungary 34.6 18.2 (La Vecchia et al., 2010) 
Czech Republic 35.8 17.9 (La Vecchia et al., 2010) 
Spain 27.0 14.0 (Sanchez et al., 2010) 
France 17.5 10.1 (La Vecchia et al., 2010) 
Germany 22.3 13.9 (GEKID, 2013) 
Italy 16.4 10.3 (Arfè et al., 2011) 
 
 
1.1.3. CRC in the United Kingdom (UK) 
 
According to the UK Office for National Statistics (ONS), 163,100 
males and 159,800 females were diagnosed with cancer (all types) each year 
in the UK during 2008-2010 (Office for National Statistics, 2012). Of these, 
the average annual number of CRC cases was 22,517 in males and 17,864 
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in females, corresponding to an incidence of 58 new cases per 100,000 men 
and 37 new cases per 100,000 women. In the same period, an average of 
8,569 men and 7,207 women died from CRC annually, which translated into 
mortality rates of 21/100,000 in men and 13/100,000 in women. A wide 
variation in CRC incidence has been demonstrated in the UK according to 
ethnic groups, with a higher occurrence amongst “whites” compared to “non-
whites” (Ali et al., 2013). Recent data have shown a stabilisation in CRC 
incidence and a reduction in CRC mortality in England and in the UK (La 
Vecchia et al., 2010). As depicted in figure 1.3, an analysis of Southeast 
England’s population has demonstrated a steady decrease in CRC mortality 
since 1972 (Sanjoaquin et al., 2007). 
 
Figure 1.3. Colorectal cancer incidence and mortality in the Southeast England 
population. From (Sanjoaquin et al., 2007). 
 
Although CRC mortality in the UK is declining, it is still higher than in 
some other European countries. When compared to Norway and Sweden, 
mortality due to CRC in England was higher, mainly due to deaths in the first 
3 months after diagnosis (Morris et al., 2011). It was also demonstrated to be 
higher than in France (Dejardin et al., 2013), with most of the difference 
being attributed to early mortality especially within 1 year after diagnosis.  A 
detailed analysis of this first year mortality due to CRC in England 
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demonstrated that most of the excess of deaths were confined to 
socioeconomically deprived groups (Moller et al., 2012).  
 
1.2. The context of Brazil 
 
Cancer is a disease with strong ethnic and geographic influence. As 
described above, there is an enormous variation in cancer incidence and 
mortality throughout the world (Crocetti et al., 2013, Li et al., 2013a, 
Kamangar et al., 2006). Besides, it has been demonstrated that some cancer 
biomarkers are present at different frequencies in different ethnic 
populations. For instance, epidermal growth factor receptor (EGFR)-
activating mutations are recognised to be an important predictive marker in 
non-small cell lung cancer (Rosell et al., 2005). However, these particular 
mutations occur more frequently in Asian patients compared to their 
counterparts from Western countries (Shigematsu et al., 2005). Therefore, 
when studying cancer biomarkers, it is important to understand the ethnic 
background of the population under study in order to draw accurate 
conclusions about any result obtained, especially regarding the validity of 
those conclusions for other populations. The research described in this thesis 
involves analyses of samples obtained from a cohort of Brazilian patients 
with CRC.  
Brazil is the 5th largest country in the world both by geographic area 
and population size. According to the 2010 national Census, it has almost 
200 million inhabitants (Censo, 2010), which represents approximately 52% 
of the South American and 3% of the world’s population (Giolo et al., 2012). 
Around five hundred years after the initial Portuguese colonisation, the 
composition of the Brazilian population is the result of important waves of 
migration between the 18th and 20th centuries, mainly by Europeans, Asians 
and Africans (slaves)  (Levy, 1974). This diverse ethnic background makes 
the study of a Brazilian cohort attractive in terms of validating cancer 
biomarkers.  
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1.2.1. Colorectal cancer in Brazil 
 
According to the Brazilian National Cancer Institute (INCA), the 
estimated incidence of CRC was 14.75 cases per 100,000 men and 15.95 
cases per 100,000 women in 2012 (INCA, 2011). Those numbers are 
possibly underestimates since a large portion of the Brazilian population is 
not covered by population-based cancer registries and most of these data 
come from death certificates (Franca et al., 2008). Despite these drawbacks, 
several reports have clearly shown an increase in CRC incidence and 
mortality in Brazil in recent years. Assessing the mortality between 1980 and 
2004, an ascending trend for both males and females has been 
demonstrated, as shown in figure 1.4 (Chatenoud et al., 2010). A similar 
trend was also described by Silva et al. (Silva et al., 2011). A recent 
publication reported that Brazil has had the greatest increase in CRC 
incidence amongst 184 countries analysed (Arnold et al., 2016). As a result 
of the continental size of the country, along with the remarkable variations in 
dietary habits and socio-economic conditions, mortality rates vary strikingly 
among Brazilian regions. An evaluation of the number of deaths due to CRC 
in different Brazilian state capitals has been performed (das Neves et al., 
2005). The authors reported rates, per 100,000 persons, ranging from 1.2 
(female) and 2.8 (male) in Teresina – Piauí state, to 10.4 and 11.8 in Porto 
Alegre – Rio Grande do Sul state. Since the former is one of the poorest 
Brazilian states and the latter is one of the wealthiest, it is supportive of a 
correlation between CRC rates and socio-economic status in the country. 
This notion is further supported by a study in which the authors found a clear 
relationship between increased income and higher CRC mortality in the 
Brazilian population (Guimarães et al., 2013).  
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Figure 1.4. Trends in colorectal cancer mortality in Brazil, from 1980 to 2004. From 
(Chatenoud et al., 2010) 
 
Another indicator of the increasing importance of CRC for the 
Brazilian Public Health System was given by Torres et al., who demonstrated 
that the costs associated with hospital admissions due to CRC increased 
more than 100% from 1996 to 2008 despite an overall decrease in the cost 
per admission (Torres et al., 2010). Although rising, CRC incidence and 
mortality in Brazil are still less than those seen in developed countries. This is 
explained, at least in part, by the delayed urbanisation and development of 
the country compared to the richest nations in the world. Nonetheless, in the 
last few decades the country has experienced a transformation due to 
economic growth and urbanisation, associated with a lifestyle closer to that 
seen in North America and Europe (Oliveira et al., 2010, Azevedo et al., 
2008, Dumith et al., 2011). Besides this, longevity is also increasing in the 
country, so that a shift from a relatively young to an older population is 
occurring (Ferri, 2012). Hence, all data available to date indicate the 
possibility of a massive increase in CRC cases and its associated costs in 
Brazil over the next few decades unless effective strategies are put in place 
to prevent this occurrence.  
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1.3. The biology of colorectal cancer  
 
1.3.1. Fundamentals of carcinogenesis 
 
Cancer cells are characterised by uncontrolled growth and escape 
from anti-cancer defence mechanisms. In order to develop and progress, 
malignant tumours must modify the well-designed network that controls 
growth, division and the interaction with the environment (Weinberg, 2007). 
Since most of the effectors of those processes are proteins, it is intuitive to 
conclude that alterations in the activity of specific proteins are necessary to 
generate cells and tissues with those hallmarks. These proteins are produced 
by genes involved in the control of cell proliferation, survival and 
chromosomal stability. Such cornerstone genes can be grouped into two 
broad categories: oncogenes (or proto-oncogenes) and tumour-suppressor 
genes (Schmandt and Mills, 1993). Proto-oncogenes are genes which 
encode proteins involved in inducing cell proliferation. The majority of these 
proteins are transcription factors, chromatin modellers, growth factors, growth 
factor receptors, signal transducers, and apoptosis regulators (Croce, 2008). 
Consequently, proto-oncogenes play important roles in regulating the 
homeostasis of normal cells. When their function is abnormally activated 
(gain-of-function by chromosomal rearrangements, amplifications, mutations 
or epigenetic modifications), they are named oncogenes and, as a result of 
the permanent proliferative stimulus, confer a growth advantage or increased 
survival to the cells in which such alterations occur (Croce, 2008). An 
illustrative example is the HER-2 gene (also termed ERB-B2), a member of 
the epidermal growth factor receptor family. The product of this gene, a 
tyrosine-kinase trans-membrane receptor, is normally expressed on the cell 
surface and is sensitive to the effects of growth factor ligands (Hung and Lau, 
1999). In certain cases of cancer (such as some breast and gastric tumours), 
the gene encoding HER-2 undergoes amplification, which causes an 
increase in the expression of the receptor on the cell surface (Sellami et al., 
1991, Marx et al., 2009). Therefore, cells are stimulated to proliferate even 
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under the influence of small amounts of growth factors, conferring more 
aggressiveness to these tumours (Kaptain et al., 2001).  
On the other hand, tumour suppressors are genes responsible for 
halting cellular growth and proliferation in physiological settings. When 
inactivated (loss-of-function), tumour suppressors lose their controlling 
functions, allowing cells to replicate with no obstacle (Hansen et al., 1988). 
The first tumour suppressor gene cloned in humans was the Retinoblastoma 
gene (RB) (Friend et al., 1986). The product of this gene – the protein RB, 
controls the transition of cells from G1 to S-phase. Hence, its inactivation 
leads to uncontrolled transition to the phase of DNA synthesis. Mutations in 
RB were initially identified in patients suffering from a type of ocular cancer 
known as retinoblastoma (Classon and Harlow, 2002). Later, these mutations 
were found in several other types of cancer. Currently, different forms of 
inactivation of the RB pathway are thought to be present in virtually all 
cancers (Hahn and Weinberg, 2002, Sherr and McCormick, 2002), and many 
other functions have been attributed to the protein besides controlling G1/S 
transition (RB function will be further addressed below) (Rubin and Sage, 
2013, Uchida, 2012). The list of oncogenes and tumour suppressors is 
extensive and beyond the scope of this thesis. These examples aim solely to 
provide a general overview of the concepts involved.  
Although attractive, the notion that a unique mutation in either a proto-
oncogene or a tumour suppressor is sufficient to cause a malignant 
phenotype is too simplistic. In fact, while alterations of these critical genes 
can be the initial step for cancer development, many more mutations are 
necessary for malignant transformation. This model, referred to as multistep 
carcinogenesis, predicts that, after an initial genetic defect that facilitates 
genomic instability and/or cellular replication, an accumulation of additional 
mutations must occur in order to enable a given cell to exhibit all the features 
of cancer (Yamada and Mori, 2007, Duesberg and Li, 2003). It has been 
demonstrated that about 80 mutations that alter amino acid sequences occur 
in a typical colorectal cancer (Wood et al., 2007). Statistical analysis has 
shown that only 15 or fewer of these 80 mutations are drivers involved in the 
initiation, progression or maintenance of the tumour. The majority of the 
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mutations are only passengers (harmless) and are accumulated during 
tumour progression (Wood et al., 2007). These drivers and passengers must 
be clearly differentiated when they are evaluated as candidate cancer 
biomarkers or drug targets.  
Based on this concept of multistep carcinogenesis, Hanahan and 
Weinberg proposed a model to illustrate the constellation of capabilities 
which a given cell (and the tissue it forms) must acquire in order to develop 
the capacity of uncontrolled replication, progression, invasion and metastasis 
(Hanahan and Weinberg, 2011). These “hallmarks of cancer” are briefly 
described below: 
 
a. Sustaining proliferative signalling 
 
The cell cycle clock which ultimately controls cell proliferation is 
regulated by many factors. Eukaryotic cells have developed an 
extraordinarily complex network of signals that orchestrate cellular growth 
and division. Basically, this network is made up of extracellular factors 
(growth factors and inhibitors) and intracellular signalling pathways 
(Weinberg, 2007). The interaction between the extracellular and intracellular 
components is usually performed via trans-membrane proteins (receptors). 
Therefore, when a growth factor approaches the cell surface from the 
extracellular matrix, adjacent cells or the cell itself, it binds to the extracellular 
domain of the membrane receptor. The receptor then transmits a signal to 
the intracellular domain. Once in the cytoplasm, the signal continues 
travelling through a signalling cascade until it reaches its final destination 
(Hynes and MacDonald, 2009, Witsch et al., 2010, Lemmon and 
Schlessinger, 2010). There are many classes of growth factors/receptors and 
an even greater number of intracellular signalling pathways. The most 
important ones for colorectal carcinogenesis will be addressed later. As an 
example, figure 1.5 illustrates the epidermal growth factor receptor (EGFR) 
pathway. Therefore, in order to sustain proliferative signalling, cancer cells 
must develop autonomy in one or several pathways. This can be achieved 
through genetic alterations that lead to the sustained supply of growth factors 
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(Witsch et al., 2010), continuous activation of membrane receptors (Lemmon 
and Schlessinger, 2010, Audigier et al., 2013) or autonomy of critical points 
within the intracellular signalling network (Bell and Ryan, 2005).   
 
 
Figure 1.5. The EGFR signalling network. Ligands from the extracellular space bind 
to trans-membrane receptors. In this case, the signal is transmitted to the 
intracellular space through the activation of a tyrosine-kinase in the cytoplasmic 
domain of the receptor. This kinase phosphorylates downstream effectors triggering 
a signalling cascade which ultimately regulates the transcription of various genes 
linked to growth, proliferation and metastasis. Numbers in each ligand block indicate 
the respective high-affinity HER receptor among HER1 (1), HER2 (2), HER3 (3) and 
HER4 (4). HB-EGF, heparin-binding EGF. From (Arteaga, 2002), adapted from 
(Yarden and Sliwkowski, 2001). 
 
b. Evading growth suppressors 
 
Several stimulators of cell multiplication are counterbalanced by 
inhibitory mechanisms and the result of this equilibrium dictates whether the 
cell must proliferate or not (Weinberg, 2007). The protein RB plays a central 
role in the so called “cell cycle clock” (Dick and Rubin, 2013). It controls the 
cell’s transition from G1 to S-phase, which triggers DNA synthesis and 
prepares the cell for division (Classon and Harlow, 2002). Therefore, RB is 
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termed the gatekeeper of the cell cycle. However, RB determines the cell’s 
fate based on various stimuli. As depicted in figure 1.6, RB works in 
conjunction with the E2F transcription factor family. When non-
phosphorylated, RB binds to E2F preventing its translocation into the nucleus 
thereby inhibiting cell proliferation. Following a proliferative stimulus, RB is 
phosphorylated by cyclin proteins (cyclin D and E) and their cyclin-dependant 
kinase (CDKs) cognates, causing the release of E2F. Once free from RB 
attachment, E2F translocates into the nucleus where it activates the 
transcription of various pro-mitotic genes (Classon and Harlow, 2002).  
 
                                             
Figure 1.6. Interaction between Rb, E2F transcription factors and cyclins/CDKs 
during cell cycle progression. From (Coller, 2007). 
 
Another important element of cell cycle control is p53. This protein is 
responsible for the surveillance of cells against conditions that cause threats 
to cell viability, especially DNA damage (Levine and Oren, 2009). In 
situations in which the threatening condition cannot be corrected, p53 
activates several different pathways that can halt cellular growth (Baker et al., 
1990a, Diller et al., 1990), induce apoptosis (Yonish-Rouach et al., 1991, 
Shaw et al., 1992) or senescence (Wang et al., 1998, Xue et al., 2007). 
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Figure 1.7 summarises some of the several mechanisms by which p53 
responds to physiological stress.  
 
 
Figure 1.7. Different physiological stresses provoke the release of p53 from MDM2 
inhibitory effect, thus increasing the concentration of p53. Once increased, the 
protein activates several different repairing mechanisms in order to correct the 
damage or, ultimately, cause irreversible cell arrest (senescence) or death 
(apoptosis). From (Levine and Oren, 2009). 
 
c. Resisting cell death 
 
Apoptosis, or programmed cell death, is a process that enables 
tissues to control the number of cells in a particular site and to remove cells 
termed to be unnecessary or defective (Elmore, 2007). The process is 
extremely important both during embryonic development and adult life. Cell 
proliferation and cell death, despite being opposite cellular fates, are 
remarkably interdependent and linked to each other by several molecular 
players (Lowe et al., 2004). In general, there are two different programmes 
which trigger apoptosis: the “intrinsic” or stress/mitochondrial pathway and 
the “extrinsic” or death receptor pathway (figure 1.8). The former activates 
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pro-apoptotic effectors present in the mitochondrial inter-membrane space. 
Mitochondrial membrane permeability is controlled by the balance between 
pro-apoptotic and anti-apoptotic factors. The Bcl-2 family of proteins is 
responsible for this equilibrium (Adams and Cory, 2007). The Bcl-2 protein 
was the first apoptotic regulator to be identified and was initially found in 
follicular lymphomas. Since its discovery, Bcl-2 hyper-expression has been 
demonstrated in a number of tumours and this expression is associated with 
resistance to chemotherapy-induced apoptosis (Amundson et al., 2000). At 
least other 16 members of the family were later discovered (Czabotar et al., 
2014) and function as “life/death switches” of cellular fate. In a simplistic 
view, apoptosis occurs when the pro-survival Bcl2/BclxL buffer is breached, 
allowing the dominance of the pro-apoptotic Bax/Bak subfamily, which leads 
to permeabilisation of the mitochondrial membrane and release of apoptotic 
factors such as cytochrome c and cell-death adaptor Apaf-1. These effectors, 
in turn, trigger the activation of caspase-9 leading to the initiation of a 
downstream proteolytic cascade that also includes caspases-3, -6 and -7 
(Lowe et al., 2004, Czabotar et al., 2014). Once fully activated, caspases 
cleave proteins important for cell and genome integrity resulting in cell death. 
Cancer cells develop mechanisms that disrupt this balance and increase cell 
resistance to apoptosis. Malignant cells frequently exhibit down-regulation of 
pro-apoptotic proteins (such as Bax, Bak, Bid, Bik, Noxa, and Puma), down-
regulation of death receptors and up-regulation of the anti-apoptotic 
mediators Bcl-2 and Bcl-xL (Safa, 2016). Furthermore, signalling pathways 
involved in proliferation and apoptosis resistance are also generally hyper-
activated. For example, up-regulated PI3K/AKT/mTOR signalling is observed 
in many cancers (Safa, 2016). 
Cancer cells can also develop mechanisms of resistance against 
treatment-induced cell death. Up-regulation of proteins of the ATP-binding 
cassette (ABC) family such as multidrug resistance (MDR) and multidrug 
resistance-associated proteins (MRPs) can cause the efflux of cytotoxic 
agents from the cell, thus reducing DNA damage (Al-Dimassi et al., 2014, 
Safa, 2016). Breast cancer resistance protein (BCRP), another member of 
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the ABC family, is also over-expressed in a range of tumours, resulting in 
resistance against a variety of anticancer agents (Al-Dimassi et al., 2014).  
 
 
Figure 1.8. General overview of the “intrinsic” (also known as stress or mitochondrial 
pathway) and the “extrinsic” (or death receptor) apoptotic pathways. From (Czabotar 
et al., 2014). 
 
On the other hand, the “extrinsic” pathway is activated through the 
binding of surface “death receptors” such as Fas/CD95, TNFR (tumour 
necrosis factor receptor) and DF-5 with their cognate ligands FasL, TNF-α 
and TRAIL (Lowe et al., 2004). When activated, these receptors form the 
“death-inducing signalling complex” (DISC) which causes the activation of 
apical caspase-8 (and caspase-10 in humans). These caspases can either 
trigger directly the downstream caspase cascade or recruit the mitochondrial 
pathway. 
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As described earlier, p53 has a pivotal role in the regulation of 
apoptosis. It performs this function both by acting as a transcription factor 
(inhibiting or stimulating the transcription of specific genes) and by acting 
directly on various elements of the regulatory machinery of the cell cycle 
(Levine and Oren, 2009).  Several pro-apoptotic members of the Bcl-2 family 
of genes (including puma, noxa, bid and bax) are transcriptional targets for 
p53, as are some components of the death-receptor signalling complex 
(Fridman and Lowe, 2003). P53 can also facilitate cytochrome c release from 
the mitochondrial membrane. TP53 mutations are some of the most common 
genetic alterations in cancer (Levine and Oren, 2009), and they severely 
compromise stress-induced and DNA damage-induced apoptosis.  
 
d. Enabling replicative immortality 
 
Besides the surveillance executed both by RB and p53, normal cells 
have an additional mechanism of proliferation control: a limitation in their 
replicative capacity. When in culture, normal cells are able to only replicate a 
certain number of times, after which they undergo senescence, a permanent 
non-replicative state and, then, apoptosis (Cristofalo and Pignolo, 1993, 
Hayflick and Moorhead, 1961). The main mechanism by which cell replication 
is limited is the presence of telomeres and the decreased (or absent) activity 
of the enzyme telomerase. Telomeres are the ends of linear chromosomes 
consisting in hexanucleotide tandem repeats of DNA associated with proteins 
(Blackburn, 1991). This repetitive terminal segment is responsible for 
protecting chromosomes against unions between the ends of non-
homologous chromosomes. They allow the end of the linear chromosome to 
be replicated completely without loss of important coding bases at the 5’ end 
of each DNA strand (Blackburn, 1991, Shay and Wright, 2011). However, 
due to the unidirectional replication of DNA, the length of the telomere is 
shortened during each cell division. Therefore, after a certain number of cell 
cycles, the telomere becomes too short to guarantee chromosomal stability 
and DNA-damage signalling is activated, leading to cellular senescence 
(Blackburn, 1991). Thus, the presence of a telomere and its shortening after 
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each cell cycle limits the number of cell divisions and is a powerful protective 
measure against cancer development. Telomeres can be maintained by an 
enzyme called telomerase whose function is to specifically replicate the 
terminal portion of the telomere. When fully expressed, this enzyme is able to 
maintain telomere length and to prevent the occurrence of telomere 
shortening (Blackburn, 1991). Cells that physiologically sustain a high rate of 
proliferation such as embryonic, germline, hematopoietic and stem cells must 
undergo a disproportionately large number of cell divisions compared to most 
other cell types. In order to achieve that, these cells have active telomerase. 
However, the majority of adult human tissues lack any telomerase function 
(Collins and Mitchell, 2002). Consequently, to acquire unlimited replicative 
capacity, cancer cells must find ways to override telomere shortening. The 
preferential way by which cancers solve this problem is through the 
production of telomerase itself (Shay and Wright, 2011). About 80 to 90% of 
all tumours exhibit telomerase activity. How the remaining cases maintain 
their telomeres or replicative activity remains poorly understood (Günes and 
Rudolph, 2013). 
 
e. Inducing angiogenesis 
 
Oxygen and nutrients are fundamental for all types of tissues. Cancers 
are even more dependent on an adequate blood supply in order to sustain 
their high proliferative rates. It has been estimated that a solid tumour could 
grow only to a critical size of 1-2 mm (or about 106 cells) without the 
formation of new blood vessels (Carmeliet, 2005).  
Angiogenesis is the synthesis of new blood vessels from pre-existing 
vessels, stimulated by the release of vascular growth factors e.g. vascular 
endothelial growth factor (VEGF) (Carmeliet, 2005, Prager and Poettler, 
2012). VEGF, also named VEGF-A, is a member of the VEGF/Platelet 
derived growth factor (PDGF) family of structurally related mitogens. Its 
expression is up-regulated by a variety of growth factors including PDGF, 
fibroblast growth factor (FGF), epidermal growth factor (EGF), tumour 
necrosis factor (TNF), transforming growth factor beta (TGF-β) and 
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interleukin-1 (Carmeliet, 2005). Another important inducer of VEGF 
expression is hypoxia. VEGF mRNA expression is increased 10- to 50-fold in 
response to lowering the oxygen level from 21% to 0-3% (Shweiki et al., 
1992). Therefore, as tumours grow, a multitude of growth factors operate in 
conjunction with the hypoxic state to generate large amounts of VEGF. 
Besides inducing endothelial cell proliferation and blood vessel growth, 
VEGF also promotes inhibition of apoptosis, increase in vascular 
permeability, chemotaxis and production of matrix proteases (Carmeliet, 
2005). 
Apart from the VEGF pathway, there are several less understood 
alternative angiogenic pathways such as the FGF, Notch Delta-like ligand 4 
(DLL4) and PDGF pathways (Ferrara, 2010). A recent study showed that 
Norrin, a non-Wnt ligand capable of activating the canonical Wnt pathway, is 
produced by colorectal cancer cells and directly regulates endothelial 
proliferation (Planutis et al., 2014). The importance of these alternative 
angiogenic mechanisms is still to be fully understood.  
 
f. Activating invasion and metastasis 
 
Tumours are organised structures resembling organs, with different 
components and compartments. Apart from malignant cells, the tumour 
microenvironment encompasses the extracellular matrix (ECM), fibroblasts, 
mesenchymal stem cells, endothelial cells, immune cells and a network of 
cytokines and growth factors (Ye et al., 2014). The interaction between 
cancer cells and the microenvironment is fundamental for cancer initiation, 
invasion and metastasis (Talmadge and Fidler, 2010, Barkan et al., 2010, 
Friedl and Alexander, 2011, Bhowmick et al., 2004). The ECM is in 
immediate contact with the tumour cells and functions as a source of growth, 
survival, motility and angiogenic factors (Barkan et al., 2010). Fibroblasts are 
responsible for the synthesis, deposition and remodelling of the ECM and 
produce growth factors which stimulate tumour cells in a paracrine manner 
(Bhowmick et al., 2004). 
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The microenvironment is even more important for the development of 
metastasis - the spread and growth of tumour cells in distant organs. In 1889, 
the English surgeon Stephen Paget suggested that metastasis did not occur 
simply due to the arrest of tumour-cell emboli in the vasculature (which was 
the prevalent hypothesis at that time). Instead, he proposed the “seed and 
soil” hypothesis, according to which circulating tumour cells (“seeds”) should 
settle in a suitable tissue or organ (“soil”), establish a favourable interaction 
with the local environment and grow to form new tumours (Talmadge and 
Fidler, 2010). This explains why different types of tumours have different 
patterns of metastasis and different preferences for specific organs. Modern 
research has supported this concept and the interaction between tumour and 
environment in the development of metastasis has gained more importance 
(Langley and Fidler, 2011). Figure 1.9 shows an example of the multistage 
process of metastasis development. 
 
 
Figure 1.9. The multistage process of metastasis development. From (Talmadge 
and Fidler, 2010). 
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Another important aspect of metastasis is the heterogeneity of the 
tumour cell population. Different cancer cells, even within the same tumour, 
have different invasive and metastatic potentials (Talmadge and Fidler, 
2010). Only a small fraction of the malignant cells are able to cause 
metastasis (Fidler, 1970) and this is probably due to the acquisition of genetic 
alterations which allow them to interact with the microenvironment in distant 
organs in a favourable way. 
 
g. Genome instability and mutation 
 
The occurrence of the constellation of genetic disturbances necessary 
for cancer formation is largely dependent on a succession of genomic 
alterations. Normal cells have an extraordinary ability to maintain genome 
stability. In order to overrule this protective mechanism, pre-cancerous cells 
develop defects affecting various components of the DNA-maintenance 
machinery, often referred to as the “caretakers” of the genome (Kinzler and 
Vogelstein, 1997). 
Chromosomal instability (CIN) is one of the most consistent features 
of malignancy (Duesberg and Li, 2003). It is defined as a high rate of 
alteration in chromosomal structure and number. Besides CIN, other frequent 
forms of genomic instability are microsatellite instability – expansion or 
contractions of the number of oligonucleotide repeats in microsatellite 
sequences, and mutations in DNA-mismatch repair genes (Negrini et al., 
2010). These alterations allow the pre-malignant cell to acquire cancerous 
hallmarks.  
 
h. Tumour-promoting inflammation 
 
It has long been known that tumours are infiltrated by distinct cells of 
the immune system. Historically, this immune infiltrate has been considered a 
defence mechanism by the host attempting to eradicate the tumour and its 
presence was viewed as a favourable prognostic factor (Pagès et al., 2010). 
However, chronic inflammation has also been observed prior to tumour 
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development in many scenarios. Clear examples of tumour-promoting 
inflammation are seen in gastric, colorectal and head and neck cancers, 
among others (Coussens and Werb, 2002). Even premalignant adenomatous 
lesions exhibit immune cell infiltration and dysregulation in several 
inflammatory cytokine genes (McLean et al., 2011). Additionally, the use of 
aspirin, an anti-inflammatory drug, has been shown to consistently reduce 
the development of colorectal adenomas and current data also suggest a 
possible suppressive effect on CRC development (Drew et al., 2016). Taken 
together, these findings show that inflammation is sometimes an essential 
component of tumour development (Bondar and Medzhitov, 2013).  
The mechanisms leading to tumour-promoting inflammation are not 
completely understood. However, several data show that the actions of 
cytokines, especially TNF-α, TGF-β and interleukins -1, -6, and -12 play an 
important role in the conversion from immune surveillance to tumour 
promotion (Mumm and Oft, 2008, Grivennikov and Karin, 2011). 
Furthermore, interleukin-10, a potent anti-inflammatory factor, appears to 
operate as a master switch in this transition by regulating other cytokines 
(Oft, 2014). 
 
i. Reprogramming energy metabolism 
 
It has recently been proposed that alteration in energy metabolism is 
also a “hallmark” of cancer (Hanahan and Weinberg, 2011). However, the 
first observations that cancer cells change their metabolic profile to 
counterbalance the shortage of oxygen and glucose (typically occurring in 
tumour growths) were provided by Otto Warburg many decades ago 
(Warburg et al., 1927). Since then, Warburg and other researchers have 
demonstrated that cancer tissues shift their metabolism from normal oxygen-
consuming cell respiration (or mitochondrial oxidative phosphorylation) to 
oxygen-independent glycolysis, what is called the “Warburg-effect” (Hanahan 
and Weinberg, 2011, Hsu and Sabatini, 2008). During this process, cancer 
cells stop using oxygen in glucose metabolism and rely mostly on glycolysis 
to generate energy. Although advantageous in an oxygen-deprived 
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environment, glycolysis has an 18-fold lower efficiency in terms of energy 
generation compared to oxidative phosphorylation. Once driven by the 
“Warburg-effect”, cancer cells maintain the preference for glycolysis even in 
the presence of oxygen. However, tumours are often also glucose-deprived 
due to the inadequate blood flow. To compensate for this, malignant cells up-
regulate glucose transporters, notably GLUT1, which increases glucose 
transport to the cytoplasm (Hsu and Sabatini, 2008). 
Lactic acid is the direct by-product of anaerobic glucose metabolism 
via glycolysis and is a prominent feature of tumour microenvironments 
(Denko, 2008). A recent study has tested the hypothesis that lactic acidosis 
could reduce glucose-dependence in cancer cells (Wu et al., 2012a). The 
authors exposed glucose-deprived 4T1 cell lines to media containing 
hydrochloric acid (acidosis), lactic acid (lactic acidosis), sodium lactate 
(lactosis) and control. They showed that the presence of lactic acidosis 
extended remarkably cellular survival compared to the other groups and that 
viable cells were still present even after 65 days of glucose deprivation. 
These findings may explain why tumours are more resistant to glucose 
starvation than normal tissues.  
 
j. Evading immune destruction.  
 
As mentioned earlier, immune defence has long been thought to play 
a major role in cancer control. Several experimental models 
(immunocompromised animals) and immunodeficient patients exhibit higher 
rates of cancer development (Buell et al., 2005, Swann and Smyth, 2007), 
further supporting this concept. Tumour infiltration by immune cells is 
associated with improved prognosis in some types of cancer (Pagès et al., 
2010). Therefore, cancer cells must be able to circumvent immune 
surveillance and escape immune-mediated destruction (Swann and Smyth, 
2007).  
Initially, the prevalent hypothesis was that the immune system would 
exert a continuous surveillance against tumour formation. More recently, the 
50 
 
concept of immune editing has been widely accepted (Schreiber et al., 2011, 
Dunn et al., 2002). According to this model, the interaction between immune 
and malignant cells occurs in a three-step process, often referred to as the 
“three Es”: elimination, equilibrium and escape. In the first phase, the 
immune system destroys the entirety or a portion of the tumour cell 
population. If some of the tumour cells remain after this initial attack, these 
malignant cells enter in a dynamic equilibrium with the immune cells, where 
lymphocytes exert a selective pressure that is effective enough to contain, 
but not fully destroy the many genetically unstable and mutating malignant 
cells. During this period, the remnant cancer cells develop additional 
mutations either reducing their immunogenicity or inhibiting the action of 
immune cells. After this, some malignant clones are able to avoid immune 
surveillance indefinitely leading to tumour growth and dissemination (Dunn et 
al., 2004).  
 
1.3.2. CRC-specific carcinogenesis 
 
Cancer is a common term used to describe more than a hundred 
different pathologies (Weinberg, 2007). Although most of them share the 
hallmarks described earlier, each cancer has a particular set of features. 
Since colorectal cancer is the focus of this research, an overview of the 
alterations most commonly present in CRC is described below.  
 
a. The adenoma-carcinoma sequence 
 
CRC provides an excellent system for the study of carcinogenesis in 
humans. It is one of the few cancer types in which it is possible to obtain 
biological samples from very early lesions to advanced tumours. It has long 
been recognised that the majority of colorectal tumours arise from benign 
polyps (Stryker et al., 1987, Muto et al., 1975). Several clinical-
epidemiological data support this concept. For example, the prevalence of 
adenomatous polyps peaks 5 years earlier than the incidence of CRC (Muto 
et al., 1975) and the incidence of both lesions (polyps and cancer) shows a 
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strong correlation in different geographical regions (Clark et al., 1985). In 
addition, follow-up studies conducted prior to the introduction of endoscopic 
polypectomy showed that adenomas can undergo regression, growth or 
become malignant (Stryker et al., 1987, Leslie et al., 2002). Most colorectal 
polyps are hyperplastic, and this histological subtype does not seem to be 
associated with CRC. Conversely, the adenomatous polyp, or adenoma (a 
dysplastic epithelial lesion), is probably the most important precursor lesion 
(Jass, 2007). The estimated prevalence of adenomas in the United States 
population is 25% by age 50 and 50% by age 70 (Rex et al., 1993). 
Around 25 years ago, Vogelstein and Fearon proposed a model for 
colorectal carcinogenesis which suggested that CRC occurs as a result of the 
accumulation of inactivating mutations in tumour suppressor genes and 
activating mutations in oncogenes (Vogelstein et al., 1988, Fearon and 
Vogelstein, 1990). The most common alterations found in CRC, at that time, 
were activating mutations in the oncogene KRAS and inactivations and/or 
deletions in the chromosomal regions 5q (later found to be the site of the 
APC gene), 17p (where the TP53 gene is located) and 18q (SMAD4 gene 
site) (Fearon and Vogelstein, 1990). Later, it became clear that inactivation of 
APC and activation of KRAS were early events in CRC carcinogenesis. On 
the other hand, mutations of TP53 and various other genes accumulated 
later during tumour development (Ahnen, 2011). On average, there are 
around 80 mutations in the genome of the malignant cells in a typical case of 
CRC (Wood et al., 2007). Notably, only about 15 of these mutations 
contribute actively to the malignant phenotype and are referred to as “driver” 
mutations. Figure 1.10, shows the proposed progression from normal 
epithelium to adenoma to carcinoma and the most commonly involved 
genetic alterations. 
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Figure 1.10. Genetic model of colorectal carcinogenesis. The illustration highlights 
the main genetic alterations which drive CRC development. From (Leedham and 
Wright, 2008). 
 
b. Wnt signalling pathway  
 
Among several signalling pathways involved in carcinogenesis, the 
Wnt pathway plays a particularly important role in CRC development. This 
signalling cascade is normally involved in controlling embryonic development 
and tissue homeostasis in adults (Holland et al., 2013, Clevers and Nusse, 
2012). It is named after the fusion of two gene names: wingless (wg) and its 
vertebrate homolog integrase 1 (int-1) (Baarsma et al., 2013). The 
mammalian genome encodes 19 Wnt proteins and 10 Frizzled (FDZ) 
membrane receptors (van Amerongen et al., 2008). According to the results 
of the Cancer Genome Atlas Network, the Wnt signalling pathway is altered 
in 93% of CRC cases (Cancer Genome Atlas Network, 2012). There are two 
theoretical mechanisms for Wnt activation: the canonical and the non-
canonical signalling pathways. As figure 1.11 illustrates, the canonical (or β-
catenin – dependent) pathway depends on the binding of Wnt ligands to FZD 
receptors on the cell membrane. In the absence of Wnt ligands, FZD is 
inactive and, as a consequence, the protein Dishevelled (DVL) is also non-
phosphorylated and inactive (Baarsma et al., 2013). This inactivation allows a 
group of proteins (APC, Axin, CK-1 and GSK-3) to work as a β-catenin-
targeted “destruction complex”. This complex phosphorylates β-catenin, 
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which is then destroyed by the proteasome system (Baarsma et al., 2013). 
By contrast, in the presence of Wnt ligands, FDZ becomes active, associates 
with LPR5/6 – another membrane receptor, and phosphorylates DVL, which 
results in disengagement and disruption of the “destruction complex”. As a 
result, β-catenin is no longer phosphorylated and destroyed, and 
accumulates in the cytoplasm. Then it translocates to the nucleus and, in 
conjunction with the TCF/LEF family of transcription factors, activates its 
target genes (Baarsma et al., 2013, Clevers and Nusse, 2012). The precise 
mechanism by which this happens is still poorly understood. Some classical 
examples of Wnt/β-catenin target genes are c-Myc (He et al., 1998) and 
CCND1 (Tetsu and McCormick, 1999). However, several other genes have 
been added to the group of targets and an updated list can be found at the 
Nusse Laboratory website (http://web.stanford.edu/group/nusselab/cgi-
in/wnt/target_genes). Overall, 80% of CRCs have defects that lead to either 
APC inactivation (majority of cases) or β-catenin over-expression (minority of 
cases), both resulting in up-regulation of the Wnt pathway (Cancer Genome 
Atlas Network, 2012).  
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Figure 1.11. The canonical Wnt signalling pathway. The illustration shows the 
actions of Wnt pathway elements in the absence (left) or presence (right) of Wnt 
ligands. From (Baarsma et al., 2013). 
 
The other postulated mechanism for Wnt activation is the non-
canonical pathway. It is defined as Wnt- or FDZ-initiated signalling that is 
independent of β-catenin transcriptional function (Semenov et al., 2007). 
Several different and less characterised functions have been attributed to the 
non-canonical Wnt pathway including planar cell polarity, calcium influx, bone 
metabolism and control of atypical protein kinase C pathways, to cite a few 
(Semenov et al., 2007, van Amerongen, 2012). Wnt3a (a prototypical 
canonical Wnt ligand) and Wnt5a (a prototypical non-canonical ligand) are 
thought to trigger Ser/Thr phosphorylation on LRP6 and Ror2 (a non-
canonical membrane receptor) respectively, using common intracellular 
components (van Amerongen et al., 2008, Grumolato et al., 2010). After 
activation of the receptors, intracellular signalling cascades are triggered 
targeting their respective effectors and genes. 
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However, there has been a recent change in the way these two 
apparently distinct pathways are viewed. It has been shown that the type of 
receptor displayed on the cell surface rather than the type of ligand is the 
most important factor in defining canonical or non-canonical activation (van 
Amerongen et al., 2008, van Amerongen, 2012). In addition, it is now known 
that Wnt ligands from either “class” can elicit both β-catenin-dependent and 
independent responses depending on the receptor profile of the cell (van 
Amerongen et al., 2008). Therefore, our knowledge about the Wnt pathways 
is evolving and it is expected that in the future we will have a better 
understanding of their roles in physiological and pathological conditions, thus 
allowing the development of Wnt-targeted tools for diagnosis and treatment 
(Anastas and Moon, 2013). 
 
c. Adenomatous Polyposis Coli (APC) in hereditary and sporadic 
CRC 
 
Since the 1920s, a hereditary form of CRC has been recognised in 
which the occurrence of the tumour was preceded by the development of 
hundreds to thousands of intestinal adenomatous polyps (Plawski et al., 
2013). The disease exhibited an autosomal dominant inherited pattern and 
had a nearly complete penetrance for CRC by the age of 50 years. Familial 
Adenomatous Polyposis, or FAP, was frequently associated with deletions of 
the chromosomal region 5q21. In the early 1990s, germline mutations at that 
site (later named Adenomatous Polyposis Coli gene - APC) were found to be 
the cause of this hereditary colorectal cancer syndrome (Kinzler et al., 1991, 
Nishisho et al., 1991), providing the first direct link between the Wnt 
signalling pathway and human disease. Several types of APC mutation occur 
in FAP individuals. The most common are small deletions leading to changes 
in the reading frame and the creation of premature termination codons 
(Plawski et al., 2013, Kerr et al., 2013). Other forms are large deletions, 
splice site mutations, small deletions plus insertions, large insertions, 
complex rearrangements and mutations in regulatory sequences (Plawski et 
al., 2013). Apart from the classical FAP syndrome, other forms of 
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“attenuated” FAP are characterised by fewer polyps (usually less than 100) 
and a lower risk of malignant transformation. These have been associated 
with mutations at the 5’ end of APC gene and alternative splicing (Plawski et 
al., 2013).  
After the unequivocal demonstration that germline APC mutations 
are the cornerstone of hereditary FAP, APC somatic mutations were also 
demonstrated in the vast majority of sporadic CRC cases, establishing this 
genetic defect as the earliest and most common mutation in cancers of the 
colon and rectum (Cancer Genome Atlas Network, 2012).  
 
d. β-catenin as a prognostic factor 
 
The expression of β-catenin in CRC tissues has been evaluated in 
several studies (Chen et al., 2013). The majority have analysed the 
associations between the expression of β-catenin and clinicopathologic 
variables such as stage, differentiation and prognosis. The effect of β-catenin 
accumulation on the survival of patients is controversial. A meta-analysis 
addressing this specific question included 18 studies (analysing β-catenin 
expression by immunohistochemistry) and found heterogeneous results 
(Chen et al., 2013). Nonetheless, it suggested that the nuclear accumulation 
of β-catenin, but not the cytoplasmic expression of this protein, is associated 
with advanced tumour stage and worse prognosis. Reinforcing the 
contradictory findings, a recent large study not included in that meta-analysis 
showed that loss of membranous and cytoplasmic β-catenin was associated 
with shortened survival, but its nuclear expression was not associated with 
any significant outcome (Bruun et al., 2014). Therefore, despite the multitude 
of research conducted in this field, the definitive role of β-catenin expression 
in terms of CRC prognosis is far from elucidated.  
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e. C-MYC is an essential target for Wnt/β-catenin activation 
 
MYC lies at the crossroad of many growth-promoting signalling 
pathways (Dang, 2012). The protein was first reported in association with the 
MYeloCytomatosis viral oncogene in animal models and is now known to be 
one of the most amplified oncogenes in several different human cancers 
(Beroukhim et al., 2010). MYC mRNA is short-lived and affected by different 
microRNAs. The protein itself is post-translationally modified, ubiquitinated 
and degraded quickly, with a half-life of 15-20 minutes (Gregory and Hann, 
2000). Mutations in the residues Thr-58 and Ser-62 (the targets for 
phosphorylation and degradation) are common in Burkitt lymphomas and 
cause stabilisation of the protein (Thomas and Tansey, 2011, Wang et al., 
2011). One of the main mechanisms by which MYC works is as a 
transcription factor. A study mapping potential Myc binding sites throughout 
the genome found that up to 6,000 genes could be targets for this 
oncoprotein. Of these, 700 responded to MYC activation with alterations in 
their mRNA levels (Zeller et al., 2006). Other MYC functions involve non-
transcriptional actions, regulation of microRNAs and recruitment of histone-
acetylases (Dang, 2012).  
Myc has been demonstrated to be an efficient oncogene in murine 
models and cell lines, and its knock-down in cancer cells is associated with 
reduced proliferation and increased apoptosis (Dang, 2012). The same anti-
tumour effect was demonstrated by inhibiting endogenous Myc in animal 
models of lung and pancreatic cancer (Soucek et al., 2008, Sodir et al., 
2011). 
This oncogene is overexpressed in most CRC cases (Chan et al., 
2008). However, the gene is rarely mutated in this disease (Cancer Genome 
Atlas Network, 2012), suggesting that an upstream factor is responsible for 
inducing MYC transcription. MYC is a known target for the Wnt pathway (He 
et al., 1998). Several experiments have shown that either APC inactivation or 
β-catenin activation result in overexpression of this gene in human and 
animal models (He et al., 1998, Sansom et al., 2004). Myc contributes to all 
the phenotypic changes observed in mouse intestinal mucosa after Apc 
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deletion such as alterations in cell proliferation, differentiation, migration and 
tissue architecture. Remarkably, co-deletion of both Apc and Myc results in a 
normal intestinal phenotype, thus providing strong evidence that Myc is not 
only important but rather essential for intestinal tumourigenesis (Sansom et 
al., 2007, Myant and Sansom, 2011). 
Interestingly, despite the role of MYC in cancer development, its over-
expression in CRC samples determined by Northern blot analysis was 
associated with good prognosis (Smith and Goh, 1996). Recent work using 
immunohistochemistry found similar results, and showed that patients whose 
tumours over-expressed nuclear MYC had better survival rates than those 
with low nuclear expression (Toon et al., 2014). 
 
f. DNA mismatch repair defects – another important cause of 
sporadic and hereditary CRC 
 
The DNA mismatch repair (MMR) system is one of the enzymatic 
mechanisms responsible for genome homeostasis (Sameer et al., 2014). It is 
involved in the identification and repair of specific types of errors in DNA 
replication. When this system fails, the rate of errors increases 100- to 1000-
fold, particularly in so-called DNA microsatellites – short tandem repeats of 
between 1-5 DNA bases scattered throughout an individual’s genome 
(Sameer et al., 2014).  
The main genes associated with MMR in eukaryotes are MutS 
homologs (MSHs), and MutL homologs (MLHs). There are five highly 
conserved MSHs (MHS2-MSH6) and four MLHs (MLH1, MLH3, post meiotic 
segregation 1 or PMS1, and PMS2) (Jun et al., 2006). If any of those MMR 
elements is inactive, DNA is no longer replicated with the necessary high 
fidelity, thus allowing oncogenic mutations to occur.  
A defect in MMR is found in 15% of sporadic CRC cases and is the 
second most important mechanism responsible for colorectal carcinogenesis 
(Sameer et al., 2014). Most of these cases are caused by epigenetic 
silencing of MMR genes, MLH1 being the most commonly affected (Li et al., 
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2013b, Iacopetta et al., 2010). Due to the fact that microsatellites are parts of 
the DNA that are particularly sensitive to replication errors when any MMR 
mechanism is inactivated, it often results in microsatellite instability (MSI). 
MSI is defined as a change of any length caused by either insertions or 
deletions of repeating units in a microsatellite within a tumour compared to 
normal tissue (Sameer et al., 2014). MSI is categorised using a panel of five 
allocated microsatellite loci or markers known as the Bethesda panel. MSI-
high frequency (or MSI-H) is defined by the presence of instability in 2 or 
more markers, or more than 30% of a larger panel; MSI-low frequency (or 
MSI-L) occurs when only one marker is affected (or 10-30% of a larger 
panel); and microsatellite stability (or MSS) is characterised by absence of 
instability in any marker (Boland et al., 1998). Therefore, the presence of 
MSI-H is a surrogate marker for a MMR defect in colorectal cancer. 
Apart from the importance of MMR inactivation in sporadic CRC 
development, it has also great importance in the origin of a type of hereditary 
cancer syndrome. A familial predisposition for CRC in patients without 
intestinal polyposis (contrasting with FAP patients) was initially described in 
1913 in the United States (Warthin, 1913). Many years later, Henry Lynch 
described two large families with similar characteristics: predisposition to 
colorectal and other cancers (endometrial and stomach), thus defining a 
condition termed hereditary non-polyposis colorectal cancer (HNPCC), also 
known as Lynch syndrome (Lynch et al., 1966, Lynch et al., 1999). It is now 
known that 90% of HNPCC cases are caused by autosomal-dominant 
mutations in either MLH1 or MSH2 (Sameer et al., 2014, Geiersbach and 
Samowitz, 2011). As depicted in figure 1.12, HNPCC is the most common 
form of hereditary CRC cancer followed by FAP.  
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Figure 1.12. Molecular classification of CRC. The figure defines various categories 
of CRC according to the genetic origin (Lynch vs FAP vs sporadic) and the status of 
the MMR machinery (MSI-H vs MSI-L/MSS). Additionally, it shows the proportional 
contributions of CIMP and important oncogene mutations (KRAS and BRAF) for 
colorectal carcinogenesis. From (Brenner et al., 2014). 
 
g. CpG island methylator phenotype (CIMP) 
 
A third mechanism responsible for CRC development has recently 
been proposed and is now widely accepted: the epigenetic alteration of gene 
expression (Bae et al., 2013). Epigenetic modifications are changes in gene 
expression that are not associated with alterations in DNA sequence. 
Promoter methylation is one of the best known mechanisms of epigenetic 
silencing. DNA methylation occurs at the 5’ cytosine moiety of CpG 
nucleotides. In humans, CpG nucleotides are aggregated (forming “CpG 
islands”) in certain regions of gene promoters. It has been demonstrated that 
a concordant pattern of hypermethylation of multiple CpG island loci is 
present in a number of CRC cases. This is referred to as the CpG island 
methylator phenotype, or CIMP (Toyota et al., 1999). Following these results, 
researchers have confirmed the presence of CpG island hypermethylation in 
the promoter of several genes known to be associated with colorectal 
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carcinogenesis, such as APC, MCC, MLH1, MGMT, SMAD4, MSH6, p16 and 
others (Sameer et al., 2014). 
CIMP-positive tumours do not follow the classical adenoma-
carcinoma sequence. The precursor lesion which gives rise to these cancers 
is the so-called sessile serrated polyp/adenoma (Yamane et al., 2014). 
These lesions are normally flat (sessile), frequently located in the proximal 
colon and resemble the architecture of hyperplastic polyps. Serrated 
carcinomas can originate from the precursor lesion and exhibit high rates of 
BRAF mutations and MSI (Bae et al., 2013). Besides this distinct mechanism, 
CIMP-positive tumours also exhibit different epidemiological and pathological 
features such as predominance in women, older age of occurrence, 
increased production of mucin, increased de-differentiation and, as in the 
precursor lesions, higher rates of MSI and BRAF mutation (Bae et al., 2013, 
Nazemalhosseini Mojarad et al., 2013).  
 
h. Other important pathways and genes 
 
There are many other important pathways and genes involved in 
colorectal carcinogenesis. Alterations in these elements are present in a 
sizable proportion of sporadic CRCs (usually developed later during multistep 
carcinogenesis) and are the cause of a small fraction of hereditary cancer 
cases (Fearon, 2011).  
The Ras family of small guanosine nucleotide binding proteins 
function as molecular switches downstream of growth factors. These proteins 
participate in the regulation of many different intracellular signalling pathways 
such as the PI3K-Akt-mTOR and the Ras-Mek-Erk pathways (Malumbres 
and Barbacid, 2003), as illustrated in figure 1.13. The three members of the 
Ras family – KRAS, HRAS and NRAS – are common sites of somatic 
mutation in human cancers. KRAS mutations are present in 40% of CRCs 
while another small fraction of colorectal tumours have NRAS mutations 
(Fearon, 2011). 
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Figure 1.13. A simplified view of the Ras pathway. Under stimuli from different 
sources (especially growth factors), Ras protein changes from GDP- to GTP-status 
and activates several signalling pathways. GAP: GTPase activating protein. GEF: 
guanine nucleotide exchange factor. RTK: receptor tyrosine kinase. From (Stephen 
et al., 2014). 
 
Although RAS mutations are common in CRC, mutations in other 
elements of the RAS pathway are less frequent. For example, mutation in the 
EGFR gene (an upstream regulator of Ras) occurs in only 5% of CRCs and 
RAF mutations are also present in the same proportion of cases (most being 
associated with CIMP, as mentioned earlier) (Fearon, 2011). PIK3CA, the 
gene responsible for the synthesis of PI3K, is mutated in approximately 15-
25% of CRCs and PTEN mutations are present in 10% of sporadic cases 
(Fearon, 2011).  
Loss-of-heterozygozity (LOH) is a key mechanism for inactivating a 
normal allele in heterozygous tumour suppressor genes, thus leaving only 
one mutated allele. Around 70% of CRCs exhibit LOH on chromosomal 
regions 17p and 18q (Fearon, 2011). Region 17p harbours the tumour 
suppressor gene p53, which is thought to be the main target of LOH 
because, in most cases, the remaining TP53 allele carries a somatic 
mutation (Baker et al., 1990b). However, the same appears to be the case for 
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SMAD2 and SMAD4 genes which are located at the 18q region (Fearon, 
2011). These genes encode proteins that function downstream to the TGF-β 
receptor complex. Both the occurrence of SMAD mutations (5-15% of CRCs) 
and TGF-β receptor mutations (around 25% of CRCs) (Grady et al., 1999) 
result in inactivation of the TGF- β tumour suppressor pathway. 
As is the case for most cancer types, with the progression of the 
carcinogenic process, many other mutations accumulate and any attempt to 
address this multitude of genetic alterations would be unsuccessful and only 
contribute to confusion. Only the most important and frequently involved 
genes/pathways have therefore been mentioned in order to provide a more 
general overview of colorectal carcinogenesis. 
 
i. The consensus molecular subtypes of CRC 
 
Several molecular classifications of CRC have been proposed. Given 
the broad interconnectivity between these categorisations, an international 
consortium was formed in order to assess the different systems and this 
group proposed a unified molecular classification of CRC (Guinney et al., 
2015). These consensus molecular subtypes (CMS) identify most of the 
genetic, molecular and cellular events related to CRC carcinogenesis and 
discussed above. Figure 1.14 shows the CMS, the proportion observed for 
each category and the main cellular and molecular events observed. Briefly, 
CMS1 tumours exhibit MSI and CIMP features. Immune cell infiltration is also 
commonly observed. CMS2 is marked by Wnt/MYC activation and somatic 
copy number alterations. In CMS3 tumours, metabolic dysregulation is the 
hallmark. CMS4 tumours exhibit features of epithelial-mesenchymal 
transformation (Guinney et al., 2015). Classification of CRC based on 
molecular characteristics rather than morphology may improve cancer 
treatment by allowing the use of therapies targeting biologically relevant 
molecular events (Dienstmann et al., 2017). 
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Figure 1.14. The consensus molecular subtypes (CMS) of CRC. CIMP, CpG island 
methylator phenotype; MSI, microsatellite instability; SCNA, somatic copy number 
alterations. From (Guinney et al., 2015). 
 
1.4. Clinical aspects of CRC 
 
Colorectal tumours arise from premalignant lesions (polyps) in a 
process which takes up to 10 to 20 years to be completed (Kuntz et al., 
2011). During most of this period, the disease is asymptomatic and can only 
be detected through active screening. Clinical manifestation usually occurs 
when the disease is sufficiently advanced to cause complications. The most 
common signs and symptoms associated with CRC are rectal bleeding, 
change in bowel habit (diarrhoea, constipation or difficult evacuation), weight 
loss, abdominal pain and anaemia due to iron deficiency (John et al., 2011).  
When CRC is suspected from a patient´s history and physical 
examination (including digital rectal examination), imaging studies of the 
colon are recommended. Barium enema x-ray can provide an adequate 
evaluation of the colon. However, it is less sensitive for small lesions and 
requires endoscopic evaluation to confirm the nature of any alteration found 
(Rockey et al., 2005). Most clinicians therefore now favour colonoscopy as 
the first line test for CRC diagnosis. Colonoscopy permits the evaluation of 
the entire colon, resection of small premalignant lesions and biopsy of larger 
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polyps and tumours. The majority of intestinal cancers are adenocarcinomas 
or its variations (mucinous, signet-ring type, etc.) (Quirke et al., 2012). These 
lesions are histologically categorised according to the degree (or grade) of 
differentiation – a marker for tumour aggressiveness. Well-differentiated 
tumours maintain a relatively organised architecture resembling the normal 
colon whereas undifferentiated lesions exhibit higher mitotic rates, no tissue 
organisation and no similarities with the normal epithelium. Other features 
detailed on a pathology report are tumour size, depth of invasion, 
lymphovascular or lymph node invasion, resection margin involvement and 
the presence of tumour budding (Quirke et al., 2012).  
Once a CRC diagnosis has been made, the next clinical step is the 
evaluation of disease extension, a process called staging. Physical 
examination and image analysis are performed in order to identify signs of 
tumour spread both locally and at distance. X-rays, computed tomography 
scans, magnetic resonance imaging and positron-emission tomography 
(PET) are all used for this purpose (Dewhurst et al., 2012). Two staging 
systems are mainly used for CRC classification: Dukes’ staging and TNM 
(tumour-node-metastasis) staging. Figure 1.15 illustrates and compares 
these systems. Cancer staging provides fundamental information about the 
prognosis and guides the modalities of treatment that should be employed. 
Overall survival is closely related to stage at diagnosis as shown in figure 
1.16.  
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Figure 1.15. CRC staging systems. On the left, the figure shows the extension of 
disease in each stage. Stage 0 is defined as the presence of premalignant lesion 
(high grade dysplasia or carcinoma in situ). In stage I, an invasive cancer is limited 
to the intestinal mucosa or submucosa. In stage II, the tumour extends beyond the 
muscularis propria but is confined to the intestinal wall. In stage III, the tumour 
spreads to regional lymph nodes. Finally, stage IV is defined by the presence of 
metastasis in distant organs. On the right, a table comparing TNM and Dukes’ 
staging is provided. Figure adapted from http://www.hopkinscoloncancercenter.org/ 
 
 
 
Figure 1.16. Distribution of stages at diagnosis and 5-year survival of patients with 
colorectal cancer. Figure from: http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/bowel/ survival 
 
The only curative treatment for CRC patients is the surgical removal of 
the tumour. However, many patients with apparently limited disease who 
undergo resection will ultimately relapse and die from CRC. For that reason, 
other treatment modalities are frequently used to try to improve the cure rate. 
Dukes’ stage at  
diagnosis 
Percentage of cases 
Five-year  
survival 
A 8.7% 93.2% 
B 24.2% 77.0% 
C 23.6% 47.7% 
D  9.2% 6.6% 
Unknown 34.3% 35.4% 
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Chemotherapy is usually administered after surgery for patients with late 
stage disease (i.e. stages III and IV) and has resulted in improvements in 
cure rates and overall survival (Tsai et al., 2011, Chen et al., 2010b). 
Radiation therapy is also frequently used for patients with rectal tumours 
before or after surgery to improve local disease control. The use of 
preoperative radiotherapy also increases the chance of anal sphincter 
preservation (Glimelius, 2013). The majority of patients with metastatic 
disease are incurable and the main goal of treatment in these cases is to 
alleviate symptoms and prolong survival. The use of palliative chemotherapy 
has resulted in significant prolongation of survival compared to supportive 
care alone (Chen et al., 2010b, Funaioli et al., 2008).  
The knowledge gained from the study of the molecular biology of 
CRC has translated into new forms of therapy for patients with advanced 
disease. Drugs targeting specific molecular players or pathways involved in 
tumour development are now being routinely used in the treatment of 
patients with CRC. For example, the angiogenic pathway has been targeted 
by using inhibitors of VEGF (Prenen et al., 2013). Anti-VEGF agents currently 
available for clinical use include Bevacizumab, Aflibercept and Regorafenib. 
Additionally, the EGF pathway is another successful target in CRC treatment. 
Cetuximab and Panitumumab are monoclonal antibodies which bind to the 
EGF receptor causing its inactivation (Prenen et al., 2013). Although the 
inhibition of VEGF or EGF signalling results in clinical benefits, the mean 
survival of patients with metastatic disease rarely exceeds 24 months even 
with the use of these agents (Dattatreya, 2013). Efforts to find biomarkers to 
predict a higher chance of benefit from these new therapies are beginning to 
produce good results. An illustrative example is the identification of KRAS 
mutation as a negative predictor of response to EGFR-targeted drugs, thus 
allowing the selection of only KRAS-wild type patients to receive these 
treatments (De Roock et al., 2010). This selection has resulted in 
improvements in response rate and overall survival in this group of patients 
(Prenen et al., 2013). These achievements highlight the importance of 
identifying more predictive biomarkers to guide cancer treatment. 
  
68 
 
1.5. CRC screening 
 
As explained earlier, colorectal tumours usually develop following a 
well-defined stepwise process from normality to cancer. This transformation 
is thought to occur over many years and thus offers an excellent window of 
opportunity for tumour detection (Kuntz et al., 2011, Kuipers et al., 2013). 
Therefore, CRC is a suitable candidate for population-based screening 
strategies. Various screening methods have been developed and tested over 
the last few decades (Kuipers et al., 2013). Some of these methods have 
now been validated and have been adopted in several regions and countries 
(Benson et al., 2008). However, there are many drawbacks associated with 
the current screening tools and research still continues with the aim of 
improving the accuracy and compliance with CRC screening (Kuipers et al., 
2013). This section provides an overview of the currently available screening 
methods and addresses some of the new strategies in this field.  
 
1.5.1. Current methods of CRC screening 
 
Current CRC screening tests are broadly grouped as early detection 
tools or cancer-prevention tools. Early detection tools include faecal occult 
blood tests (FOBTs) and faecal immunological tests (FITs). These are cheap, 
non-invasive methods which detect microscopic amounts of blood in the stool 
(Kuipers et al., 2013). When positive, the individual must undergo an 
additional test to confirm the presence of a lesion. This is usually done by 
endoscopic examination of the rectum and sigmoid (flexible sigmoidoscopy, 
FS) or the entire large bowel (colonoscopy). When used as the primary 
screening tool, FS and colonoscopy are termed cancer-prevention tools due 
to their ability to both diagnose and treat precursor lesions (Kuipers et al., 
2013).  
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Guaiac faecal occult blood test (gFOBT) 
 
A gFOBT card uses paper impregnated with guaiac, a phenolic 
compound present in the resin of a South American hardwood tree 
(Guaiacum officinale), onto which faeces is applied. In the presence of haem, 
a component of haemoglobin, oxygen released from hydrogen peroxidase 
will oxidise guaiac to form a blue-coloured compound (Benton et al., 2015). A 
typical test kit consists of two small panels for a faecal smear and testing is 
usually performed using three cards (sampling three consecutive bowel 
movements) (Kuipers et al., 2013). When present in faeces, haem catalyses 
a chemical reaction which results in a blue colour appearing on the test 
paper. The threshold for positivity varies in different research or clinical 
settings. Some screening programmes refer subjects for colonoscopy when 
at least one panel test is positive, whereas others use thresholds of 5 to 6 
panels (Kuipers et al., 2013). 
Guaiac FOBT is one of the most studied and validated methods for 
CRC screening. Evidence for its usefulness comes from four large 
prospective, randomised trials published in the 1990s (Kronborg et al., 1996, 
Hardcastle et al., 1996, Kewenter et al., 1994, Mandel et al., 1993). These 
studies conducted in the UK, Sweden, Denmark and the USA offered gFOBT 
on an annual or biennial basis to individuals of different ages (ranging from 
45 to 80 years old) and compared the results with non-screened controls. A 
systematic review combining those four trials (320,000 participants, 8 to 18 
years of follow-up) showed a reduction in CRC-specific mortality by 
approximately 16% (Hewitson et al., 2008). Recent updates of the original 
trials have confirmed the long-term benefits of gFOBT screening in reducing 
CRC mortality (Shaukat et al., 2013, Scholefield et al., 2012). 
Despite the fact that gFOBT is an affordable screening tool which 
has been proven to be beneficial, a major shortcoming of this method was 
evident in all trials: it had limited sensitivity for detecting cancer and poor 
performance in detecting adenomas (Kuipers et al., 2013). A study 
performing colonoscopies in individuals who had previous negative gFOBTs 
found CRCs in 4.5% and 8.6% of women and men, respectively (Schoenfeld 
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et al., 2005). Another study showed that gFOBT only detected 74% of 
colonoscopy-proven invasive cancers and 36% of advanced adenomas (Oort 
et al., 2010). Additionally, a Scottish trial demonstrated that interval cancers, 
those occurring after a negative result and before the next test date was due, 
comprised 31.2% of CRC cases after the first round of screening, 47.7% after 
the second and 58.9% after the third (Steele et al., 2012). This suggests that 
the sensitivity of gFOBT decreases as the screening is repeated and that 
some cancers may never bleed sufficiently to yield a positive result (Kuipers 
et al., 2013). Specificity is another concern. Firstly, haem is not specific to 
humans and there is a theoretical risk of false-positives caused by dietary 
factors. Secondly, haem is stable throughout the gastrointestinal tract, so a 
positive result might be due to bleeding in the upper portions of the 
gastrointestinal tract (Kuipers et al., 2013). As a result, the positive predictive 
value (PPV) for gFOBT varies from 0.9% to 18.7% for CRC and from 6% to 
54.5% for adenomas (Hewitson et al., 2008). This means that a large 
proportion of patients will undergo colonoscopies unnecessarily. 
Furthermore, population compliance with gFOBT has been reported to be 
low, with uptake ranging from 34% to 55% in the community setting (Leuraud 
et al., 2013, Rees and Bevan, 2013). Despite these disadvantages, the 
strong evidence supporting its benefits and the low cost of the method has 
made gFOBT the preferred screening technique in many regions and 
countries (Benson et al., 2008). 
 
Faecal immunochemical test (FIT) 
 
FITs use antigen-antibody reaction to detect the presence of human 
globin in faeces. The test is more sensitive than the gFOBT since it detects 
smaller amounts of blood and allows for quantification of globin concentration 
in the faeces (Duffy et al., 2011, van Rossum et al., 2008). The FIT is 
theoretically also more specific for colonic bleeding because it detects only 
human blood and globin is not stable throughout the gastrointestinal tract. 
This means that bleeding from the upper portions of the digestive system is 
not likely to result in a positive test (Duffy et al., 2011). Several studies have 
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consistently proven that FIT performs better that its guaiac-based counterpart 
not only in terms of detection rate but also in population uptake (van Rossum 
et al., 2008, Hol et al., 2010, Oort et al., 2010).  
However, FIT is more expensive than gFOBT and the samples are 
less stable at ambient temperature, thus requiring the test to be performed as 
promptly as possible (Duffy et al., 2011). In addition, the instability of globin in 
the gastrointestinal tract makes FIT less sensitive for detecting proximal 
colonic lesions (Haug et al., 2011). Most importantly, contrary to gFOBT, FIT-
based strategies have not been evaluated in large prospective trials with 
adequate follow-up to provide survival data and their real capacity to reduce 
CRC deaths remains unclear. Notwithstanding these drawbacks, FIT is 
increasingly becoming preferred over gFOBT and this method has been 
accepted in many screening programmes worldwide (Allison et al., 2014).  
 
Flexible sigmoidoscopy (FS) 
 
Guaiac-FOBT was the only screening method supported by 
prospective randomised trials until the late 2000s, when several studies 
conducted in Europe and in the USA demonstrated the benefit of FS, the use 
of a flexible endoscope to image de distal portion of the colon, as a screening 
tool (Segnan et al., 2011, Atkin et al., 2010, Schoen et al., 2012, Hoff et al., 
2009, Thiis-Evensen et al., 1999). The procedure is performed without 
sedation and with simple bowel preparation using an enema. A meta-
analysis/systematic review evaluated the results from all those trials, and 
concluded that FS reduces the incidence of CRC by 18% and mortality by 
28% in an intention-to-treat analysis. When analysing only those subjects 
who actually adhered to the screening programme, reductions of 32% and 
50% in incidence and mortality respectively were observed (Elmunzer et al., 
2012).  
The use of FS as a population-based screening strategy has some 
major problems. Firstly, it requires proper facilities, trained personnel and has 
higher costs than gFOBT and FIT (Kuipers et al., 2013). Secondly, it is 
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associated with a lower population uptake than the previously cited methods 
(Hol et al., 2010, Atkin et al., 2010, Segnan et al., 2011). Lastly, it does not 
allow evaluation of the proximal colon, thus potentially missing some lesions 
(Schoenfeld et al., 2005). For this reason, many experts consider 
colonoscopy a better option for endoscopic screening (Kuipers et al., 2013). 
 
Colonoscopy 
 
Colonoscopy is a diagnostic procedure which uses a flexible video-
endoscope to image the whole colon. It is usually performed with complete 
bowel cleansing and varied degrees of sedation. Colonoscopy is widely used 
as a primary screening method in several countries such as the USA, 
Canada, Germany and Poland (Kuipers et al., 2013). The first study to 
provide strong evidence supporting the use of colonoscopy for CRC 
screening was the case-control National Polyp Study in the USA. This trial 
included patients who had undergone colonoscopic polypectomy and were 
followed up carefully. The authors reported a reduction in the incidence of 
CRC by 76-90% (Winawer et al., 1993). Later, a long-term follow-up report 
suggested a 53% reduction in CRC mortality (Zauber et al., 2012). A 
reduction in CRC incidence ranging from 11% to 19% (depending on sex- 
and age-groups) was also demonstrated in studies analysing the results of 
the German nationwide colonoscopy-based screening programme (Brenner 
et al., 2009, Pox et al., 2012). 
The main drawbacks for the widespread use of colonoscopy are its 
costs, availability, invasiveness and complications. Colonoscopy is one of the 
most expensive screening tests available and demands well-equipped 
facilities and highly trained teams, thus limiting its use for deprived 
communities (Gupta et al., 2014). Even when available, the invasive aspect 
of the test, associated with the need for bowel preparation results in 
cumulative population uptake rates as low as 15-17% as demonstrated in the 
German nationwide programme (Pox et al., 2012). Complication rates in 
colonoscopies have declined recently and population based studies have 
shown rates of serious complications or perforations of 0.058% to 0.082% 
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(Pox et al., 2012, Arora et al., 2009). However, complication rates vary 
considerably in small practice facilities in community settings and can be as 
high as 0.63% (Arora et al., 2009). Another negative aspect of colonoscopy is 
the fact that this procedure also has a lower sensitivity for small lesions and 
those located in the proximal colon in the same way that happens with FS 
(Kuipers, 2014). Although widely accepted as a screening method, 
colonoscopy is not an ideal tool and, therefore, new strategies are being 
assessed to improve the accuracy and cost-effectiveness of CRC screening.  
 
CT-colonography 
 
Although not as thoroughly tested as the previous methods, CT-
colonography is an accepted method for CRC screening in some regions, 
particularly the USA (Levin et al., 2008). CT-colonography (or virtual 
colonoscopy) uses computed tomography technology to image the entire 
colon with the aid of iodinated contrast agents and bowel distension. It 
requires less bowel preparation and can detect 70-100% of the advanced 
neoplasms (advanced polyps and invasive cancers) that are visualised by 
colonoscopy (Johnson et al., 2008, Kim et al., 2007a, Graser et al., 2009, 
Stoop et al., 2012). It had higher population uptake when compared with 
colonoscopy in a study setting (Stoop et al., 2012). Nonetheless, contrary to 
the initial expectations, patients complained more about the burden of CT-
colonography than colonoscopy, particularly the disturbed bowel movements 
that were caused by the iodine contrast agent. In addition, CT-colonography 
is less cost-effective than other screening modalities, thus limiting its 
application as a widespread screening method (Kuipers et al., 2013). 
 
1.5.2. Colorectal cancer screening practices in the UK and in Brazil 
 
In the early 2000s, a pilot study was conducted in the UK to analyse 
the feasibility of introducing a population-based screening programme for 
CRC. It was performed in regions of Scotland and England and was based 
on the UK gFOBT study (Hardcastle et al., 1996). More than 478,000 
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residents from the designated areas aged 50-69 years were invited to 
participate and the uptake was 56.8%. The overall positive rate was 1.9% 
and the rate of cancer detection was 1.62 per 1000 people screened (UK 
Colorectal Cancer Screening Pilot Group, 2004). The complication rate in 
those undergoing colonoscopy was low (0.56%) as was the perforation rate 
(0.05%), with no deaths being attributable to the procedure. Each site 
subsequently reported results from the second and third rounds of the 
screening test and this confirmed the feasibility and safety of the strategy. 
The programme costs £5,900 per life-year saved, which was considered to 
be acceptable for a screening programme (Rees and Bevan, 2013). Based 
on these results, in 2006 a national biennial gFOBT screening programme 
was initiated in the UK, including individuals 60-69 years-old. The age limit 
was further extended to 60-74 years in 2010. Since then, almost 15,000 CRC 
cases have been identified by screening with a clear predominance of early-
stage tumours compared to non-screen-diagnosed cancers. This has 
resulted in better survivals as depicted in figure 1.16 (Rees and Bevan, 
2013). More recently, FS was also added as a screening option for 
individuals at age 55 in the UK as a result of several studies showing the 
benefit of this strategy in reducing incidence and/or mortality due to CRC 
(Segnan et al., 2011, Atkin et al., 2010, Schoen et al., 2012, Hoff et al., 
2009).  
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Figure 1.17. Comparison between screen-detected versus non-screen-detected 
cancers. a) a shift from late stages (Dukes’ stages C and D) to predominantly early 
stage tumours (Dukes’ stages A and B) is observed when the diagnosis is made 
during a screening test; b) the corresponding effect of early diagnosis on survival. 
Adapted from (Rees and Bevan, 2013). 
 
In Brazil, the Unified Health System (“Sistema Unico de Saúde” - SUS) 
provides health care for the entire Brazilian population. However, 
approximately 20% of the population uses private health insurance for most 
of their medical needs resulting in very divergent standards of care (Pinto 
and Soranz, 2004). Even so, there is no large scale CRC screening 
programme in Brazil in either the public or the private sectors. Literature 
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addressing CRC screening in Brazil is scarce and most reports come from 
small studies (Perez et al., 2008, Altenburg et al., 2007). One of the largest 
trials invited part of the population over 40 years-old from a small city to 
undertake gFOBT. In total, 4,567 tests were delivered and the uptake was 
approximately 80%. The positivity rate was 10.7% and these patients were 
further invited to undergo colonoscopy. Fifty nine polyps and 9 carcinomas 
were identified, resulting in incidences, in the screened population, of 1.3% 
and 0.2%, respectively (Perez et al., 2008).  
CRC screening is advised by Brazilian medical societies (Assis, 2011) 
and even by the government-sponsored National Cancer Institute. However, 
as cited earlier, no official publicly- or privately-funded programme is 
currently being conducted within the country. As a result, particularly for the 
80% of population relying exclusively on SUS, most CRC cases are 
diagnosed at late stages (Valadão et al., 2010) with a corresponding increase 
in the mortality rate and the economic burden for the nation (Torres et al., 
2010).  
 
1.5.3. New strategies under research 
 
Based on the evidence described, it is clear that the currently used 
tools are far from fulfilling the requirements for a good screening method. 
Consequently, there are several new approaches under investigation aiming 
to develop more successful strategies for CRC screening (Miller and Steele, 
2012, Di Lena et al., 2013, Bosch et al., 2011, Nguyen and Weinberg, 2016). 
Most of these methods are based on the identification of cancer markers in 
faeces or blood. The presence of cancer markers in the faeces occurs due to 
leakage of substances into the intestinal lumen (e.g. haemoglobin), active 
secretion by luminal cells (mucins, etc.) or exfoliation of cells to the lumen 
carrying cellular components such as proteins, DNA and RNA. The 
mechanisms responsible for the translocation of cancer markers into the 
bloodstream are less clear and may involve circulating tumour cells, 
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macrophage release or tumour-derived plasma microvesicles (Bosch et al., 
2011).   
 
Faecal markers 
 
The pursuit of CRC markers in faeces has some theoretical 
advantages. Tumours exfoliate more than the normal epithelium, resulting in 
large numbers of malignant cells in the sample. Also, DNA from normal 
colonocytes is degraded during apoptosis (which precedes cell shedding), 
whereas tumour cell-derived DNA suffers less degradation due to the anti-
apoptotic properties of cancer cells, thus resulting in longer and more stable 
DNA (Bosch et al., 2011). 
The current methods for detecting DNA alterations in faeces screen for 
mutations, aberrant methylation or both. Since some genes are frequently 
mutated in CRC, several analyses have been undertaken based on the 
identification of DNA mutations in faeces. Mutations in KRAS, TP53, APC 
and others have been used individually or in combination, resulting in low 
accuracies (Miller and Steele, 2012, Di Lena et al., 2013, Ahlquist et al., 
2000). Attempts to improve these results were made by associating mutation 
patterns with MSI markers and the DNA integrity assay (DIA), a marker for 
long DNA typical of exfoliated tumour cells. The first assay to combine KRAS, 
TP53 and APC mutations with a MSI marker (BAT26) and DIA showed high 
sensitivity (91% for carcinomas and 82% for adenomas larger than 1cm) and 
high specificity (93% for both) (Ahlquist et al., 2000). Unfortunately, later 
studies have not reproduced these results and lower sensitivities have been 
reported. In a comparative study using a panel of 21 genes, Imperiale et al. 
showed a sensitivity of 52% for the DNA test compared with 13% for FOBT 
for detecting invasive cancers, whereas both tests exhibited poor sensitivities 
for detecting advanced adenomas (18% and 11% for the DNA test and FOBT 
respectively) (Imperiale et al., 2004). The use of methylation patterns has 
also been explored since the discovery of the hypermethylator phenotype in 
CRCs. Screening for methylation in specific CpG islands resulted in a 
sensitivity of 38-94% for CRC (21-70% for adenomas) and a specificity of 79-
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100% (Bosch et al., 2011). The combination of both strategies seems to be 
the most promising. Recently, Imperiale et al. reported the results of a study 
comparing FIT with a multitargeted panel combining the following markers: 
KRAS mutation, aberrant NDRG4 and BMP3 methylation, ACTB plus a 
haemoglobin immunoassay. Sensitivities for advanced precancerous lesions 
were 47.4% for the stool DNA test and 23.8% for FIT. For invasive cancers, 
sensitivities were 92.3% and 73.8%, respectively. However, specificities were 
86.6% and 94.9%, favouring FIT (Imperiale et al., 2014). Despite the lack of 
long term studies showing benefit in reducing mortality, several faecal DNA 
tests are commercially available and this technique is currently accepted for 
screening purposes in the USA (Levin et al., 2008). 
Faecal RNA has also been used as a screening tool. MMP7 (encoding 
matrix metalloproteinase-7) and PTGS2 (encoding prostaglandin G/H 
synthase 2) have been assessed in small case-control studies and have 
shown conflicting results (Bosch et al., 2011). The use of a larger panel (9 
genes) has shown more promising results with a sensitivity of 78% and a 
specificity of 100%. However, the sample sizes in this and other similar 
studies have been very small and these results must be validated in larger 
cohorts (Bosch et al., 2011). MicroRNAs – short, non-coding 18-22 
nucleotide RNAs, have also been evaluated for screening purposes (Miller 
and Steele, 2012, Di Lena et al., 2013). Several miRNAs are over-expressed 
in cancer and this seems to be a promising technique for early diagnosis, 
although it is still at a very early stage of development (Di Lena et al., 2013). 
Apart from haemoglobin, various proteins (such as calprotectin, CEA, 
lysozyme, albumin, α1-antitrypsin, MUC1, lactoferrin, α-defensin 1, DAF, M2-
PK, and CLU) have been assessed in faeces from CRC patients. None of 
them is however sensitive and specific enough to be adopted for screening 
purposes and many have cross-specificity with inflammatory bowel disease 
(Bosch et al., 2011).  
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Blood markers 
 
The use of faecal tests has faced low acceptance by the population as 
demonstrated by the screening trials and population-based programmes 
discussed earlier. Venepuncture, although somewhat invasive, is less 
inconvenient than manipulating, storing and mailing stool (Bosch et al., 
2011). Furthermore, the majority of the target population for CRC screening 
is likely to have blood tests for other purposes periodically, making it even 
easier to incorporate a new screening test.  
Studies analysing the presence of DNA mutations in blood shortly 
followed the first reports of DNA mutations in the stool of CRC patients. In 
general, the same target mutations (mainly KRAS and APC) have been 
analysed in the blood as have been in stool samples. Sensitivities for DNA 
mutations in blood were lower when compared with the faecal analysis, and 
no improvement was observed when combining mutations and aberrant 
methylation (Bosch et al., 2011). The use of isolated methylation patterns has 
also been tested. A promising marker, the aberrant methylation of SEPT9, 
was recently tested against FIT in a colonoscopy-controlled trial. The authors 
reported a sensitivity of 73% for the SEPT9 test and 68% for FIT, while the 
specificities were 81.5% and 97.4%, respectively (Johnson et al., 2014). The 
lower specificity for DNA-based tests both in faecal and blood samples raises 
concerns about the real meaning of false-positive results. They could 
represent an inherent lack of specificity of the test or occult neoplasms that 
are not yet detectable by colonoscopy.    
Blood RNA expression analysis is another alternative method under 
investigation. Most studies have focused on CEA, CK19 and CK20 
expression for CRC detection. Although variations in study design prevent 
direct comparisons between results, sensitivities have been reported 
between 8%-75% for individual markers and 60%-89% for combinations 
(Bosch et al., 2011). Specificities have ranged from 78% to 100%. Micro 
RNAs are more stable in plasma than mRNAs due to their small size and 
associated proteins and many have been tested in blood samples as 
potential cancer screening markers (Slaby et al., 2009, Yi et al., 2016). For 
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example, miR-92 expression was able to discriminate between CRC patients 
and normal controls with a sensitivity and specificity of 89% and 70%, 
respectively (Ng et al., 2009). Combined use of miR-29a and miR-92a 
showed improved specificity, while maintaining the same sensitivity (Huang 
et al., 2010). The use of genome-wide expression profiles is also being 
evaluated. Although some promising results have been produced, more 
research is still needed to clarify the importance of this technology for CRC 
screening (Bosch et al., 2011).  
The emerging field of proteomics has increased the interest in the 
study of proteins as biomarkers of diseases. New technologies such as 
matrix-assisted laser desorption ionisation time-of-flight (MALDI-TOF) and 
surface-enhanced laser desorption/ionization (SELDI-TOF) mass 
spectrometry, permit the identification of peptide patterns that can 
differentiate serum from CRC patients and control individuals (Bosch et al., 
2011). However, no protein marker has shown an adequate performance to 
be used for CRC screening until now. The most studied and used protein 
marker for the evaluation of CRC patients is carcinoembryonic antigen 
(CEA). Although CEA is useful for post treatment surveillance, the accuracy 
of CEA for screening is dismal (Tan et al., 2009). Other proteins have 
however exhibited promising results such as: sCD26 (90% sensitive, 90% 
specific), Alpha-defensin 1 (69% sensitive, 100% specific), Laminin (89% 
sensitive, 89% specific), CCSA-2 (89%-97% sensitive, 78%-84% specific), 
TIMP-1 (60% sensitive, 98% specific), and Clusterin (56% sensitive, 100% 
specific) (Bosch et al., 2011). None of them, however, has been validated to 
date for screening use. Using a proteomic approach (SDS-PAGE and 
MALDI-TOF), researchers selected CRMP-2 among 325 proteins in 
secretomes of cell lines from 12 cancer types. Testing the protein level in 
plasma from 201 CRC patients and 201 healthy controls (associated with the 
level of CEA), they found a sensitivity of 77% and a specificity of 95% for this 
protein (Wu et al., 2008). Therefore, the detection of blood-borne proteins for 
CRC screening holds great promise, although it needs to be further studied 
and new markers are highly necessary.   
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1.6. Proteomic dissection of Wnt activation models and the discovery 
of novel candidate biomarkers 
 
A biomarker is defined as “a characteristic used to measure and 
evaluate objectively normal biological processes, pathogenic processes, or 
pharmacological responses to a therapeutic intervention” (Atkinson et al., 
2001). In practice, biomarkers are used for diagnosing diseases, predicting 
clinical outcome (prognostic biomarkers), predicting response to specific 
treatments (predictive biomarkers) or for surveillance after treatment 
(Pritzker, 2015, Atkinson et al., 2001).  
No protein has yet been validated as a CRC biomarker for screening 
purposes, and very few markers are currently used for prognostic and 
predictive reasons (Gonzalez-Pons and Cruz-Correa, 2015). 
Carcinoembryonic antigen (CEA) is the only accepted marker for detecting 
recurrence after treatment of CRC, although its performance remains 
suboptimal (Tan et al., 2009). However, the study of colorectal cancer 
proteomics both in human and animal models has provided important pieces 
of evidence about CRC carcinogenesis. Several candidate biomarkers have 
been suggested using this approach (de Wit et al., 2013, Alvarez-Chaver et 
al., 2014). For example, Leclerc et al. recently reported an analysis of an 
intestinal tumourigenesis model induced by low dietary folate in 
methylenetetrahydrofolate-reductase deficient mice (Mthfr+/-) (Leclerc et al., 
2014). They showed a higher expression of several members of the Nurd 
(nucleosome remodelling and histone deacetylation) complex, Kras, Sumo 
(small Ub-like modifiers)-related proteins, heat shock proteins and fatty acid 
metabolism-related proteins. In another study, de Wit et al. reported the 
differential proteomic profiling of the CRC secretome, using CRC samples 
compared to adjacent normal mucosa, and CRC cell lines. They found 409 
proteins that were more abundant in CRC versus normal tissues (de Wit et 
al., 2014). Based on consistency and abundance, and after performing a 
clustering analysis, they selected 7 potential candidate biomarkers to be 
further assessed in future studies: SSRP1, SUP16H, RRM1, DNMT1, MCM3, 
MCM5, MCM6 and TRIM28.  
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Nevertheless, few of the candidate biomarkers that have been 
reported in proteomic studies have been assessed in human blood (Alvarez-
Chaver et al., 2014). In addition, most recent studies in CRC have not 
focused on specific genetic pathways. Conversely, they have screened for 
general differential expression patterns between cancer tissues and adjacent 
mucosa. As most of the genetic alterations present in CRC (and the resulting 
possible alterations in protein expression) are “passengers” instead of 
“drivers” of the carcinogenic process (Wood et al., 2007), a more focused 
proteomic analysis targeting specific pathways known to be involved in CRC 
development would be expected to yield more promising biomarker 
candidates. 
As the Wnt pathway is the most important driver of the early stages of 
colorectal tumourigenesis, the proteomic profiling of Wnt activation-based 
models is likely to provide candidate biomarkers which could ultimately 
translate into useful clinical tools for CRC screening, prognosis or prediction 
of response to treatment. A study with this purpose has been previously 
conducted in our group by Hammoudi et al. who performed a proteomic 
dissection using two different murine models of Apc inactivation (Hammoudi 
et al., 2013). One of them was the AhCre+ Apcfl/fl mouse, an animal bearing 
loxp-flanked Apc alleles and a Cre-recombinase transgene. When this animal 
is exposed to β-naphthoflavone injections, Cre-recombinase transcription is 
activated and this results in the deletion of the loxp-flanked Apc alleles 
specifically in the intestinal epithelium, thus causing an acute activation of the 
Wnt pathway (Sansom et al., 2004). The other model used was the ApcMin/+ 
mouse. This animal has a germline mutation in one Apc allele simulating a 
FAP patient, and spontaneously develops multiple intestinal neoplasms (Min) 
during its life-span (Su et al., 1992, Moser et al., 1990). Both models were 
compared with Apc+/+ animals of the same genetic background.  Analysing 
epithelial cell extracts and intestinal tissues, the authors found 81 proteins to 
be up-regulated in Apcfl/fl versus Apc+/+ mice. Ingenuity Pathway Analysis 
(IPA) suggested that 13 of these proteins could also be detected in blood or 
serum. Four were excluded due to low specificity for CRC or reagent issues. 
The 9 remaining candidates were further assessed using 
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immunohistochemistry, Western Blotting and qPCR. After these steps, 6 
promising candidates were selected for ELISA (using mouse serum) and for 
testing in human CRC tissues and adjacent normal mucosa using qPCR. 
Finally, four candidate proteins were suggested as potential biomarkers in 
CRC: Nucleolin (NCL), Prohibitin (PHB), Cytokeratin 18 (CK-18) and 
Ribosomal protein L6 (RPL6) (Hammoudi et al., 2013). Further unpublished 
work performed in our group has reinforced the high expression of these 
biomarkers (Dr Fei Song, currently working at Infrafrontier GmbH, Munich, 
Germany). Additionally, it has expanded the candidate list by adding 
Nucleosome assembly protein 1 – like 1 (NAP1L1), Splicing factor 
arginine/serine-rich 2 (SFRS2), Fatty acid binding protein 6 (FABP6), 
Nucleophosmin, and DEAD box protein 5 (DDX5) to the group of candidate 
proteins (John R Jenkins, Personal Communication).  
To further refine the selection of the candidate biomarkers, a 
colleague, Dr Shahram Ali Ibrahim, carried out additional studies to validate 
the expression patterns of these candidate proteins using animal models, cell 
lines and human CRC samples from the Countess of Chester Hospital NHS 
Foundation Trust (Ibrahim, 2014). His work identified NAP1L1, RPL6, 
HMGB1 and Prohibitin as the most promising candidates. Furthermore, 
based on a report that showed that CDC5L over-expression displaces 
SFRS2 from nuclear speckles (Engemann et al., 2002), Ibrahim´s work also 
suggested antagonistic actions between these proteins during Wnt activation, 
which could trigger an apoptotic burst. As a result of all the work mentioned 
above, a final list of candidate biomarkers was selected for further studies 
focusing on human tissue and blood samples. These proteins will be 
evaluated throughout the present project and are therefore briefly described 
in the next section. 
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1.6.1. Novel candidate biomarkers 
 
Nucleosome assembly protein 1 – like 1 (NAP1L1) 
  
NAP1 is a protein involved in nucleosome assembly and disassembly 
and was initially discovered in HeLa cells (Park and Luger, 2006). The 
nucleosome is the basic unit of chromatin and is formed in a 2-step process: 
a tetramer of the histone subunits H3 and H4 is first deposited onto the DNA. 
Then, the process is completed by the addition of 2 heterodimers of the H2A 
and H2B subunits. NAP1L1 is the human counterpart of yeast NAP1, and is 
thought to work as a histone “chaperone”, carrying histone subunits during 
chromatin remodelling (Park and Luger, 2006). Other suggested functions of 
NAP1L1 include roles in gene transcription and cell cycle regulation (Park 
and Luger, 2006). The protein localises predominantly in the cytoplasm (in 
HeLa cells), with a low but definitive amount also being detected in the 
nucleus (Okuwaki et al., 2010). Studies using murine pluripotent stem cells 
have suggested that NAP1L1 is important in maintaining the undifferentiated 
state, and NAP1L1 gene knockdown in these cells causes differentiation into 
cardiomyocytes and mesoderm development (Gong et al., 2014, Li et al., 
2012).  
There is also some evidence that NAP1L1 is involved in 
carcinogenesis. One study showed that NAP1L1 expression was increased 
in small intestinal neuroendocrine (carcinoid) tumours compared with 
colorectal adenocarcinomas and normal adjacent tissues (Kidd et al., 2006). 
Another author demonstrated that silencing the NAP1L1 gene resulted in 
decreased tumour proliferation in pancreatic neuroendocrine cancer cell lines 
and xenografts (Schimmack et al., 2014). Additionally, NAP1L1 was shown to 
be over-expressed in CRC and hepatoblastomas (Line et al., 2002, Nagata et 
al., 2003). However, the literature assessing whether NAP1L1 is a potential 
cancer biomarker remains poor. 
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Ribosomal protein L6 (RPL6) 
  
Ribosomes, the fundamental organelles responsible for protein 
biosynthesis, are made up of two components: ribosomal RNA (rRNA) and 
ribosomal proteins (RPs). There are around 80 different RPs, whose function 
involves the stabilisation of specific rRNA structures in ribosomal subunits 
and the promotion of correct folding of rRNAs during ribosomal assembly (Lai 
and Xu, 2007). In addition, RPs exhibit various poorly understood extra-
ribosomal functions. Several different RPs have been shown to be over-
expressed in some types of cancer such as breast, prostate, oesophageal, 
cervical and hepatocellular tumours (Wu et al., 2011). However, RPL6, the 
candidate biomarker suggested from the work described previously, has only 
been associated with one type of cancer (gastric neoplasms) and has been 
addressed to a limited extent in the scientific literature (Du et al., 2005, Gou 
et al., 2010, Wu et al., 2011). Studies have shown that RPL6 expression is 
associated with cell proliferation and growth in gastric cancer cell lines. 
Additionally, it has been suggested that the mechanism by which RPL6 could 
affect these processes is via Cyclin E regulation in the cell cycle (Wu et al., 
2011, Gou et al., 2010) and regulation of the Bcl-2/Bax equilibrium for 
apoptosis (Du et al., 2005). In addition, using multidrug resistant cell line 
models, the authors demonstrated that RPL6 is important for the prevention 
of apoptosis caused by cytotoxic drugs and that RPL6 knockdown can 
sensitise cells to the destructive effects of those compounds (Du et al., 
2005). It has been suggested that RPL6 over-expression in gastric cancer 
samples could be a negative prognostic factor resulting in reduced survival 
(Wu et al., 2011). To the best of our knowledge, apart from Hammoudi´s 
work previously discussed, no study has reported the role of RPL6 in 
colorectal tumours.  
 
Prohibitin (PHB) 
  
The PHB gene is located at the chromosomal position 17q21 and 
encodes a protein that is ubiquitously expressed and present in multiple 
86 
 
cellular compartments (Zhou and Qin, 2013). It is associated with several 
biological functions depending on its localisation. In the nucleus, PHB 
regulates the cell cycle, senescence mechanisms and causes tumour 
suppression (Zhou and Qin, 2013). In mitochondria, it is involved in the 
control of oxidative stress (Thuaud et al., 2013, Chowdhury et al., 2017), 
protein synthesis (He et al., 2012), maintenance of mitochondrial DNA copy 
number (Kasashima et al., 2008), mitophagy (Galluzzi et al., 2017) and 
transport of newly synthesised proteins (Nijtmans et al., 2000). In the plasma 
membrane, it acts as a lipid scaffold to maintain membrane integrity (Thuaud 
et al., 2013, Zhou and Qin, 2013). It has been suggested that PHB regulates 
cell proliferation and growth through the interaction with tumour suppressors 
such as p53 and RB, and proto-oncogenes such as MYC (Zhou and Qin, 
2013). Furthermore, recent studies have established that PHB activates the 
Ras-Raf-MEK-Erk signalling cascade, an important pathway associated with 
cell proliferation and survival (Chowdhury et al., 2014). This results in 
enhancement of Bcl-2 expression and decreases in both Bax-Bak activation 
and cytochrome c release from mitochondria, causing inhibition of apoptosis. 
Supporting this concept, a study by Kim et al. showed that PHB knockdown 
using siRNA enhanced sensitivity to anthralin-mediated cell death in human 
keratinocyte cell lines (Kim et al., 2007b).  
In cancers, there have been contradictory findings regarding PHB 
expression and significance. In ovarian cancer, a study showed reduced PHB 
expression in cancer tissues compared with normal specimens (Jia et al., 
2014). Reduced expression of PHB has also been found in hepatocellular 
and cholangiocarcinoma cells (Fan et al., 2016). In contrast, PHB over-
expression has been demonstrated in lung (Jiang et al., 2013, Guo et al., 
2012), breast (Najm et al., 2013), gastric (Kang et al., 2008), thyroid 
(Franzoni et al., 2009), prostate (Ummanni et al., 2008), superficial (Wu et 
al., 2007) and invasive bladder cancers (Cao et al., 2016). Among these 
studies, the few which reported clinical correlation showed that increased 
expression of PHB was associated with a better prognosis for breast and 
superficial bladder cancer, whilst it was deleterious in lung (poor survival), 
gastric (poor differentiation) and invasive bladder (poor survival) tumours. 
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Noteworthy, Kang et al. also tested serum from gastric cancer patients and 
healthy controls using ELISA and did not find any difference in the 
concentration of PHB between these groups (Kang et al., 2008). In colorectal 
cancer patients, Chen et al. demonstrated an increased expression of PHB in 
cancer tissues compared to normal matched mucosa and adenomas (Chen 
et al., 2010a). No difference was however observed between normal samples 
and adenomas. In this study, although a positive correlation was found 
between PHB over-expression and poor differentiation, no association was 
demonstrated with tumour stage or survival.  
 
High mobility group box 1 (HMGB1) 
  
HMGB1 is a remarkably multifunctional protein which possesses 
diverse biological functions (Ohmori et al., 2011). A comprehensive review 
about its biology, also covering other members of the family, has recently 
been published (Kang et al., 2014). This group of proteins (HMGs) was 
named due to the high mobility pattern showed in polyacrylamide gels. 
Interestingly, the same ability is seen in the intracellular movement of the 
protein. HMGB1 was first isolated from calf thymus and is predominantly 
located in the nucleus of cells. Nonetheless, the protein can leave the nuclear 
space in less than 2 seconds and is able to shuttle to the cytoplasm and even 
to the extracellular space (Kang et al., 2014). Inside the cell, HMGB1 is 
involved in DNA replication, repair and recombination, as well as transcription 
and genomic stability. The protein can translocate to the extracellular matrix 
either through passive release (from dead or injured cells) or active secretion 
(from immune and cancer cells). Thereafter, HMGB1 can bind to several cell 
receptors such as the receptor for advanced glycation end products (RAGE) 
and Toll-like receptors (TLR). When bound, the complex induces chemotaxis, 
migration, proliferation and differentiation of tumour and immune cells (Kang 
et al., 2013). These effects have an important role in inflammatory and 
immune diseases.  
As a result of its complex functions, HMGB1 has both pro and anti-
tumour effects in cells expressing RAGE (Ohmori et al., 2011, Kang et al., 
88 
 
2013). Some of the pro-tumourigenic properties of HMGB1 are: a) 
sustenance of an inflammatory environment; b) changes in energy 
metabolism; c) promotion of invasion and metastasis; d) inhibition of anti-
tumour immunity, and e) promoting angiogenesis. By contrast, HMGB1 can 
also prevent tumours via: i) interaction with tumour suppressors; ii) increase 
of genome stability, and iii) increase of autophagy (Kang et al., 2013). In the 
last 20 years, HGMB1 has been quite extensively studied in cancer. It has 
been associated with carcinogenesis in colon, breast, lung, prostate, cervical, 
skin, kidney, stomach, pancreatic, liver, bone and blood cancers (Kang et al., 
2014). In CRC, a recent study assessing tumour tissues using 
immunohistochemistry showed that 56% of samples expressed high levels of 
HMGB1 and this over-expression was associated with adverse prognostic 
factors such as tumour stage and differentiation (Süren et al., 2014). Other 
research demonstrated that tumours with both nuclear and cytoplasmic 
expression of HMGB1 had less lymphocyte infiltration and a decreased 5-
year survival rate (Peng et al., 2010). Lee et al. evaluated HMGB1 levels in 
sera from patients with CRC and healthy controls and compared the findings 
with another serum biomarker, carcinoembryonic antigen (CEA). For 
diagnostic purposes, HMGB1 results exhibited a better specificity compared 
to CEA (96% vs 90.7%); however, the sensitivity was worse (20.1% vs 
25.6%). The authors suggested that both tests could be used in combination, 
since HMGB1 performed slightly better in early stage lesions whereas CEA 
had better accuracy for late stage tumours (Lee et al., 2012).   
 
Splicing factor arginine/serine-rich 2 (SFRS2) or Serine/arginine-rich 
splicing factor 2 (SRSF2) or SC35 
 
Serine/arginine rich (SR) proteins are a family of RNA binding proteins 
characterised by RNA recognition motifs and a signature SR domain 
enriched with serine and arginine repeats (Fu, 1995). SR proteins play an 
essential role in both constitutive and alternative splicing (Fu, 1995, 
Graveley, 2000, Manley and Tacke, 1996, Anko, 2014). SFRS2 (also called 
SRFS2 or SC35 – it will be referred solely to as SFRS2 hereafter), has been 
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particularly associated with genomic stability, cell proliferation and 
organogenesis in mammalians (Xiao et al., 2007). Studies have shown that 
SFRS2 is also involved in transcriptional elongation (Lin et al., 2008), mRNA 
stabilisation (Qian et al., 2011) and regulation of apoptosis (Merdzhanova et 
al., 2008). The importance of alternative splicing for cell physiology is 
highlighted by the fact that more than 90% of human genes undergo this 
alternative processing, resulting in diverse protein isoforms (Wang et al., 
2008, Pan et al., 2008). Mounting evidence suggests that alternative splicing 
is also an important driving force for carcinogenesis, interfering with 
oncogene function, signalling cascades and response to the tumour 
microenvironment (Biamonti et al., 2014).  
Few studies have addressed the role of SFRS2 in cancer models. 
Studying lung cancer cell lines and tumour xenografts, Merdzhanova et al. 
showed that SFRS2 is important in the control of pro-angiogenic and anti-
angiogenic isoforms of VEGF-A (Merdzhanova et al., 2010). Edmond et al. 
demonstrated that post-translational modifications of SFRS2 are involved in 
the control of cell fate in response to the cytotoxic agent cisplatin (Edmond et 
al., 2011). In head and neck cancer cell lines, Sharma et al. have shown that 
SFRS2 causes E-cadherin mis-splicing and transcript degradation, thus 
decreasing the expression of this protein - a feature associated with 
metastatic transformation (Sharma et al., 2011). We have not been able to 
find any published study evaluating the role of SFRS2 in colorectal cancer.  
 
Cell division cycle 5-like (CDC5L) 
 
CDC5L, the human homolog of the product of the cdc5+ gene in 
Schizosaccharomyces pombe, is an essential protein involved in the 
composition of a larger multi-protein complex which is part of the 
spliceosome (Ajuh et al., 2000). This structure is responsible for processing 
the pre-mRNA into mature mRNA. The importance of CDC5L for mRNA 
processing is supported by experiments showing that its depletion causes 
ineffective splicing, although the spliceosome itself is still formed (Ajuh et al., 
2000). Apart from this well-established function, there is also evidence that 
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CDC5L is important for cell cycle progression (Bernstein and Coughlin, 
1998). A study demonstrated that different patterns of CDC5L 
phosphorylation resulted in distinctive mRNA processing and that the protein 
might be a target for cyclin-dependent kinase 2 (CDK-2), a factor associated 
with S-phase progression (Gräub et al., 2008). Another possible mechanism 
for cell cycle control involves “checkpoint” actions. It has been shown that 
CDC5L interacts with the cell-cycle checkpoint kinase ataxia-telangiectasia 
and Rad3-related protein (ATR) and the resulting complex works by halting 
cell proliferation in response to DNA damage (Zhang et al., 2009).  
Additionally, recent research showed that CDC5L knockdown in HeLa cells 
caused dramatic mitotic arrest and chromosomal misalignment, eventually 
leading to what is called mitotic catastrophe (Mu et al., 2014). 
There are few studies assessing the role of CDC5L in cancer. 
Although there is one study reporting its over-expression in cervical cancer 
(Mu et al., 2014), most of the literature refers exclusively to osteosarcoma, a 
bone cancer typically found in children and young adults (Mu et al., 2014, Lu 
et al., 2008, Martin et al., 2014). Initial reports in the late 2000s suggested 
that CDC5L might be the oncogene involved with the amplification of region 
6p12-p21 frequently observed in osteosarcomas (Lu et al., 2008). Recently, 
another study analysed the expression of 17 candidate genes in 
osteosarcoma patients aiming to assess their potential for predicting 
response to preoperative (neoadjuvant) chemotherapy. Their results 
confirmed that CDC5L, RUNX, CDK4 and RECQL4 expressions are 
correlated with poor response to treatment (Martin et al., 2014). Apart from 
these studies, we were not able to find any other evaluation of CDC5L in 
other cancer types, including CRC.  
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1.7. Hypothesis 
 
The candidate proteins selected from the proteomic dissection of 
animal models of colorectal carcinogenesis based on Apc inactivation may 
be useful colorectal cancer biomarkers for early diagnosis, prognosis or 
prediction of response to treatment. Furthermore, mechanistic studies 
assessing these candidates may provide important new data about the 
biology of CRC.  
 
1.8. Aims of the study 
 
a. To assess the expression of candidate proteins previously selected in 
our research group using human clinical samples from individuals 
without intestinal neoplastic lesions, with colorectal polyps and with 
colorectal cancer, thus encompassing the entire normal-adenoma-
carcinoma sequence; 
 
b. To explore the gene expression pattern of these candidates in normal 
and neoplastic colorectal tissues; 
 
c. To test the concentrations of promising candidate proteins in the blood 
of individuals with and without CRC; 
 
d. To identify possible mechanisms by which these biomarkers are 
involved in intestinal carcinogenesis; 
 
e. To investigate whether there is any association between the 
expression of these candidate proteins and prognosis in CRC patients; 
 
f. To compare, whenever possible, the results obtained in two 
populations with diverse ethnic, geographic and social backgrounds 
(UK and Brazil), thus increasing the validity of any conclusions.  
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Chapter Two: 
Patients, materials and methods 
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2. CHAPTER 2 – PATIENTS, MATERIALS AND METHODS 
 
2.1. Ethical approval 
 
All samples from the prospective “Brazilian cohort” were collected after 
the nature of the research had been explained to individuals, its potential 
benefits and risks had been discussed, and “informed consent” had been 
confirmed. The research project was approved by the ethical boards listed 
below, including the retrospective collection of samples and data for the 
“prognostic cohort”. A research code was assigned to each subject, so that 
direct identification of the person was not possible throughout the work. This 
research was approved by the Committee for Research Ethics of the Hospital 
Universitario Julio Muller - Federal University of Mato Grosso, Cuiaba – 
Brazil, and by the Brazilian National Commission for Research Ethics 
(CONEP), decision number: 1.628.901. 
Samples from the UK cohort were also collected with informed 
consent and following research ethics committee approval (NREC number 
12/NW/0011). 
 
2.2. Brazilian samples  
 
a. Cancer patients 
 
The “Brazilian cohort” of samples was prospectively collected in the 
city of Cuiaba, capital of the state of Mato-Grosso, Brazil. The author of this 
thesis participated directly in the process of sample collection along with a 
colleague (Dr Lenuce Ydy, Surgical Oncologist). Clinicians from different 
hospitals and cancer centres were asked to identify patients with a recent 
diagnosis of CRC for whom a surgical resection of the tumour was 
scheduled. Then, the patient was interviewed, the nature of the research was 
explained and they were invited to participate. If they agreed, “informed 
consent” was obtained and a “clinico-epidemiological data form” was 
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completed. On the day of the surgery, before anaesthetic induction, blood 
was collected in tubes with and without EDTA (BD Vacutainer, Becton and 
Dickinson). These blood samples were processed within 5 hours according to 
the procedures detailed in section 2.9. Serum and plasma were extracted 
and stored at -80°C. Immediately after the surgical resection, the specimen 
was opened through the intestinal wall opposite to the tumour. Fragments 
from the tumour and from the apparently normal adjacent mucosa (at least 
10cm from the tumour) were collected in 10% formalin in phosphate buffered 
saline (PBS) pH 7.4, incubated for 24 hours, and then processed into paraffin 
blocks for future histological work. In order to obtain tissues for RNA 
expression analysis, we also collected tumour and adjacent samples in 
cryovials, and these were immediately frozen in liquid nitrogen. When this 
research project started, the investigator had already collected 50 pairs of 
samples (tumour and adjacent). However, although a specialised company 
was hired to transfer the material from Brazil to the UK, all samples defrosted 
during the shipment due to delays in the customs authority and insufficient 
dry ice in the package. After experiencing these problems, we decided to use 
a preservative solution (Allprotect®, Qiagen) instead of nitrogen snap-
freezing to guarantee the preservation of tissues. Therefore, all the samples 
used in the mRNA expression analysis were placed immediately after 
collection in Allprotect®, incubated overnight at 4°C and stored at -80°C until 
they were used. Samples from cancer patients were collected between 
January 2013 and August 2015. After excluding samples which did not 
contain representative tissues and those which experienced technical 
problems during storage or transportation, the number of cancer samples 
suitable for analysis was:  
i. Formalin-fixed, paraffin-embedded samples: 32 cases (tumour and 
adjacent mucosa) 
ii. Allprotect®-treated tissue samples: 25 cases (tumour and adjacent 
mucosa). 
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b. Polyp-bearing individuals and normal controls 
 
In order to obtain samples from individuals with colorectal polyps, we 
established a partnership with a colonoscopy clinic in Cuiaba (Dr Wladimyr 
Dias Moreno, Gastrocenter). Subjects referred to the clinic to undergo 
colonoscopy for a variety of symptoms (intestinal bleeding, constipation, 
diarrhoea, etc) or for CRC screening (asymptomatic) were identified, the 
research was explained and they were invited to participate. If they agreed, 
“informed consent” was obtained. During the colonoscopy, if one or more 
polyps were identified and no other alteration in the intestine was found, 
blood samples were collected and processed as explained in section 2.9. 
The polyps were then removed, immersed in formalin and sent for 
pathological analysis. This is the standard protocol after the identification of 
polyps and was not a research-related procedure. After the pathological 
assessment had been completed and the final report was released, the 
paraffin blocks were retrieved from the pathology laboratory for future 
histological and immunohistochemical evaluations. Alternatively, if no polyp, 
tumour or any other lesion was apparent, the individual was recruited as a 
normal control. Blood samples were collected and processed. Fragments 
from the normal mucosa were taken and placed into two flasks, one 
containing 10% buffered formalin (later processed into paraffin blocks) and 
the other with Allprotect® as explained above. Unfortunately, we were not 
able to collect fresh polyp samples either in liquid N2 or in Allprotect® 
because the diagnostic routine demands that all polyps removed be sent for 
pathological analysis. The number of samples collected from these 
individuals was: 
i. Polyp-bearing individuals: 18 adenoma samples.  
ii. Normal controls: 10 intestinal mucosa samples. 
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c. Samples from cancer patients with more than 4 years 
follow-up for prognostic assessment - the prognostic 
cohort 
 
To test whether or not a correlation existed between the expression of 
candidate biomarkers and clinical outcomes in CRC patients, we decided to 
perform an analysis of the expression of the proteins in a larger retrospective 
cohort. To do so, we established a partnership with a Brazilian pathologist 
(Dr Ivana Menezes) and a pathology laboratory in Cuiaba (Laboratorio Sao 
Nicolau). This is the reference laboratory for immunohistochemistry in that 
region. It has extensive expertise in this procedure and highly trained 
technical personnel.  
The first phase of the collection was a survey in the records of two 
pathology laboratories (Laboratorio Sao Nicolau and the Julio Muller 
University Hospital Pathology Lab) aiming to identify cases of CRC who had 
undergone surgery more than four years ago. Next, we tracked the health 
service where the patient was initially evaluated to find whether the patient 
was followed up in that service or in any other service in which clinical 
information was traceable. Alternatively, if no clinical information was 
available, we checked the Brazilian electronic death database – Mortality 
Information System (“Sistema de Informação de Mortalidade” – SIM), a 
database with all deaths and its causes in the country. Lastly, we retrieved 
the paraffin blocks from these patients from the pathology lab archives. In 
total, we collected blocks from 96 patients. Twenty-one cases were excluded 
due to lack of tumour tissue in the block or because death occurred within 30 
days from the operation, thus suggesting postoperative complication as the 
cause. Consequently, 75 cases were included in the final prognostic analysis 
(detailed in Chapter 6).  
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2.3. UK samples 
 
Twenty-six individuals who underwent resection surgery at the 
Countess of Chester Hospital NHS Foundation Trust (Chester-UK) provided 
tissue samples that were included in this study. All specimens had malignant 
tumours from different stages, of which 7 also had normal adjacent mucosa 
in the block. Ten specimens had colonic polyps in addition to invasive 
tumours (6 low-grade and 4 high-grade adenomas). Lesions were classified 
as low- or high-grade dysplasia or invasive cancer according to the Royal 
College of Pathologists guidelines (Loughrey et al., 2014). Both the neoplasm 
and the adjacent mucosa (when present in the block) were included in a 
tissue microarray (TMA) and used for the analysis. 
  
2.4. Clinicopathologic data collection 
 
All Brazilian subjects involved in the prospective part of this research 
were interviewed by the investigators. During this interview, data regarding 
identification (name, name of the mother, address, phone number, national 
identification number, etc.), ethnicity and geographic background were 
collected. In addition, all information available concerning disease status 
such as scan or endoscopic test results was recorded. In patients who 
underwent a surgical procedure, the type of surgery and outcome was also 
added to the form. The final pathology report was obtained for every polyp 
and cancer patient, as well as the colonoscopy report for the polyp and 
control individuals.  
Clinicopathologic meta-data from the UK cohort were retrospectively 
collected by Nadeem Al-Khafaji (University of Liverpool) using the 
MEDITECH and MediSecNet online databases, as part of his MRes research 
project.  
 
Regarding the prognostic cohort, we assessed the records of the 
health service where the patient was followed up after surgery to obtain 
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survival information. In addition, the official Brazilian electronic death 
database was assessed in order to confirm that the mortality data were 
accurate. Overall survival was recorded as the interval between diagnosis 
and death from any cause (when death has occurred) or the date when the 
database was last checked (when death has not occurred).  
 
2.5. Haematoxylin and eosin (H&E) staining and pathological review 
  
In order to ascertain the presence of the target tissue in the paraffin 
blocks, each sample was evaluated by a pathologist either in Brazil (Dr Ivana 
Menezes, Sao Nicolau lab) or in the UK (Dr Timothy Andrews, Royal 
Liverpool University Hospital) using H&E staining. The staining was 
performed as follows: 4-micrometre sections were obtained from each block 
using a rotational manual microtome. Sections were dewaxed in xylene twice 
(5 minutes each), and then hydrated in a series of ethanol solutions with 
decreasing concentration (100% twice, 3 minutes each; 90% and 70%, two 
minutes each) and distilled de-ionised water (5 minutes) in a fume hood. 
Next, the sections were immersed in haematoxylin for 3 minutes and washed 
in running tap water during 10 minutes. Then, sections were incubated in 
eosin for 2.5 minutes and briefly washed in tap water. The stained sections 
were then dehydrated in increasing concentrations of ethanol (70%, 90% and 
100% twice for 2 minutes each). Finally, sections were cleared in xylene 
twice (5 minutes each) and mounted. The same protocol was used in our 
laboratory every time we needed to re-evaluate the tissue present in the 
blocks (for example, after many sections had been taken from the block to 
reassure that target tissues were still present).  
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2.6. Immunohistochemistry (IHC) 
 
2.6.1. Initial validation of candidate biomarkers 
 
Samples collected from the Countess of Chester Hospital (UK-cohort) 
were arranged in a tissue microarray (TMA). A TMA is a cost-effective way of 
exploring the immunohistochemical expression of biomarkers in cancer 
tissues (Milanes-Yearsley et al., 2002, Ilyas et al., 2013). It is constructed by 
the transference of paraffin embedded tissue cores from several donor 
blocks into a single recipient block, therefore allowing the analysis of dozens 
or hundreds of samples in a single slide (Parsons and Grabsch, 2009). All 
individual paraffin blocks were sectioned, stained with H&E and evaluated by 
an experienced pathologist (Dr Timothy Andrews). The most representative 
areas were marked in the slide in order to facilitate tissue collection. Using a 
manual tissue microarrayer (MTA-1, Beecher Instruments Inc., Sun Prairie, 
Wisconsin, USA), three cores (0.6mm each) from each block were collected 
and transferred into recipient blocks. All subsequent analyses of the UK-
cohort were carried out using TMA sections. The same procedure was 
performed using the Brazilian cohort for the construction of a TMA. However, 
we experienced a very high rate of core detachment from the slides produced 
using this microarray. The reasons for this problem were not clear, but it 
might involve the fixation process, the quality of the paraffin or even the 
conditions of storage of the blocks. Several procedures were attempted to 
decrease the rate of tissue loss (longer APES coating, incubation at 58°C 
prior to dewaxing, different slide brands, etc). Nonetheless, the loss of cores 
was still too high to allow the use of TMAs for the analysis of the Brazilian 
cohort. As a result, all the subsequent IHC staining procedures involving 
these samples were performed using individual whole sections.  
Paraffin blocks (either TMAs or individual blocks) were cut into 4-
micrometre sections. These sections were placed onto 
aminopropyltriethoxysilane (APES – Sigma, Gillingham, UK) -coated glass 
slides and left to dry in a laboratory oven at 37°C overnight. The slides were 
dewaxed in xylene as described for H&E. Then, the slides were immersed in 
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100% ethanol twice for 5 minutes. In order to block the activity of 
endogenous peroxidases, the slides were incubated in a solution containing 
3% hydrogen peroxide in methanol for 10 minutes. Next, the slides were 
rehydrated in ethanol solutions (90% and 70%, 2 minutes each) and in 
distilled, de-ionised water (5 minutes). Afterwards, the sections were washed 
in Tris-buffered saline-Tween 0.1% (TBS-T) in an orbital shaker twice (5 
minutes each). Heat-induced epitope retrieval was performed by immersing 
the slides in 10 mM citrate buffer pH 6.0. Heat was generated using a 
microwave oven at full power (800 watts) for two 10-minute sessions, with 
more citrate buffer added in the interval to top up the container and prevent 
the samples from drying out. The slides were then allowed to cool down for 
10 minutes and washed in running tap water for additional 10 minutes. After 
that, the sections were washed in Tris-buffered saline (TBS) three times 
(from this step on, all TBS washes were performed for 5 minutes in an orbital 
shaker). To prevent secondary antibodies from binding to non-specific 
epitopes, the sections were incubated with 10% normal goat serum (Dako, 
Ely, UK) in TBS-T for 45 minutes at room temperature. Then, the slides were 
incubated with the primary antibody diluted in 10% normal goat serum in 
TBS-T overnight, at 4°C, in a humid chamber, using specific and optimised 
dilutions for each antibody tested (see table 2.1 for antibodies specifications 
and table 2.2 for reagent specifications). Next day, the sections were washed 
twice in TBS and a biotinylated secondary antibody solution was applied; 
incubation occurred during 30 minutes at room temperature. Goat anti-mouse 
or goat anti-rabbit secondary antibodies were used according to the species 
in which the primary antibody was raised, at a dilution of 1:200 in 5% normal 
goat serum in TBS. Slides were again washed twice in TBS and incubated 
with an avidin-biotin-peroxidase complex (Vectastain Elite ABC kit – 
Peterborough, UK) for 30 minutes at room temperature. After two more 
washes in TBS, the stain development was performed by applying a pre-
prepared 3,3’-diaminobenzidine (Sigmafast DAB tablets – Sigma, Gillingham, 
UK) substrate solution onto the slides, followed by incubation for 4-5 minutes 
at room temperature. When satisfactory staining had been achieved, further 
colour development was blocked by briefly washing the slides with distilled 
de-ionised water and by a wash in TBS for 5 minutes. Finally, sections were 
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counterstained with haematoxylin for 5 minutes and washed in running tap 
water until the desired blue intensity had been achieved (usually 5 to 10 
minutes). Then, the slides were dehydrated in increasing concentrations of 
ethanol (70% and 90%, 2 minutes each and 100% twice for 3 minutes each) 
and cleared in xylene twice (5 minutes each) before being mounted using 
DPX™ mounting medium (Sigma) and glass coverslips.    
 
Table 2.1. Antibodies and specifications used in the IHC experiments. 
PRIMARY ANTIBODIES   
Antibody/manufacturer Host/clonality Dilution in 10% goat 
serum in TBS-T 
β-catenin/BD transduction 
laboratories 
Mouse/polyclonal 1:50 
NAP1L1/Abcam Rabbit/polyclonal 1:4,000 
RPL6/Proteintech Rabbit/polyclonal 1:200 
Prohibitin/Abcam Rabbit/monoclonal 1:200 
HMGB1/Abcam Rabbit/polyclonal 1:1,000 
SC35 or SFRS2/Abcam Mouse/monoclonal 1:250 
CDC5L/Abcam Rabbit/monoclonal 1:10,000 
SECONDARY ANTIBODIES  (biotinylated)  
Antibody/manufacturer Host/clonality Dilution in 5% goat 
serum in TBS 
Anti-rabbit/Dako Goat/polyclonal 1:200 
Anti-mouse/Dako Goat/polyclonal 1:200 
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Table 2.2. Reagents and buffers used in the IHC experiments. 
Reagent/buffers Composition/manufacturers 
TBS 6.05 g of TRIS base (Sigma) and 8.76 g of NaCl (Sigma) 
to 1 litre of distilled water and adjusting pH to 7.4. 
TBS-T 1mL of Tween 20 (Sigma) added to 1 litre of TBS. 
Citrate buffer 2.94 g of Tri-sodium citrate dihydrate (Sigma) to 1 litre of 
distilled water and adjusting pH to 6. 
H2O2-methanol 12 mL of 30% H2O2 (Sigma) in 400 mL of methanol. 
Avidin-biotin-
horseradish peroxidase 
complex 
2 drops of reagent A and 2 drops of reagent B (Vectastain 
Elite ABC kit) in 5 mL of TBS, prepared 30 minutes before 
use.  
DAB 1 tablet of Sigmafast DAB (Sigma) plus 5µL of 30% H2O2 
(Sigma) in 5 mL of TBS (protected from light).  
 
 
IHC stained slides were photographed for subsequent analysis. 
Whole-sections were recorded at 200x and 400x magnification using a Leica 
laser microdissection microscope and camera set (Leica Biosystems, Milton 
Keynes, UK). TMA slides were scanned at 200x magnification using the 
Aperio SlideScanner platform (Leica Biosystems, Milton Keynes, UK). The 
protocols used for scoring the images are detailed in the chapter describing 
the IHC validation work (Chapter 3).  
 
2.6.2. Prognostic study 
 
For the assessment of the prognostic significance of the expression of 
the candidate biomarkers (Chapter 6), a different IHC protocol was used. 
Most clinical pathology laboratories currently use pre-optimised buffers and 
solutions in order to save time and increase productivity. Therefore, the 
validation of our candidate biomarkers using techniques similar to the 
standard practices of clinical labs would increase the external validity of any 
findings. The protocol adopted in this part of the research was the routine 
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technique used in the Sao Nicolau laboratory (Cuiaba/Brazil), a pathology lab 
which has extensive expertise in IHC procedures. The experiments are 
described below (all branded solutions and buffers were purchased from 
Cell-Marque™/Sigma-Aldrich [Rocklin, California, USA]): Four micrometre 
sections were cut using a rotary microtome. Slides were dried at 60°C for 20 
minutes. Then, samples were dewaxed in xylene and rehydrated as 
described before. After a wash step in distilled water, slides were immersed 
in Trilogy™ pre-treatment solution and incubated at 96°C for 30 minutes for 
epitope retrieval. After this, the slides were allowed to cool down and were 
washed in phosphate buffered saline (PBS) for 10 minutes. Peroxide block™ 
solution was then added and samples were incubated for 20 minutes. 
Another PBS wash was performed for 5 minutes. Next, the primary antibody 
solution (same concentrations as those described above) was placed onto 
the samples and incubation for 20 minutes was allowed at room temperature. 
Slides were washed in PBS for 5 minutes. HiDef Detection™ amplifier 
(secondary antibody solution) was then applied to the slides and they were 
incubated for 15 minutes. After a 5-minute PBS wash, the former step was 
repeated using HiDef Detection™ detector (a horseradish peroxidase 
polymer solution). Again, the slides were washed in PBS for 5 minutes. 
Finally, colour development was performed by incubating the slides with DAB 
substrate™ chromogen for 3 minutes. Stained slides were counterstained 
with haematoxylin, dehydrated and mounted as described earlier. Lastly, 
slides were photographed at 200x and 400x magnification using an Axio 
Scope.A1 microscope coupled with an AxioCam HRc camera (Zeiss, 
Oberkochen, Germany). These digital images were used for electronic 
scoring. Noteworthy, some samples were stained using both the protocol 
described here and that in the previous section in order to confirm that the 
staining pattern was similar. These comparative staining procedures were 
performed at different time points during the research and the results are 
discussed in the respective chapters (Chapters 3 and 6).  
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2.7. Quantitative-polymerase chain reaction (qPCR) 
 
RNA extraction from tissues  
 
Each tissue sample was taken from the -80°C freezer and defrosted 
on ice. Fragments of 20 to 30 µg of tumour or adjacent tissue samples were 
used, as recommended by the manufacturer of the RNA extraction kit 
(RNeasy® Mini Kit, Qiagen, Hilden, Germany). Regarding normal control 
samples, as these were collected by colonoscopy-guided forceps biopsies 
which yield very small fragments, we used all the material available for each 
case, usually 7 to 10 µg of tissue. Samples were placed into 1.5mL tubes 
containing 600µL of buffer RLT (proprietary solution rich in guanidine 
isothiocyanate) and were disrupted using a rotor-stator homogeniser 
(TissueRuptor®, Qiagen, Hilden, Germany) using short pulses of 30 seconds 
to avoid overheating the sample. The lysate was centrifuged at full speed for 
3 minutes. The supernatant was carefully removed by pipetting and this was 
transferred into a new microcentrifuge tube. One volume of 70% ethanol was 
added and the solution was gently mixed by pipetting. Up to 700µL of this 
sample was then transferred to an RNeasy spin column, which was placed 
into a 2mL collection tube and centrifuged at ≥ 8000x g for 15 seconds. The 
flow-through was discarded and on-column DNase treatment was performed 
as follows: 350µL of buffer RW1 (proprietary ethanol solution rich in 
guanidine salt) was added to the column, which was centrifuged at ≥ 8000x g 
for 15 seconds and the flow-through was discarded. The DNase incubation 
mix was prepared by adding 10µL of DNase I stock solution and 70µL of 
buffer RDD, a proprietary solution to provide conditions for efficient on-
column DNA digestion (both reagents provided in the RNase-free DNase Set, 
Qiagen, Hilden, Germany). This solution was placed onto the column and left 
on the bench top for 15 minutes. After this, 350µL of buffer RW1 was added 
to the column, centrifuged at ≥ 8000x g for 15 seconds and the flow-through 
was discarded. After DNase treatment, 500µL of buffer RPE (proprietary 
washing buffer containing ethanol) was added to the column and centrifuged 
at ≥ 8000x g for 15 seconds. This step was repeated with the same volume 
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of buffer RPE and centrifuged at ≥ 8000x g for 2 minutes in order to dry out 
the column membrane and remove any residual ethanol. Finally, the spin 
column was placed in another clean and labelled tube and 30µL of RNase-
free water was added to the column to elute the RNA. The column/tube set 
was centrifuged at ≥ 8000x g for 1 minute to collect the eluted RNA. This step 
was repeated using the collected eluate in order to increase RNA 
concentration. Extracted RNA samples were stored at -80°C until use.  
 
RNA extraction from cell lines 
   
The extraction of RNA from cells lines was also performed using the 
RNeasy® Mini Kit. Procedures were essentially the same as described for 
tissue samples, except the initial tissue disruption step. Instead, cells were 
harvested by trypsinisation. Then, approximately 2.0 x 106 cells were 
centrifuged at 300x g for 5 min and the supernatant was discarded. Next, 
350µL of buffer RLT were added to the pellet, vortexed and homogenised 
using a rotor-stator. Subsequently, 350µL 70% ethanol was added to the 
homogenate and mixed by pipetting. Thereafter, RNA extraction procedures 
followed the same steps described previously.  
 
Assessment of RNA quality 
 
RNA quality was assessed in terms of quantity, purity and integrity 
prior to any downstream applications. Quantity and purity were analysed by 
measuring the absorbance of the RNA solution using a NanoDrop 2000® 
spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). Two 
microlitres of each sample were placed in the optical pedestal and the 
absorbance at 260nm and 280nm was measured. An absorbance of 1.0 at 
260nm is equivalent to approximately 40 ng/µL of RNA. An A260/280 ratio 
between 1.8 and 2.2 indicates “pure” RNA. In this study, only samples with 
more than 50 ng/µL RNA concentration and with A260/280 readings between 
1.9 and 2.1 were used. RNA integrity was assessed by the use of a 
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denaturing “bleach” agarose gel electrophoresis according to a published 
protocol (Aranda et al., 2012). The presence of bands corresponding to 28S 
and 18S ribosomal RNAs was assessed. Only samples with distinct 28S and 
18S bands in an intensity ratio of approximately 2:1 were used.  
 
First strand cDNA synthesis 
 
After RNA extraction, the next step was the synthesis of the 
complementary DNA (cDNA). For this purpose, we used the TaqMan® 
Reverse Transcription Reagents kit (Applied Biosystems, Carlsbad, CA, 
USA) according to the manufacturer´s protocol, as below: 
For each cDNA synthesis reaction (20 µL final volume), we added 
2.0µL of 10x RT buffer, 1.4µL of 25mM MgCl2, 4.0µL of 10mM dNTP mix, 
1.0µL of RNase inhibitor (20U/µL), 1.0µL of MultiScribe™ Reverse 
Transcriptase (50U/µL), 1.0µL of 50 µM Oligo d(T)16 and the RNA template. 
Nuclease-free water was added to make up to the final volume. Although the 
manufacturer states that up to 1µg of RNA can be used per reaction, 
excessive amounts of extracted RNA can cause problems. The presence of 
RT inhibitors mainly due to the carry-over of contaminants or internal 
inhibitors can affect RT efficiency (Pugniere et al., 2011, Bustin et al., 2015). 
Quantities of RNA less than the maximum 1µg may render some RT 
reactions more efficient. For this reasons, it is suggested that each 
researcher test the efficiency of the RT kit with different amounts of RNA 
input, a recommendation supported by the manufacturer of the kit used in 
this research (“Relative Gene Expression Workflow document”, available at 
http://tools.thermofisher.com/content/sfs/brochures/cms_075428.pdf, last 
accessed in 29/12/15). Therefore, we determined the reverse transcription 
dynamic range as per the protocol provided by the document above. Briefly, 
we carried out RT reactions using a serial dilution of RNA input, from 1µg to 
62.5ng (i.e. from 1/1 to 1/16 of the maximum recommended quantity). The 
cDNA generated from these diluted samples was then assessed by qPCR 
and standard curves were produced so that the efficiency of the RT reactions 
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using different RNA input was verified. These procedures were performed for 
all the biomarkers that we intended to test. These experiments established 
that RNA input of approximately 300ng was the appropriate amount for cDNA 
synthesis. Consequently, all cDNA produced from human samples was 
derived from reactions of 20µL using 300ng of RNA as template.  
 
qPCR equipment and reagents 
 
Quantitative PCR reactions were performed using the 7500 Fast Real-
Time PCR System (Applied Biosystems, Foster City, CA, USA). All reactions 
were carried out in triplicate. Non-template controls (no cDNA added) were 
used in every qPCR run. For each reaction, the following reagents were 
used: 10µL of TaqMan® Fast Advanced Master Mix; 1µL of TaqMan® Gene 
Expression Assay (detailed below) for the target; 1µL of TaqMan® Gene 
Expression Assay for the endogenous control (ACTB) as a duplex reaction; 
2µL of diluted cDNA template and 6µL of nuclease-free water to complete the 
final volume of the reaction. Given the extreme sensitivity of qPCR, many 
researchers recommend that the cDNA produced during the reverse 
transcription be diluted before using it for gene expression assessment. This 
can decrease the presence of PCR inhibitors from the RT step in the same 
way explained earlier and allow the use of minor quantities of precious 
samples per reaction. However, overdilution can cause a given sample to 
reach the exponential phase of amplification too late during the PCR (after 
cycle 35, for example), thus impairing the accuracy of the method. To define 
the optimal cDNA dilution for our experiments, we tested different 
concentrations of cDNA samples using assays for all targets in order to make 
sure the threshold cycle (Ct) was between cycles 15 and 30. In these 
experiments, we used cDNA in the following dilutions: 1:1, 1:2, 1:4, 1:8 and 
1:16. The results of this evaluation demonstrated that all dilution factors were 
suitable for the analysis (see Chapter 4), and we chose the dilution factor 1:4 
to be used in subsequent qPCR experiments. TaqMan® Gene Expression 
Assays were used in this work. These “single-tube assays” contain a set of 
primers (reverse and forward), a fluorescent probe specific to the gene 
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sequence being studied and an optimised buffer. The specifications of the 
assays used are described in the table below: 
 
Table 2.3. Specifications of the TaqMan® gene expression assays used in this 
experiment. Beta-actin was used as the reference gene (or internal control). 
Gene 
Symbol 
Entrez Gene 
ID 
Description NCBI 
Location 
Chromosome 
TaqMan® assay Id(*) 
CTNNB1 1499 catenin (cadherin-
associated protein), 
beta 1 
Chr.3: 
41240942 - 
41281939 
Hs00355049_m1 
NAP1L1 4673 nucleosome 
assembly protein 1-
like 1 
Chr.12: 
76438672 - 
76478738 
Hs00748775_s1 
RPL6 6128 ribosomal protein 
L6 
Chr.12: 
112842994 - 
112847443 
Hs03044365_g1 
PHB 5245 prohibitin Chr.17: 
47481420 - 
47492242 
Hs00855044_g1 
ACTB  60 actin, beta Chr.7: 
5566779 - 
5570232 
Hs99999903_m1 
* Primer and probe sequences for pre-optimised TaqMan® assays are patent-
protected. Therefore, the assay Id is mentioned. 
 
Cycling conditions were as follows: 1 initial hold for 2 minutes at 50ºC 
for uracil-N glycosylase (UNG) incubation; 1 hold for 20 seconds at 95ºC 
(polymerase activation), 40 PCR cycles of 3 seconds at 95°C (denaturation) 
followed by 30 seconds at 60°C (annealing/extension). These conditions are 
specific for the use of TaqMan® Fast Advanced Master Mix. 
 
Data analysis 
 
Results were produced using the method of comparative CT, also 
referred to as the 2-ΔΔCT method (Livak and Schmittgen, 2001, Schmittgen 
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and Livak, 2008). This is a relative quantification technique in which the 
difference in the expression of the gene of interest in different conditions is 
assessed relative to some housekeeping gene (also known as endogenous 
control or reference gene). Details of the procedures involved in the qPCR 
analyses are presented in the dedicated chapter along with the results and 
discussion (Chapter 4). 
 
2.8. Cell culture and RNA interference experiments 
 
Cell line 
 
CRC cell lines have been widely used in studies assessing tumour 
biology, drug response and biomarkers (Mouradov et al., 2014). HCT116 
cells are derived from a colonic adenocarcinoma removed from a male 
patient (Ilyas et al., 1997, Morin et al., 1997). In this study, both TP53 wild-
type and TP53 null HCT116 cells were used (Bunz et al., 1998). Cell lines 
were provided by Professor Bert Vogelstein (Johns Hopkins University, 
USA). 
 
Culture reagents and protocol 
 
The reagents and conditions used for cell culture are described below: 
 
Growth medium: McCoy´s 5a + Glutamax™ medium (Gibco®) + 10% heat-
inactivated foetal bovine serum (Gibco®) + 100 units/ml penicillin + 100µg/ml 
streptomycin (Sigma®). 
 
Protocol: 
 A vial containing 1 x 106 cells was taken out of the liquid nitrogen and 
thawed in a 37°C water bath. Cells were then re-suspended in 15mL of 
growth medium and transferred into a 75 cm2 flask. The flask was placed into 
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a 5% CO2 incubator at 37°C. Next day, the growth medium was replaced to 
avoid toxicity caused by the DMSO contained in the freezing medium. When 
70-90% confluence was achieved, growth medium was aspirated and 
discarded. The cell layer was briefly rinsed with 5mL of PBS (Gibco®) and 
cells were detached from the flask by trypsinisation using 5mL of 0.25% 
trypsin-EDTA (Sigma®). When the cells were dispersed, 5mL of complete 
growth medium was added and the cells were collected by gentle pipetting. 
Then, 1mL of cell suspension was added to a new flask and completed with 
growth medium to 15mL. Flasks were placed into a 5% CO2 incubator at 
37°C. Growth medium was changed every 48 hours if split confluence had 
not been reached. 
 
Transfection reagents and protocol 
 
Transfection conditions previously optimised in our laboratory were 
used in these experiments. All transfection reagents were purchased from 
GE Dharmacon™ (Lafayette, CO, USA). Specific siRNAs (ON-TARGETplus 
SMART pool siRNA®) targeting NAP1L1 (product number L-017274-01-
0005) and RPL6 (product number L-012955-00-0005) were used. 
Additionally, a GAPDH-directed siRNA pool (product number L-001830-10-
05) and a non-targeting (scrambled) siRNA pool (product number L-001810-
10-05) were also used as positive and negative controls, respectively. The 
delivery of siRNA to cells is impaired by its negative charge which hinders 
cell membrane penetration. In addition, the presence of RNAses in the 
culture medium also makes the use of siRNAs challenging. To circumvent 
these issues, methods of nucleic acid delivery have been developed such as 
viral vectors, electroporation and liposomal delivery (Gao and Huang, 2009). 
GE Dharmacon™ offers liposomal-based transfection reagents (TRs) 
optimised for siRNA experiments using different cell lines. The company 
suggests Dharmafect 2® (hereafter referred to as TR2) as the ideal medium 
for transfecting HCT116 cells. Therefore, this was the selected option.  
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Using the same reagents described in the “Culture reagents and 
protocol” section above, we prepared distinct culture media to be used in the 
transfection procedures, as below: 
 
- Complete medium: same components described as “growth 
medium” above, used for maintaining cells before transfection;  
- Antibiotic-free medium: same components of “complete medium” 
except the antibiotics. This medium was used 24 hours before, 
during and after transfection, as cell membranes become very 
permeable to various substances, including antibiotics, upon the 
use of transfection reagents. This may cause excessive cell toxicity 
and should be avoided; 
- Serum-free medium (glutamine only): used for preparing and 
diluting the siRNAs before adding the solution to the antibiotic-free 
medium.  
 
The protocol used for siRNA transfection is summarised below: 
a. Initially, lyophilised siRNA pools were resuspended in 1x siRNA buffer 
at 20µM stock concentration and analysed in a Nanodrop™ to 
ascertain the RNA concentration. This solution may be kept at 4°C for 
up to 6 weeks or aliquoted and frozen (-20°C);  
b. Cells reaching 70-80% confluence were trypsinised, detached and 
counted using a Bio-Rad TC10™ Automated Cell Counter;  
c. Using 6-well culture plates, 300,000 cells per well were allowed to 
attach for 24 hours in 2mL of antibiotic-free medium;  
d. Next day, siRNA reagent was prepared by diluting the 20µM stock 
solution in 1x siRNA buffer to a concentration of 5µM. In separate 
tubes, working siRNA and TR2 solutions were prepared (volumes per 
well): 
Tube A: siRNA solution: 20µL of 5µM siRNA were added to 180µL 
of serum-free medium, gently mixed and incubated for 5 minutes;  
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Tube B: TR2 solution: 4µL of TR2 were added to 196µL of serum-
free medium, gently mixed and incubated for 5 minutes; 
e. The contents of tubes A and B were added, gently mixed and 
incubated for 20 minutes; 
f. 1.6mL of antibiotic-free complete medium was added and gently 
mixed. Final transfection solution contained siRNA at 50nM;  
g. Culture medium in plate wells was aspirated and discarded. Then, 
2.0mL of the transfection solution was added to each well; 
h. Cells were incubated in a 5% CO2 incubator at 37°C; 
i. Cells were harvested by trypsinisation, counted as above and kept on 
ice until final use.  
 
All the transfection procedures were carried out using NAP1L1, RPL6, 
GAPDH and non-targeting siRNAs, and included both TP53 wild-type and 
null HCT116 cells. Additionally, non-transfected cells were analysed 
alongside to assess the toxicity caused by the transfection substances. 
Experiments were run in duplicate for each condition. Quantitative PCR was 
used to confirm knockdown efficiency. From reagent preparation to cell 
handling, all procedures were performed in sterile conditions within tissue 
culture hoods.   
 
Sulforhodamine B proliferation assay 
 
Sulforhodamine B (SRB) assay is a widely used proliferation test 
based on the estimation of cellular density via the determination of total 
protein content in culture plate wells (Vichai and Kirtikara, 2006). In this 
study, HCT116 cells (TP53 wild-type and null) underwent siRNA experiments 
as described above. After 48 hours of incubation with the transfection 
reagents, cells were harvested, counted and used in SRB assays as 
described below (Vichai and Kirtikara, 2006): 
a. Cell suspension concentrations were adjusted to 1,000 cells per 
100µL using complete medium; 
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b. Using 96-well plates, 100µL of cell suspension from each condition 
was added to plates in 6 replicate wells. The format was set as 
untransfected, non-targeting siRNA and targeting siRNA in 
adjacent columns. NAP1L1- and RPL6-silenced cells were 
assessed in separate plates. Three plates were used for each 
protein in order to assess SRB staining 24, 48 and 72 hours after 
plating; 
c. Plates were incubated at 37°C in 5% CO2. At the time-points above 
mentioned, a plate for each protein was collected and fixed, as 
below: 
- Without removing the medium, 100µL of cold 10% 
trichloroacetic acid (Sigma) was added to each well and 
incubated at 4ºC for 1 hour; 
- Plates were then washed in slow-running tap water. 
Excess water was removed using paper towels. Plates 
were allowed to air dry overnight and were stored until 
the last plates were fixed; 
d. When all plates had been fixed and dried, SRB staining was 
performed: 
- 100µL of 0.4% SRB (Sigma) in 1% acetic acid (Fisher 
Scientific UK) was added to each well and incubated at 
room temperature for 30 minutes; 
- Plates were rinsed 4 times with 1% acetic acid solution. 
Excess liquid was removed using paper towels; 
e. A basic solution (200µL of 10mM Tris base solution, pH 10.5, 
Sigma) was added to each well and incubated in an orbital shaker 
for 5 minutes; 
f. Optical density was measured at 510nm using a Tecan Sunrise™ 
96-well plate reader. Signal-to-background ratios were calculated. 
 
Gene expression array plates 
 
In order to explore possible effects of our biomarkers on other CRC-
related genes and pathways, we decide to test how gene silencing via siRNA 
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targeting our candidates would affect the expression of a collection of genes 
known to be involved in CRC development. To achieve this, gene candidates 
whose silencing resulted in impaired cell proliferation were identified in the 
siRNA experiments described above. Then, RNA was extracted and cDNA 
was synthesised according to the protocols explained in section 2.6. These 
cDNA samples were loaded into Human Developmental Phases of Colorectal 
Cancer® array plates (Applied Biosystems, Carlsbad, CA, USA) and run in a 
7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, 
USA), using the cycling conditions recommended by the plate manual. 
Details of these experiments, including the genes assessed, are described in 
the corresponding sub-chapter (section 4.6.3).  
 
2.9. ELISA 
 
Sample collection, processing and storage 
 
Blood samples were collected from healthy controls, individuals with 
colorectal adenoma or colorectal cancer patients and processed no more 
than 5 hours after collection. For serum extraction, blood was collected in 
anticoagulant-free Vacutainer tubes (Becton Dickinson). Tubes were left 
undisturbed at room temperature for at least 30 minutes until a firm clot had 
been formed. Next, each tube was centrifuged at 2,000x g for 10 minutes at 
4ºC. The supernatant (serum) was transferred into cryovials and was stored 
in -80°C freezers until use or shipping. For plasma extraction, EDTA-treated 
Vacutainer tubes were used. Tubes were centrifuged for 10 minutes at 
2,000x g. The supernatant (plasma) was carefully transferred into cryovials 
and stored as describe for serum. Samples collected in Brazil were 
transported to the UK by a company that specialised in biological sample 
transportation (Biocair International Ltd) and were kept under freezing 
temperatures during the entire shipment time by the use of dry ice. Upon 
arrival at the destination, samples were immediately placed in scientific 
freezers at -80°C. The source and number of samples used in this research 
are detailed in the dedicated chapter covering immunoassays (Chapter 5). 
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Assay procedure 
 
On the day of the first experiment, samples were defrosted and kept 
on ice. Each sample was aliquoted into several cryovials, each one 
containing 120µl of serum or plasma. The aliquots to be used immediately 
were diluted at 1:3 using sterile PBS, and were used in the ELISA 
experiments. All remaining aliquots were placed in the -80°C freezer for later 
use. In subsequent experiments, individual vials were defrosted, diluted as 
described and totally used (any leftover was discarded), thus avoiding 
several freeze-thaw cycles. 
Although we tested various ELISA kits from different manufacturers, 
they all shared almost identical assay protocols. General procedures for the 
ELISA experiments are summarised below (all solutions provided with the 
kits): 
1. Prepare all reagents, samples and standards; 
2. Add 100µl of standards or samples to each well. Incubate for 
2 hours at 37°C; 
3. Aspirate and add 100µl of prepared Detection Reagent A. 
Incubate for 1 hour at 37°C; 
4. Aspirate and wash 3 times; 
5. Add 100µl of prepared Detection Reagent B. Incubate for 30 
minutes at 37°C; 
6. Aspirate and wash 5 times; 
7. Add 90µl of Substrate Solution. Incubate for 15-25 minutes at 
37°C (do not exceed 30 min); 
8. Add 50µl of Stop Solution. Read plate at 450nm.  
 
ELISA plates were read using a Tecan Sunrise™ 96-well plate reader 
at 450nm. Results were produced by loading plate results (raw readings) into 
an online ELISA results tool (www.elisaanalysis.com). The chosen method of 
analysis was the four-parameter logistic (4PL) regression model. 
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2.10. MSD-based electrochemiluminescence 
 
Due to poor inter-plate reproducibility and low sensitivity demonstrated 
by the NAP1L1 ELISA kits used, the development of an in-house assay was 
added to the aims of this research project. The platform chosen was 
electrochemiluminescence using equipments and reagents provided by Meso 
Scale Discovery® Inc (MSD). This platform allows the development of 
immune-based assays with high sensitivity and specificity, and a wide 
dynamic range. All the procedures performed and the results produced are 
presented in a dedicated sub-chapter within this thesis (Chapter 5, section 
5.5). 
 
2.11. Statistical analysis 
 
Several types of data were produced during this research. Continuous 
numerical variables (intervals or ratios) were first assessed regarding 
normality (Kolmogorov-Smirnov test) and homogeneity of variance (Levene´s 
test). When the parametric assumption was met, comparisons between 
groups were performed by using Student´s t-tests (two groups) or analysis of 
variance – ANOVA (three or more groups). Tukey´s HSD test (for equal 
variances) or Dunnett´s T3 test (for unequal variances) was used for pair-
wise comparisons in this case. Alternatively, when normality could not be 
ascertained, non-parametric tests were used: Mann-Whitney U test (for 
comparing two groups) or Kruskal-Wallis test (for three or more groups). 
Dunn-Bonferroni test was the post-hoc comparative test of choice in the latter 
case. Correlation between continuous variables was assessed by using 
Pearson´s (for parametric data) or Spearman´s (for non-parametric data) 
correlation coefficients. 
Categorical data were compared using the Chi-square test (or Fisher´s 
exact test in case of less than five expected counts per cell in the 
contingency table). 
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For the survival analysis, groups were assessed using the Kaplan-
Meier method, and survival curves were compared by log-rank tests. When 
significant differences were observed, Cox proportional hazards model was 
used for multivariate analysis. 
Two-sided p values <0.05 were accepted as significant in the entire 
study. All statistical analyses were performed using the software IBM® 
SPSS® Statistics version 22. 
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Chapter Three: 
Immunohistochemical validation 
of the candidate biomarkers in 
human tissues 
  
119 
 
3. CHAPTER 3 – IMMUNOHISTOCHEMICAL VALIDATION OF THE 
CANDIDATE BIOMARKERS IN HUMAN TISSUES 
 
3.1. Introduction  
 
Previous research conducted in our group using animal models of 
CRC based on Apc inactivation found potential biomarkers that were 
differentially expressed in tissues and blood from affected mice (Ibrahim, 
2014, Hammoudi et al., 2013). If also present in human CRC samples, these 
alterations could potentially be useful in clinical practice as diagnostic tools. 
Furthermore, a biomarker may be used as a prognostic or predictive test, 
when it provides information regarding clinical outcome or response to 
specific treatments, respectively (Pritzker, 2015). Despite extensive research, 
few cancer biomarkers have hitherto progressed from basic research to the 
clinic (Diamandis, 2014). In this context, proteomic approaches such as the 
methods used in our previous work are amongst the most promising 
strategies for biomarker discovery (Li and Chan, 2014, Tjalsma, 2010, 
Alvarez-Chaver et al., 2014, de Wit et al., 2013).  
Immunohistochemistry has recently become a widespread ancillary 
technique in histopathology (Lin and Chen, 2014). It is an inexpensive, 
reproducible, and widely available method for assessing protein content and 
localisation in cells and tissues. The technique has played a very important 
role in the identification of diagnostic, prognostic or predictive markers in 
many types of cancer (Chamberlain et al., 2015, Zaha, 2014, Toffart et al., 
2014, Varma and Jasani, 2005). In CRC patients, IHC has mainly been used 
for assessing the status of various mismatch repair proteins (MLH1, MSH2 
and MSH6) either as a screening procedure for hereditary non-polyposis 
colorectal cancer (HNPCC) (Steinhagen et al., 2012) or for prognostic 
stratification (Yoon et al., 2011). Several proteins have been tested in CRC 
tissues for their diagnostic or prognostic significance, although none has 
become a standard biomarker.  
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The aim of this chapter is to assess the immunohistochemical 
expression of selected candidate biomarkers in tissues from individuals with 
colorectal adenoma, cancer and normal controls. Additionally, in order to 
validate the candidates in different populations (with different ethnicity and 
genetic background), we used samples collected from health services in 
Brazil and in the UK, as detailed in Chapter 2 - Methods. For this purpose, 
we tested different scoring systems to assure accuracy, reproducibility and 
practicality. The process of selection and optimisation of an appropriate 
scoring method is described below. 
 
3.2. Scoring systems: development, testing and optimisation 
 
Despite being a powerful research and clinical technique, IHC has 
several potential pitfalls. Its performance is affected by many conditions, from 
sample collection and fixation to the final analytical steps (Lin and Chen, 
2014). In addition, a standardised scoring system must, ideally, be used to 
increase objectivity and to assure the reproducibility of the method (Taylor, 
2014). Unfortunately, none of the biomarkers evaluated in this project has an 
accepted scoring method. Among these proteins, β-catenin has been the 
most assessed in immunohistochemical studies. It has been evaluated both 
in colorectal cancer (Chen et al., 2013, Morikawa et al., 2011, Bruun et al., 
2014) and in other neoplasms (Cuello-Carrion et al., 2015, Xu et al., 2015, Li 
et al., 2014a, Li et al., 2014b). However, there has been no agreement as to 
the best way of scoring tissues stained for β-catenin expression. 
Researchers have used a variety of quantitative or semi-quantitative methods 
for analysing the cytoplasmic or nuclear presence of this protein (Morikawa et 
al., 2011, Chen et al., 2013, Yoshida et al., 2015). Recent evidence suggests 
that the translocation of β-catenin into the nucleus is the critical event for 
colorectal carcinogenesis and that nuclear localisation is associated with 
tumour aggressiveness and poor survival (Yoshida et al., 2015, Chen et al., 
2013). Therefore, for scoring β-catenin-stained animal tissues, our group has 
been using a system which takes into account the nuclear/cytoplasmic 
balance of staining (Ibrahim, 2014), as explained later.  
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Regarding the other biomarkers included in this study, most of them 
have been poorly evaluated by IHC to date or have not been evaluated at all 
(this will be further explored in the next sections). Our previous data 
suggested that most of these proteins also exhibited a nuclear/cytoplasmic 
imbalance in animal models of CRC. For that reason, in the absence of an 
established scoring method and taking into account the fact that these 
candidate biomarkers were derived from Wnt activated systems (as is the 
case for β-catenin itself), we decided to explore the nuclear/cytoplasmic 
localisation of these proteins as well.  
We tested different means of scoring, from manual to electronic 
counting, and the results obtained using these different methods were 
compared in order to maximise objectivity and reproducibility. The process of 
development and optimisation of the scoring systems is presented below.  
 
A modified H-score obtained by manual counting of individual cells  
 
In pathology and research practice, most IHC slides are currently 
evaluated by a pathologist or investigator by visual inspection under a light 
microscope. In general, a scale-based scoring system is used to describe 
these observations. The first popular scoring protocol was the H-score which 
was proposed by McCarty et al. in 1986 (McCarty et al., 1986). This method 
is based on a semi-quantitative assessment of staining intensity and 
distribution, and uses a mathematical formula to produce a final score. Later, 
a simpler scoring system gained popularity: the Allred- or quick-score 
(Harvey et al., 1999). This procedure also assigns scores for the intensity 
and proportion of staining, but simply sums the values to produce a general 
score. 
In this research, we started the work by scoring each slide using a 
method developed in our group for β-catenin-stained tissues, adapted from 
the H-score. It takes into account the intensity and localisation of the protein 
in the membrane, cytoplasm and nucleus of cells, and will hereafter be 
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referred to as a “modified H-score”. Score 0 represents a low level or 
negative staining of both the nucleus and the cytoplasm, with membranous 
staining only being observed; score 1 indicates increased staining of the 
cytoplasm, but little or no staining of the nucleus (cytoplasmic localisation); 
score 2 represents positive and equal staining of both the cytoplasm and the 
nucleus, and score 3 denotes strong nuclear staining, darker than that 
present in the cytoplasm (nuclear localisation). For this assessment, we used 
the scientific image manager ImageJ – an open-source software provided by 
the US National Institutes of Health that has been widely used for more than 
25 years (Schneider et al., 2012) and which is publicly available via 
rsbweb.nih.gov/ij/ (last accessed in 26 September 2015). The “Cell Counter” 
plugin was used to individually score all identifiable target cells within the field 
(a minimum of 100 cells per field). After this, an overall score was generated 
using the formula: modified H-score = [(proportion of 0) x 0] + [(proportion of 
1) x 1] + [(proportion of 2) x 2] + [(proportion of 3) x 3], with final scores 
ranging from 0 to 3. Figure 3.1 illustrates patterns of staining corresponding 
to different scores. 
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Figure 3.1. Modified H-score system explained. (A-D): tissues exhibiting relatively 
homogeneous staining patterns exemplifying modified H-scores of 0 (A, normal 
tissue), 1 (B, cancer), 2 (C, cancer) or 3 (D, cancer) (magnification: 200x). (E): 
tissue showing a much more common (heterogeneous) staining pattern (original 
magnification: 400x). In all cases, each individual cell in the field was assessed and 
assigned a score from 0 to 3 as seen in F (magnified image to show the scoring 
marks).  
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Using this method, we initially scored the UK-cohort of samples that 
had been stained for β-catenin, NAP1L1 and RPL6. In order to assess the 
reproducibility of the technique, two different researchers (Cleberson Queiroz 
(CQ) and Nadeem Al-Khafaji (NA)) performed the scoring separately. Both 
individuals are not trained pathologists. Therefore, the scoring process 
started after a brief period of training under the supervision of Dr Timothy 
Andrews (Liverpool – UK). During two days, the mentioned professional 
provided guidance for the correct identification of target areas in IHC slides. 
Tissue microarrays containing the samples were sectioned and stained 
according to the protocol described in Chapter 2 - Methods. After that, 
stained slides were scanned at 200x magnification using the Aperio 
SlideScanner platform (Leica Biosystems, Milton Keynes, UK). The modified 
H-score was calculated as explained above. Two fields were analysed for 
each sample. For this preliminary analysis, we divided the UK-cohort into the 
following groups, according to the pathologic diagnosis: normal adjacent 
colonic tissue, low-grade adenoma, high-grade adenoma, polyp cancer and 
cancer (subdivided into its different stages). As can be seen in figure 3.2, the 
final median scores produced by the two researchers exhibited similar 
patterns for the proteins tested. However, some discordant results were 
produced. Due to the fact that the trend was similar for most markers, a 
mean of the scores from both investigators was generated and this was used 
for the statistical analysis presented later. Consequently, the 
immunohistochemical analyses shown in the next sections for β-catenin, 
NAP1L1 and RPL6 relative to the UK-cohort were performed using the 
method described above. Unfortunately, several blocks retrieved from the 
Countess of Chester hospital, and that were used for the construction of the 
TMA, had insufficient target tissues to allow their use for the evaluation of the 
other candidates. As a result, the assessment of the remaining proteins was 
limited to analysis of the Brazilian cohort. 
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Figure 3.2. Comparison between 
the manual modified H-scores 
produced by two different 
researchers. On the x axis, the 
cases are divided into groups 
according to the pathologic 
diagnosis: normal adjacent colonic 
tissue; low-grade adenoma (LGA); 
high-grade adenoma (HGA); polyp 
cancer; invasive cancer (stages I, 
II, III and IV). Red boxes represent 
the scores from CQ, whereas 
green boxes indicate the scores 
from NA. The scatter-plot 
represents scores for individual 
cases. β-catenin scores from both 
researchers were highly consistent 
and similar, except for later 
stages. Regarding NAP1L1 and 
RPL6, the trend of modification in 
the scores from normal to cancer 
tissues is clearly the same 
according to the evaluation by 
both researchers. However, a 
difference in median scores is 
noted. Boxplots represent 
medians and interquartile ranges. 
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Analysing the nuclear and cytoplasmic expression of the biomarkers 
using electronic scoring tools 
 
Despite being accepted scoring methods, H-score and quick-score (or 
any other procedures derived from them) have important and common 
pitfalls. They are time-consuming and, most importantly, are influenced by 
the visual perception of the observer (Varghese et al., 2014, Jaraj et al., 
2009, Taylor, 2014). As a result, minor differences in colour development 
time during the IHC assay or in haematoxylin counterstaining can affect the 
final score. Additionally, a long and intensive training in histopathology is 
necessary to decrease the degree of subjectivity in this analysis, although in 
specific situations, even trained medical pathologists exhibit a large inter-
observer variability when assessing IHC markers (Jaraj et al., 2009). 
For all these reasons, electronic tools for the automatic scoring of 
digital IHC images have been developed (Rizzardi et al., 2012). Most scoring 
softwares use the colour deconvolution algorithm, in which the brown staining 
produced by DAB is separated from the blue counterstaining from 
haematoxylin resulting in two separate images (Helps et al., 2012, Ruifrok et 
al., 2003, Ruifrok and Johnston, 2001), although alternative methods based 
on statistical modelling have recently been reported (Shu et al., 2016). The 
majority of these modern systems are expensive, use dedicated software and 
hardware, and require extensive pre-testing optimisation. These features 
have prevented the widespread use of this technology (Varghese et al., 
2014). Nonetheless, there are a few simpler, free-of-charge applications 
available which are intended to facilitate the process of IHC scoring. These 
packages use the same colour deconvolution algorithm and do not require 
any proprietary programme or hardware. Some of these systems have been 
tested in various research scenarios and have been shown to have similar or 
better performances than visual scoring (Varghese et al., 2014, Tuominen et 
al., 2010, Sysel et al., 2013, Prasad et al., 2011, Hammes et al., 2007).  
Therefore, in order to improve the accuracy and objectivity of the 
assessment of our candidate biomarkers, we decided to test two electronic 
scoring systems using samples from the Brazilian cohort of patients. The 
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reason for testing two methods is because none of the available systems 
allows the measurement of both the nuclear and the cytoplasmic expression 
of proteins concurrently. Hence, we opted for testing these tools separately 
using different applications. For this purpose, we used two freely-available 
plugins developed for ImageJ: “IHC Profiler” and “ImmunoRatio”. The 
optimisation and testing process for each of these methods is explained 
below. 
 
The use of “IHC Profiler” for the cytoplasmic assessment of IHC stained 
slides 
 
In 2014, Varghese et al. published the results of the development and 
validation of an electronic plugin for automatic IHC scoring compatible with 
ImageJ – IHC Profiler (Varghese et al., 2014). The authors tested this tool in 
tissues stained for several markers in a large and diverse set of cancer 
samples obtained from the Human Protein Atlas database 
(http://www.proteinatlas.org). The plugin was based on the colour 
deconvolution process (as depicted in figure 3.3) and was shown to be highly 
accurate in the analysis of the images when compared with visual scoring by 
a pathologist.   
 
Figure 3.3. The colour deconvolution process used by the IHC Profiler plugin to 
generate separate images for DAB (brown) and haematoxylin (blue). Only the DAB-
stained image is assessed for stain intensity. The result is presented as the 
proportions of areas with high-positive, positive, low-positive or negative staining 
and a final result is provided. From (Varghese et al., 2014).  
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In order to test the suitability of IHC Profiler for the assessment of the 
expression of our biomarkers, we initially analysed the expression of β-
catenin in samples from the Brazilian cohort of patients. After staining 
according to the protocol previously described, each individual slide was 
analysed under the microscope and the images were recorded. Before 
actually analysing the image, we selected representative areas in the field of 
view in order to exclude as much non-target tissues (such as stroma, 
immune infiltrate, fat, staining artefacts, etc) as possible. This process is 
illustrated in figure 3.4.  
 
 
Figure 3.4. The selection of the target area to be analysed. As the plugins measure 
all stained areas in a field, images were edited in order to remove non-target tissues 
as shown in the picture. This procedure is important to reassure precision in the 
scoring process.  
 
Next, we analysed all the samples using the cytoplasmic channel of 
IHC Profiler. This is a very straightforward process and involves selection of 
the image, identification and removal of non-target areas and application of 
the plugin. The result is presented as the percentage of areas with negative, 
low-positive, positive and high-positive scores. Additionally, an overall result 
is provided using one of these categories. However, this “final score” is less 
sensitive than using the proportions as tissues with small but significant 
differences in the staining pattern may be categorised in the same group, as 
can be noted in figure 3.5. Therefore, in order to improve accuracy and allow 
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the identification of minor differences in tissue staining, we decided to ignore 
this overall score and use the proportions of different staining intensities to 
generate an H-score-like value, using a formula similar to the one that we 
previously used for the modified H-score in the analysis of the UK-cohort: 
modified IHC Profiler score = [(proportion of negative) x 0] + [(proportion of 
low-positive) x 100] + [(proportion of positive) x 200] + [(proportion of high-
positive) x 300], with final scores ranging from 0 to 300. 
 
Figure 3.5. Examples of cytoplasmic scoring results produced by IHC Profiler in β-
catenin stained tissues (original images are shown). Figure A represents normal 
colonic epithelium with a low proportion of “positive” and “high-positive” areas, as is 
expected for normal intestinal mucosa. B, C and D show cancer tissues with 
different staining patterns. Note that, although B and C exhibit clearly different 
staining patterns and proportional scores, both are equally classified as “positive” 
tissues. For this reason, we disregarded the final result and used the proportions to 
calculate an H-score-like value (continuous variable) using the formula described in 
the text above.  
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The last step in the process of testing the suitability of IHC Profiler for 
the analysis of our biomarkers was to compare the results obtained using this 
method and our former scoring system for β-catenin (visual modified H-
score), as well as other scoring results published in the literature. As will be 
presented in the next sections, the results obtained with IHC Profiler were 
concordant with the results from the modified H-score even when comparing 
samples obtained from different populations (UK and Brazil). These findings 
encouraged us to use IHC Profiler for the analysis of the cytoplasmic 
expression of our biomarkers in the Brazilian cohort.  
In the original publication, IHC Profiler was used for the evaluation of 
both cytoplasmic and nuclear markers (Varghese et al., 2014). However, in 
our study, we experienced problems when using the nuclear channel for the 
evaluation of our proteins. Despite the use of the threshold-setting function in 
the nuclear channel, the results were discordant compared to the visual 
inspection of the images and the visual modified H-score. As illustrated in 
figure 3.6, we found accurate results only when testing markers (not from our 
candidate list) that were exclusively expressed in the nucleus such as 
oestrogen receptor. We made contact with the researcher responsible for the 
development of the tool (Dr. Abhijit De, Molecular Functional Imaging Lab, 
ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, India – personal 
communication), and he confirmed that the tool could not be precise for 
“adapting proteins” which move from the cytoplasm to the nucleus and vice 
versa. Additionally, although there is no consensus in the evaluation of β-
catenin nuclear expression, the majority of studies included in a recent meta-
analysis of its prognostic significance in CRC measured the percentage of 
positive nuclei rather than the intensity of staining (Chen et al., 2013). The 
same seems to be the case for most nuclear biomarkers currently used in 
clinical scenarios such as oestrogen and progesterone receptors (Kurosumi, 
2003), and the proliferation marker Ki67 (Mu et al., 2015). Therefore, for the 
nuclear evaluation of our markers, we decided to test another ImageJ plugin: 
ImmunoRatio. 
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Figure 3.6. IHC Profiler nuclear analysis of oestrogen receptor and β-catenin. The 
plugin is highly accurate for the assessment of oestrogen receptor expression in 
breast cancer tissue as it is a nuclear exclusive marker (picture from the Human 
Protein Atlas, available at www.proteinatlas.org, last accessed in 10/06/17)(Uhlen et 
al., 2015). For β-catenin, although most nuclei were clearly negative or weakly 
positive, the result showed high proportions of “high-positive” and “positive” scores 
(CRC sample). Therefore, IHC Profiler was not considered a suitable tool for the 
assessment of the nuclear expression of our biomarkers.  
 
Assessing the nuclear expression of biomarkers using ImmunoRatio 
 
ImmunoRatio was developed in 2010 as, according to the authors, 
“the first publicly available, easily installable web-based application for the 
immunohistochemical analysis of nuclear markers, such as oestrogen and 
progesterone receptors and Ki67” (Tuominen et al., 2010). These markers 
were evaluated both visually by pathologists and using the plugin, and a very 
high correlation coefficient was reported. Later, its use was further tested for 
Ki67 immunostaining and expanded to other nuclear makers with good 
accuracy (Sysel et al., 2013). The application also uses the colour 
deconvolution algorithm for DAB-haematoxylin stain separation (Ruifrok and 
Johnston, 2001, Ruifrok et al., 2003) along with several optimising functions 
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such as blank field correction, background subtraction, adaptive thresholding 
and nuclear segmentation (Tuominen et al., 2010). These functions are 
illustrated in figure 3.7. Currently, ImmunoRatio can be used as an online tool 
or it can be freely downloaded as an ImageJ plugin at the University of 
Tampere (Finland) webpage link http://153.1.200.58:8080/immunoratio/ (last 
accessed in 26 September 2015). 
 
 
Figure 3.7. ImmunoRatio analysis algorithm. The several steps performed by the 
application during the assessment of an IHC stained image are summarised here. 
The final result is presented as a montage showing the original and final images, 
and the percentage of positive nuclear area. From (Tuominen et al., 2010). 
 
Despite the fact that ImmunoRatio was initially tested for nuclear 
exclusive markers, it can also be used for proteins that are present in both 
the cytoplasm and nucleus according to the information provided by the 
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research group that developed this plugin (Jorma Isola MD, PhD; Professor 
of Cancer Biology, University of Tampere - Finland, BioMediTech – personal 
communication). Before analysing the images, a threshold optimisation step 
is necessary. It allows the investigator to fine-tune the sensitivity of the 
method for the identification of the nuclear areas (based on the haematoxylin 
staining) and the positively stained areas (DAB staining), as depicted in 
figure 3.8. This process is usually performed using positive and negative 
control images, as well as a few test samples in order to assure that the 
score produced is consistent with the expected visual score for those images. 
In our study, we carried out the staining of all samples at the same time and 
using the same conditions for each particular marker. After the “thresholding” 
was complete, all images were scored using the same settings in order to 
guarantee comparability among the samples. As different makers were 
assessed following separate staining procedures, the process of thresholding 
was repeated accordingly for each protein.  
 
 
Figure 3.8. The sensitivity of the plugin can be fine-tuned using the built-in 
thresholding capability. These figures illustrate different results obtained when 
different DAB threshold values were applied. The same can be done for 
haematoxylin staining (not shown). 
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After the optimisation step, the samples from the Brazilian cohort of 
patients that had been stained for β-catenin were scored using ImmunoRatio 
and the results were compared with the modified H-score obtained from the 
UK-cohort and with the published literature. ImmunoRatio results showed 
high nuclear localisation of β-catenin in neoplastic tissues compared with the 
normal mucosa, thus reflecting exactly what was found using the modified H-
score and what is expected based on the literature (results will be presented 
in the next section). Therefore, we also used ImmunoRatio to score the other 
candidate biomarkers in the Brazilian cohort.  
 
3.3. Evaluation of β-catenin immunostaining confirms Wnt pathway 
activation in neoplastic tissues 
 
In this section, the results obtained during the analysis of β-catenin 
stained samples will be described. Data will be presented according to the 
hypotheses that were formulated. As explained in the previous sections, the 
results from the evaluation of the UK-cohort were obtained using the manual 
(or visual) modified H-score, whereas the results for the Brazilian cohort were 
obtained by electronic scoring using IHC Profiler and ImmunoRatio. When 
available, the results for both cohorts are compared. As the manual scoring 
results in a single value, we present it using a box-plot chart. However, the 
electronic scoring produced two values per image (cytoplasmic and nuclear 
scores separately). Therefore, we decided to use a dual bar-and-line graph 
with different colours to allow simultaneous visualisation of the results. Figure 
3.9 provides an example of β-catenin staining pattern in a CRC sample and 
the adjacent intestinal epithelium. 
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Assessment of β-catenin expression in adenomas, cancer and adjacent 
tissues – UK-cohort 
 
For the evaluation of the UK-cohort, we divided the samples into 4 
groups: adjacent non-neoplastic colonic mucosa, low-grade adenomas, high-
grade adenomas and invasive cancers. The aim of this analysis was to 
confirm Wnt pathway activation in our samples, therefore validating our 
scoring tools for the analysis of the remaining biomarkers. As can be noted 
when comparing these groups with those used in the preliminary testing and 
optimisation steps of the manual and electronic scoring methods (see figure 
3.2 in the previous section), we decided to make some modifications. The 
“polyp cancer” group - invasive cancers incidentally found after a 
polypectomy, was excluded due to the low number of samples and the 
heterogeneity of these cases in terms of staging. Additionally, the various 
Figure 3.9. An example of β-
catenin staining pattern. A 
predominantly membranous 
localisation is observed in the 
normal epithelium, whereas a 
strong cytoplasmic and 
nuclear staining is seen in the 
cancer cells. These tissues 
were collected from a patient 
with stage IV (Dukes’ stage D) 
CRC. Magnification: 630x.  
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cancer groups were amalgamated into a single group, as there were no 
apparent differences in the expression of the biomarkers across different 
cancer stages. As depicted in figure 3.10, the results showed a clear 
increase in modified H-score from the adjacent non-neoplastic colonic 
mucosa to the low-grade adenoma group, and this increase was sustained in 
more advanced neoplastic lesions (high-grade adenomas and invasive 
cancers). This denotes a translocation of the protein from the cell membrane 
into the cytoplasm and the nucleus and is a surrogate marker of Wnt pathway 
activation.  
 
Figure 3.10. Modified H-scores for β-catenin in the UK-cohort. A clear increase in 
cytoplasmic and nuclear protein localisation is seen from the earliest neoplastic 
stages, which is maintained in more advanced and invasive lesions. *** p<0.001 
(Kruskal-Wallis test followed by Mann-Whitney U test for post-hoc pair-wise 
comparisons and Bonferroni correction).  
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Assessment of β-catenin expression in cancer versus adjacent tissues 
– Brazilian cohort 
 
For the evaluation of the Brazilian cohort, we initially had only adjacent 
normal mucosa and tumour tissues. As the number of samples was higher 
compared to the UK-cohort, we decided to test again whether or not there 
was any difference in β-catenin staining across the different cancer stages. 
For this purpose, we split the samples into 2 groups: early stage, 
encompassing stages I and II (corresponding to Dukes’ stages A and B) and 
late stage, including stages III and IV (Dukes’ stages C and D).  
Despite the use of different scoring methods (as explained earlier) and 
a different patient population, the results exhibited in figure 3.11 showed the 
same pattern as was observed in the UK-cohort. A clear and statistically 
significant increase in both nuclear and cytoplasmic localisation of β-catenin 
was observed in cancer tissues compared to the adjacent mucosa. No 
difference was however seen when comparing early-stage versus late-stage 
cancer groups. These findings provided strong support for the use of this 
electronic scoring system to analyse the expression of the other biomarkers 
that we subsequently tested.  
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Figure 3.11. Electronic scoring of the Brazilian cohort stained for β-catenin. Blue 
bars represent the mean nuclear score obtained using the ImmunoRatio plugin. 
Green line represents the mean cytoplasmic score produced by the IHC Profiler 
plugin. Additional blue and green lines and asterisks show statistically significant 
differences between groups. Marked increases in both nuclear and cytoplasmic 
scores were observed in cancer groups compared to the adjacent mucosa. No 
difference was seen between different cancer stages. *** p<0.001 (Kruskal-Wallis 
test followed by post hoc Dunn-Bonferroni test for pair-wise comparisons). Error 
bars represent ± 2 SE. N = sample numbers.  
 
Comparison between normal mucosa from control individuals and 
adenoma tissues 
 
The results from the UK-cohort regarding β-catenin immunostaining 
suggested that protein translocation from membrane into the inner parts of 
the cells occurs early during the adenoma-carcinoma sequence. The initial 
set of Brazilian samples encompassed cancer and adjacent normal samples 
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only. Therefore, in order to validate the results obtained initially, we decided 
to expand the collection of samples to include colorectal adenomas. 
Additionally, instead of comparing the adenomas with adjacent tissues, we 
also collected mucosa samples from individuals who had no colonoscopic 
evidence of intestinal lesion (normal controls). Most experimental studies 
using human samples compare neoplastic tissues with the apparently normal 
adjacent mucosa only. However, in many cases, cancer is the result of the 
effect of carcinogenic factors that affect large areas of the organ, a process 
known as “field cancerisation”. This is particularly true for epithelial cancers 
which commonly arise as a result of local factors. Some reports have shown 
that the transcriptomic profile of tissues adjacent to different tumour types is 
different from the normal epithelium from individuals without cancer, including 
CRC (Sanz-Pamplona et al., 2014, Chandran et al., 2005, Raudenska et al., 
2015b). Therefore, assessing a cohort of normal control samples might 
reinforce the conclusions of our study.  
In this analysis, we included 10 samples from normal control patients 
and 18 samples of colorectal adenomas. Only 2 of the 18 adenomas were 
high-grade lesions. The remaining 16 cases exhibited low-grade dysplasia. 
Hence, we combined all the adenomas into a single group for the purposes 
of comparison. Whole-sections were stained for β-catenin as described in 
Methods and the analysis and scoring were carried out using the electronic 
plugins described above (IHC Profiler and ImmunoRatio). As depicted in 
figure 3.12, the assessment of β-catenin immunostaining in these samples 
showed that nuclear localisation of the protein was increased in adenomas 
when compared to normal epithelium. The cytoplasmic staining seemed to be 
increased as well, although this was not statistically significant. These 
findings reflect what was observed with the UK-cohort and reinforce the 
concept that Wnt pathway activation is an early event during colorectal 
carcinogenesis.  
 
140 
 
 
Figure 3.12. Analysis of β-catenin immunostaining in normal and adenoma samples 
from the Brazilian cohort of patients. The nuclear score was significantly higher in 
the adenoma group, denoting Wnt pathway activation at this early time point in the 
adenoma-carcinoma sequence (p values yielded by Mann-Whitney U test). There 
was also a trend towards an increase in cytoplasmic staining in the adenoma group, 
but this was not statistically significant. Error bars represent ± 2 SE. N = sample 
numbers. 
 
The preliminary analysis of β-catenin expression in these tissues 
permitted us to confirm that Wnt signalling pathway is activated in all 
neoplastic groups – a finding consistent with several previous reports 
(Yoshida et al., 2015, Abdelmaksoud-Damak et al., 2015, Kobayashi et al., 
2000) and with a large published meta-analysis (Chen et al., 2013). At the 
same time, the results support the use of the scoring systems that we have 
subsequently employed for the other candidate biomarkers. Below, the 
results for the remaining candidate proteins are presented. Both cohorts (UK 
and Brazil) were used for the evaluation of NAP1L1 and RPL6. The analysis 
of PHB, HMGB1, SFRS2 and CDC5L was limited to the Brazilian cohort due 
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to the shortage of target tissues in the TMA block produced from the UK-
cohort, as explained previously.   
 
3.4. Expression of NAP1L1 in the adenoma-carcinoma sequence 
 
Sections from the UK-cohort TMA were stained for NAP1L1 using the 
protocol and conditions described in Chapter 2. Scanned slides were 
analysed according to the procedures explained earlier, during the 
description of the manual modified H-score. Figure 3.13 shows an example 
of the NAP1L1 staining pattern in normal and cancer tissues. The results 
from this analysis are shown in figure 3.14. A decrease in the median 
modified H-score was observed in the high-grade adenoma group; this was 
also observed in the invasive cancer group. Interestingly, and different from 
what was observed for β-catenin, we did not notice any difference in NAP1L1 
immunostaining between the adjacent mucosa and the low-grade adenoma 
group. This suggests that the displacement of the protein from the nuclei of 
the cells occurs only when the dysplastic process progresses into a more 
aggressive phenotype.  
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Figure 3.13. An example of 
NAP1L1 staining pattern. 
Normal epithelium shows 
strong nuclear and 
cytoplasmic staining. Cancer 
tissues exhibit a decrease in 
the nuclear content of the 
protein. The cytoplasmic 
staining is also decreased, 
although to a minor degree in 
this case. These tissues 
were collected from a patient 
with stage III (Dukes’ stage 
C) CRC. Magnification: 630x.  
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Figure 3.14. Modified H-scores for NAP1L1 in the UK-cohort. A clear decrease in 
cytoplasmic/nuclear protein localisation is seen in the high-grade adenoma group 
and in the invasive cancer group, compared to both the adjacent mucosa and the 
low-grade adenoma groups. *** p<0.01 for adjacent vs high-grade; p<0.001 for 
adjacent vs cancer. p<0.001 for low-grade vs high-grade and vs cancer (Kruskal-
Wallis test followed by Mann-Whitney U test for post-hoc pair-wise comparisons and 
Bonferroni correction). N = sample numbers. 
 
To further investigate these results, whole-sections from blocks 
included in the Brazilian cohort were also stained for NAP1L1 and were 
scored using the electronic plugins. The results using this alternative cohort 
confirmed the findings from the UK-cohort, and showed a decrease in both 
the nuclear and the cytoplasmic expression of the protein in cancer samples 
(see figure 3.15). Again, no difference was seen between different cancer 
stage groups. Taken together, these findings provide strong evidence for an 
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important role of NAP1L1 content and localisation in colorectal 
carcinogenesis.  
 
 
Figure 3.15. Electronic scoring of the Brazilian cohort stained for NAP1L1. Both the 
nuclear and the cytoplasmic scores were decreased in the cancer groups compared 
to the adjacent mucosa. No difference was observed between different stages of 
cancer.  *** p<0.001 (Kruskal-Wallis test followed by post hoc Dunn-Bonferroni test 
for pair-wise comparisons). Error bars represent ± 2 SE. N = sample numbers. 
 
To assess how early this alteration occurred and to confirm the results 
from the UK-cohort, we also assessed the NAP1L1 immunostaining pattern 
in normal mucosa samples from control individuals and in the adenoma 
samples included in the Brazilian cohort. As depicted in figure 3.16, no 
difference was observed in protein content or localisation between normal 
tissues and adenomas. This result mirrors the patterns observed in adjacent 
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tissues and low-grade adenomas in the UK-cohort. Unfortunately, the low 
number of high-grade adenomas in the Brazilian cohort did not allow us to 
compare this group with the others. However, if the results from the UK-
cohort are correct, these findings might support a concept of using NAP1L1 
immuno-localisation as a biomarker for the conversion of low-grade into high-
grade dysplasia. 
  
 
Figure 3.16. Analysis of NAP1L1 immunostaining in normal and adenoma samples 
from the Brazilian cohort. No difference was observed between normal and 
adenoma samples (Mann-Whitney U test). Error bars represent ± 2 SE. N = sample 
numbers. 
 
Most of the scientific literature regarding NAP1L1 expression in cancer 
tissues is limited to intestinal and pancreatic neuroendocrine tumours, a 
group of neoplasms which have different genotypic and phenotypic profiles 
compared to CRC (Schimmack et al., 2014, Kidd et al., 2006). The only 
report of the analysis of NAP1L1 in human CRC that we have found was a 
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study published in 2002 showing that NAP1L1 mRNA expression was 
increased in tumours relative to the adjacent mucosa (Line et al., 2002). No 
immunohistochemical study evaluating this protein in CRC tissues has been 
found. Therefore, our results provide the first description of the NAP1L1 
immunostaining pattern in CRC and highlight the potential importance of this 
protein during colorectal carcinogenesis.  
 
3.5. Expression of RPL6 in the adenoma-carcinoma sequence 
 
Following the same procedures used for the assessment of the 
previous biomarkers, we analysed the immunohistochemical expression of 
RPL6 in samples from both the UK and Brazilian cohorts. The staining 
pattern (figure 3.17) and results (figure 3.18) for the UK-cohort were highly 
consistent with the pattern observed for NAP1L1. A clear-cut difference in 
RPL6 immuno-localisation was observed between adjacent/low-grade 
dysplastic adenoma groups versus high-grade dysplastic adenoma/cancer 
groups. This suggests that this protein could also possibly differentiate 
between low-risk and high-risk polyps (high-grade dysplasias), besides being 
a cancer maker.  
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Figure 3.17. An example of 
RPL6 staining pattern. 
Cancer tissues exhibited 
decreased levels of staining 
in both the cytoplasm and the 
nucleus of the cells, a similar 
pattern to NAP1L1 immuno-
staining. These tissues were 
collected from a patient with 
stage I (Dukes’ stage A) 
CRC. Magnification: 630x.  
148 
 
 
Figure 3.18. Modified H-scores for RPL6 in the UK-cohort. As was observed with 
NAP1L1, a decrease in cytoplasmic/nuclear protein localisation was seen in the 
high-grade adenoma group and in the invasive cancer group, compared to both the 
adjacent mucosa and the low-grade adenoma groups. * p=0.05 for adjacent vs high-
grade; p<0.001 for adjacent vs cancer; p=0.05 for low-grade vs high-grade; p=0.01 
for low-grade vs cancer (Kruskal-Wallis test followed by Mann-Whitney U test for 
post-hoc pair-wise comparisons and Bonferroni correction). N = sample numbers. 
 
As before, we also tested the Brazilian cancer cohort using IHC 
Profiler and ImmunoRatio for cytoplasmic and nuclear scoring, respectively. 
As can be seen in figure 3.19, the nuclear analysis showed a statistically 
significant decrease in RPL6 immuno-expression in cancer tissues compared 
to the adjacent non-neoplastic colon group. However, the magnitude of the 
difference was smaller when compared to the results obtained with the 
manual modified H-score used in the UK-cohort. Although it is theoretically 
149 
 
possible that different populations exhibit different patterns of biomarker 
expression (as explained in Chapter 1 – Introduction), our hypothesis is that 
the electronic tool is not sensitive enough to detect small differences in 
staining for this marker. The cytoplasmic scores were similar between all the 
groups tested. This finding does not necessarily disagree with the results 
obtained for the UK-cohort, as the modified H-score used in that analysis is 
mainly influenced by the nuclear rather than the cytoplasmic score.  
 
 
Figure 3.19. Electronic scoring of the Brazilian cohort stained for RPL6. A decrease 
in nuclear scores was observed in cancer tissues compared to the adjacent mucosa 
group. Different stage groups exhibited similar scores. No difference was observed 
in the cytoplasmic immunostaining score between the groups. ***p<0.001, *p=0.05 
(Kruskal-Wallis test followed by post hoc Dunn-Bonferroni test for pair-wise 
comparisons). Error bars represent ± 2 SE. N = sample numbers. 
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Next, we performed the evaluation of RPL6 immuno-expression in 
normal samples and adenomas from the Brazilian cohort of patients. Again, 
the results were concordant with the analysis of NAP1L1. Neither the 
cytoplasmic nor the nuclear staining scores showed any difference between 
normal mucosa and adenomas. The results are presented in figure 3.20.   
 
 
Figure 3.20. Analysis of RPL6 immunostaining in normal and adenoma samples 
from the Brazilian cohort. As observed with NAP1L1, no difference was found 
between normal and adenoma samples (Mann-Whitney U test). Error bars represent 
± 2 SE. N = sample numbers. 
 
The only type of cancer in which RPL6 expression has been well 
studied is gastric adenocarcinoma (Wu et al., 2011, Gou et al., 2010, Du et 
al., 2005). An elevated gene expression was initially demonstrated in 
multidrug-resistant gastric cancer cell lines (Du et al., 2005). Later, the same 
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group showed that RPL6 immuno-expression was negative in normal gastric 
mucosa, positive in the cytoplasm of the majority of gastric cancer tissues 
and only rarely present in the nuclei of cancer cells (Gou et al., 2010). In our 
study of the expression of RPL6 in CRC, we found a different result, with 
normal colorectal epithelium exhibiting strongly positive immunostaining 
(especially in the nucleus). However, in CRC cancer tissues, RPL6 immuno-
expression was apparently similar to that previously described in gastric 
cancer.  
Taken together, these results suggest that both NAP1L1 and RPL6 
have similar cellular distributions in normal, pre-malignant and malignant 
colorectal tissues. Both proteins exhibited a differential staining pattern from 
the high-grade dysplastic adenoma stage (as opposed to β-catenin which 
showed nuclear translocation from the low-grade adenoma stage) suggesting 
that these markers may play a role in the acquisition of a more aggressive 
phenotype by the adenoma. These findings definitely warrant further studies 
about the role of these proteins during the colorectal carcinogenesis.   
 
3.6. Expression of Prohibitin (PHB) in CRC tissues 
 
The remaining candidates were not assessed in the UK-cohort for the 
reasons previously explained (insufficient samples). Therefore, an analysis of 
the immuno-expression of PHB in the Brazilian cohort is now described. 
Staining procedures were performed according to the protocol and conditions 
specified in Chapter 2. Figure 3.21 shows an example of PHB 
immunostaining in normal adjacent and tumourous colonic tissues. This 
protein also exhibited a decrease in nuclear expression in cancer tissues 
compared with the adjacent unaffected mucosa.  
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The electronic evaluation carried out with the plugin ImmunoRatio 
confirmed this observation (figure 3.22). A statistically significant decrease in 
the nuclear score was observed in cancer tissues compared with the 
adjacent mucosa. However, results obtained with IHC Profiler showed that 
the cytoplasmic immuno-expression of PHB was actually increased in 
malignant cells (figure 3.22). This increase was not easily perceived by visual 
inspection of the images. If correct, these findings suggest that the protein is 
displaced from the nucleus into the cytoplasm during malignant 
transformation.  
 
Figure 3.21. An example of 
PHB staining pattern. Normal 
tissues generally exhibited 
positive nuclear and 
cytoplasmic staining, 
whereas cancer cells showed 
decreased nuclear staining 
whilst keeping cytoplasmic 
positivity. These tissues were 
collected from a patient with 
stage III (Dukes’ stage C) 
CRC. Magnification: 630x.  
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Figure 3.22. Electronic scoring of the Brazilian cohort stained for PHB. A decrease 
in nuclear scores was observed in cancer tissues compared to the adjacent mucosa 
group whereas an increase in the cytoplasmic score was seen. Different cancer 
stage groups exhibited similar scores. ***p<0.001 (Kruskal-Wallis test followed by 
post hoc Dunn-Bonferroni test for pair-wise comparisons). Error bars represent ± 2 
SE. N = sample numbers. 
 
To assess how early these alterations occur, we also analysed normal 
mucosa from healthy controls and adenoma samples from polyp-bearing 
individuals. As illustrated in figure 3.23, although the nuclear score exhibited 
a trend towards decreased expression in adenomas, this did not reach 
statistical significance. No difference was observed in the cytoplasmic score. 
As was the case for NAP1L1 and RPL6, this suggests that the expression of 
this protein is not altered in benign low-grade adenomas and it specifically 
identifies malignant tissues. We could not assess whether or not this protein 
was altered in high-grade adenomas due to the low number of such cases in 
the Brazilian cohort (2 cases only).  
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Figure 3.23. Analysis of PHB immunostaining in normal and adenoma samples from 
the Brazilian cohort. Again, no difference was found between normal and adenoma 
samples although a trend towards a decreased nuclear expression in adenoma 
tissues is noted (Mann-Whitney U test). Error bars represent ± 2 SE. N = sample 
numbers. 
 
Prohibitin has been quite well studied in cancer models and tissues. 
For example, PHB immuno-expression has been shown to be reduced in 
ovarian cancer (Jia et al., 2014). Conversely, it was increased and 
associated with adverse prognostic features in lung (Jiang et al., 2013, Guo 
et al., 2012), breast (Najm et al., 2013), gastric (Kang et al., 2008), thyroid 
(Franzoni et al., 2009), prostate (Ummanni et al., 2008) and bladder cancers 
(Wu et al., 2007). In CRC, Chen et al. reported an analysis of PHB 
expression using IHC (Chen et al., 2010a). Their results were similar to ours 
in terms of the cytoplasmic expression of the protein. They found an 
increased expression in cancer tissues compared to the adjacent unaffected 
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mucosa. Additionally, they demonstrated that the cytoplasmic expression of 
PHB was similar between normal tissues and adenomas, another finding 
consistent with our results. They have however not reported an analysis of 
the nuclear expression of the protein as we have. Therefore, besides 
demonstrating further evidence for the differential expression of PHB in the 
cytoplasm of CRC cells, we provide the first insight of the nuclear staining 
pattern of this protein in this disease.  
  
3.7. Expression of HMGB1 in CRC tissues 
 
Adjacent non-neoplastic and cancerous tissues from the Brazilian 
cohort were sectioned and stained as per the IHC protocol described in 
Chapter 2 and the images produced were analysed using the ImageJ-based 
electronic plugins IHC Profiler and ImmunoRatio. As figure 3.24 shows, we 
observed a similar pattern of staining in both adjacent normal and colorectal 
tumour tissues. A uniform nuclear positivity was seen in almost all assessed 
tissues, whereas the cytoplasmic staining was consistently weak in malignant 
and non-malignant samples. The results from the electronic scoring and the 
statistical evaluation confirmed that both tissue types had equivalent staining 
scores (see figure 3.25). As no difference was seen in HMGB1 expression 
between cancer and adjacent tissues and considering the limited availability 
of precious human samples, we did not proceed with further analysis of 
normal and polyp samples.  
 
156 
 
 
Figure 3.24. An example of 
HMGB1 staining pattern. We 
observed a similar 
expression of this protein in 
both normal and cancer 
tissues. Overall, the cells 
showed positive nuclear 
expression and only weak 
staining in the cytoplasm. 
These tissues were collected 
from a patient with stage II 
(Dukes’ stage B) CRC. 
Magnification: 630x.  
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Figure 3.25. Electronic scoring of the Brazilian cohort stained for HMGB1. No 
difference was observed either in nuclear or in cytoplasmic staining when comparing 
the different groups. (Kruskal-Wallis test). Error bars represent ± 2 SE. N = sample 
numbers. 
 
As mentioned in Chapter 1 - Introduction, HGMB1 has been 
extensively studied in cancer models and clinical samples including colon, 
breast, lung, prostate, cervical, skin, kidney, stomach, pancreatic, liver, bone 
and blood cancers (Kang et al., 2014). With reference to CRC, recent 
immunohistochemical evaluations have shown that cancer samples 
expressed higher levels of HMGB1 compared to normal adjacent tissues and 
this over-expression was associated with adverse prognostic factors (Süren 
et al., 2014, Zhang et al., 2015a, Ueda et al., 2014). Additionally, it was 
demonstrated that tumours with both nuclear and cytoplasmic expression of 
HMGB1 had less lymphocyte infiltration and decreased 5-year survival rates 
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(Peng et al., 2010). However, another report showed that HMGB1 nuclear 
immunostaining was the same in cancer and normal samples (Lee et al., 
2012) – a finding concordant with our results.  
HMGB1 has both pro- and anti-apoptotic roles in cell biology (Kang et 
al., 2013) and is involved in several disease conditions as well as cancer 
(Kang et al., 2014). This multitude of functions makes the possibility of using 
HMGB1 as a CRC-specific biomarker unlikely and probably explains the 
apparently contradictory findings in the literature.  As our assessment did not 
confirm HMGB1’s importance as a CRC biomarker in our sample set, we 
decided not to proceed with its evaluation in the subsequent steps of our 
research. 
 
3.8. Evaluation of SFRS2 and CDC5L expression in CRC tissues  
 
The last two candidates tested in this immunohistochemical evaluation 
were SFRS2 and CDC5L. Possible roles of these proteins in colorectal 
carcinogenesis were suggested by a previous study conducted by our group 
(Ibrahim, 2014). In the present analysis, we carried out IHC experiments 
similarly to those conducted for the previous makers using samples obtained 
from the Brazilian cohort of patients.  
SFRS2 exhibited an almost equal pattern of nuclear/cytoplasmic 
balance in both normal adjacent and cancerous tissues. Homogeneous 
nuclear positivity was observed in malignant and non-malignant tissues. 
However, the intensity of nuclear staining was slightly stronger in cancer 
tissues than in the adjacent normal mucosa. Although difficult to perceive 
visually (figure 3.26), the electronic scoring produced statistically significant 
differences between normal and cancer groups (figure 3.27). No difference 
however was observed in the cytoplasmic score. Despite the statistically 
positive result in terms of nuclear expression, we regarded the magnitude of 
this difference to be small and unlikely to be clinically helpful. 
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Figure 3.26. An example of 
SFRS2 staining pattern. 
Positive nuclear staining was 
observed in normal adjacent 
and cancer tissues whereas 
weak cytoplasmic staining 
was shown in both cases. 
These tissues were collected 
from a patient with stage I 
(Dukes’ stage A) CRC. 
Magnification: 630x.  
160 
 
 
Figure 3.27. Electronic scoring of the Brazilian cohort stained for SFRS2. A small 
increase in the nuclear score was observed in cancer tissues compared to the 
adjacent mucosa. Although statistically significant, this difference was considered 
minor and probably clinically irrelevant (*p<0.05; ***p<0.01, Kruskal-Wallis test 
followed by post hoc Dunn-Bonferroni test for pair-wise comparisons). No difference 
was seen between groups regarding the cytoplasmic scoring. Error bars represent ± 
2 SE. N = sample numbers. 
 
A similar result was observed for CDC5L. We noticed a very strong 
staining pattern in both adjacent normal and cancer tissues (see figure 3.28). 
Despite the use of the primary antibody solution in an over-diluted 
concentration compared with the recommended dilution (recommended: 
1/250 – 1/500; used: 1/10,000), we still observed very strong DAB-staining 
(figure 3.28). As a result, the median nuclear scores were close to 100% in 
all groups. Despite this, small increases in the nuclear score were observed 
in the cancer groups. As the variance of the results was narrow within each 
group, this small difference reached statistical significance (figure 3.29). In 
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our opinion however, although this difference was statistically significant, it is 
very unlikely to have a clinical application. 
 
 
 
Figure 3.28. An example of 
CDC5L staining pattern. 
Despite the use of over-
diluted primary antibodies, a 
very strong staining pattern 
was observed in both normal 
and cancer samples. These 
tissues were collected from a 
patient with stage II (Dukes’ 
stage B) CRC. Magnification: 
630x.  
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Figure 3.29. Electronic scoring of the Brazilian cohort stained for CDC5L. As 
observed for SFRS2, a very small but statistically significant increase in the nuclear 
score was observed in cancer tissues compared to the adjacent mucosa (*p<0.05, 
Kruskal-Wallis test followed by post hoc Dunn-Bonferroni test for pair-wise 
comparisons). No difference was seen between groups regarding the cytoplasmic 
scoring. Error bars represent ± 2 SE. N = sample numbers. 
 
We were not able to find any report of either SFRS2 or CDC5L 
immuno-expression in colorectal cancer tissues. Most of the studies 
assessing these markers have used other cancer models and cell lines, and 
have focused mainly upon gene expression and post-translational protein 
modifications (Merdzhanova et al., 2010, Edmond et al., 2011, Gräub et al., 
2008, Mu et al., 2014, Lu et al., 2008). In this study, we did not find any 
relevant difference in SFRS2 or CDC5L expression that could indicate a 
potential role of these proteins as immunohistochemical CRC biomarkers. 
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Therefore, we did not investigate these two candidates further in the 
subsequent steps of this research. 
 
3.9. Discussion 
 
The discovery of novel CRC biomarkers to assist in early diagnosis, 
prognostic stratification and prediction of response to treatment is an urgent 
medical need. Immunohistochemistry has been routinely used to assess the 
expression of proteins with prognostic or predictive value in other types of 
cancer such as breast (Zaha, 2014) and lung carcinomas (Pekar-Zlotin et al., 
2015), soft tissue sarcomas (Hornick, 2014) and lymphomas (Higgins et al., 
2008). Besides, it is also an essential technique in the attempt to elucidate 
the origin of metastatic cancer from an occult primary site (Conner and 
Hornick, 2015, Oien and Dennis, 2012). In CRC, immunohistochemistry has 
mainly been used to identify the colorectal origin of metastatic lesions based 
of the presence CDX (an intestine specific transcription factor) and 
cytokeratin 20, and the absence of cytokeratin 7 (Coghlin and Murray, 2015). 
Mismatch repair deficiency (a surrogate marker for hereditary non-polyposis 
colorectal cancer) is also assessed using MLH1 and MSH2 immunostaining 
and it seems that the status of these mismatch-repair proteins in sporadic 
CRC has a prognostic role (Coghlin and Murray, 2015). Apart from these 
limited examples, no robust IHC biomarker has been validated for use in 
clinical practice. It highlights the importance of discovering new tools to better 
stratify cases and improve outcomes from treatment. Additionally, the 
definition of low-risk and high-risk adenomas is currently based on 
microscopic architecture, i.e. grade of dysplasia (Risio, 2010) and 
endoscopic features such as size, shape and number (Kurome et al., 2008). 
The discovery of an immunohistochemical profile to help accurately identify 
lesions with a higher risk of progression could potentially improve the 
management of individuals with colorectal polyps.  
Mutations resulting in inactivation of APC or over-activation of β-
catenin (both leading to the activation of Wnt pathway) are the earliest and 
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most common genetic defects in human CRC (Cancer Genome Atlas 
Network, 2012). Our group has hypothesised that the study of animal models 
of CRC based on Apc gene inactivation could lead to the discovery of novel 
useful cancer biomarkers. For this purpose, a model of acute Apc inactivation 
(AhCre+ Apcfl/fl mouse) and a model of chronic Apc deletion (ApcMin/+ mouse) 
have previously been studied by our group (Hammoudi et al., 2013, Ibrahim, 
2014). This work has resulted in a list of potential candidate biomarkers 
which have now been subjected to a validation study using human samples. 
In this study, we tested different IHC scoring systems to assess the 
expression of our candidate biomarkers in different pathological stages of the 
adenoma-carcinoma sequence and have used samples from two 
geographically distinct populations. Our first finding is that, independent of 
the scoring method used or the population assessed, the results were highly 
consistent. This shows that either the manual or the electronic scoring 
systems used are suitable for the evaluation of our candidate proteins. 
Additionally, it suggests that the expression pattern of the potential 
biomarkers is likely to be similar in different ethnic groups, as was 
demonstrated in this analysis using two different populations. This is 
important because specific genetic alterations or the expression of 
biomarkers may vary across different populations. For example, it has been 
shown that EGFR mutations in sporadic lung cancer are more common in 
Asian patients (Shigematsu et al., 2005) and BRCA germline mutations 
(resulting in increased risk of several types of cancer, especially breast 
carcinomas) are more prevalent in Ashkenazi Jews (Struewing et al., 1997).     
As our candidate biomarker list was originally derived from animal 
models of Apc inactivation, our initial task was to assess Wnt signalling 
pathway activation in our samples. This was clearly demonstrated (in the 
form of β-catenin cytoplasmic and nuclear localisation) in neoplastic lesions 
from low-grade adenomas to invasive cancers and our findings were 
concordant with the literature (Wong et al., 2004, Wong et al., 2003, Chen et 
al., 2013). Next, we assessed the remaining candidates using both a manual 
modified-H score, and electronic nuclear and cytoplasmic scores 
(ImmunoRatio and IHC Profiler plugins, respectively). Results obtained for 
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NAP1L1 and RPL6 revealed an opposite pattern of immuno-expression when 
compared to β-catenin. Both proteins exhibited a clear decrease in nuclear 
expression in neoplastic tissues compared to the adjacent mucosa. 
Interestingly, the expression of NAP1L1 and RPL6 in low-grade adenomas 
was similar to that observed in the adjacent normal mucosa (UK-cohort) and 
normal control samples (Brazilian cohort), as opposed to β-catenin which 
exhibited an altered staining pattern even in low-grade adenomas. These 
findings suggest that both NAP1L1 and RPL6 might be useful 
immunohistochemical biomarkers for colorectal cancer and for high-grade 
(high-risk) adenomas. No published study assessing the immuno-expression 
of these two proteins in CRC tissues or adenomas has been found. 
Therefore, our data provide the first description of the IHC pattern of 
expression for both biomarkers in this context and suggest a possible role for 
these proteins in determining the progression from low-grade to high-grade 
adenomas and the subsequent development of CRC.  
Another candidate that showed a clear differential expression pattern 
in our study was Prohibitin (PHB). As was the case for NAP1L1 and RPL6, 
PHB showed decreased nuclear staining in colorectal cancer tissues 
compared to the adjacent mucosa whereas an increase in cytoplasmic 
staining was observed. This interesting finding suggests that the protein 
might be displaced from the nucleus towards the cytoplasm during malignant 
transformation. Again, these alterations were specifically seen in cancer 
tissues and not in low-grade adenomas. Increased cytoplasmic expression of 
PHB in CRC has also been demonstrated in another study (Chen et al., 
2010a). Taken together, these results support the potential use of PHB as a 
CRC biomarker.  
HMGB1 is a multifunctional protein involved in many disease 
conditions (Kang et al., 2014). Its role in carcinogenesis has been a subject 
of scientific debate (Kang et al., 2013). In CRC tissues, HMGB1 immuno-
expression has been extensively studied and mixed results have been 
published (Süren et al., 2014, Zhang et al., 2015a, Ueda et al., 2014, Lee et 
al., 2012, Peng et al., 2010). Our analysis performed using electronic scoring 
tools in cancer and adjacent tissues from the Brazilian cohort did not 
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demonstrate any difference in HMGB1 expression between the groups. A 
uniformly positive nuclear staining was observed in both tumour and adjacent 
tissues, whilst a negative cytoplasmic staining was seen in both conditions. 
These results are concordant with the findings from Peng et al. who 
demonstrated that all of the adjacent tissues in their CRC cohort exhibited 
positive nuclear and negative cytoplasmic HMGB1 staining. In the cancer 
counterpart, the same pattern was observed in 81.5% of cases (Peng et al., 
2010).   
SFRS2 and CDC5L were suggested as potential biomarkers of CRC in 
our prior study (Ibrahim, 2014). Neither of these proteins has been previously 
evaluated in CRC tissues. Our assessment of SFRS2 and CDC5L immuno-
expression showed a very small increase in nuclear staining for both 
proteins. Although statistically significant, the small magnitude of these 
differences means that the findings are very unlikely to be clinically relevant.    
The cause of this “switching” pattern of expression observed with 
NAP1L1, RPL6 and PHB (which seem to exit the nucleus during malignant 
transformation) is not clear. Gene expression may be altered secondary to 
Wnt pathway activation as occurs with MYC (He et al., 1998, Myant and 
Sansom, 2011) or protein localisation may be affected by post-translational 
modifications, as in the case of β-catenin following APC inactivation (Clevers 
and Nusse, 2012). Alternative splicing could also be involved in this setting, 
causing the alterations that we observed. 
Altogether, our findings suggest that potential cancer biomarkers 
derived from animal models of Apc inactivation may yield valid candidates for 
human CRC. NAP1L1, RPL6 and Prohibitin immuno-expressions were 
consistently altered in malignant and high-grade premalignant colorectal 
neoplasms in a clear, reproducible and statistically significant manner. 
Whether the immuno-expression patterns of these proteins can be used as 
diagnostic tools or for risk stratification requires further investigation. The 
possibility of using these markers to identify adenomatous polyps which have 
a higher risk of progression to invasive cancer is particularly attractive. 
However, the assessment of the suitability of these proteins for this purpose 
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requires a larger longitudinal study and is beyond the remit of the present 
work. In the next chapters, I will further describe the assessment of the 
expression of these biomarkers using different methodologies and different 
matrices such as blood and frozen tissues. In addition, I will explore the 
prognostic importance of these proteins in CRC. As HMGB1, SFRS2 and 
CDC5L were not significantly altered in neoplastic colorectal tissues 
compared to the adjacent normal mucosa they have not been further 
assessed in the next steps of this research. 
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4. CHAPTER 4 – STUDY OF THE RNA EXPRESSION OF THE 
BIOMARKERS IN HUMAN SAMPLES AND THE EFFECTS OF GENE 
SILENCING ON A CRC CELL LINE 
 
4.1. Introduction 
 
As mentioned earlier, work conducted in our laboratory showed that 
some of the candidates exhibited altered gene expression in tissues from 
animal models of Apc inactivation (Hammoudi et al., 2013, Ibrahim, 2014). 
Therefore, we decided to perform an assessment of the mRNA expression of 
our candidate biomarkers in human samples in order to validate the previous 
results. For this analysis, we used quantitative polymerase chain reaction 
(qPCR), as per the protocols described in Chapter 2.   
Polymerase chain reaction (PCR) is a process that uses an in vitro 
reaction based on the activity of the enzyme DNA polymerase in order to 
amplify specific DNA sequences (Mullis et al., 1986, Saiki et al., 1988). With 
the capacity of producing 100 billion copies from a single sequence in a few 
hours, the method has been extensively used for identification of mutations, 
screening of pathogens, generation of forensic evidence, isolation of genes 
for cloning experiments, to cite a few examples (Templeton, 1992). 
Quantitative (also called “real-time”) PCR was first described in 1992 
(Higuchi et al., 1992) as a method that uses fluorescent substances that bind 
to DNA amplicons generated during each PCR cycle. With the use of 
thermocyclers capable of continuously measuring the intensity of 
fluorescence, it permits a real-time quantification of the amplification products 
after each cycle.  
This technology has become an ancillary technique in cancer research 
and clinical practice. Its applications include the detection of residual disease 
in leukaemia, assessment of tumour immunology, measurement of DNA copy 
number and detection of genomic mutations and polymorphisms (Mocellin et 
al., 2003). However, the performance of the test is highly dependent on 
several steps which must be carried out meticulously, from sample collection 
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and storage to the final reagent optimisation. The method of assessing the 
results is also essential for obtaining accurate results. Despite the thousands 
of published studies using qPCR in cancer research, many of them have 
flaws or omissions in the report that prevent proper validation of the findings 
(Bustin et al., 2013). This is specifically the case in CRC research. A review 
of the published literature has shown that 75% of the papers did not report 
the efficiencies of the PCR reactions, an essential parameter for assessing 
the validity of the results (Dijkstra et al., 2014). Several other omissions were 
also found in the same survey. As a consequence of such heterogeneity in 
the description of qPCR studies, a standardisation process became 
necessary. In 2009, an attempt to correct this issue was initiated with the 
publication of the Minimum Information for Publication of Quantitative Real-
Time PCR Experiments (MIQE) guidelines (Bustin et al., 2009). This 
consensus proposed a list of mandatory or recommended data that should 
ideally be included in any report of qPCR experiment. Although the 
publication from Dijkstra et al. cited above included studies published from 
2006 to 2013 (thus encompassing studies published 4 years after the 
publication of the recommendations), only 1% of them has cited the MIQE 
guidelines. In our research, we tried to follow the relevant MIQE 
recommendations whenever they applied.  
The specific qPCR platform chosen for this research was the gene 
expression technology provided by Applied Biosystems – TaqMan® assays 
(Foster City, CA, USA), which use the so called 5´- nuclease activity of DNA 
polymerase. These assays include a pair of primers (forward and reverse) 
and a sequence-specific hydrolysis probe. At the 5´ end of the probe, a 
fluorescent reporter dye is attached. At the opposite 3´ end, a non-
fluorescent dye (also known as “quencher”) is located. Due to the proximity of 
these two dyes, a phenomenon called “fluorescent resonance energy 
transfer” (FRET) occurs. In FRET, the emissions from the fluorescent dye are 
strongly reduced by the presence of a quencher. During each PCR cycle, the 
probe anneals with the target sequence. When the polymerase, during the 
extension period of the cycle, reaches the probe, the enzyme´s 5´- 
exonuclease activity cleaves the probe from the 5´ end, thus releasing the 
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reporter dye. Once free from the probe and, consequently, liberated from 
quencher inhibition, the reporter emits fluorescence. The fluorescence 
accumulates as the successive cycles progress and it is recorded by the 
qPCR thermocycler. TaqMan® technology was selected because it is a 
widely accepted system and also because Applied Biosystems´ qPCR 
equipment was available in the labs involved in this research in both the UK 
and Brazil.  
The choice of a proper reference gene for the normalisation of qPCR 
experiments is deemed to be an essential step for accurate results. Ideally, 
the reference gene should maintain the same expression level in all 
experimental conditions. However, there is no agreement on which genes are 
ideal references for CRC. ACTB (the gene encoding β-actin) has been the 
most commonly used endogenous control to normalise qPCR experiments in 
CRC (Dijkstra et al., 2014). Nonetheless, several validation studies assessing 
its role as a CRC reference gene have produced inconsistent results. One 
report has shown that ACTB expression levels have a slightly higher 
coefficient of variation than beta-2-microglobulin (B2M) and peptidylprolyl-
isomerise A (PPIA) in CRC and normal adjacent samples (Kheirelseid et al., 
2010). Another study suggested that the use of one of the gene pairs 
HPRT1/PPIA or IPO8/PPIA is better than using ACTB alone (Sørby et al., 
2010). Conversely, Miyata et al. have recently shown that ACTB and TATA-
box binding protein (TBP) were stably expressed in CRC when compared 
with the adjacent mucosa (Miyata et al., 2015). In the same report, HPRT, 
GAPDH, SDHA, UBC, B2M and 18S rRNA all exhibited altered expression. 
Given the lack of a standard reference gene in this context, we decided to 
use ACTB as our endogenous control. Besides our candidate biomarkers 
(NAP1L1, RPL6 and PHB), we also assessed β-catenin gene (CTNNB1) 
expression to have a better understanding of the status of Wnt signalling 
pathway in these cases. 
The functions of particular genes can be explored by interfering with 
gene activity. Gene expression stimulation or silencing may provide important 
clues regarding its role in cell physiology. Given the paucity of information 
concerning our candidate biomarkers in terms of cell biology regulation, RNA 
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interference studies were performed targeting the candidates which have 
exhibited significant gene expression alterations in the human tissue analysis 
explained above. Details of these experiments are described later in this 
chapter.  
 
4.2. Clinical samples 
 
This study involved exclusively samples collected in Brazil. Cancer 
and adjacent samples were collected during the surgical procedure 
immediately after the removal of the specimen, thus avoiding long term tissue 
hypoxia. Samples were immediately immersed in Allprotect® (Qiagen), 
incubated overnight at 4°C and stored at -80°C until they were used. Normal 
control samples were collected from individuals who had no endoscopic 
abnormality during colonoscopy. These samples were also incubated in 
Allprotect® and stored similarly to the cancer samples. RNA extraction and 
cDNA synthesis were processed as described in Chapter 2. The clinical and 
demographic characteristics of the individuals included in this analysis are 
summarised in table 4.1. As can be noticed, the groups were well matched in 
terms of age. However, there was a predominance of males in the cancer 
group whilst females were the majority in the normal group. It has been 
demonstrated that women are more likely to seek medical attention for health 
promotion and to participate in screening programmes than men (Sach and 
Whynes, 2009). This may be even more relevant in regions without an 
organised programme such as Brazil and may have contributed to the 
predominance of women in the normal control cohort. 
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Table 4.1. Clinical and demographic characteristics of the individuals included in the 
qPCR analysis.  
Characteristics Normal control 
(n=10) 
Cancer 
(n=25) 
p 
    
Mean age (range) 54.8 (41-74) 55.9 (34-83) NS 
Gender    0.001* 
Male 2 16  
Female 8 9  
Stage   NA 
I-II - 42% - 
III-IV - 58% - 
* Fisher´s exact test. NS: non-significant. NA: not applicable.  
 
4.3. Assessment of qPCR assay efficiencies 
 
When using commercially available qPCR assays, many researchers 
assume that the kits have very high efficiencies. However, as recommended 
by the MIQE guidelines, this must be confirmed to be the case in the 
experimental conditions of each PCR lab. Additionally, the manufacturer of 
the kit that we used also recommends that the efficiency be tested before the 
use of the assays (Relative Gene Expression Workflow document, available 
at http://tools.thermofisher.com/content/sfs/brochures/cms_075428.pdf, last 
accessed on 29/12/15). Checking the PCR efficiency is essential, as the 
most commonly used method for analysing the results, the “comparative Ct” 
or “2 -ΔΔCT” (“Livak”) method is only suitable for experiments in which the 
efficiencies of the amplification for the endogenous control and the target 
gene are similar and close to 100%. The developers of the method 
recommend that the efficiencies do not differ by more than 10%, and lie 
between 1.8 and 2.2 (equivalent to 90 to 110% of efficiency) (Schmittgen and 
Livak, 2008). 
In this research, we followed the recommendation provide by the 
manufacturer of the kit (described above). The assessment of PCR 
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efficiencies was performed by the amplification of a dilution series (10-fold 
dilutions, 5 points) using cDNA from one control sample. This process was 
repeated for each gene (reference gene and targets). The threshold cycle, or 
Ct, was annotated for each dilution point and a regression curve was plotted. 
Using the ABI 7500 real-time PCR system software, the slope of the curve 
was calculated and the efficiency of the reaction was obtained. Figure 4.1 
shows the result produced for CTNNB1. The assay exhibited an efficiency of 
93.6%. Efficiency results for ACTB, NAP1L1, RPL6 and PHB ranged from 
90.0% to 96.7%. Therefore, the assumptions of both similar and high 
efficiencies were satisfied for all genes and the comparative Ct method was 
deemed adequate for our analyses. 
 
 
Figure 4.1. Graph representing the assessment of PCR efficiency for CTNNB1. A 
10-fold dilution curve (5 points) was produced using cDNA from one sample and the 
dilutions underwent amplification in triplicate. A linear curve was obtained, showing 
that the dilutions were properly prepared. In this case, an efficiency of 93.6% was 
found. Similar procedures were performed for the other genes. 
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4.4. Defining the best cDNA dilution for the qPCR experiments 
 
In Chapter 2, it was explained that the amount of RNA used in the 
reverse transcription step for cDNA synthesis may affect the efficiency of the 
reaction mainly due to contamination carry-over and internal inhibitors (Bustin 
et al., 2015, Pugniere et al., 2011). The same notion applies to the qPCR 
step. RT reagents can work as PCR inhibitors, thus affecting the 
performance of the final reaction (Gallup and Ackermann, 2006). To address 
this issue, most gene expression researchers dilute the cDNA from 1:2 to 
1:100, and use the diluted stock solution to carry out qPCR experiments. 
However, when working with genes whose level of expression is not well 
known, it is highly advised that different cDNA dilutions be tested in order to 
choose an appropriate concentration. This step aims to avoid the use of 
excessively concentrated post RT solution (thus preventing any 
contamination carry-over) and to reassure that the Ct for each gene is 
located between cycles 15 and 30, a range in which the qPCR reaction is 
more accurate.  
In our experiments, 300ng of RNA were used in the RT step after 
testing different quantities, as described previously. In order to find an 
adequate cDNA dilution, we performed amplification using a dilution series 
(2-fold, 5 points) ranging from 1:1 to 1:16 (one control sample). Experiments 
were repeated for all genes, both targets and reference. For each gene 
tested, all dilutions resulted in Cts between 15 and 30 (as an example, see 
the amplification plot for CTNNB1 in figure 4.2). Given these results, we 
could confidently choose any of the dilutions tested. To avoid using 
unnecessary amounts of precious samples, but also preventing any 
particularly low expressing sample from exhibiting late amplification, we 
decided to use the 1:4 dilution in these experiments.  
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Figure 4.2. Assessment of different cDNA template dilutions using CTNNB1 assay. 
The serial dilution produced distinct and ordered amplification curves, with all Cts 
lying between cycles 15 and 30. Similar results were obtained for the other genes.   
 
Although most publications in the literature describe gene expression 
studies comparing only tumour samples and adjacent normal epithelium, we 
decided to include in our analysis normal samples which had been obtained 
from individuals without any endoscopy-detectable neoplasm or inflammatory 
condition. The reason for this is the evidence in the literature of altered gene 
expression in the apparently normal mucosa adjacent to epithelial tumours 
(Raudenska et al., 2015a, Sanz-Pamplona et al., 2014, Chandran et al., 
2005), a phenomenon known as “field cancerisation” or “field effect”. 
Consequently, a more comprehensive understanding of the role of the 
candidate genes in both the tumour and the surrounding environment could 
be obtained. In the next sections, the results from the assessment of the 
expression of the candidate genes in human tissues will be presented. 
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4.5. Expression of the candidate genes in human tissues 
 
4.5.1. Expression of CTNNB1 in human tissues 
 
In addition to the immunohistochemical expression/localisation of β-
catenin work detailed in Chapter 3, we also assessed CTNNB1 mRNA 
expression in our sample cohort. For this purpose, cDNA from normal 
control, adjacent unaffected colon and cancer tissues was analysed by qPCR 
according to the protocols described in Chapter 2. Each reaction was carried 
out in triplicate and non-template controls were used in each PCR plate. As 
shown in figure 4.3, we observed similar expression levels comparing normal 
controls and adjacent non-neoplastic samples. However, a small but 
significant increase in mRNA expression was observed in cancer samples 
compared to adjacent unaffected colon samples (but not to normal controls).  
 
 
Figure 4.3. CTNNB1 mRNA expression in normal, adjacent and cancer samples. 
When normalised to β-actin, CTNNB1 exhibited stable levels in normal (RQ 1.0; 
min-max 0.92-1.09) and adjacent (RQ 0.85; min-max 0.71-1.01) samples. In cancer 
samples, CTNNB1 expression was slightly increased (RQ 1.42; min-max 1.26–
1.60). Although small, this expression was significantly higher compared to the 
adjacent but not to the normal group. * p<0.05 (Kruskal-Wallis test followed by post 
hoc Dunn-Bonferroni test for pair-wise comparisons). 
178 
 
The literature is rich in reports of the immunohistochemical expression 
of β-catenin in several cancer types. However, few studies have analysed β-
catenin gene expression either in CRC or in other cancers. The limited 
number of results that we found has shown contradictory findings. Anwar et 
al. demonstrated a 21-fold increase in CTNNB1 mRNA expression in CRC 
tissues compared to both the “adjoining” (2-5cm from the tumour) and 
“normal adjacent” mucosa (5-10cm from the tumour) (Anwar et al., 2015). 
Conversely, a Chinese report showed a decreased expression of CTNNB1 in 
cancer tissues when compared to the adjacent epithelium (Qin et al., 2006). 
Another study found no difference in CTNNB1 expression when comparing 
tumours and adjacent tissues (Truant et al., 2008). Our results support the 
concept that CTNNB1 activation is not a hallmark of CRC as only a minor 
increase in expression was observed in cancer tissues compared to adjacent 
tissues. The difference between normal and cancer tissues was not 
statistically significant. Additionally, no difference was seen when comparing 
normal to adjacent tissues.  
 
4.5.2. Expression of NAP1L1 in human tissues 
 
NAP1L1 mRNA expression was assessed in CRC, adjacent mucosa 
and normal controls using a TaqMan® gene expression assay. Before 
analysing the samples, PCR efficiency was assessed and the optimal 
amount of RNA template was determined, as detailed above. Then, the 
experiment was carried out and the results were compared using ACTB as 
the reference gene and the comparative Ct method. There was an evident 
and statistically significant increase in NAP1L1 expression in both tumours 
(8.28-fold) and adjacent tissues (7.18-fold) when compared to normal 
controls, as shown in figure 4.4. No difference between tumours and adjacent 
tissues was observed.   
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Figure 4.4. NAP1L1 mRNA expression in normal, adjacent and cancer samples. A 
major increase in NAP1L1 expression was observed in both adjacent (RQ 7.18; min-
max 4.50-11.44) and tumour (RQ 8.28; min-max 5.92-11.60) tissues compared to 
normal controls (RQ 1.00; min-max 0.89–1.13). *** p<0.001 (Kruskal-Wallis test 
followed by post hoc Dunn-Bonferroni test for pair-wise comparisons). 
 
Few researchers have studied NAP1L1 expression in cancer tissues. 
Drozdov et al. compared small intestinal neuroendocrine tumours (NETs) and 
normal enterochromaffin cell preparations, and showed a 13.7-fold increase 
in NAP1L1 expression in tumour tissues (Drozdov et al., 2009). However, no 
analysis of the adjacent mucosa was performed. Studying both NETs and 
CRCs, Kidd et al. suggested that NAP1L1 was increased in NETs but not in 
CRCs (Kidd et al., 2006). However, the comparisons were made with the 
respective adjacent mucosas and no tissue from healthy individuals was 
tested. Therefore, their results are not discordant when compared with ours. 
Line et al. evaluated NAP1L1 mRNA expression in CRC and adjacent tissues 
as a secondary endpoint in a study primarily aimed at finding sero-reactive 
biomarkers (Line et al., 2002). They showed that, among 15 cases of CRC, 
seven exhibited moderate increases in NAP1L1 expression (ranging from 2.9 
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to 9.3-fold) and eight cases showed expression levels similar to the 
corresponding adjacent mucosa. Again, the fact that they used only adjacent 
tissues may have prevented them from finding a more pronounced 
differential expression. To the best of our knowledge, these results show for 
the first time a differential expression of NAP1L1 in CRC and adjacent 
tissues, suggesting a possible role for this candidate biomarker not only in 
malignant transformation but also in the process of field cancerisation.  
The precise interpretation of these findings in comparison with the 
results of the assessment of NAP1L1 immunohistochemical expression 
(Chapter 3) requires further research. We previously observed an evident 
decrease in the nuclear immuno-expression of NAP1L1 in cancer tissues 
when compared with the adjacent unaffected colonic mucosa. As we now 
demonstrate that the mRNA expression of this marker is similarly increased 
in both samples – tumour and adjacent, it is likely that another event may 
have occurred during the process of malignant transformation, affecting the 
protein content and distribution within the cell. Either increased protein 
degradation or post-translational modifications might have caused the 
decreased immunostaining observed. Alternatively, the protein might have 
left the cell via excretion, secretion or leakage. In the study mentioned above, 
Line et al. showed that NAP1L1 caused an immunogenic response in a 
subset of CRC patients but not in healthy volunteers, thus supporting the 
notion that the protein may leave the cell upon cancer development (Line et 
al., 2002). 
 
4.5.3. Expression of RPL6 in human tissues 
 
Similar experiments were performed to assess RPL6 gene expression. 
Using TaqMan pre-optimised assays, we compared the transcript levels of 
this candidate biomarker in tumours, adjacent tissues and normal controls. In 
the same way that we observed in the immunohistochemical work, RPL6 
gene expression mirrored the pattern observed for NAP1L1. As depicted in 
figure 4.5, an increase in RPL6 expression was found in both adjacent and 
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tumour tissues when compared to normal controls. Although this difference 
was statistically significant, the magnitude of the over-expression was less 
than that observed for NAP1L1. Again, no difference was observed between 
tumours and adjacent tissues.  
 
 
Figure 4.5. RPL6 mRNA expression in normal, adjacent and cancer samples. 
Similarly to NAP1L1, RPL6 expression was significantly increased in both adjacent 
(RQ 2.08; min-max 1.48-2.91) and tumour (RQ 2.38; min-max 1.94-2.92) tissues 
compared to normal controls (RQ 1.00; min-max 0.91–1.10). The magnitude of the 
difference, however, was less prominent. * p<0.05 (Kruskal-Wallis test followed by 
post hoc Dunn-Bonferroni test for pair-wise comparisons). 
 
RPL6 expression and function has previously been studied mainly in 
gastric carcinomas. A Chinese group has demonstrated that this protein has 
important roles in cell proliferation (Gou et al., 2010, Wu et al., 2011) and 
drug resistance in gastric cancer cell lines (Du et al., 2005). Regarding CRC, 
the only study that we have found was the report from our group by 
Hammoudi et al. In this study, a slight increase (1.88-fold) in RPL6 mRNA 
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expression was observed in tumours compared to the adjacent mucosa in a 
cohort of 15 patients (Hammoudi et al., 2013). The present study reinforces 
the results from Hammoudi, showing a more evident increase in RPL6 
expression in tumours compared with normal controls. Additionally, as 
occurred with NAP1L1, RPL6 was shown to be over-expressed in the 
adjacent mucosa as well, bringing up the possibility that this gene might play 
a role in field cancerisation.  
The same comments made in relation to NAP1L1 
immunohistochemical and mRNA expressions also apply to RPL6. The 
apparent discordant results (decreased nuclear IHC expression and 
increased gene expression) suggest that some post-translational event might 
have occurred affecting RPL6 content and distribution. In fact, the clear 
correlation between the patterns of expression observed using two different 
techniques raises the possibility that these proteins are important and 
possibly related to each other in the process of colorectal carcinogenesis.  
 
4.5.4. Expression of PHB in human tissues 
 
The assessment of PHB expression was performed in the same 
manner described for the previous markers, using the conditions shown 
above and in Chapter 2. The comparative Ct method revealed a continuous 
increase in PHB expression from normal controls to adjacent tissues and to 
cancer samples. However, these differences were not statistically significant 
(figure 4.6). 
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Figure 4.6. PHB mRNA expression in normal, adjacent and cancer samples. Despite 
the apparent higher expression in adjacent and cancer tissues, no statistically 
significant difference was observed between groups. Relative quantifications were 
1.00 (min-max 0.93–1.08), 2.46 (min-max 1.48-4.11), and 3.29 (min-max 2.29-4.73) 
for normal controls, adjacent samples and tumours, respectively (p=0.089; Kruskal-
Wallis test). 
 
PHB expression has been studied in various cancer types using either 
immunohistochemistry (Guo et al., 2012, Jia et al., 2014, Wu et al., 2007) or 
combined techniques including qPCR (Franzoni et al., 2009, Jiang et al., 
2013, Kang et al., 2008, Ummanni et al., 2008). All these studies have shown 
differential expression in cancer tissues compared to normal controls or 
adjacent tissues. In CRC, Chen et al. used comparative proteomics to screen 
for potential biomarkers. Using matrix-assisted laser desorption/ionization 
time of flight mass spectrometry (MALDI-TOF/TOF-MS), they found an over-
expression of PHB in cancer samples when compared to the adjacent 
mucosa (Chen et al., 2010a). Furthermore, IHC and Western blot confirmed 
protein accumulation in malignant tissues, a finding concordant with our 
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results presented in the previous chapter. Transcript levels, however, were 
not assessed in that study.  
In our analysis, a trend pointing towards an increased expression of 
PHB mRNA in cancer tissues was seen. Nonetheless, statistical significance 
was not reached. This is probably due to the relatively small number of cases 
per group and the wide variation in the relative quantification ratios in the 
adjacent and cancer groups. The only report of PHB gene expression in CRC 
that we were able to find was, again, Hammoudi´s study in which the authors 
reported an 1.32-fold increase in CRC when compared to the adjacent 
mucosa (p=0.020) (Hammoudi et al., 2013). Along with the findings of the 
present research, it suggests that PHB transcript levels might be only 
marginally increased in CRC. Therefore, another mechanism different from 
gene over-expression might be responsible for the increased protein levels 
observed in our study (previous chapter) and also reported by Chen et al. 
Impaired protein degradation and post-translational modifications may 
explain these findings.  
 
4.6. RNA interference studies 
 
RNA interference is the process of gene expression silencing induced 
by short double-stranded RNA fragments such as small interfering RNAs or 
microRNAs (Rana, 2007). Small interfering RNAs (siRNAs) are produced 
when long double-stranded RNA is cleaved by Dicer, a type III RNAse 
enzyme, into fragments 21-23 nucleotides long. Each one of these fragments 
is incorporated into a protein complex called RNA-induced silencing complex 
(RISC). The antisense-, also called guide-strand, serves as a template for the 
identification of the target sequence. When the target mRNA is recognised 
by, and bound to RISC, translational repression or transcript cleavage 
occurs, as depicted in figure 4.7 (Rana, 2007). The technique for artificially 
inducing RNA interference using siRNAs was first introduced by Fire et al. in 
1998 (Fire et al., 1998). Since then, the use of siRNAs has shown a massive 
growth in several research fields, from basic investigations to the discovery of 
potential gene therapies (Pecot et al., 2011).  
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Figure 4.7. Mechanisms of RNA interference. Micro-RNAs are endogenously 
produced from pre-miRNAs cleaved by Dicer (A). Alternatively, siRNAs are 
exogenously delivered to the cell, undergo endocytosis and become free in the 
cytoplasm after escaping from the endosome (B). In either case, the short RNA 
fragment is incorporated into RISC. The guide strand provides the template for 
mRNA recognition. Once bound to RISC, the transcript undergoes translational 
repression or cleavage. From (Pecot et al., 2011).  
 
Elevated levels of NAP1L1 and RPL6 were observed in CRC and 
adjacent tissues when compared with normal control mucosa, as detailed 
earlier in this chapter. It has also recently been shown that NAP1L1 over-
expression induces cell proliferation in murine stem cells (Yan et al., 2016). 
Other authors have demonstrated that the silencing of this gene caused 
immature P19CL6 cells (Li et al., 2012) and pluripotent stem cells (Gong et 
al., 2014), both murine cell lines, to differentiate into mature cardiomiocytes. 
As for RPL6, a study of the effect of gene knockdown using siRNA showed a 
negative impact on proliferation and cell cycle progression in human gastric 
cancer cell lines (Wu et al., 2011). Collectively, these findings suggest that 
these genes are promoters of proliferation and repressors of differentiation, 
two key events during the carcinogenesis process. Therefore, we 
hypothesised that these genes could also be important for proliferation in 
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human CRC cell lines. To test this hypothesis, HCT116 cells were selected 
and RNA interference experiments using siRNAs were performed. CRC cell 
lines have been widely used in studies assessing tumour biology, drug 
response and biomarkers. Several commonly used cell types are considered 
good representatives of primary colorectal tumours (Mouradov et al., 2014). 
HCT116 cells are derived from a colonic adenocarcinoma removed from a 
male patient. This cell line has a constitutively active Wnt signalling pathway 
caused by a mutation in CTNNB1 (a three-base deletion in codon 45, exon 
3), whilst the APC gene is wild-type (Ilyas et al., 1997, Morin et al., 1997). To 
assess the effect of TP53 status on gene function, both TP53 wild-type and 
TP53 null HCT116 cells were tested.  
The reagents and conditions used in these experiments were 
optimised by another researcher in our group prior to this study (Ibrahim, 
2014). All the procedures undertaken have been detailed in Chapter 2. After 
gene knockdown, a proliferation assay was performed in order to investigate 
whether or not NAP1L1 and RPL6 regulate proliferation in this cell line. If a 
positive association was found, RNA extracted from transfected cells was 
used in a CRC developmental qPCR array plate to assess other CRC-related 
genes that were potentially affected by the knockdown of our markers. 
 
4.6.1. Assessing the efficiency of gene silencing 
 
HCT116 cells (TP53 wild-type and null) were cultured and interference 
experiments using siRNAs were performed as detailed in Chapter 2. Before 
analysing the results, an initial mandatory step was the assessment of 
silencing efficiency. To be successful, a siRNA experiment must be able to 
significantly reduce gene expression when compared to non-transfected cells 
or cells transfected with non-targeting (scrambled) siRNA. Therefore, the first 
task in this part of the investigation was the assessment of the relative 
reduction in mRNA levels after the knockdown of NAP1L1 and RPL6. For this 
purpose, cells were harvested 48 hours after siRNA transfection, RNA was 
extracted and cDNA was produced. Figure 4.8 shows the results for TP53 
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wild type cells. RNA interference resulted in a profound decrease in mRNA 
levels of both NAP1L1 and RPL6, when compared to non-transfected cells or 
cells transfected with non-targeting siRNA.  
 
 
Figure 4.8. Assessment of gene expression interference efficiency in TP53 wild-type 
HCT116 cells. NAP1L1 mRNA levels (A) exhibited a 90% decrease in cells 
transfected with targeting siRNA whilst scrambled-siRNA-transfected cells showed 
only a 15% reduction. As for RPL6 (B), transfection with targeting and non-targeting 
siRNA resulted in 75% and 20% gene silencing, respectively (error bars: +/-2SE; 
biological replicates: 2, technical replicates: 3).   
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Scrambled siRNA caused only a minor (less than 20%) decrease in 
gene expression when compared to non-transfected cells. These results 
confirm that successful and specific gene knockdown was achieved in TP53 
wild-type HCT116 cells.  
As for TP53 null HCT116 cells (figure 4.9), again a strong reduction in 
gene expression was demonstrated by the use of siRNAs targeting either 
NAP1L1 or RPL6. However, in the case of NAP1L1, a 30% reduction in 
transcript levels was also noticed when using scrambled non-targeting 
siRNA, thus highlighting a moderate degree of non-specific silencing. This 
suggests that selective targeting might have occurred, making this scrambled 
siRNA a poor negative control for this experiment. Limited time and 
resources unfortunately prevented us from testing different non-targeting 
siRNAs in this study. RPL6 transcript levels did not exhibit any reduction with 
scrambled siRNA in TP53 null HCT116 cells. As specific silencing (caused by 
targeting siRNAs) was, in general, much more prominent than non-specific 
knockdown, we decided to proceed with the assessment of TP53 null cells in 
the planned proliferation experiments.  
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Figure 4.9. Assessment of gene expression interference efficiency in TP53 null 
HCT116 cells. (A) NAP1L1 exhibited more non-specific silencing as scrambled-
siRNA produced a 30% mRNA level reduction. However, targeting siRNA showed a 
higher knockdown efficiency - 75% reduction. (B) RPL6 exhibited a much more 
specific pattern of silencing. Transfection with targeting and non-targeting siRNA 
resulted in 71% and 4% gene silencing, respectively (error bars: +/-2SE; biological 
replicates: 2, technical replicates: 3).   
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4.6.2. Effect of NAP1L1 and RPL6 silencing on cell proliferation 
 
Sulforhodamine B (SRB) assay is a widely used proliferation test 
based on the estimation of cellular density via the determination of total 
protein content in culture plate wells (Vichai and Kirtikara, 2006). SRB, a 
bright pink aminoxanthene dye with two sulfonic groups, binds to basic 
aminoacid residues under mild acidic conditions and dissociation occurs in 
basic conditions in a stoichiometric fashion (Skehan et al., 1990). Therefore, 
the amount of dye extracted from stained cells is proportional to the cell 
mass. Following the protocol detailed in Chapter 2, we performed SRB 
assays using HCT116 cells starting 48 hours after cell transfection.  
 
TP53 wild-type HCT116 cells 
 
In the SRB assay experiments, non-transfected and scrambled-siRNA-
transfected TP53 wild-type HCT116 cells showed a high proliferation rate, as 
denoted by the fast increase in cell density during the experiments (results in 
figure 4.10). NAP1L1 siRNA transfection caused no effect on cell 
proliferation. Therefore, at least using the SRB technique, a role for NAP1L1 
in cell proliferation could not be confirmed. Conversely, RPL6 siRNA 
provoked a strong and significant inhibition in cell growth from day 1 to 3. 
Non-targeting siRNA did not cause any degree of proliferation blockade, thus 
suggesting that RPL6 silencing was the only factor responsible for this effect. 
This confirms the involvement of the RPL6 gene in the proliferation of this 
CRC cell line.  
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Figure 4.10. Effect of NAP1L1 and RPL6 knockdown on the proliferation of TP53 
wild-type HCT116 cells (SRB assay). NAP1L1 silencing had no effect on cell 
proliferation, whilst RPL6 knockdown resulted in clear inhibition of cell growth when 
compared to non-transfected cells or cells transfected with scrambled-siRNA 
(*p<0.05; ***p<0.001; ANOVA with post-hoc Dunnett T3 test; error bars: +/-2SE; 
N=1, n=3). 
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TP53 null HCT116 cells 
 
The interpretation of the proliferation results in TP53 null cells was 
more problematic. On superficial inspection, siRNA targeting either NAP1L1 
or RPL6 resulted in significant inhibition of cell proliferation on day 2 of the 
SRB assay (figure 4.11). However, a careful analysis revealed some issues. 
First, the proliferation rates were considerably lower than those observed 
with TP53 wild-type cells. No cell group exhibited more than a 2-fold increase 
in cell mass during the entire experiment. Additionally, cell density peaked at 
day 2, and then, decreased in the non-transfected and scrambled-siRNA 
transfected groups, whilst keeping low cell mass in the silenced group. The 
reason for this inhibition may be related to an increased sensitivity to nutrient 
deprivation in cells lacking a functional p53, given that the culture medium is 
not replaced during the proliferation assay. It has previously been 
demonstrated that TP53 mutation or silencing result in increased cell death 
under glucose deprivation in melanoma (Chavez-Perez et al., 2014) and 
breast cancer cell lines (Rodriguez et al., 2012).  
Together, these results permit us to conclude that RPL6 gene 
silencing caused an important inhibition on the proliferation of TP53 wild-type 
HCT116 cells. Conversely, NAP1L1 knockdown had no effect upon the 
growth of the same cell line. No definite conclusion can be drawn regarding 
the effect of NAP1L1 or RPL6 knockdown on TP53 null cells due to the 
general low rate of proliferation and increased amounts of cell death 
observed during these experiments. Therefore, only TP53 wild-type HCT116 
cells were used in the next part of this research – the assessment of the 
effect of RPL6 silencing on the expression of known CRC-related genes.  
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Figure 4.11. Effect of NAP1L1 and RPL6 knockdown on the proliferation of TP53 
null HCT116 cells (SRB assay). Minimal inhibition of cell growth was observed in 
cells transfected with siRNAs targeting both NAP1L1 and RPL6 on day 2 only. 
Noteworthy, the overall proliferation rate was exceptionally low for all conditions, as 
shown by the low increase in optical densities from days 0 to 3 (zero to 2.0-fold 
increase). Additionally, most conditions exhibited a reduction in cell mass by day 3. 
(* p<0.05; **p<0.01; ANOVA with post-hoc Dunnett T3 test; error bars: +/-2SE; N=1, 
n=3).  
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4.6.3. Effect of RPL6 silencing on CRC-related genes 
 
RPL6 gene silencing caused a clear and strong inhibition of the 
proliferation of TP53 wild-type HCT116 cells. Therefore, we hypothesised 
that this gene could influence the expression of other CRC-related genes and 
pathways. To assess this possibility, we extracted RNA from cells that had 
been transfected with scrambled and targeting siRNA. After the synthesis of 
cDNA, samples were loaded into Human Developmental Phases of 
Colorectal Cancer® array plates (Applied Biosystems, Carlsbad, CA, USA) 
along with the appropriate PCR master mix. This array plate assesses the 
expression of 28 CRC-related genes in addition to 4 endogenous controls 
(listed in table 4.2).  
 
 Table 4.2. Genes assessed in the CRC array plate. 
18S                  eukaryotic 18S rRNA – control 
GAPDH                 glyceraldehyde-3-phosphate dehydrogenase – control 
HPRT1                              hypoxanthine phosphoribosyltransferase 1 – control 
GUSB                  glucuronidase, beta – control 
APC                              adenomatous polyposis coli 
BAX                  BCL2-associated X protein 
CTNNB1                 catenin (cadherin-associated protein), beta 1 
DCC                             deleted in colorectal carcinoma 
E2F4                  E2F transcription factor 4 
KRAS                              Kirsten rat sarcoma viral oncogene homolog 
MMP1                  matrix metalloprotease 1  
MMP2                  matrix metalloprotease 2  
MMP3                  matrix metalloprotease 3  
MMP7                  matrix metalloprotease 7  
MMP8                  matrix metalloprotease 8  
MMP9                                matrix metalloprotease 9  
MMP10                              matrix metalloprotease 10  
MMP11                     matrix metalloprotease 11 
MMP12                              matrix metalloprotease 12  
MMP13                              matrix metalloprotease 13  
MMP19                              matrix metalloprotease 19 
MMP20                  matrix metalloprotease 20 
MMP26                              matrix metalloprotease 26 
MMP28                              matrix metalloprotease 28 
MLH1                                mutL homolog 1 
MSH2                  mutS homolog 2 
MSH3                  mutS homolog 3  
MSH6                  mutS homolog 6  
PTGS2                              prostaglandin-endoperoxide synthase 2  
SMAD4                   SMAD family member 4 
TGFBR2                  transforming growth factor, beta receptor II  
TP53                  tumour protein p53 
 
195 
 
Five target genes showed no amplification in the experiments (DCC 
and MMPs 3, 8, 20 and 26). The remaining 23 targets and 4 endogenous 
controls exhibited good amplification curves and were therefore included in 
the final analysis. Several methods for comparing relative quantification 
results are available, most of them involving fold-change, p-values produced 
by t-tests, or combinations of both (McCarthy and Smyth, 2009). As this was 
an exploratory analysis based on a single biological replicate (plated in 
triplicate), no or minimal within-group variability was expected. Therefore, 
simple fold-change was selected as the method for screening potentially 
altered genes. A two-fold increase or decrease in gene expression was 
considered the biologically relevant cut-off.  
Relative quantification was calculated using the comparative CT 
method. Figure 4.12 depicts the relative expression of 23 CRC-related genes 
observed in RPL6-silenced TP53 wild-type HCT116 cells compared to cells 
that had been transfected with scrambled-siRNA. Two genes exhibited 
increased expression above the selected fold-change cut-off: BAX (RQ: 2.3, 
fold-change: 2.3) and MSH2 (RQ: 68, fold-change: 68). Conversely, two 
other genes showed relevant decreases in their relative expression: MMP-12 
(RQ: 0.0025, fold-change: - 400) and MMP-13 (RQ: 0.28, fold-change:- 3.57). 
Some other genes also demonstrated minor variations in gene expression 
but these have not been included in this discussion.  
As RPL6 knockdown provoked an inhibition of cell proliferation in 
HCT116 cells, it is intuitive to suppose that this gene is involved in the 
malignant phenotype of these CRC cells. Although it might be the result of 
some direct anti-proliferative effect, a reduction in RPL6 expression could 
cause an alteration in the expression of other genes or pathways associated 
with CRC growth. BAX and MSH2 were shown to be up-regulated upon 
RPL6 knockdown. The products of both genes are important players in 
physiological mechanisms of cancer control. BAX is a protein belonging to 
the BCL-2 family, a group of proteins that regulate apoptosis, specifically 
having pro-apoptotic properties (Czabotar et al., 2014). Apoptosis is one of 
the main regulators of cell proliferation and is an essential barrier against 
cancer development and progression. Supporting our finding, RPL6 has been 
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previously shown to inhibit BAX expression in gastric cancer cells (Du et al., 
2005). The importance of BAX as an anti-cancer factor is highlighted by the 
attempts to induce the up-regulation of this protein as a form of cancer 
therapy (Cory and Adams, 2005, Liu et al., 2016). The role of MSH2 in the 
protection against carcinogenesis has already been discussed in Chapter 1. 
It is part of the DNA mismatch repair (MMR) system, a mechanism of 
defence against errors in DNA replication frequently inactivated in colorectal 
cancers (Sameer et al., 2014). MSH2 expression was strikingly up-regulated 
in RPL6-silenced cells (68-fold). This suggests that the over-expression of 
RPL6 observed in colorectal tumours and the adjacent non-neoplastic 
mucosa (shown earlier in this chapter) might result in a strong inhibition in 
MSH2 expression, thus favouring the occurrence of potentially carcinogenic 
mutations. To the best of our knowledge, there has been no previous report 
of an association of RPL6 and either the apoptosis pathway or the DNA-
mismatch repair system in CRC.  
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Figure 4.12. The effect of RPL6 gene silencing on the expression of CRC-related 
genes in TP53 wild-type HCT116 cells. Horizontal lines represent the fold-change 
cut-offs (+/- 2-fold-change). BAX and MSH2 exhibited increased gene expression, 
whilst MMP-12 and MMP-13 showed decreased transcriptional levels upon RPL6 
silencing (N=1, n=3).  
 
Matrix metalloproteinases (MMPs) are proteins that are associated 
with neoplastic matrix remodelling, cellular invasion and angiogenesis (Gialeli 
et al., 2011), and have recently been recognised as having several other 
functions from cancer initiation to metastasis (Shay et al., 2015). The 
involvement of MMPs in CRC has been extensively studied and several 
reviews about the subject are available (Herszenyi et al., 2012, Zucker and 
Vacirca, 2004). Our study has shown that the expressions of MMP-12 and 
MMP-13 were reduced after RPL6 knockdown (see figure 4.12 above). 
Increased MMP-12 expression has been associated with adverse prognostic 
factors and reduced survival in cancers of the lung (Hofmann et al., 2005), 
stomach (Zheng et al., 2013) and melanomas (Zhang et al., 2015b). 
Moreover, MMP-12 polymorphism has been linked to an increased risk of 
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advanced stage at diagnosis in patients with CRC (VAN Nguyen et al., 2013). 
Similarly, MMP-13 expression has also been linked to worse prognosis and 
metastasis in various cancers such as gastric (del Casar Lizcano et al., 
2003), oral (Huang et al., 2016) and breast (Zhang et al., 2008) carcinomas, 
and sarcomas (Zyada and Shamaa, 2008). Regarding CRC, MMP-13 over-
expression has consistently been associated with advanced tumour stage, 
metastasis and poor survival (Yang et al., 2012, Yamada et al., 2010, 
Leeman et al., 2002). Collectively, these findings point to an important role of 
these two MMPs during colorectal carcinogenesis. Thus, the resultant 
decrease in the expression of MMP-12 and MMP-13 upon RPL6 knockdown 
would result in an inhibitory effect on cellular features important to the 
malignant phenotype. No association between RPL6 and metalloproteinases 
has previously been reported.   
 
4.7. Discussion 
 
Quantitative PCR has become a popular method for translational 
research in oncology. It can be used for screening of potentially useful 
biomarkers and for validation of candidates identified by proteomic or 
genomic approaches (Skrzypski, 2008, Clark-Langone et al., 2007, Scott et 
al., 2011). An example of the successful use of qPCR in this setting is the 
development of the Oncotype Dx, a qPCR-based panel of breast cancer 
biomarkers capable of defining the risk of recurrence after surgical treatment 
of early stage tumours (Paik et al., 2004). Based on the recurrence score 
provided by the test, clinicians can tailor treatments and avoid unnecessary 
toxic therapies in low-risk patients. This test has been widely used for node-
negative, hormone receptor-positive breast cancer. The company 
responsible for the development of Oncotype Dx has also created a similar 
test for colon cancer, the Oncotype Dx Colon Cancer Assay (Clark-Langone 
et al., 2007, Clark-Langone et al., 2010). However, this version of the test 
has not gained as much acceptance as the breast cancer assay, mainly due 
to the lack of robust clinical evidence of benefit from its use (Webber et al., 
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2010). Therefore, the discovery of CRC biomarkers by qPCR is still an open 
and promising research field.  
The selection of the candidate biomarkers under study here was 
based mainly on the results from previous studies in our group performed by 
Abeer Hammoudi, who showed increased expression of RPL6 and PHB 
(Hammoudi et al., 2013) in animal models of intestinal carcinogenesis, and 
by Shahram Ibrahim, who suggested NAP1L1 as a potential CRC biomarker 
(Ibrahim, 2014). CTNNB1 was also tested, in order to better clarify the Wnt 
pathway status in our samples. The qPCR experiments were performed after 
testing the conditions in several optimisation and quality-control steps 
previously described.  
The expression of CTNNB1 was similar in normal controls and 
adjacent tissues, and was only slightly increased in tumour samples. As 
mentioned earlier, the few reports describing CTNNB1 expression in CRC 
have shown contradictory results (Anwar et al., 2015, Qin et al., 2006, Truant 
et al., 2008). Gene mutations, rather than increased gene expression, 
appears to be relevant in colorectal carcinogenesis, as several reports have 
consistently demonstrated the presence of CTNNB1 mutations in some 
cases of sporadic CRC (Cancer Genome Atlas Network, 2012, Anwar et al., 
2015). Moreover, activation of the Wnt signalling pathway in CRC is more 
commonly a result of APC mutations resulting in accumulation of β-catenin 
via decreased degradation than a consequence of increased mRNA 
expression.   
Regarding our candidate biomarkers, we observed a strikingly similar 
pattern of expression for NAP1L1 and RPL6, a correlation that was also 
observed in the immunohistochemical work presented in Chapter 3. Both 
genes were shown to be highly expressed in both the tumour and the 
adjacent mucosa from patients with CRC when compared to normal controls. 
These findings suggest that these genes may be involved in “field 
cancerisation” or “field effect”, a phenomenon first introduced by Slaughter et 
al. in 1953 (Slaughter et al., 1953) and well described in cancer development. 
It is largely attributed to genetic and epigenetic modifications leading to 
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altered gene expression (Baba et al., 2016), making tissues adjacent to 
tumours prone to develop new primary cancers. In one report assessing CRC 
tissues, epigenetic modifications were found in adjacent tissues collected 
either 2cm or 8cm from the primary tumour (Park et al., 2016). We analysed 
adjacent tissues collected 10cm or more from the tumour and still observed a 
differential expression suggesting that environmental factors might affect 
large portions of the intestine. Although we have not specifically assessed 
epigenetic modifications, gene expression is directly or indirectly affected by 
such alterations, suggesting this mechanism as a possible explanation for the 
results observed. NAP1L1 has been shown to have important functions in 
maintaining dedifferentiation in cancer-derived (Li et al., 2012) and 
pluripotent stem cells (Gong et al., 2014). It also regulates proliferation in 
murine stem cells (Yan et al., 2016). Taken together, these results suggest 
that NAP1L1 might be a fundamental player in cancer development and 
progression. RPL6 gene expression and function have been far less explored 
in cancer research. Studies using gastric cancer cell lines have suggested an 
important role in proliferation and multi-drug resistance (Du et al., 2005, Wu 
et al., 2011, Gou et al., 2010). Additionally, this protein has been shown to 
interact with the MDM2-p53 complex upon ribosomal stress, operating as a 
feedback loop for p53 activity in embryonic and cancer cells lines (Bai et al., 
2014). The paucity of data regarding RPL6 function in carcinogenesis impairs 
the formulation of a precise hypothesis to explain our findings. P53 loss-of-
function might explain the increased expression of RPL6 in cancer tissues 
(based on the feedback loop just explained). However, it would not provide 
an explanation for the increased expression in the adjacent tissues, as TP53 
mutations are considered late events in colorectal carcinogenesis.  
Differences in demographic characteristics between groups should 
also be taken into account when interpreting these findings. In this study, 
groups were well balanced in terms of age. Thus, genetic and epigenetic 
changes due to the aging process are unlikely to have influenced the results. 
All samples were collected in the same region, thus minimising the possibility 
of ethnicity misbalance. On the other hand, there was a predominance of 
men in the cancer cohort whilst women formed the majority of the normal 
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control individuals. Although no relationships between gender, sex hormones 
and the expression of our candidates have been reported, further research 
involving gender-matched cohorts could clarify this issue. There are other 
factors related to the procedures used for sample collection (i.e. colonoscopy 
versus surgery) that might also explain the observed differences in gene 
expression between normal and cancer/adjacent samples. For example, the 
bowel preparation and type of anaesthesia were different between these two 
procedures. The potential impact of these differences in our results would 
also require additional research. 
Another point of discussion is the apparent discordance between the 
findings of the immunohistochemical and the gene expression studies that 
we report. Both NAP1L1 and RPL6 exhibited a reduction in nuclear 
immunostaining in cancer tissues when compared to the adjacent unaffected 
colonic mucosa, whilst these genes showed increased expression in both 
tumour and adjacent samples, compared to normal controls. Concordance 
between mRNA expression and protein content has long been demonstrated 
to be poor as a result of post-transcriptional, post-translational and protein 
degradation regulation (Vogel and Marcotte, 2012). A recent large-scale 
analysis of 16,561 genes and corresponding proteins in 200 normal and 
cancer samples showed a Spearman´s Rho correlation coefficient of only 
0.45 (Kosti et al., 2016). Only 6.1% of the gene/protein pairs exhibited 
statistically significant correlations (Rho values ranging from 0.77 to 1.0). 
None of the genes tested in this section of our research were listed in this 
group, thus providing support for the RNA/protein dissociation that we 
observed. Besides the mechanisms mentioned above, extracellular 
translocation may also explain the absence of protein accumulation within the 
cells. The results from Line et al. showing that NAP1L1 is an antigenic 
protein that produces an immune response in a subset of patients with CRC 
but not in healthy individuals provide the rationale for this hypothesis (Line et 
al., 2002). The dissection of the precise mechanisms underlying NAP1L1 and 
RPL6 cellular distribution is beyond the scope of this research. Nonetheless, 
the assessment of the expression of these proteins in blood derived from 
CRC patients and healthy individuals might result in a clinically useful 
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biomarker with potential implications for cancer screening, diagnosis and 
surveillance. Therefore, the assessment of NAP1L1 and RPL6 protein 
concentration in blood using immuno-based assays was undertaken and the 
details of these experiments are described in the next chapter.  
Based on the differential expression of NAP1L1 and RPL6 between 
tumour/adjacent tissues and normal controls, we decided to perform a study 
of the mechanistic consequences of gene silencing on cell proliferation and 
on the expression of other CRC-related genes. By using siRNAs, we 
successfully blocked the transcription of these two genes in a colorectal 
cancer cell line (TP53 wild-type and null HCT116 cells). Next, we carried out 
experiments to assess the effect of gene silencing on cell proliferation. 
NAP1L1 silencing did not produce any alteration of cell proliferation in TP53 
competent cells. The literature suggests that NAP1L1 regulates the 
differentiation and proliferation of stem cells (Li et al., 2012, Gong et al., 
2014, Yan et al., 2016) and pancreatic neuroendocrine tumours (Schimmack 
et al., 2014). Therefore, altered NAP1L1 expression in CRC might not be 
associated with proliferation but with the maintenance of an undifferentiated 
status. Differently, RPL6 silencing resulted in strong inhibition of cell growth 
in the same cell type. A similar effect has already been demonstrated in 
gastric cancer cell lines (Wu et al., 2011, Du et al., 2005), reinforcing the 
importance of this gene for the proliferation of cancer cells. HCT116 cells 
with deleted TP53 demonstrated a more erratic pattern of proliferation when 
transfected with scrambled or targeting siRNAs. Moreover, a low basal 
proliferation rate (even in the non-transfected group) and possible cell toxicity 
were noticed during the proliferation assay. These issues prevented us from 
drawing any definite conclusion regarding the silencing of NAP1L1 and RPL6 
in cells without a functioning TP53.  
RPL6 knockdown of TP53 wild-type cells was further analysed in order 
to assess the effects of gene silencing on the expression of CRC-related 
genes. Using qPCR-based techniques, we demonstrated that, among 23 
genes known to be associated with CRC, RPL6 knockdown resulted in 
increased expression of BAX and MSH2 and decreased expression of MMP-
12 and MMP-13. BAX and MSH2 are important players in protecting against 
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cancer development, whilst MMPs are effectors in cancer invasion, 
metastasis and angiogenesis, among other features associated with a 
malignant phenotype. Taken together, these results suggest some possible 
mechanisms by which RPL6 up or down-regulation could control CRC cell 
behaviour, thus explaining the influence of this gene on cell proliferation and, 
possibly, other malignant features. Although these findings are hypothesis 
generating, further research is strongly recommended in order to clarify the 
role of RPL6 during carcinogenesis in general and in CRC in particular. 
PHB is a ubiquitous protein with an essential role in protection against 
oxidative stress, a factor known to be involved in carcinogenesis (Jones, 
2008). Other cellular functions regulated by PHB include proliferation and 
survival via interactions with signalling cascades such as the Ras-Raf-MEK-
Erk pathway and caspases (Chowdhury et al., 2014). In our study, PHB gene 
expression results did not suggest a clear role of this gene in CRC. Although 
a trend pointing to increased transcript levels in adjacent and tumour tissues 
was observed, this was not statistically significant. The small sample size 
might explain this negative result. However, the results from Hammoudi et al. 
showed only a 1.32-fold increase in PHB expression in tumour versus 
adjacent samples (Hammoudi et al., 2013). This may suggest that PHB 
mRNA over-expression is not as marked in CRC as it has been 
demonstrated in other cancer types (Franzoni et al., 2009, Jiang et al., 2013, 
Kang et al., 2008, Ummanni et al., 2008). Consequently, we decided not to 
further study PHB gene function using additional methods in this project. 
However, the differential cellular distribution of this protein revealed by our 
immunohistochemical studies deserves further clarification. We will therefore 
explore possible associations between PHB immuno-expression and clinical 
and prognostic variables in a dedicated chapter (Chapter 6), along with the 
other promising markers: NAP1L1 and RPL6.  
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5. CHAPTER 5 – ASSESSING BLOOD CIRCULATING CANDIDATE 
PROTEIN BIOMARKERS FOR COLORECTAL CANCER: ENZYME-
LINKED IMMUNO-ASSAY ANALYSIS (ELISA) AND DEVELOPMENT OF 
AN ELECTROCHEMILUMINESCENCE (ECL) ASSAY FOR NAP1L1 
 
5.1. Introduction 
 
The results described up to this point have clearly shown a differential 
expression of our candidate protein biomarkers in tissues from CRC patients. 
However, the immunohistochemistry and qPCR experiments both required 
tissue fragments for analysis. These samples, in turn, require invasive 
procedures such as endoscopy or surgery. Ideally, a biomarker test should 
provide diagnostic, prognostic or predictive information in the least harmful 
manner. In this regard, blood tests are favoured as being minimally-invasive 
and are a widely accepted way of obtaining biological samples. For example, 
a German study has shown that only 37% of patients offered screening 
colonoscopy accepted this test. From the population that refused 
colonoscopy, only 15% accepted an alternative stool test, whilst 83% 
accepted a blood test for SEPT9 (Adler et al., 2014). In fact, blood collection 
is part of the routine workup of most health conditions. The uncomplicated 
collection and storage of blood derivatives such as plasma and serum 
together with the comprehensive proteome represented in these biological 
fluids ensure that it will remain the preferred diagnostic material for the 
foreseeable future (Rifai et al., 2006). 
In the biomarker discovery workflow (see figure 5.1), an initial 
extensive prospection of candidate biomarkers using methods such as liquid 
chromatography tandem mass spectrometry (LC-MS/MS) is usually 
performed (Rifai et al., 2006). This process is known as an “unbiased” 
approach, as there are no anticipated biomarker candidates. Subsequently, 
the proteins that exhibit differential expression are further assessed using 
more targeted techniques. This is the pathway that we have been following in 
this research after the initial findings published by Hammoudi (Hammoudi et 
al., 2013). The first method that was devised to accurately measure the 
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concentrations of peptides and proteins in biological fluids was 
radioimmunoassay (RIA). It was first reported in 1960 (Yalow and Berson, 
1960) and revolutionised laboratory medicine by allowing the precise 
quantification of important substances. Nonetheless, the use of radioactively 
labelled substances requires complex facilities to decrease occupational 
exposure and environmental contamination. To address this issue, Perlmann 
and Engvall in Sweden, and Schuurs and van Weemen in the Netherlands 
conceptualised and developed modifications of the RIA and replaced the 
radioactive compound with an enzyme as the reporter label (Engvall and 
Perlmann, 1971, Van Weemen and Schuurs, 1971). In the late 1970s and 
early 1980s, enzyme immunoassays (EIA) finally matched the RIA´s 
exquisite sensitivity. This achievement, coupled with the practicality and the 
possibility of automation soon made ELISAs and other non-radioactive EIAs 
the most used methods for protein quantification in biological fluids (Lequin, 
2005). Currently, ELISAs are one of the most widely employed approaches 
for verification and validation of new biomarkers (Del Campo et al., 2015, 
Rifai et al., 2006).  
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Figure 5.1. Main phases of biomarker discovery and validation. The process starts 
with a low-throughput technique (i.e. using few samples) that is capable of analysing 
hundreds or thousands of analytes, such as LC-MS/MS. This is called the 
“unbiased” step. Then, more targeted methods are used in order to confirm the 
differential expression of the candidate biomarkers using larger numbers of 
samples. LC-MS/MS, liquid chromatography tandem mass spectrometry; MRM, 
multiple reaction monitoring; IHC, immunohistochemistry; WB, Western blotting. 
Figure from (Del Campo et al., 2015), adapted from (Rifai et al., 2006).  
 
There are a number of different ELISA formats in laboratory practice. 
The sandwich-ELISA is the most commonly used due to its high sensitivity 
and specificity (Price and Newman, 1997). In this format, two antibodies (a 
capture antibody and a detection antibody) are used. Although 
immunoassays are deemed ideal methods for biomarker validation in 
biological fluids, the performance of the test is highly dependent upon several 
steps during the development and optimisation of the assay. A wide range of 
variables from antibody specificity to the composition and concentration of 
the different reagents can affect the final result (Del Campo et al., 2015). If 
the required sensitivity is not achieved with the enzymatic method, alternative 
reactions such as fluorescence or chemiluminescence may be used (Price 
and Newman, 1997). Additionally, the best matrix for immunoassays, plasma 
or serum, is highly variable and depends on each specific analyte (O'Neal et 
al., 2014, Alsaif et al., 2012). Therefore, the appropriate matrix should be 
determined for each protein prior to any validation study.  
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Several CRC-associated biomarkers have been assessed in blood. 
Fung et al. analysed 32 proteins as potential biomarkers and found that three 
of them, Insulin like growth factor binding protein 2 (IGFBP2), Dickkopf-3 
(DKK3), and Pyruvate kinase M2 (PKM2), constituted a diagnostic panel for 
early-stage CRC with a performance superior to FOBT (Fung et al., 2015). 
Pengjun et al. demonstrated that a panel of cytokines, CEA and CA 19-9 
measured by ELISA could assist in CRC detection (Pengjun et al., 2013). 
Several authors have also shown that circulating methylated Septin 9 can 
also be used for CRC diagnosis (deVos et al., 2009, Grutzmann et al., 2008, 
Toth et al., 2012). However, none of the suggested panels have been 
thoroughly assessed in large validation cohorts and the real benefit of their 
use remains unproven. Here, we decided to test the proteins that had been 
identified in previous work from our group. The concentrations of RPL6 and 
PHB have previously been demonstrated to be increased in blood from 
animal models of intestinal carcinogenesis (Hammoudi et al., 2013). 
NAP1L1, a protein differentially expressed in tissues from both animal 
models of CRC and human cancer samples (Ibrahim, 2014), was also shown 
to be increased in a preliminary study from our group (data discussed in the 
next section). Therefore, we undertook an ELISA study of these proteins to 
investigate whether they were differentially expressed in the blood of CRC 
patients. This could potentially lead to the development of a new panel of 
CRC biomarkers.  
Commercial ELISA kits have theoretically been tested and optimised 
by their manufacturers. However, laboratory conditions may vary and the 
performance of these kits should be externally validated in order to guarantee 
their accuracy. A good way to assess the quality of a kit is by checking the 
reproducibility of the results from previous studies which have used the test 
in different settings. Nonetheless, this is not always possible as many 
proteins are poorly studied and, sometimes, have not been assessed at all in 
published papers. When validated kits are not available, the assessment of 
new candidate biomarkers requires the development and optimisation of 
novel kits. Commercial kits for NAP1L1, RPL6 and PHB are currently 
provided by some manufacturers. However, none of our candidate 
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biomarkers has previously been well studied using ELISA. Searching the 
English-language literature using PubMed, Scopus and Web of Science 
databases with the keywords “ELISA”, “enzyme-linked immunosorbent 
assay”, “immunoassay” and the protein names, we found no report of 
NAP1L1, RPL6 or PHB assessment using ELISA in cancer or in any other 
health condition. Only a single Chinese-language study had evaluated PHB 
in cervical carcinoma patients using ELISA (only the abstract is available in 
English). The authors reported a decreased concentration of PHB in the 
serum of cervical cancer patients compared to normal controls (Yan et al., 
2013). Therefore, no standard commercial kit was identified for any of our 
candidate biomarkers and no literature background was found to guide our 
experiments. Consequently, we decided to start our assessment using kits 
that had previously been tested by our group in some preliminary 
experiments (described below). Subsequently, we also decided to test both 
biofluids – serum and plasma, in order to improve the yield of valid results. 
 
5.2. Preliminary ELISA data 
 
The initial experiments assessing ELISA kits to measure the candidate 
biomarkers were performed by Nadeem Al-Khafaji as part of his MRes 
project in our research group (unpublished work). In this evaluation, he 
prospectively collected serum samples from individuals who underwent 
colonoscopies at the Countess of Chester Hospital (Chester, UK) and at the 
Royal Liverpool University Hospital “Inflammatory Bowel Disease Clinic” 
(Liverpool, UK). As this analysis aimed mainly to evaluate the suitability of 
the ELISA kits, few colorectal cancer cases were included. Individuals 
providing serum for this assessment had the following endoscopy/pathology 
diagnoses: normal colon (12 cases), Crohn´s disease (10), ulcerative colitis 
(11), low-grade dysplastic colonic adenomas (4), current CRC (1) and 
previously resected CRC with a suspected recurrence (1). For the purpose of 
hypothesis generation, the two later cases were combined together (cancer 
group) and were compared to the remaining non-malignant groups.  
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The kits used for this analysis were designed by Cloud-Clone Corp 
(Houston, USA) and assembled by Uscn Life Science Inc (Wuhan, China). 
These providers were chosen because their kits had previously been tested 
by Hammoudi et al. using blood from animal models of CRC with promising 
results (Hammoudi et al., 2013) and because they manufactured kits for all 
the candidate proteins that we needed to test: NAP1L1, RPL6 and PHB. After 
initial optimisations, serum samples were diluted to 1:3 in sterile PBS and 
were tested in duplicate using the protocol recommended by the 
manufacturer and described in Chapter 2. Plate reading was carried out 
using a Tecan Sunrise™ 96-well plate reader at 450nm. 
The initial purpose of this experiment was to determine whether or not 
protein concentrations would lie within the detection range of the kit. For this 
sample set, all kits were able to detect the serum concentration of all 
samples tested. Next, the concentrations of the proteins in each group were 
compared to provide insights regarding possible trends and guide the 
following stages of our investigation. When the concentration of the proteins 
was collectively plotted as a panel and the individual groups were compared, 
we observed a trend towards overall increased expression in the CRC group 
compared to the non-malignant groups (see figure 5.2A). The comparison 
between malignant and non-malignant groups for individual proteins 
exhibited the same trends for NAP1L1 and PHB (figure 5.2B and C) but not 
for RPL6 (figure 5.2D).  
 
211 
 
 
Figure 5.2. Preliminary ELISA results for the assessment of NAP1L1, PHB and 
RPL6 in serum samples from individuals with CRC (2 cases) and several non-
malignant conditions (37 cases). When plotted as a panel, a trend towards 
increased expression of the proteins was observed (A). Although the limited number 
of samples prevents any solid conclusion at this stage, the comparison between the 
malignant and non-malignant conditions showed increased NAP1L1 and PHB 
expressions in CRC cases (B and C). No such trend was observed for RPL6 (D). 
*p<0.05; **p<0.01 (Mann-Whitney U test). Reproduced with permission from 
Nadeem Al-Khafaji.  
 
These initial findings provided the basis for continuing our assessment 
of these candidates in a validation phase. Based on these results, we 
decided to test the same ELISA kits using another sample cohort which 
included more CRC and colonic adenoma cases. We also decided to omit 
samples from patients with inflammatory bowel diseases, as no trend had 
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been observed in this group of samples. Therefore, normal individuals, 
individuals with colorectal adenomas and CRC patients were included.  
 
5.3. Clinical samples 
 
For this investigation, we used a new set of serum and plasma 
samples collected at the Countess of Chester Hospital from normal 
individuals, individuals with adenomatous polyps and CRC patients – the UK 
cohort. Samples were also collected from similar groups of patients in the city 
of Cuiaba, Brazil, forming the Brazilian cohort. UK samples were collected 
during the years 2015/2016 whilst Brazilian samples were collected from 
2013 until mid-2015. Similar protocols were used for sample collection, 
processing and storage of the two cohorts. Noteworthy, Brazilian samples 
were shipped to the UK under optimal conditions (dry ice) using a company 
specialised in the transportation of biological samples. Thus, the main 
difference between these two groups was the length of storage, although 
minor differences during collection and processing cannot be excluded as 
local technicians prepared most of the samples. Some samples were used 
during the initial tests and assay optimisations. Given the various procedures 
involved in these phases, several samples were therefore totally used and, 
consequently, were not available for the final experiments. Therefore, we 
kept a set of samples from each cohort unused until the final experiments, so 
that we could produce final results for the same samples in each part of this 
study. In order to reassure that only clinical groups with a representative 
number of samples were assessed, we decided to test only normal controls 
and cancer samples for the Brazilian cohort, as there were few adenoma 
cases within this sample set. For the UK cohort, given the presence of larger 
numbers of samples in each group, we compared normal controls, low- and 
high-grade adenomas and cancer samples. Table 5.1 describes the 
demographic characteristics of the individuals from the Brazilian cohort who 
provided the samples that were tested in the final immunoassay experiments 
carried out in this study. Unfortunately, the same information was not 
available for the individuals from the UK cohort due to the fact that this 
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investigator is not registered as a clinician in the UK and did not have access 
to clinical information for UK patients. 
 
Table 5.1. Clinical and demographic characteristics of the individuals from the 
Brazilian cohort included in the final immunoassay experiments. Mean age for 
cancer group was significantly higher than for normal individuals.  
Characteristics Normal control 
(n=10) 
Cancer 
(n=30) 
p 
    
Mean age (range) 43 (23-56) 55 (34-83) 0.009* 
Gender    NS 
Male 4 16  
Female 6 14  
Stage   NA 
I-II - 47%  
III-IV - 53%  
* t- test. NS: non-significant. NA: not applicable.  
 
5.4. ELISA testing using commercial kits 
 
In this section, we describe the issues and results that were obtained 
when commercial ELISA kits were used to test these sample cohorts. As 
mentioned earlier, our starting point was the platform from Cloud-Clone Corp 
tested preliminarily. Although we used similar protocols and conditions as 
before, we encountered several difficulties when trying to reproduce the 
results that have previously been demonstrated. Among the most serious 
issues, low sensitivity (many samples lying below the detection range) and 
poor inter-plate consistency (similar kits yielding different results for the same 
samples) were the most relevant. In order to overcome these problems, we 
tested kits purchased from different manufacturers and also a different 
sample matrix (plasma). In the following sub-sections, a summary of these 
experiments and the results for each protein are provided. As the 
comprehension of the issues and findings observed requires a detailed 
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understanding of individual ELISA results for particular cases, tables 
displaying results for all samples tested in each relevant experiment are 
provided. When appropriate, graphs showing mean concentrations and 
statistical information are also shown.  
 
5.4.1. NAP1L1 kits – testing and results  
 
The Cloud-Clone Corp NAP1L1 ELISA kit (product number 
SEH571Hu) served as our starting point in this assessment. NAP1L1 
isoform-1 (Homo sapiens) is made of 391 amino acids. According to the 
manufacturer (personal communication), the immunogenic sequence for this 
kit ranges from Ala2 to Lys197. The detection range for this kit is reported to 
be 0.119 – 20.0ng/mL. Using the protocols suggested by the manufacturer 
and the sample conditions used in the preliminary phase described earlier, 
we attempted to replicate the initial results. Testing ten serum samples from 
each of the four groups (normal, low-grade adenoma, high-grade adenoma 
and cancer) in duplicate, we obtained the results depicted in table 5.2. As 
can be seen, different from the preliminary test results, various samples 
exhibited optical readings below the detection range of the kit, thus 
preventing any comparison between groups. In order to rule out any 
experimental error, a similar kit from the same provider was tested with other 
samples from this same cohort. Although meticulous care was taken during 
sample preparation and assay procedures, similar results were obtained 
(these results will be shown later when the comparison between serum and 
plasma is discussed). Once the possibility of technical error had been 
excluded, another issue that might have played a part was sample collection 
and storage. However, in this experiment we used samples collected both in 
Chester-UK (labelled with the initials JJ) and in Cuiaba-Brazil (all the 
remaining samples). Brazilian samples were collected between 1 and 3 years 
prior to the experiments being undertaken; Chester samples were collected 
only weeks or a few months prior to the analysis, and both were stored at -
80ºC until use. The initial results for both groups were very similar, thus 
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suggesting that inadequate sample preparation and storage were unlikely 
sources of inconsistency. Based on these results, we concluded that this kit 
did not exhibit the necessary consistency and dynamic range for the 
validation of our candidate biomarkers. Therefore, different kits needed to be 
tested.  
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Table 5.2. Initial ELISA results for NAP1L1 using the Cloud-Clone kit. 
Group Sample Id 
Concentration 
(ng/mL) 
 
Normal N2 2.332 
   N3 0.506 
   N4 0.368 
   N5 6.678 
   N6 invalid value 
   N7 0.956 
   N8 0.248 
   N11 0.458 
   N22 invalid value 
   N23 0.49 
 Low-grade 
adenoma P2 0.568 
   P3 1.098 
   P4 invalid value 
   P5 0.768 
   P6 0.276 
   P7 1.316 
   P8 invalid value 
   P9 invalid value 
   P10 0.854 
   P18 0.99 
 High-grade 
adenoma JJ047 invalid value 
   JJ058 invalid value 
   JJ093 0.154 
   JJ111 invalid value 
   JJ138 1.22 
   JJ156 invalid value 
   JJ165 invalid value 
   CR68 0.732 
   CR78 invalid value 
   CR95 1.14 
 Cancer CR62 0.466 
   CR65 invalid value 
   CR67 0.278 
   CR70 invalid value 
   CR73 0.274 
   CR76 1.934 
   CR80 0.676 
   CR83 0.422 
   CR85 invalid value 
   CR86 invalid value 
 
    
Ten serum samples from each of 
the four groups were tested. A 
large proportion of the samples 
exhibited readings below the 
detection range of the kit 
(assigned as “invalid value”). 
Thus, no average concentration 
could be calculated and no 
comparison between groups 
could be carried out. This 
performance was different from 
the results obtained using the 
same kit in the preliminary phase.  
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In order to clarify whether the poor results were due to the suboptimal 
performance of that specific kit, we decided to test plates from other 
manufacturers that used different protein epitopes as the immunogen. This 
represented quite a challenge as all of the contacted providers reported that 
their kits used the same or largely overlapping areas of the NAP1L1 N-
terminal region. One of the only kits that targeted a different area of the 
protein was provided by DL Develop – product number DL-NAP1L1-Hu 
(Wuxi, China). The immunogen used in this kit spans from Ala2 to Thr289, 
thus encompassing a larger area of NAP1L1 than the Cloud-Clone kit 
described above. Its product sheet describes performance parameters (such 
as detection range, sensitivity and precision) very similar to those provided 
by the Cloud-Clone kit. Assay procedures recommended by the 
manufacturers were also identical.  
Using the same samples tested in the previous experiment, we 
assessed the performance of the DL Develop NAP1L1 ELISA kit. This step 
aimed mainly to investigate whether or not this kit had a better sensitivity 
than the one provided by Cloud-Clone Corp, thus being able to define 
NAP1L1 concentrations for all samples. The results for this test are shown in 
table 5.3. Differently from the Cloud-Clone kit, the DL Develop NAP1L1 kit 
produced optical density readings within the detection range for all cases and 
concentrations were defined for all serum samples. However, a careful 
analysis of these results revealed some additional problems. Firstly, most of 
the concentrations were low, close to the lower limit of detection for the kit. 
This finding was different from the results produced in the preliminary phase, 
although it must be highlighted that a different kit was then used. Additionally, 
despite observing a trend of increased NAP1L1 concentration in the serum of 
CRC patients, this was not statistically significant (see figure 5.3).  
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Table 5.3. ELISA results for NAP1L1 using the DL Develop kit. 
Group 
Sample 
Id 
Concentration 
(ng/mL) 
Median 
(ng/mL) 
Normal N2 0.186 
   N3 0.172 
   N4 0.17 
   N5 0.297 
   N6 0.387 
   N7 0.266 
   N8 0.206 
   N11 0.216 
   N22 0.194 
   N23 0.194 0.2288 
Low-grade 
adenoma P2 0.218 
   P3 0.309 
   P4 0.198 
   P5 0.156 
   P6 0.284 
   P7 0.21 
   P8 0.316 
   P9 0.288 
   P10 0.194 
   P18 0.21 0.2383 
High-grade 
adenoma JJ047 0.234 
   JJ058 0.204 
   JJ093 1.06 
   JJ111 0.19 
   JJ138 0.176 
   JJ156 0.258 
   JJ165 0.23 
   CR68 0.267 
   CR78 0.168 
   CR95 0.198 0.2985 
Cancer CR62 0.238 
   CR65 0.198 
   CR67 0.236 
   CR70 0.706 
   CR73 1.024 
   CR76 0.132 
   CR80 0.26 
   CR83 0.262 
   CR85 0.346 
 
 
CR86 0.321 0.3723 
 
The results are different from 
the Cloud-Clone kit, even 
though these are the same 
samples. All the samples 
produced readings within the 
detection range of this assay. 
Notably, all calculated 
concentrations were very low 
compared with the preliminary 
results. Median concentrations 
for each group were 
calculated and compared, as 
seen in the figure below.   
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Figure 5.3. Graphic representation of NAP1L1 serum concentrations using the DL 
Develop kit. A trend of increased concentration was observed in serum samples 
from high-grade adenomas and CRCs. However, this difference was not statistically 
significant (p=0.287, Kruskall-Wallis test). N=10 cases per group.  
 
Next, we directly compared the results produced by the two kits that 
we tested, as we used the same samples and the same assay procedures in 
both experiments. If concordant, we could conclude that the accuracies of 
both kits were similar, and therefore, we could opt for the DL Develop plate 
due to its better detection range and lower limit of detection. Unfortunately, 
however, this was not the case. As table 5.4 depicts, the concordance 
between the two plates was extremely poor. Some samples exhibiting higher 
concentrations in the Cloud-Clone plate showed low concentrations in the DL 
Develop plate, and vice versa. Calculated Pearson´s correlation coefficient 
was r = - 0.13, denoting an insignificant negative correlation between the 
results produced by the two assays. 
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Table 5.4. Comparison of results obtained with NAP1L1 ELISA plates from Cloud-
Clone and from DL Develop. Some samples were retested in another Cloud-Clone 
plate to assess the consistency of that kit.  
Sample 
1st Cloud-Clone plate 
(ng/mL) 
2nd Cloud-Clone plate  
(ng/mL) 
DL Develop plate  
(ng/mL) 
N2 2.332 1.86 0.186 
N3 0.506 - 0.172 
N4 0.368 invalid value 0.17 
N5 6.678 - 0.297 
N6 invalid value - 0.387 
N7 0.956 - 0.266 
N8 0.248 - 0.206 
N11 0.458 - 0.216 
N22 invalid value - 0.194 
N23 0.49 - 0.194 
P2 0.568 - 0.218 
P3 1.098 - 0.309 
P4 invalid value - 0.198 
P5 0.768 - 0.156 
P6 0.276 - 0.284 
P7 1.316 - 0.21 
P8 invalid value - 0.316 
P9 invalid value - 0.288 
P10 0.854 - 0.194 
P18 0.99 - 0.21 
JJ047 invalid value - 0.234 
JJ058 invalid value invalid value 0.204 
JJ093 0.154 0.346 1.06 
JJ111 invalid value invalid value 0.19 
JJ138 1.22 1.28 0.176 
JJ156 invalid value invalid value 0.258 
JJ165 invalid value - 0.23 
CR68 0.732 - 0.267 
CR78 invalid value - 0.168 
CR95 1.14 - 0.198 
CR62 0.466 - 0.238 
CR65 invalid value - 0.198 
CR67 0.278 - 0.236 
CR70 invalid value - 0.706 
CR73 0.274 - 1.024 
CR76 1.934 - 0.132 
CR80 0.676 - 0.26 
CR83 0.422 - 0.262 
CR85 invalid value - 0.346 
CR86 invalid value - 0.321 
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As also shown in the table above, seven serum samples were re 
tested in duplicate in another Cloud-Clone kit in order to ascertain the inter-
assay coefficient of variation (reported by both manufacturers as being 
<12%). Coefficient of variation is computed by the formula: CV (%) = 
(SD/mean) x 100, where SD is the standard deviation (Connett and Lee, 
1990). Four samples showed concentrations below the detection range in 
one or both plates. The three samples with valid results exhibited a CV of 
25.3% between plates. Therefore, although higher than the CV reported by 
the manufacturers, the consistency between the two Clone plates was better 
than the concordance between Cloud-Clone and DL Develop plates.   
The aforementioned results did not allow us to confidently select a 
platform to proceed. At this point, therefore, we decided to test a different 
biological fluid (plasma), to check whether this would produce more 
consistent results. For this experiment, we selected 18 cases representing 
normal controls, high-grade adenomas and CRC. Samples were chosen 
based on the availability of both serum and plasma in sufficient quantities to 
be used in this and in subsequent tests, if necessary. Serum and plasma 
from each case were tested in duplicate using the Cloud-Clone NAP1L1 
ELISA kit. This experiment also intended to test the CV of this kit, as 
described above, because we re-tested 7 samples. Strikingly, this analysis 
revealed that all plasma samples exhibited valid readings, whilst the serum 
samples repeated the pattern of a high proportion of readings being below 
the detection range (see table 5.5). Furthermore, whenever valid readings 
were obtained for both plasma and serum samples for a particular case, the 
former was higher than the latter. This remarkable finding imposed a totally 
new perspective for our investigation. It suggested that plasma instead of 
serum should be used in any further experiment for the assessment of 
NAP1L1. This finding, if confirmed, may also have implications for future 
studies assessing the concentration of this protein in blood samples.    
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Table 5.5. Comparison of NAP1L1 results between plasma and serum samples 
using a Cloud-Clone ELISA kit. Whilst serum samples performed similarly to 
previous observations using the same plate, all plasma samples yielded valid 
results. Additionally, whenever concentrations for both plasma and serum were 
valid, plasma concentrations were higher than serum concentrations.  
  Plasma   Serum   
 Groups Samples (ng/mL) Samples (ng/mL) 
Normal Chester JJ001P 0.902 JJ001S invalid value 
  JJ002P 1.544 JJ002S 0.438 
  JJ007P 0.396 JJ007S invalid value 
Normal Brazil N2P 2.698 N2S 1.86 
  N4P 0.536 N4S invalid value 
High-grade 
Chester JJ058P 0.71 JJ058S invalid value 
  JJ093P 1.682 JJ093S 0.346 
  JJ111P 0.712 JJ111S invalid value 
  JJ138P 2.338 JJ138S 1.28 
  JJ156P 0.744 JJ156S invalid value 
Cancer Chester JJ057P 1.692 JJ057S invalid value 
  JJ113P 0.78 JJ113S invalid value 
  JJ126P 0.842 JJ126S invalid value 
  JJ143P 1.2 JJ143S invalid value 
  JJ145P 0.862 JJ145S invalid value 
  JJ166P 1.564 JJ166S invalid value 
  JJ079P 0.732 JJ079S invalid value 
  JJ121P 1.508 JJ121S invalid value 
 
Although the demonstration of higher concentrations of NAP1L1 in 
plasma samples certainly opens an exciting new scientific avenue, the 
comparison of the median concentrations between patient groups did not 
show any noticeable difference, at least in this very small sample set (figure 
5.4). Any conclusion could however only be made after testing a larger 
sample set and using a consistent assay. For this purpose, we chose to 
proceed with testing plasma samples only. As none of the kits that we tested 
(Cloud-Clone and DL Develop) proved to be ideal platforms, we decided to 
test a third kit. This time, a UK-based provider with substantial expertise in 
manufacturing immunoassays – Abbexa Ltd, was chosen. 
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Figure 5.4. Mean plasma NAP1L1 concentration results using the Cloud-Clone 
ELISA kit. The comparison of the results between the groups did not show a 
significant difference (p=0.866, Kruskal-Wallis test). However, the limited number of 
samples per group prevented any robust conclusion. N= 5 normal controls, 5 high-
grade adenomas and 8 invasive cancer cases.  
 
 
The NAP1L1 ELISA kit from Abbexa – product number abx152455 
(Cambridge, UK) targets the protein area between Ala2 to Lys197 (personal 
communication), the same area used as the epitope for the Cloud-Clone kit. 
Assay procedures and performance features reported by the manufacturer 
were essentially the same as those reported for the previous two kits. Using 
96-well plates, we aimed to test plasma samples from the most 
representative groups for each cohort (UK and Brazil). In order to further 
assess whether or not the length of storage had an effect on the results, we 
analysed each cohort separately, as the UK cohort had a significantly shorter 
sample storage time than the Brazilian cohort. Brazilian samples available for 
this assessment were mainly normal controls and CRC cases. Thus we 
decided to focus on assessment of those two groups. For the UK cohort, as a 
larger number of samples from patients who had adenomas were present, 
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we tested samples from all four groups (normal controls, low-grade 
adenomas, high-grade adenomas and CRC).  
Plasma samples from the Brazilian cohort showed several results 
below the detection range of the kit, as shown in table 5.6. However, the 
proportion of invalid values was lower than that observed when we tested 
serum samples. Additionally, taking only valid results into account, the mean 
concentrations per group were considerably higher than those observed 
when testing serum samples. These findings reinforced the notion that 
NAP1L1 concentrations are easier to measure in plasma than in serum. 
However, comparison of the mean concentration of the valid results did not 
show any difference between normal controls and CRC cases (figure 5.5). A 
wide range of results was observed within each group, suggesting that 
NAP1L1 levels are variable and heterogeneous in both normal individuals 
and CRC patients. Noteworthy, the lowest valid result in this test was 
0.822ng/mL, a value well above the claimed inferior limit of detection of the 
kit (0.105ng/mL, according to the manufacturer). It suggests that the 
performance of this kit, at least in our laboratory, was inferior to the 
specifications provided by the company.  
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Table 5.6. Abbexa NAP1L1 ELISA kit results using plasma samples from the 
Brazilian cohort.  
NORMAL 
(n=10) Sample Id 
Concentration  
(ng/mL) 
CANCER 
(n=30) Sample Id 
Concentration 
 (ng/mL) 
  N1P 2.205   CR60P 2.997 
  N2P invalid value   CR62P 3.078 
  N3P 0.897   CR63P 3.102 
  N4P invalid value   CR64P 2.079 
  N5P invalid value   CR65P 1.86 
  N6P 5.268   CR67P 1.155 
  N7P 11.904   CR68P invalid value 
  N8P 1.872   CR69P 1.677 
  N11P 16.473   CR70P 5.133 
  N28P 16.482   CR71P 1.383 
  
 
    CR72P 2.277 
  
 
    CR73P invalid value 
  
 
    CR74P 0.822 
  
 
    CR75P 1.548 
  
 
    CR76P invalid value 
  
 
    CR77P invalid value 
  
 
    CR78P 1.776 
  
 
    CR79P 1.35 
  
 
    CR97P 1.452 
  
 
    CR81P invalid value 
  
 
    CR82P 11.73 
  
 
    CR84P 7.191 
  
 
    CR85P 3.261 
  
 
    CR86P 21.903 
  
 
    CR87P 3.441 
  
 
    CR88P 6.411 
  
 
    CR89P 0.855 
  
 
    CR90P 18.27 
  
 
    CR91P 1.197 
        CR92P 3.681 
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Figure 5.5. Mean NAP1L1 concentration in plasma samples from the Brazilian 
cohort (Abbexa kit). This graph was plotted excluding the invalid results in order to 
facilitate a visual comparison. No significant difference was demonstrated. Indeed, a 
trend of decreased NAP1L1 concentration in the cancer group was observed. 
(p=0.242, Mann-Whitney U test) N: 10 normal controls, 30 invasive cancers. 
 
Our next task was to test the UK cohort using the same ELISA kit. We 
tested samples from 10 normal controls, 10 patients with low-grade 
adenomas, 7 patients with high-grade adenomas and 13 CRC patients. 
Results are shown in table 5.7 and in figure 5.6, below. From the 40 samples 
tested, only two exhibited readings below the detection range. This was less 
than the number of invalid samples observed in the Brazilian cohort (shown 
above). Additionally, the mean values in the UK-groups were higher than 
those seen in the Brazilian groups. In this experiment, the mean 
concentration was not statistically different between the four groups. 
However, a trend towards increased NAP1L1 concentration in the cancer 
group was noticed. An identical trend was previously observed when testing 
serum samples using the DL Develop kit (see figure 5.3), the only kit able to 
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produce valid results for all the serum samples. However, the magnitude of 
the readings was lower in that case, probably due to the use of serum 
instead of plasma.  
 
Table 5.7. Abbexa NAP1L1 ELISA kit results using plasma samples from the UK 
cohort. Only two invalid results were produced. Concentrations were higher than 
those observed with the Brazilian cohort.  
Normal  (n=10) Low-grade   (n=10) High-grade     (n=7) Cancer  (n=13) 
Sample Id  (ng/mL) Sample Id 
 
(ng/mL) Sample Id 
 
(ng/mL) Sample Id 
 
(ng/mL) 
JJ001 1.461 JJ005 2.268 JJ047 Invalid JJ057 8.655 
JJ002 14.058 JJ006 14.331 JJ058 13.221 JJ079 6.885 
JJ007 6.216 JJ010 5.229 JJ093 19.311 JJ113 40.647 
JJ012 11.496 JJ011 2.655 JJ111 14.745 JJ121 5.772 
JJ013 14.469 JJ019 13.278 JJ138 7.527 JJ126 16.515 
JJ015 23.724 JJ021 10.752 JJ156 14.037 JJ132 33.804 
JJ016 0.666 JJ022 17.505 JJ165 3.681 JJ136 13.932 
JJ018 1.575 JJ023 19.68     JJ143 12.795 
JJ020 17.682 JJ041 Invalid     JJ144 12.894 
JJ024 15.255 JJ050 8.103     JJ145 12.777 
    
  
    JJ149 17.724 
    
  
    JJ157 6.288 
            JJ166 2.748 
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Figure 5.6. Mean NAP1L1 concentration in plasma samples from the UK cohort 
(Abbexa kit). A non-significant trend towards increased concentration in cancer 
samples was observed (p=0.885, Kruskal-Wallis test). A similar trend was seen 
when testing serum using the DL Develop kit (figure 5.3). Notably, these two 
experiments demonstrated the best sensitivities (fewer or no invalid values 
produced) among all the plates tested. N: 10 normal, 10 low-grade adenomas, 7 
high-grade adenomas and 13 cancer samples. 
 
Together, these results suggest that the length of storage may, 
indeed, affect NAP1L1 concentration in blood samples. Alternatively, some 
other unclear factor related to sample collection or processing might also play 
a part, as the Brazilian and the UK cohorts were obviously collected in 
different settings, although following similar protocols. This could even 
explain the discrepancy of these results when compared with our preliminary 
data. In those experiments, Al-Khafaji analysed serum that had been 
collected only a few weeks earlier, whilst here we used samples that had 
been kept in freezers for time periods ranging from several months to a few 
years. Although statistical significance was not observed, a trend towards 
increased NAP1L1 levels in cancer patients was observed in those 
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experiments which had better performances – the ones that produced fewer 
or no results below the lower limit of detection. The lack of adequate 
immunoassays and the use of samples with relatively long storage time could 
have prevented us from identifying a clear differential concentration of this 
protein in cancer patients. Any conclusions could only be confidently made 
with the use of accurate methods of protein measurement. Based on these 
assumptions, we realised that we had two possible ways to proceed with this 
investigation: we could either collect new samples prospectively and test 
them within a few weeks; or we could develop an assay which had better 
sensitivity and consistency than the ELISA kits that we had used until now. 
The first option was deemed unrealistic due to time constraints associated 
with this research. Additionally, we would still need to sort out issues related 
to the inconsistency of the kits. For these reasons, we chose the second 
option and set out to develop an in-house immunoassay for NAP1L1.      
For this purpose, we selected the Meso Scale Discovery® (MSD) 
electrochemiluminescence (ECL) platform. Chemiluminescence methods are 
supposedly more sensitive than ELISAs (Price and Newman, 1997). MSD – 
ECL assays have been demonstrated to outperform ELISAs in the 
assessment of several proteins (Kuhle et al., 2016, Guglielmo-Viret and 
Thullier, 2007, Leary et al., 2013). Details of this method, the assay 
development process and the quality control tests are described in section 
5.5, together with the results of the analysis of our samples. 
Before discussing these ECL assays, we will describe the results of 
measuring RPL6 and Prohibitin concentrations in the blood using ELISA kits.  
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5.4.2. RPL6 kits – testing and results  
 
Similarly to NAP1L1 evaluation, the starting point for RPL6 analysis 
was the ELISA kit produced by Cloud-Clone Corp that was used in the 
preliminary study (product number SEF046Hu). This kit uses antibodies 
targeting the area between Ala2 and Phe288 (personal communication), 
almost the entire protein which has 288 amino acids. According to the 
product manual, the lower limit of detection for this kit is 0.061ng/mL, 
considerably lower than the limit for the NAP1L1 kit from the same 
manufacturer (0.119ng/mL). Therefore, a better performance would be 
expected. Serum samples from the four groups were initially tested. Indeed, 
as can be seen in table 5.8, the lower limit of detection of this kit allowed 
valid results to be detected for most of the serum samples tested. 
Interestingly, all four invalid results were observed in the high-grade 
adenoma group (three samples from the UK and one sample from Brazil). 
The reason for this finding is not clear. The comparison between the 
remaining three groups showed similar RPL6 concentrations in normal 
samples, low-grade adenomas and cancer samples. In fact, a non-significant 
trend towards a decreased concentration was observed in the cancer group 
(see figure 5.7).  
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Table 5.8. Initial ELISA results for RPL6 using the Cloud-Clone kit.  
Group 
Sample 
Id 
Concentration 
(ng/mL) 
Median 
(ng/mL) 
   Normal N2 3.123 
      N3 2.724 
      N4 1.552 
      N5 3.645 
      N6 1.827 
      N7 1.796 
      N8 2.286 
      N11 7.558 
      N22 1.24 
      N23 0.7 2.6451 
   Low-grade 
adenoma P2 1.598 
      P3 9.312 
      P4 3.882 
      P5 1.386 
      P6 1.37 
      P7 2.838 
      P8 0.944 
      P9 1.71 
      P10 1.068 
      P18 1.816 2.5924 
   High-grade 
adenoma JJ047 0.768 
      JJ058 0.378 
      JJ093 Invalid 
      JJ111 0.744 
      JJ138 1.364 
      JJ156 Invalid 
      JJ165 Invalid 
      CR68 4.089 
      CR78 1.75 
      CR95 Invalid Invalid 
Cancer CR62 2.026 
      CR65 2.464 
      CR67 1.972 
      CR70 2.558 
      CR73 2.678 
      CR76 0.702 
      CR80 2.17 
      CR83 1.588 
      CR85 0.456 
      CR86 2.643 1.9257 
   
       
Serum samples were tested 
and the four groups were 
compared. Four out of 40 
samples demonstrated 
readings below the detection 
range, all of which were in the 
high-grade adenoma group. 
This performance was better 
than that demonstrated by the 
NAP1L1 kit from the same 
manufacturer. 
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Figure 5.7. Mean serum RPL6 concentration results using the Cloud-Clone ELISA 
kit. The high-grade adenoma group was excluded from this comparison due to 
several invalid results. Mean protein concentrations were not statistically different 
(p=0.396, Kruskal-Wallis test). N: 10 samples per group. 
 
Next, we retested some of the samples used in the Cloud-Clone 
assay, using an ELISA kit from Abbexa (product number abx570790, 
Cambridge, UK) to assess the concordance between different kits. In this kit, 
the protein epitope spans the same area as the Cloud-Clone plate described 
above. Assay sensitivity, detection range and protocol procedures were 
identical to the previous kit. As depicted in table 5.9, disregarding the 
undetectable levels observed in either or both plates, the concordance 
between results obtained using the two RPL6 kits was superior to the 
concordance between the different NAP1L1 plates tested earlier. However, 
discrepancies were still observed and no kit could be deemed an accurate 
platform. We have not compared results between groups due to the number 
of invalid readings and the limited number of cases per group. 
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Table 5.9. Comparison of results obtained with RPL6 ELISA plates from Cloud-
Clone and Abbexa.  
Sample 
CloudClone plate 
(ng/mL) 
Abbexa plate 
(ng/mL) 
N2 3.123 0.914 
N4 1.552 1.298 
N8 2.286 1.14 
N23 0.7 0.384 
JJ058 0.378 Invalid 
JJ093 Invalid Invalid 
JJ111 0.744 Invalid 
JJ138 1.364 1.18 
JJ156 Invalid Invalid 
CR62 2.026 2.206 
CR65 2.464 2.546 
CR70 2.558 2.364 
CR73 2.678 2.99 
CR76 0.702 Invalid 
 
Although the previous experiments have not suggested differences in 
serum RPL6 concentrations between patient groups, we also tested the 
expression of this protein in plasma samples, as the optimal matrix for this 
assessment had not been established. For this analysis, we selected a total 
of 18 cases (6 normal, 5 high-grade adenomas and 7 cancers) from both the 
Brazilian and UK cohorts. The criterion for selecting these cases was, again, 
the availability of sufficient sample volumes for this and additional 
experiments, if necessary.  
Serum and plasma samples from each case were then tested using 
the Abbexa RPL6 ELISA plate (table 5.10). Similar findings were observed 
when compared to the results for NAP1L1 plasma-versus-serum assessment 
(table 5.5, above). Noteworthy, several undetectable levels were obtained for 
serum samples, whilst all (except one) plasma samples yielded readings 
within the detection range. Additionally, as occurred with NAP1L1, plasma 
levels were consistently higher than serum levels – more than 10-fold in 
some cases, suggesting that plasma rather than serum could again be the 
optimal biological fluid for RPL6 assessment. Samples from the UK cohort 
(with the initials JJ) tended to produce higher values than the Brazilian 
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samples, again suggesting that sample processing or storage conditions may 
influence protein concentration. Consequently, we focused our attention on 
the analysis of a larger number of plasma samples as the final strategy in the 
evaluation of RPL6 as a potential CRC blood biomarker.   
 
Table 5.10. Comparison of RPL6 results between plasma and serum samples 
using an Abbexa ELISA kit. Plasma samples exhibited higher protein 
concentrations than serum samples for individual cases.  
  Plasma   Serum   
 Groups Samples (ng/mL) Samples (ng/mL) 
Normal Brazil N2P 1.538 N2S 0.914 
  N4P 1.754 N4S 1.298 
  N8P 4.068 N8S 1.14 
  N23P 2.75 N23S 0.384 
Normal Chester JJ001P 3.264 JJ001S 0.536 
  JJ002P 13.786 JJ002S 0.632 
High-grade 
Chester JJ058P 16.762 JJ058S Invalid 
  JJ093P 14.156 JJ093S Invalid 
  JJ111P 10.816 JJ111S Invalid 
  JJ138P 14.082 JJ138S 1.18 
  JJ156P 16.368 JJ156S Invalid 
Cancer Brazil CR62P 5.548 CR62S 2.206 
  CR65P 6.798 CR65S 2.546 
  CR70P 8.648 CR70S 2.364 
  CR73P Invalid CR73S 2.99 
  CR76P 3.12 CR76S Invalid 
Cancer Chester JJ079P 5.14 JJ079S Invalid 
  JJ121P 11.026 JJ121S Invalid 
Note: the aim of this experiment was solely to compare RPL6 concentrations 
between plasma and serum samples. No comparison between groups was 
performed.  
 
As we did for NAP1L1, we analysed RPL6 concentrations in plasma 
samples from Brazil and from the UK separately in order to further investigate 
whether different handling or storage conditions had an effect on protein 
concentrations. Abbexa RPL6 ELISA plates were used. Again, we tested 
plasma from normal controls and cancer patients for the Brazilian cohort. As 
illustrated in table 5.11, all samples produced valid results. The mean plasma 
RPL6 concentration between groups was similar (figure 5.8). In general 
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however, a wide variation was observed within each group (6- to 8-fold) 
highlighting the heterogeneity of protein expression within these groups. 
 
Table 5.11. Abbexa RPL6 ELISA kit results using plasma samples from the Brazil 
cohort.  
NORMAL 
(n=10) Sample Id 
Concentration  
(ng/mL) 
CANCER 
(n=30) Sample Id 
Concentration 
 (ng/mL) 
  N1P 3.35   CR60P 6.40 
  N2P 2.57   CR62P 4.77 
  N3P 3.06   CR63P 5.07 
  N4P 2.26   CR64P 6.97 
  N5P 2.20   CR65P 5.03 
  N6P 3.08   CR67P 4.00 
  N7P 3.30   CR68P 3.64 
  N8P 3.85   CR69P 6.16 
  N11P 12.20   CR70P 7.87 
  N28P 14.97   CR71P 3.75 
  
  
  CR72P 4.97 
  
  
  CR73P 1.66 
  
  
  CR74P 4.10 
  
  
  CR75P 6.58 
  
  
  CR76P 2.16 
  
  
  CR77P 4.32 
  
  
  CR78P 4.58 
  
  
  CR79P 6.44 
  
  
  CR97P 2.36 
  
 
    CR81P 5.72 
  
 
    CR82P 8.54 
  
 
    CR84P 8.62 
  
 
    CR85P 7.21 
  
 
    CR86P 13.03 
  
 
    CR87P 5.27 
  
 
    CR88P 12.56 
  
 
    CR89P 2.58 
  
 
    CR90P 3.97 
  
 
    CR91P 2.93 
        CR92P 5.22 
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Figure 5.8. Mean RPL6 concentration in plasma samples from the Brazilian cohort 
(Abbexa kit). No significant difference was observed between groups (p=0.072, 
Mann-Whitney U test) N: 10 normal controls, 30 invasive cancers. 
   
Next, we performed the same analysis using the UK samples. Plasma 
from 40 cases encompassing all four groups was tested using the Abbexa 
plate (table 5.12). Again, plate sensitivity proved to be adequate as valid 
results were obtained for all samples. However, mean plasma RPL6 
concentration was not statistically different between groups (figure 5.9). 
Noteworthy, mean concentrations for the UK cohort were higher than those 
observed for the Brazilian cohort. Similarly to NAP1L1, plasma RPL6 
concentration appeared to be affected by storage time or some other unclear 
factor related to sample collection or processing.  
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Table 5.12. Abbexa RPL6 ELISA kit results using plasma samples from the UK 
cohort.  
Normal    (n=10) Low-grade   (n=10) High-grade     (n=7) Cancer  (n=13) 
Sample Id  (ng/mL) Sample Id 
 
(ng/mL) Sample Id 
 
(ng/mL) Sample Id 
 
(ng/mL) 
JJ001 4.02 JJ005 4.11 JJ047 3.09 JJ057 14.42 
JJ002 20.70 JJ006 12.95 JJ058 20.38 JJ079 6.18 
JJ007 8.72 JJ010 10.98 JJ093 17.36 JJ113 10.40 
JJ012 14.69 JJ011 5.16 JJ111 11.64 JJ121 11.83 
JJ013 30.45 JJ019 13.60 JJ138 14.72 JJ126 9.89 
JJ015 27.62 JJ021 50.51 JJ156 23.58 JJ132 31.58 
JJ016 3.74 JJ022 21.49 JJ165 3.38 JJ136 25.85 
JJ018 7.47 JJ023 20.11   
 
JJ143 23.72 
JJ020 69.38 JJ041 2.76     JJ144 21.91 
JJ024 23.99 JJ050 18.73     JJ145 20.03 
    
  
    JJ149 37.19 
    
  
    JJ157 11.07 
            JJ166 4.58 
 
 
Figure 5.9. Mean RPL6 concentration in plasma samples from the UK cohort 
(Abbexa kit). Differences observed between groups were not statistically significant 
(p=0.743, Kruskal-Wallis test). Large intra-group variation was observed. N=10 
normal controls, 10 low-grade adenomas, 7 high-grade adenomas and 13 cancers. 
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In order to obtain a final assessment of the inter-plate consistency of 
the RPL6 ELISA kit used in most of our experiments (Abbexa kit), we 
compared samples used in the plasma versus serum plate (table 5.10) which 
were retested in plasma-only experiments later (tables 5.11 and 5.12). 
Sixteen plasma samples were used in both experiments. Results produced 
for each sample by the different plates were reasonably similar (coefficient of 
variation of 17.7%) and highly correlated (a Pearson´s correlation coefficient r 
= 0.96), thus confirming that this RPL6 kit is highly consistent.   
These findings suggest that the RPL6 ELISA kits tested were 
adequate tools for the assessment of the concentration of this protein in 
biological fluids. Therefore, we can confidently conclude that RPL6 blood 
levels are not significantly different when comparing normal subjects, 
individuals with low-grade and high-grade adenomas, and CRC patients. This 
conclusion is based on the assessment of two different sample cohorts and 
two biological matrices, tested with ELISA plates from two different providers. 
Consequently, we decided to terminate the investigation of RPL6 as a 
potential blood-based biomarker for CRC at this stage. However, some 
interesting findings were made. Firstly, plasma levels were consistently 
higher than serum levels. This finding has implications for any future 
research evaluating RPL6 expression in blood samples. Secondly, in 
general, the UK cohort exhibited higher detectable concentrations of this 
protein than the Brazilian cohort. This observation suggests that the length of 
storage or some other factor during sample collection or processing affects 
plasma RPL6 concentrations. NAP1L1 exhibited a similar pattern. Similarities 
between NAP1L1 and RPL6 were also seen during the IHC and qPCR work 
in this research project. It raises the hypothesis that these two proteins might 
somehow interact in their biological activities, a possibility that requires 
further investigation.   
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5.4.3. PHB kits – testing and results  
 
The assessment of PHB as a potential blood biomarker followed the 
same initial steps described in previous sections. The Cloud-Clone Corp 
ELISA plate used in the preliminary phase was again tested (product number 
SEA442Hu, detection range 0.312-20ng/mL). Forty serum samples 
representing the four clinical groups were initially analysed. Just as we 
observed with NAP1L1 and RPL6, many samples exhibited undetectable 
PHB levels, thus preventing any comparison or conclusion (individual data 
not shown to avoid unnecessary repetition).  
To assess whether plasma would also be a better matrix than serum 
for measuring PHB concentrations, we again tested both fluids using an 
Abbexa ELISA kit (48-well trial plate, product number abx152835, 
Cambridge, UK). Twelve specimens (6 serum and 6 plasma samples) were 
analysed. As depicted in table 5.13, once more, protein concentration in 
plasma was consistently higher than that observed in serum. One of the 
serum samples resulted in readings below the lower limit of detection of the 
kit. Based on these findings, we decided to proceed with this evaluation using 
plasma samples only. As the detection range of the Abbexa plate seemed to 
be adequate for this matrix, this plate was chosen for subsequent tests.  
 
Table 5.13. Comparison of PHB results between plasma and serum samples using 
an Abbexa ELISA kit. Again, plasma samples exhibited higher protein 
concentrations than serum samples for each individual case.  
Plasma   Serum   
Samples (ng/mL) Samples (ng/mL) 
JJ138P 
JJ156P 
JJ057P 
JJ113P 
JJ126P 
JJ143P 
 
16.53 
11.392 
11.784 
12.102 
20.401 
15.352 
 
JJ138S 
JJ156S 
JJ057S 
JJ113S 
JJ126S 
JJ143S 
 
1.918 
1.80 
1.287 
1.816 
Invalid 
1.96 
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Similarly to the previous experiments, we tested samples from the 
Brazilian and UK cohorts separately: normal controls versus cancer samples 
for the first cohort and all four groups for the second cohort. The analysis of 
the Brazil cohort is shown in table 5.14 and figure 5.10. Valid results were 
obtained for all samples, except one normal control subject. Compared to 
NAP1L1 and RPL6, PHB concentration exhibited less variation between 
samples resulting in a narrower standard error, and suggesting a more stable 
protein level. The comparison between normal and cancer groups however 
showed no difference in PHB concentration. 
 
Table 5.14. Abbexa PHB ELISA results using plasma samples from the Brazilian 
cohort.  
NORMAL 
(n=10) Sample Id 
Concentration  
(ng/mL) 
CANCER 
(n=30) Sample Id 
Concentration 
 (ng/mL) 
  N1P 8.27   CR60P 3.56 
  N2P 5.06   CR62P 8.93 
  N3P 7.08   CR63P 4.69 
  N4P 5.88   CR64P 9.67 
  N5P 5.67   CR65P 6.59 
  N6P 11.04   CR67P 6.32 
  N7P 2.27   CR68P 5.81 
  N8P 6.71   CR69P 10.73 
  N11P Invalid   CR70P 8.66 
  N28P 8.52   CR71P 8.28 
  
  
  CR72P 7.04 
  
  
  CR74P 4.33 
  
  
  CR75P 10.76 
  
  
  CR76P 12.32 
  
  
  CR77P 3.65 
  
  
  CR78P 12.38 
  
  
  CR79P 11.89 
  
  
  CR97P 6.58 
  
  
  CR81P 8.56 
  
  
  CR82P 9.74 
  
  
  CR84P 11.18 
  
  
  CR85P 7.89 
  
  
  CR86P 9.52 
  
  
  CR87P 8.66 
  
  
  CR88P 6.70 
  
  
  CR89P 8.03 
  
  
  CR90P 11.60 
  
 
   CR91P 9.83 
       CR92P 8.04 
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Figure 5.10. Mean PHB concentration in plasma samples from the Brazilian cohort 
(Abbexa kit). No significant difference was observed between groups (p=0.619, 
Mann-Whitney U test) N: 10 normal controls, 30 invasive cancers. 
 
For the UK cohort, all samples tested produced valid results (see table 
5.15). Again, PHB concentrations were relatively homogeneous, except for a 
few outliers. A comparison of the mean PHB concentration between the four 
clinical groups however did not reveal any significant difference (figure 5.11). 
Five samples were tested twice in separate experiments using Abbexa 
plates. The calculated inter-assay coefficient of variation for these samples 
was 11.1%.   
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Table 5.15. Abbexa PHB ELISA kit results using plasma samples from the UK 
cohort.  
Normal  (n=10) Low-grade   (n=10) High-grade     (n=7) Cancer  (n=13) 
Sample Id  (ng/mL) 
Sample 
Id  (ng/mL) 
Sample 
Id  (ng/mL) Sample Id 
 
(ng/mL) 
JJ001 15.71 JJ005 1.12 JJ047 11.26 JJ057 12.70 
JJ002 13.39 JJ006 15.30 JJ058 17.64 JJ079 10.03 
JJ007 12.47 JJ010 12.65 JJ093 116.39 JJ113 2.27 
JJ012 15.44 JJ011 9.29 JJ111 17.22 JJ121 15.99 
JJ013 19.81 JJ019 12.05 JJ138 21.22 JJ126 14.48 
JJ015 16.16 JJ021 14.11 JJ156 12.43 JJ132 20.04 
JJ016 15.16 JJ022 13.84 JJ165 10.48 JJ136 17.74 
JJ018 24.98 JJ023 15.89   
 
JJ143 14.82 
JJ020 15.99 JJ041 16.88   
 
JJ144 15.28 
JJ024 11.073 JJ050 15.51   
 
JJ145 13.74 
    
  
  
 
JJ149 18.57 
    
  
   JJ157 16.73 
          JJ166 11.83 
 
 
 
 
Figure 5.11. Mean PHB concentration in plasma samples from the UK cohort 
(Abbexa kit). Differences observed between groups were not statistically significant 
(p=0.593, Kruskal-Wallis test). N=10 normal controls, 10 low-grade adenomas, 7 
high-grade adenomas and 13 cancers. 
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Collectively, these results suggest that PHB blood concentration is 
altered neither in CRC patients nor in individuals with pre-neoplastic colonic 
lesions when compared with normal controls. The adequate performance 
demonstrated by the ELISA kits tested discouraged any further assessment 
of this protein as a potential CRC blood biomarker, as it is unlikely that a 
different platform would yield different results. However, it must be 
emphasised that, as for NAP1L1 and RPL6, PHB concentration in plasma 
was consistently higher than in serum. This finding suggests that the former 
is a better matrix than the latter for future studies assessing PHB blood 
concentrations.   
 
5.5. NAP1L1 electrochemiluminescence assay development 
 
As described in section 5.4.1, the detailed assessment of NAP1L1 as 
a potential CRC blood biomarker was impaired by the lack of sensitivity and 
consistency of the ELISA kits tested. Only a non-significant trend of 
increased protein concentration in the plasma of patients with high-grade 
adenomas and CRC was observed, but the general performance of the kits 
was poor. In order to definitively confirm or refute whether NAP1L1 has 
potential as a CRC blood biomarker, we decided to develop an in-house 
immunoassay which would hopefully have better performance and reliability 
than the commercial ELISA kits. As chemiluminescence methods are 
reportedly more sensitive than enzymatic techniques (Price and Newman, 
1997, Blackburn et al., 1991), Meso Scale Discovery® (MSD) – 
electrochemiluminescence (ECL) was the chosen platform. MSD 
performance has previously been specifically compared with other 
immunoassays. As demonstrated in table 5.16, Leary et al. showed that MSD 
is superior to ELISA and comparable to bead-based methods for the 
assessment of generic human IgG. A wider dynamic range and lower limit of 
detection were observed compared with the enzymatic method. Other 
advantages of the MSD platform are the need of lower sample volumes 
(usually 25-30µL of final volume per well), shorter procedure time and the 
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potential for multiplexing, thus allowing the evaluation of up to 10 markers in 
one microtiter plate (Leary et al., 2013, Marchese et al., 2009). 
Table 5.16. Comparison of performances between selected immunoassays targeting 
a generic human IgG. Adapted from (Leary et al., 2013) 
Platform Format Readout 
Dynamic range 
(ng/mL) 
Sensitivity 
(ng/mL) 
ELISA Plate Colorimetric 88.0-666 88.0 
MSD Plate ECL 15.6-4000 15.6 
Gyrolab Bead Fluorescence 10.5-6400 10.5 
AlphaLISA Bead Luminescence 181-1097 181.0 
 
MSD technology has proven to be superior to ELISA for the 
assessment of various proteins such as neurofilament light chains (Kuhle et 
al., 2016) and ricin B chain (Guglielmo-Viret and Thullier, 2007). An in-house 
MSD assay produced by Chaturvedi et al. was superior to ELISAs and even 
to a commercial MSD kit for the assessment of total interleukin-6, one of the 
least expressed proteins in blood samples (Chaturvedi et al., 2015). 
Marchese et al. developed a multiplex MSD assay for the concomitant 
assessment of eight anti-pneumococcal antibodies related to the vaccine 
Pneumovax 23, and this outperformed the use of standard individual ELISA 
tests for each antibody (Marchese et al., 2009). Therefore, the MSD-ECL 
platform was a suitable method to try to develop a sensitive and consistent 
assay for NAP1L1 measurement.  
 
5.5.1. Principles 
 
Sandwich-format MSD-ECL follows the same principles of other 
immunoassays such as ELISAs. A microtiter polystyrene plate is coated with 
a capture reagent which binds to the plate via hydrophobic interactions. The 
capture substance may be a protein, a carbohydrate, viral particles or cell 
components, among others (figure 5.12, upper panel). In a classical 
sandwich immunoassay, a capture antibody is used to target specific 
analytes (figure 5.12, lower panel). After the initial coating, each well 
undergoes a blocking step – incubation with a protein solution aiming to 
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occupy any uncoated space in the well, thus reducing non-specific binding 
during the following phases of the procedure. Different proteins may be used 
for blocking and the best option should be determined for each 
immunoassay. After blocking, samples containing the analyte are added to 
the wells, along with a dilution series of the standard protein. This standard 
curve is later used to interpolate each sample reading and determine 
individual sample concentrations. Next, a detection antibody is used to 
identify analytes bound to the capture reagent. This antibody may be tagged 
with a reporter substance such as alkaline phosphatase or horseradish 
peroxidase (in ELISAs), or a fluorescent/luminescent substance. 
Alternatively, a third anti-species antibody targeting the detection antibody is 
used as the reporter. Finally, a substrate (ELISAs) or an electrical current 
(ECL) is applied to the plate, allowing the reporter to react, thus producing 
colour, fluorescence or light. A microplate reader is then used to record the 
signal, which is proportional to the concentration of the analyte in each well.  
 
 
Figure 5.12. Capture reagents and assay formats used in MSD experiments. In the 
upper panel, different components are used as the capture reagent aiming to attract 
specific antibodies. In the bottom panel, capture and detection antibodies are used 
to assess a particular analyte. The reaction is reported using MSD SULFO-TAG™, 
which can be directly conjugated with the detection antibody (A), attached to it via 
biotin-streptavidin interaction (B) or linked to a tertiary anti-species antibody (C).  
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MSD-ECL plates have several adaptations, compared to ELISAs, to 
allow electricity to be used to stimulate the final reaction. Each well bottom is 
a working electrode where all the adsorption of capture reagents, analytes 
and detection reagents occur (figure 5.13). The reporter reagent is an 
antibody tagged with an electrochemiluminescent label called SULFO-
TAG™, a proprietary compound that emits light upon the electrical 
stimulation provided by the MSD plate reader. The essential chemical 
component of SULFO-TAG™ is the molecule tris(2,2′‐bipyridyl)ruthenium(II) 
or Ru(bpy)32+. When the necessary voltage is applied, this compound 
undergoes a series of oxidative-reductive reactions and interacts with a co-
reactant called tri‐n‐propylamine, or TPA+,, present in the Read Buffer. These 
reactions result in the emission of red light at 620nm and the regeneration of 
Ru(bpy)32+ to its ground state thus enhancing the sensitivity of the method 
(Wei and Wang, 2011). Additionally, the proximity-based nature of the 
reaction (only luminescent labels in close contact with the electrode will 
react) reduces non-specific signals in the solution or in the wall of the wells 
improving the accuracy of the test.  
   
 
Figure 5.13. Illustrative representation of the MSD-ECL technology. 
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General procedures suggested by the manufacturer and used in this 
assay development are: 
 
a. Coat plates with 30µL of capture antibody solution in PBS per well 
overnight at 4°C; 
b. Wash plate 3 times using 200µL of PBS-Tween 0.05%; 
c. Add blocking reagent and incubate for 1 hour in a plate shaker at 
>300rpm, at room temperature; 
d. Wash plate 3 times, as above; 
e. Add 25µL of samples or standards diluted in blocking solution to the 
assigned wells and incubate for 1 hour in a plate shaker at >300rpm, 
at room temperature;  
f. Wash plate 3 times, as above; 
g. Add 25µL of the detection antibody diluted in blocking solution and 
incubate for 1 hour in a plate shaker at >300rpm, at room temperature; 
h. Wash plate 3 times, as above; 
i. Add 25µL of SULFO-TAG™ labelled anti-species antibody at 
1.0µg/mL diluted in blocking solution and incubate for 1 hour in a plate 
shaker at >300rpm; 
j. Wash 3 times, as above; 
k. Add 150µL of 2x Read Buffer and read plate immediately. 
 
Two types of microtiter plates are produced by the manufacturer: a 
High Bind (HB) plate in which hydrophilic adsorption of capture reagents 
occurs and a Standard Bind (SB) plate in which hydrophobic interactions take 
place. It is recommended that both plate types are tested when developing a 
new assay. The plate reader used in this research was the proprietary 
SECTOR Imager 6000 and results were analysed with the MSD Discovery 
Workbench software, version 4.0. The method of analysis used was the four-
parameter logistic (4PL) regression model, with a 1/Y2 weighting. 
All MSD equipment, plates and specific reagents were manufactured 
in Rockville, MD, USA. 
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5.5.2. Assay development overview 
 
The development of a novel immunoassay requires the careful testing 
of all the components involved in the procedure. From antibody selection to 
the concentration and composition of individual reagents, each detail can 
affect the result and the validity of an immunoassay (Del Campo et al., 2015). 
The initial step in the assay development process is the design, production 
and selection of adequate antibodies. When available, commercial antibodies 
may be tested in order to find appropriate options. The aim is to find a 
combination of antibodies (capture and detection) that specifically identifies 
the target protein with the lowest background. When an adequate pair has 
been identified, the optimal concentration able to produce a satisfactory 
signal whilst maintaining a low background is pursued. These procedures 
establish the initial conditions to proceed with the assay development.  
The next step is the assay set-up aiming to test both the calibrator and 
clinical samples. The calibrator (also called reference protein or standard) is 
a purified protein or peptide that is used to produce a standard curve. 
Calibrator highest concentration, dilution factor and diluent buffers must all be 
defined. The aim of this step is to produce an optimal standard curve with a 
wide dynamic range and good dilution linearity. After obtaining an adequate 
standard curve, the next stage in assay development is the testing of clinical 
samples. In this step, the sample dilution factor to be used is defined. 
Additionally, aberrant results due to the interference provoked by the several 
constituents of the biological fluid are unveiled, a phenomenon called matrix 
interference. During all the previous steps, the composition of the blocking 
buffer, dilution buffer and wash buffer must be tested as these reagents may 
influence the signal-to-background ratio (SBR), an essential variable for a 
good immunoassay.  
Lastly, after all the optimal conditions have been identified, the novel 
assay must undergo validation or quality-control experiments. These 
procedures aim to define assay imprecision (assessed by inter- and intra-
assay CV), recovery, dilution linearity, among others (Del Campo et al., 2015, 
Andreasson et al., 2015). After all these steps have been successfully 
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performed, clinical samples can be tested in order to produce final results. An 
overview of the several experiments that were executed to produce an in-
house MSD ECL assay for NAP1L1 is now provided. 
   
5.5.3. Selection of antibodies, calibrators and plate types  
 
Anti-NAP1L1 antibodies are currently produced by several 
manufacturers. Therefore, our first task was the selection of some options for 
initial antibody screening. In this research, we opted for the use of a tertiary 
SULFO-TAG™-labelled antibody, as depicted in figure 5.12 above (bottom 
panel, item C). An essential requirement for the selection of a capture-
detection pair is the use of antibodies produced in different species (a 
mouse-derived capture antibody and a rabbit-derived detection antibody, for 
example) so that the use of an anti-species tertiary antibody is possible. 
Another strategy is to test both monoclonal and polyclonal antibodies in order 
to determine which yield the best results. Thus, we initially selected five anti-
human NAP1L1 antibodies. Two of them were monoclonal and the remaining 
three were polyclonal. Four of them were rabbit-derived and one was mouse-
derived. These initial candidates are described in more detail below: 
a. Abcam rabbit monoclonal antibody (ab178687, Cambridge, UK) – 
epitope: aa 300 to the C-terminus. The exact sequence is 
proprietary; 
b. Abcam rabbit polyclonal antibody (ab33076, Cambridge, UK) – 
epitope: aa1 – 100; 
c. Genetex rabbit polyclonal antibody (gtx112613, Irvine, CA, USA) – 
epitope: centre region of human NAP1L1. The exact sequence is 
proprietary; 
d. Genetex rabbit polyclonal antibody (gtx124370, Irvine, CA, USA) – 
epitope: not informed; 
e. Abnova mouse monoclonal antibody (H00004673-M01, Taipei, 
Taiwan) – epitope: aa 1-110. 
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The antibody screening process started with testing the reactivity of 
these candidates in the ECL platform. For this purpose, both high bind (HB) 
and standard bind (SB) plates were used. Using the general procedures 
described in section 5.5.1, the plates were coated overnight with each of the 
four rabbit anti-NAP1L1 antibodies at 10µg/mL. The next day, plates were 
incubated with the MSD proprietary Blocker A (a bovine serum albumin 
blocking solution). We then generated a 4-fold serial dilution of the standard 
protein which was provided as part of the Cloud-Clone ELISA kit that we 
tested in section 5.4.1 (initial concentration: 1,000ng/mL). Next, the Abnova 
mouse monoclonal antibody was added at 10µg/mL as the detection reagent. 
A SULFO-TAG™-labelled anti-mouse antibody was then used. After the final 
wash step, 2x Read Buffer was added to the wells and the plate was read 
using the MSD SECTOR Imager 6000 plate reader. As seen in figure 5.14, 
different concentrations of the Cloud-Clone standard protein did not show 
any difference in signal reading, proving that no antigen-antibody reaction 
had occurred. As we did not know whether this standard was an incomplete 
protein or a peptide sequence not covered by the antibodies, we decided to 
test a commercially available full-length protein instead.    
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Figure 5.14. Initial screening of antibody pairs using the Cloud-Clone NAP1L1 
standard protein as a calibrator. Four different rabbit antibodies were used for 
capture and the Abnova mouse monoclonal antibody was used for detection. No 
difference in signal was observed for solutions with different protein concentrations.    
 
For the next experiment, we purchased human NAP1L1 recombinant 
protein from Abcam (product number ab117213, Cambridge, UK). The 
procedures used in the last test were replicated. This time, as observed in 
figure 5.15, a typical standard curve was produced for each of the antibody 
combinations, thus confirming that this standard protein was properly 
identified by the antibodies and could be used as the calibrator for the next 
development steps.  
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Figure 5.15. The conditions previously used were replicated using the Abcam 
human recombinant NAP1L1 protein as calibrator. All four antibody pairs exhibited 
ascending signal readings paralleling increasing protein concentrations. However, 
an early plateau was observed in the top part of most curves.  
 
A plateau in the top portion of the majority of the standard curves 
denoted early saturation of the assay. This may be caused by excessive 
amounts of reagents such as antibodies or calibrator. Therefore, in the next 
step we tested lower antibody concentrations whilst the maximum calibrator 
concentration was also reduced to 500ng/mL (in a 2-fold dilution series). In 
addition, we tried using the Abnova monoclonal mouse antibody as the 
capture reagent and the rabbit mono and polyclonal antibodies for detection. 
Capture antibody concentrations were reduced to 2.5 and 5.0µg/mL, and the 
detection antibody concentration was 1.0µg/mL. Figure 5.16 shows an 
example of the standard curves that were obtained for one of the conditions 
tested. Similar curves were observed for each of the other conditions. 
Therefore, a meticulous assessment of individual readings was necessary to 
select the best pairing. The initial variable used to screen for adequate 
antibody conditions in immunoassay development is the signal-to-
background ratio (SBR). A high SBR coupled with a steady increase in signal 
from “zero” to top standard concentration usually translates into a wide 
dynamic range. In figure 5.17, readings (in arbitrary units) for all conditions 
tested are shown. The use of monoclonal antibodies (Abnova mouse and 
Abcam rabbit, respectively) as capture and detection reagents yielded the 
highest background (in green), resulting in low SBRs. Therefore, this 
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combination pair was promptly excluded from further experiments. From the 
remaining conditions, one antibody pair produced very high SBRs in each 
plate types: Abnova mouse monoclonal – Gtx rabbit polyclonal in the HB 
plate, and Abnova mouse monoclonal – Abcam rabbit polyclonal in the SB 
plate (highlighted with red boxes in the figure). Noteworthy, the conditions 
using the lower capture antibody concentration (2.5µg/mL) demonstrated a 
better performance. Thus, these two antibody pairs were further tested in the 
subsequent experiments. 
 
 
Figure 5.16. An example of the standard curves produced when testing the Abnova 
mouse monoclonal antibody for capture (in this case, at 2.5µg/mL) and the four 
rabbit antibodies for detection (at 1.0µg/mL).  
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Figure 5.17. Standard curve readings for each of the conditions tested in both HB 
and SB plates. Signal-to-background ratios (SBR) are used to select the best 
performing antibody pairs and concentrations. The best conditions in each plate type 
are circled with red boxes.  
 
Despite these promising results, the signal increase was not entirely 
proportional to the increase in standard concentration, resulting in flat 
standard curves (above). Again, we hypothesised that an excessive 
concentration of reagents was interfering with the performance of the test. 
Therefore, for the next stage of assay development, lower capture antibody 
concentrations were added (2.5 and 1.0µg/mL) and the top standard 
concentration was reduced to 100ng/mL. Additionally, the standard curve 
was produced using a 3-fold dilution series in order to better explore the 
lower part of the dynamic range. These assay formats also produced good 
SBRs (data not shown) and, more interestingly, demonstrated an increase in 
signal that was proportional to the different concentrations in the standard 
curve, as can be noticed by the slope of the standard curves in figure 5.18. 
However, once more a plateau was observed in the top portion of the curve 
without any flattening in the bottom part. Given the very low protein levels 
observed in the ELISA experiments described earlier, a further exploration of 
the lower part of the dynamic range was recommended.  
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Figure 5.18. The best antibody pairs and conditions previously identified are tested 
in the respective plate types (SB in the upper graph, HB in the lower graph). The 
Abnova antibody was tested at both 1.0 (blue line) and 2.5µg/mL (red line) as the 
capture reagent. Detection antibodies were used at 1.0µg/mL. 
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From the two conditions selected, we decided to proceed with assay 
development using the Abnova mouse monoclonal – Abcam rabbit polyclonal 
antibody pair. This option was chosen because this pair exhibited the best 
performance in the SB plate. As the name suggests, SB plates have 
hydrophobic surfaces with binding capacity similar to regular microtiter plates 
used in other immunoassays, such as ELISAs. This would theoretically allow 
the transfer of our in-house assay conditions to other platforms, when 
optimised. Consequently, we next tested this antibody pair in an assay using 
a further reduced top standard concentration (62ng/mL), a capture antibody 
concentration of 2.5µg/mL and a detection antibody concentration of 
1.0µg/mL. In addition, the inverted format (Abcam antibody as capture and 
Abnova antibody as detection) was also tested alongside. An additional 
experiment using the same conditions as above, but using a 4-fold dilution 
series for the standard curve was performed. This last condition is depicted in 
figure 5.19. As can be observed, the standard curve exhibited an appropriate 
format, although a clear flattening was seen in its lower part, suggesting that 
the 4-fold dilution was probably unnecessary.  
 
Figure 5.19. Experiment testing the optimal antibody pair and the selected plate type 
(SB). Abnova mouse monoclonal and Abcam rabbit polyclonal antibodies were used 
for capture-detection (blue line) and in the opposite orientation (red line).   
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The experiments previously described demonstrated that the Abnova 
mouse monoclonal antibody (H00004673-M01) at 2.5µg/mL for capture along 
with the Abcam rabbit polyclonal antibody (ab33076) at 1.0µg/mL for 
detection produced the best results when the assay was performed in SB 
plates. Additionally, the Abcam human recombinant NAP1L1 protein 
(ab117213) proved to be an adequate calibrator for the standard curve. The 
highest concentration of 62ng/mL and the 3-fold dilution series resulted in the 
best standard curve. The use of these conditions produced the steady and 
consistent curve depicted in figure 5.20. With these basic assay conditions 
established, we proceeded to assess clinical samples in order to define how 
the matrices interfere with the results and what sample dilution minimises 
these effects. 
 
 
Figure 5.20. Standard curve produced by the selected assay conditions. The 
dynamic range (0.06 – 62.5ng/mL) spans 3 logs, outperforming the ELISA kits 
previously tested. This result established the basis for the next phases of assay 
development.   
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5.5.4. Sample dilution and matrix of choice 
 
There are two main reasons for diluting samples before performing 
immunoassays: firstly, to reassure that the concentration lies within the 
dynamic range of the test (when concentrations are expected to be very high) 
and, secondly, to minimise any interfering effect from the matrix. The human 
blood proteome is made up of thousands of proteins, either in their native 
form or as several variations (including precursors, “mature” forms, 
degradation products, splice variants, glycosylated forms, etc) (Anderson and 
Anderson, 2002). Several logs of dynamic ranges are encompassed, from 
albumin (range: 35-50 mg/mL) to interleukin-6 (range: 0-5 pg/mL). Therefore, 
the study of any low-expressed protein is challenged by the multitude of other 
bioactive substances that can affect the accuracy of any test.  
In order to disclose matrix interference, the first test performed in this 
research was the assessment of dilution linearity and initial spike recovery. 
For this purpose, two serum samples (one from a cancer patient and one 
from a healthy volunteer) were tested in undiluted form, and diluted 1:2, 1:3 
and 1:4. If no matrix interference takes place, a proportional reduction in 
sample signal is expected. On the other hand, in the case of disproportional 
readings, the dilution range exhibiting concentrations closest to the expected 
values should be selected. Additionally, each sample (undiluted and diluted) 
was spiked with known amounts of the calibrator. In low-spiked samples, an 
increase of 3.1ng/mL was expected, whereas in high-spiked samples, an 
increase of 6.2ng/mL should occur. In the absence of any interference, 100% 
recovery of the spiked protein was expected. Ideally, dilution linearity and 
spike recovery should be maintained between 80-120% of the expected 
value (Andreasson et al., 2015, Leary et al., 2013). In this initial test, 
conditions in which these parameters were between 75-125% were selected. 
Results are demonstrated in table 5.17. The best performing conditions are 
highlighted in bold. As can be seen, different results were obtained for serum 
samples from cancer and normal individuals. For the cancer serum sample, 
both 1:2 and 1:3 dilutions showed poor linearity, whilst 1:4 exhibited an 
adequate correlation. Similarly, spike recovery for this sample was optimal for 
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the sample diluted 1:4, and inadequate for both the neat sample and the 
other dilutions. These findings suggest that 1:4 is probably the best sample 
dilution factor for this marker/matrix. The results of dilution linearity for the 
healthy volunteer serum were below the lower limit of detection, thus 
preventing us from drawing any conclusions. Assuming a concentration of 
zero (which underestimates the expected concentration), spike recovery was 
low for all dilutions. It is unclear whether this is the result of the non-spiked 
samples being below the detection range or due to an intrinsic factor related 
to this individual sample.  
Table 5.17. Initial tests of dilution linearity and spike recovery using serum samples. 
Results within 75-125% of the expected value are highlighted in bold. 
  Sample condition Signal 
Concentration  
(ng/mL) 
Expected  
concentration 
(ng/mL) % 
Dilution 
linearity CRC1 18131 8.75 - - 
  CRC1 1:2 15123 7.27 4.37 166 
  CRC1 1:3 14984 7.20 3.63 198 
  CRC1 1:4 8480 3.96 3.60 110 
Spike 
recovery CRC1 spike low 18702 9.03 11.85 76 
  CRC1 spike high 20201 9.76 14.95 65 
  CRC1 1:2 spike low 16882 8.13 10.37 78 
  CRC1 1:2 spike high 18319 8.84 13.47 66 
  CRC1 1:3 spike low 14115 6.77 10.30 66 
  CRC1 1:3 spike high 13759 6.59 13.40 49 
  CRC1 1:4 spike low 12626 6.03 7.06 86 
  CRC1 1:4 spike high 21695 10.49 10.16 103 
Dilution 
linearity HV3 972 below LLOD - - 
  HV3 1:2 762 below LLOD - - 
  HV3 1:3 786 below LLOD - - 
  HV3 1:4 736 below LLOD - - 
Spike 
recovery HV3 spike low 2373 0.74 3.10 24 
  HV3 spike high 3923 1.59 6.20 26 
  HV3 1:2 spike low 3728 1.49 3.10 48 
  HV3 1:2 spike high 6766 3.08 6.20 50 
  HV3 1:3 spike low 4229 1.76 3.10 57 
  HV3 1:3 spike high 7489 3.45 6.20 56 
  HV3 1:4 spike low 4292 1.79 3.10 58 
  HV3 1:4 spike high 7339 3.37 6.20 54 
LLOD: lower limit of detection. CRC1: colorectal cancer sample. HV: healthy 
volunteer sample.  
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Given the undetectable levels observed for one of the samples initially 
tested and recalling what was observed during the ELISA tests described in 
section 5.4.1, we decided to also test plasma as an alternative matrix for this 
ECL assay. Besides, taking into account the observation that the 1:4 dilution 
factor exhibited the best performance in the last test, we also aimed to test a 
further dilution – 1:8, to assess whether a range of dilution factors with steady 
linearity is observed. Therefore, in this next experiment (results shown in 
table 5.18), both plasma and serum from one CRC patient and one individual 
with Crohn´s disease (CD) were tested. Undiluted and diluted samples (1:4 
and 1:8) were analysed, both with and without spiking using the same spike 
concentrations as before.  
Our first observation was that plasma NAP1L1 concentrations were 
higher than serum levels, as was the case during the ELISA tests. The 
difference between plasma and serum concentrations was higher for the 
CRC sample (17-fold) than for the CD sample (1.9-fold). The CD sample was 
obtained from a bio-bank housed in the Department of Molecular and Clinical 
Pharmacology at the University of Liverpool and had been stored for a few 
months, whereas the CRC sample was taken from the Brazilian cohort 
(storage time: approximately 2 years). This may suggest that the storage 
time could affect serum levels of NAP1L1 more than plasma levels and 
explain, at least partially, the plasma/serum difference observed in this study. 
However, the absence of sample stability tests to assess the effect of storage 
time and temperature makes it impossible to clarify this point. In either case 
(plasma levels being truly higher than serum levels or plasma samples being 
more stable than serum), plasma would be the best matrix for the 
assessment of this protein. Another result obtained from this experiment was 
the confirmation that not only the dilution 1:4, but also 1:8 provided adequate 
linearity and spike recovery for most conditions (highlighted in bold in the 
table below). Additionally, plasma samples demonstrated better performance 
than serum samples for quality control parameters, with more conditions 
exhibiting readings within 75-125% of the expected value.  
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Table 5.18. Dilution linearity and spike recovery for serum and plasma samples. 
Results within 75-125% of the expected value are highlighted in bold. 
Sample Signal 
Concentration 
(ng/mL) 
Expected  
concentration 
(ng/mL) % 
CD004 Plasma 512 0.409 - - 
CD004 P 1:4 208 0.098 0.102 96 
CD004 P 1:8 179 0.062 0.051 121 
CD004 P 1:4 low 2488 1.927 3.198 60 
CD004 P 1:4 high 7192 4.888 6.298 78 
CD004 P 1:8 low 3145 2.373 3.162 75 
CD004 P 1:8 high 7296 4.949 6.262 79 
CD004 Serum 314 0.216 - - 
CD004 S 1:4 163 0.040 0.054 74 
CD004 S 1:8 144 0.009 0.027 35 
CD004 S 1:4 low 3300 2.476 3.140 79 
CD004 S 1:4 high 5779 4.042 6.240 65 
CD004 S 1:8 low 2969 2.255 3.109 73 
CD004 S 1:8 high 6437 4.440 6.209 71 
CR073 Plasma 1142 0.940 - - 
CR073 P 1:4 350 0.253 0.235 108 
CR073 P 1:8 249 0.146 0.118 124 
CR073 P 1:4 low 3203 2.411 3.353 72 
CR073 P 1:4 high 6947 4.743 6.453 74 
CR073 P 1:8 low 4439 3.212 3.246 99 
CR073 P 1:8 high 7206 4.896 6.346 77 
CR073 Serum 174 0.055 - - 
CR073 S 1:4 185 0.069 0.014 506 
CR073 S 1:8 154 0.026 0.007 383 
CR073 S 1:4 low 3346 2.506 3.169 79 
CR073 S 1:4 high 6110 4.240 6.269 68 
CR073 S 1:8 low 3857 2.840 3.126 91 
CR073 S 1:8 high 7075 4.819 6.226 77 
 
The linearity demonstrated for dilutions 1:4 and 1:8 (for plasma 
samples) established a suitable working range for further tests. The dilution 
1:4 was selected due to the low concentrations generally observed, aiming to 
avoid undetectable readings. Given the linearity and spike recovery 
demonstrated, plasma was identified as the best matrix for NAP1L1 
assessment, a finding concordant with our ELISA results described in section 
5.4.1. Therefore, only this matrix was assessed in the next steps of assay 
development. 
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5.5.5. Evaluation of alternative blocking agents  
 
At this stage of the work, our supply of antibodies had been depleted. 
We therefore purchased new stocks of both the Abnova mouse monoclonal 
and the Abcam rabbit polyclonal antibodies. Catalogue numbers and even lot 
numbers were exactly the same as the ones that we had been using until this 
point. In order to avoid deviations in assay performance, identical reagents 
should ideally be employed. Some substances are very sensitive to small 
variations in production or storage conditions. This is especially true for 
biological substances such as antibodies. Consequently, some parameters 
should be retested when such reagents are replaced, even when using 
similar products from the same manufacturers. We therefore tested the new 
antibodies using the same assay configuration previously selected. As figure 
5.21 shows, an adequate standard curve was again produced, confirming 
good antigen-antibody reactivity. However, when the readings were carefully 
analysed (see table 5.19, column related to the 2.5µg/mL concentration), it 
was noticed that the background signal was considerably higher than that 
observed when the antibodies that had previously been used. For that 
reason, strategies aiming to reduce non-specific binding and signal 
background were needed. Our first attempt was to reduce the capture 
antibody concentration. Along with the current 2.5µg/mL concentration, we 
also tested 1.25, 1.0 and 0.5µg/mL. As table 5.19 also shows, these 
reductions in capture antibody concentration resulted in drops in background 
signal at the cost of significant decreases in maximum concentration 
readings, thus reducing the SBR. Consequently, an alternative approach was 
necessary to reduce signal noise whilst maintaining optimal SRB and 
dynamic range.  
  
 
263 
 
 
Figure 5.21. Standard curve and dynamic range produced using new vials of 
capture and detection antibodies. The higher background exhibited by this assay 
(readings displayed in table 5.20) translated into a compressed dynamic range. The 
LLOD was 0.23ng/mL, considerably higher than that observed when testing the old 
stock of antibodies.  
 
Table 5.19. Standard curve readings and SBRs for different capture antibody 
concentrations. Standard samples tested in duplicate.   
                                Capture antibody concentration 
  
 
2.5µg/mL 1.25µg/mL 1.0µg/mL 0.5µg/mL 
Sample Concentration Signal Signal Signal Signal 
S001 62.000 195834 50269 24041 9192 
S001 62.000 244527 51350 24334 8035 
S002 20.667 64938 18686 9007 3453 
S002 20.667 64302 15711 8262 3188 
S003 6.889 19849 7190 3250 1446 
S003 6.889 20837 7249 3111 1435 
S004 2.296 5738 2987 1344 777 
S004 2.296 6002 3285 1262 905 
S005 0.765 2833 1668 745 552 
S005 0.765 3172 1732 798 580 
S006 0.255 2083 1194 533 499 
S006 0.255 2196 1271 625 560 
S007 0.085 1865 1113 484 486 
S007 0.085 1979 1107 556 438 
S008 0.000 1650 1162 412 352 
S008 0.000 1793 1041 425 390 
  SBR 127.90 46.13 57.80 23.22 
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As previously mentioned, the blocking step performed after capture 
antibody coating aims to occupy any remaining surface on the plate well with 
a non-cross-reactant protein, thus preventing nonspecific binding. The 
standard blocking reagent for MSD assays is the proprietary Blocker A, 
basically a 1% bovine serum albumin (BSA) solution. Alternatively, we tested 
1% casein diluted in either PBS or TBS as a blocking agent. The same 
solutions were also used for calibrator and sample dilution, as well as 
detection antibody and tertiary SULFO-TAG™ antibody dilution. Table 5.20 
shows the results for this experiment. Both casein blocking solutions resulted 
in striking reductions (10 to 24-fold) in signal readings across the entire 
standard curve, confirming strong inhibition of background noise. As this 
decrease was observed from top to zero concentration, the SBR was again 
used to identify the best condition. Although casein in PBS resulted in the 
lowest background, the SBR produced was the highest among the conditions 
tested.  
 
Table 5.20. Standard curve readings and SBRs for different blocking reagents. 
Standard samples tested in duplicate.   
                                               Blocking reagent   
  
 
      Blocker A         Casein in PBS       Casein in TBS 
Sample       Concentration              Signal                      Signal                    Signal 
S001 62.000 195834 19375 7588 
S001 62.000 244527 21845 7158 
S002 20.667 64938 7095 2474 
S002 20.667 64302 7213 2295 
S003 6.889 19849 2535 931 
S003 6.889 20837 2599 797 
S004 2.296 5738 875 353 
S004 2.296 6002 910 308 
S005 0.765 2833 343 177 
S005 0.765 3172 363 180 
S006 0.255 2083 174 116 
S006 0.255 2196 179 125 
S007 0.085 1865 122 109 
S007 0.085 1979 120 106 
S008 0.000 1650 94 97 
S008 0.000 1793 90 101 
  SBR 127.90 224.02 74.47 
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Therefore, one percent casein in PBS overcame the increase in signal 
background observed with the new stock of antibodies without reducing the 
dynamic range and, thus, this was selected as the blocking reagent for 
subsequent experiments. 
 
5.5.6. Final assay configuration and quality control tests 
 
The previous steps performed in this assay development project 
allowed us to establish the conditions which resulted in adequate 
performance in terms of antibody reactivity, sensitivity, low background, high 
SBR and minimal matrix interference. Figure 5.22 depicts the final standard 
curve, the limits of detection and the assay conditions. Once a new assay 
has been developed, it should undergo several quality control tests in order 
to reassure its performance in the selected matrix and in the relevant clinical 
scenario (Del Campo et al., 2015, Andreasson et al., 2015). In this research, 
the following parameters were assessed: 
 
a. Dynamic range: limits of detection are shown in figure 5.22, below;  
 
b. Precision: the usual measure of precision is the coefficient of 
variation (CV) for the results observed in repeated experiments or 
replicates. CV is calculated using the formula CV=(SD/Mean)x100, 
where SD is the standard deviation. Both intra-assay and inter-
assay CVs were calculated; 
 
c. Spike recovery: although already tested in the preliminary phase, 
recovery was tested again due to the change in the blocking 
reagent and the replacement of antibodies.  
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Figure 5.22. Final standard curve and assay configuration. The use of 1% casein in 
PBS along with the same conditions previously established allowed the production 
of an assay with optimal background, SBR and dynamic range (0.08 – 62.0ng/mL). 
AB: antibody. 
 
Prior to final spike recovery and inter-assay CV experiments, two 
plasma samples (one from a normal control and one from a CRC patient) 
were aliquoted and stored at -80°C so that all aliquots had undergone the 
same number of freeze-thaw cycles. During six consecutive days, an aliquot 
from each sample was defrosted and tested with and without spiking. In this 
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assay, spiking was performed by adding to the diluted sample a volume of 
calibrator solution (concentration: 31ng/mL) in a 1:1 ratio - the high-
concentration spike (HS). Therefore, considering the final solution, the 
expected concentration was the concentration exhibited by the non-spiked 
sample divided by 2, plus 15.5ng/mL. Additionally, we explored a low 
concentration spiking (LS), repeating the procedures described above using 
a calibrator solution at 7.5ng/mL. The expected concentration, in this case, 
was the sample concentration divided by 2, plus 3.75ng/mL. The CRC 
sample was tested under both spiking conditions, whereas the normal 
sample underwent the HS analysis only due to the scarce amount of normal 
plasma available at this late stage of development. It has been determined 
that recovery ranges from 70-80% to 120-130% were acceptable (Leary et 
al., 2013). As table 5.21 demonstrates, spike recovery for the conditions 
tested was between 111% and 115%, thus fulfilling this quality control 
criterion. Inter-assay CV expresses plate-to-plate consistency and should 
ideally be < 20% (Leary et al., 2013). It was calculated as the mean of the 
CVs observed for each sample condition in the six daily experiments. Mean 
inter-assay CV was 13.2% in this series of tests. It also satisfies the accepted 
criterion for imprecision and matches the performance disclosed by 
commercially available NAP1L1 ELISA kits (CV = 12%).  
 
Table 5.21. Final tests of spike recovery and inter-assay CVs.  
  
DAY 
1 
DAY 
2 
DAY 
3 
DAY 
4 
DAY 
5 
DAY 
6 Mean SD 
CV 
(%) 
N 1:4 5.20 5.95 5.88 6.48 4.31 4.26 5.35 0.92 17.16 
N 1:4 HS 19.50 20.10 20.40 21.50 17.80 18.70 19.67 1.31 6.64 
(Recovery) 111% 112% 114% 118% 104% 109% 111% 4.71 - 
CRC 1:4 11.30 16.30 16.50 18.00 11.50 11.20 14.13 3.12 22.11 
CRC 1:4 HS  25.90 26.70 25.60 27.00 22.60 24.30 25.35 1.65 6.50 
(Recovery) 125% 115% 110% 113% 109% 118% 115% 6.08 - 
CRC 1:4 LS  12.50 14.80 12.80 11.50 10.30 10.80 12.12 1.63 13.42 
(Recovery) 133% 124% 107% 90% 108% 116% 112% 14.94 - 
        
Mean CV: 13.17 
HS: high-concentration spike. LS: low-concentration spike. 
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Additionally, intra-assay CV was calculated comparing the variation 
between the replicates of the 80 plasma samples tested in the final assays. 
The accepted range of variation for this parameter is < 10%. A mean intra-
assay CV of 6.65% was obtained, thus, again, showing an adequate 
performance.  
Some important validation tests were not performed in this research 
due to time constraints. While repeatability – measurements performed under 
the same conditions, was reassured by the daily tests, reproducibility – 
measurements under different conditions (Rifai et al., 2006), was not fully 
tested. Sample storage stability was also not fully assessed, preventing us 
from knowing what is the effect of length and temperature of storage, or the 
number of freeze-thaw cycles on the measured level of NAP1L1. Finally, 
although dilution linearity and parallelism were assessed in the preliminary 
phase, it was limited to a maximum of 8-fold dilution. Testing further dilutions 
could establish a wider working range and provide a better view of the assay 
performance in the target matrix. Despite these issues, the overall 
consistency and accuracy demonstrated by this novel immunoassay 
outperforms the ELISA kits described in previous sections, especially in 
terms of sensitivity – exactly the major flaw exhibited by those kits. Therefore, 
we deemed this assay adequate for sample typing and decided to proceed 
with the testing of clinical samples.  
 
5.5.7. Assessment of NAP1L1 concentrations in clinical samples 
 
Using the conditions depicted in figure 5.22, we assessed NAP1L1 
plasma concentrations in our clinical samples. For this analysis, we used the 
same samples tested using the commercial ELISA kits. Therefore, for the 
Brazilian cohort, we tested normal controls (n=10) and cancer samples 
(n=30) as these were the most representative groups in that sample set. For 
the UK cohort, we used samples from four clinical groups: normal controls 
(n=10), low-grade adenomas (n=10), high-grade adenomas (n=7) and 
cancers (n=13).  
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Results from the Brazilian cohort are illustrated in figure 5.23. No 
significant difference in NAP1L1 concentration was observed between 
normal control and cancer groups. A remarkably high variation in results was 
observed among samples within clinical groups. Mean protein concentration 
(and 95% confidence interval) were 51.5ng/mL (26.2 – 129.3ng/mL) for 
normal controls, and 69.4ng/mL (33.6 – 105.2ng/mL) for cancer samples. 
Minimum and maximum concentrations were 1.23 and 357.5ng/mL in the 
normal group, and 0.4 and 314.8ng/mL in the cancer group.  
 
 
Figure 5.23. Mean NAP1L1 concentrations in the Brazilian cohort. A large variation 
in protein levels was observed, as depicted by the error bars (+/- 2 standard errors). 
No difference in protein concentration was found when comparing the groups (p = 
0.44, Mann-Whitney U test).  
 
Similarly to the Brazilian cohort, the results for the UK cohort also 
exhibited large intra-group variation, as shown in figure 5.24. Mean NAP1L1 
concentration (and 95%CIs) for the groups tested were 184.0ng/mL (63.4 – 
304.5ng/mL) for normal controls, 175.4ng/mL (80.1 – 270.6ng/mL) for low-
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grade adenomas, 283.1ng/mL (89.1 – 477.0ng/mL) for high-grade adenomas 
and 305.9ng/mL (200.2 – 411.6ng/mL) for the cancer group. A clear trend of 
increased concentration in high-grade adenomas and cancer samples was 
observed. However, this difference was not statistically significant (p = 0.21, 
one-way ANOVA). This result is strikingly similar to the observations obtained 
when testing the UK plasma samples using the DL Develop and the Abbexa 
NAP1L1 ELISA kits (compare the figure below with figures 5.3 and 5.6 in 
section 5.4.1), although the magnitude of the levels is significantly higher 
here.  
 
 
Figure 5.24. Mean NAP1L1 concentrations in the UK cohort. A trend of increased 
protein concentration was observed, although this was not statistically significant (p 
= 0.21, one-way ANOVA). Again, protein concentration exhibited large variation 
within groups. 
 
Additionally, NAP1L1 levels were considerably higher in the UK cohort 
when compared to the Brazilian samples, a finding already observed during 
the ELISA experiments. Given the low inter-assay CV (making it possible to 
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compare the results from different plates), it reinforces the hypothesis that 
storage length and conditions may affect NAP1L1 readings in 
immunoassays, as these two sample cohorts were collected at different 
periods and locations.   
This research, through the experiments described in this sub-chapter, 
resulted in the development of a novel ECL assay for NAP1L1 based on the 
MSD platform that successfully fulfills the major criteria for immunoassay 
validation. However, it failed to demonstrate a significant difference in protein 
expression between the clinical groups tested. Although a trend towards 
increased NAP1L1 concentration in patients with high grade dysplastic and 
malignant lesions was consistently observed, the heterogeneity of results 
impeded statistical confirmation of differential expression. The accuracy, 
consistency and sensitivity exhibited by this novel ECL assay reassure the 
robustness of these results. It suggests that the pursuit of alternative 
techniques is unlikely to provide different results if the same sample types 
are assessed. An unanswered question is whether the assessment of fresh 
samples or samples that had been stored for shorter periods of time would 
yield different results. Further research is, therefore, recommended to clarify 
this issue.  
 
5.6. Discussion 
 
This chapter describes experiments that were performed to assess 
whether NAP1L1, RPL6 and PHB are potential CRC blood biomarkers. The 
analysis of two cohorts from different locations was performed in an attempt 
to obtain robust and valid results. The initially selected platform was the 
ELISA, a widely available method for the assessment of protein 
concentrations in biological fluids (Lequin, 2005, Rifai et al., 2006). As no 
validated kit for the assessment of our candidate biomarkers had been 
reported, our initial task was to search for suitable options among the 
commercially available kits. Our starting point was the same plate that had 
been tested previously by our group. However, issues related to the 
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consistency and reproducibility of those kits demanded the exploration of 
different options in the form of both alternative ELISA kits and other 
immunoassay methods.  
RPL6 and PHB ELISA kits demonstrated good quality in terms of 
accuracy and consistency. However, for both proteins, initial experiments 
using serum samples demonstrated insufficient sensitivity, as several results 
were below the detection range. The use of plasma instead of serum resulted 
in higher protein concentrations for both markers using different ELISA kits, 
thus suggesting that plasma would be the favoured matrix for their 
assessment. When using plasma, valid results were obtained for most 
samples, thus allowing the comparison of protein levels in these sample 
cohorts. For the Brazilian cohort, normal controls and cancer samples were 
compared, whilst for the UK cohort samples from four clinical groups – 
normal controls, low- and high-grade adenomas and cancers, were analysed. 
However, the assessment of the protein content did not show any significant 
differences between those clinical groups. These results are in disagreement 
with the findings previously demonstrated by our research group. The most 
probable cause for this difference is the sample sizes evaluated. In the 
preliminary research described at the beginning of this chapter, only two 
cancer cases (indeed, one cancer patient and one patient with a previous 
CRC and a possible recurrence) were assessed along with 37 non-cancer 
affected individuals who had various other health conditions. In the present 
work, more cancer samples (30 from the Brazilian cohort and 13 from the UK 
cohort) were analysed. Pre-neoplastic lesions (high-grade adenomas) and 
low risk-lesions (low-grade adenomas) were also assessed, but no other 
disease state was included. Therefore, this analysis is much more 
empowered and trustworthy than the preliminary work and is probably a 
better reflection of reality. Given the consistency of results exhibited by 
plasma samples, we accepted the null hypothesis in these cases, and 
concluded that both RPL6 and PHB are not differentially expressed in blood 
from individuals with CRC or adenomas when compared with normal 
individuals.  
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However, possible interference caused by differences in sample 
collection and storage cannot be completely ruled out. For both markers, the 
protein levels in the UK cohort were higher than in the Brazilian cohort. Both 
sample sets were collected and stored according to the same protocols. 
However, the collections were performed in different locations, mostly by 
local staff, and minor but potentially relevant differences in procedures may 
have occurred. In addition, the major difference between the two cohorts was 
the length of sample storage, 1-3 years for the Brazilian cohort compared to 
weeks to a few months for the UK cohort (even less for the samples used in 
the preliminary phase). Important differences in protein reactivity may ensue 
as a result of diverse sample storage length (Macaraeg et al., 2015). As, due 
to time constraints, we were not able to perform sample stability tests, the 
effect of the length and the temperature of storage on sample results could 
not be ascertained. Therefore, the assessment of fresh samples or the 
analysis of sample stability would be recommended to resolve this question.     
All three NAP1L1 ELISA kits tested in this thesis (from Cloud Clone 
Corp, DL Develop and Abbexa) exhibited poor performances. Low 
consistency, inadequate sensitivity, and poor correlation were generally 
observed. The only consistent finding from these experiments was the 
observation that plasma NAP1L1 concentrations were always higher than 
serum concentrations, as was the case for RPL6 and PHB. Due to the poor 
quality demonstrated by these kits, we decided to develop our own in-house 
immunoassay to properly test NAP1L1 concentration in our clinical samples. 
For this purpose, we selected the MSD-ECL platform. This method has been 
used for assay development by several research groups, with results 
generally superior to ELISAs (Chaturvedi et al., 2015, Sloan et al., 2012, 
Postelnek et al., 2016). Immunoassay development protocols follow a step-
wise approach to test each reagent used under different conditions to obtain 
an acceptable performance. In this research, we tested several commercially 
available antibodies as capture and detection reagents. The antibody pair of 
Abnova mouse monoclonal - Abcam rabbit polyclonal demonstrated a good 
affinity for the calibrator (human recombinant NAP1L1 from Abcam), and 
resulted in adequate assay linearity for the standard curve. Using all the 
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optimisation procedures and conditions described in the previous sections, 
an MSD-ECL assay for NAP1L1 was successfully developed. It passed major 
quality control tests, with an overall performance surpassing the ELISA 
quality control parameters demonstrated in our study. In particular, the 
improved sensitivity and lower limit of detection obtained allowed the 
quantification of the protein content in all plasma samples tested.  
After confirming that this assay was an adequate method for protein 
quantification, final analysis of the clinical samples was performed. The same 
samples were tested as those that had been tested using the ELISA kits. The 
final assessment using this novel in-house immunoassay did not show a 
significant difference in NAP1L1 concentration between normal and cancer 
samples in the Brazilian cohort. For the UK cohort, similarly, no significant 
difference was observed when comparing the four groups tested. A trend 
towards increased plasma NAP1L1 concentrations in high-grade adenomas 
and cancer samples was observed, but the prominent heterogeneity between 
results within groups prevented statistical confirmation. Notably, this was 
exactly the same result as that obtained during the NAP1L1 ELISA tests 
using two different plates (DL Develop and Abbexa). Some of the other 
findings made during the ELISA experiments were also confirmed. Notably, 
NAP1L1 concentration was higher in plasma than serum in the ECL 
experiments. It is, therefore, highly recommended that any future research 
assessing NAP1L1 concentrations in the blood uses plasma as the preferred 
matrix for testing this protein. Additionally, the UK samples exhibited higher 
protein levels than the Brazilian samples. As discussed above, this may be 
due to differences in sample collection and storage. Stability tests are 
suggested in order to clarify this point.  
The experiments described in this chapter have therefore not 
succeeded in identifying any of these candidate proteins as CRC blood 
biomarkers. However, the results have provided interesting insights for the 
assessment of NAP1L1, RPL6 and PHB concentrations in the blood. The 
knowledge generated by this research may help future studies that plan to 
measure the concentrations of these proteins in biological fluids. It also 
highlights the superior performance of ECL-based methods, particularly using 
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the tools provided by MSD, in the development of customised 
immunoassays. Given the large variation in results, the investigation of these 
proteins, especially NAP1L1, as a prognostic rather than a diagnostic marker 
could result in clinically relevant findings. Unfortunately, our sample cohorts 
were very limited in terms of size and time of follow-up after diagnosis so 
would not permit such investigation at this time.   
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Chapter Six: 
Prognostic significance of the 
IHC expression of the 
biomarkers in CRC 
  
277 
 
6. CHAPTER 6 – PROGNOSTIC SIGNIFICANCE OF THE IHC 
EXPRESSION OF THE BIOMARKERS IN CRC  
 
6.1. Introduction 
 
As discussed in Chapter 1, a biomarker is “a characteristic used to 
measure and evaluate objectively normal biological processes, pathogenic 
processes, or pharmacological responses to a therapeutic intervention” 
(Atkinson et al., 2001). Prognostic biomarkers are clinical or laboratorial 
characteristics that are capable of predicting clinical outcome (Pritzker, 2015, 
Atkinson et al., 2001). In oncology, the most relevant clinical outcome is 
overall survival (Sherrill et al., 2012), although there are other important 
endpoints such as tumour recurrence, progression free survival, the need for 
specific medical interventions and quality of life. CRC prognostic biomarkers 
have been extensively researched and a multitude of candidates have been 
suggested in the literature. However, very few of these have been 
incorporated into routine clinical practice (Bianchi et al., 2011, Watson and 
Søreide, 2016, Sagaert, 2014). A major marker of Wnt pathway activation, β-
catenin nuclear immunostaining has been associated with worse prognosis is 
several studies of CRC, as confirmed by a large meta-analysis (Chen et al., 
2013). Therefore, we hypothesised that our candidate biomarkers (which are 
derived from Wnt activation models) might also be related to clinical outcome 
in CRC patients. 
In Chapter 3, we demonstrated that NAP1L1, RPL6 and PHB exhibited 
differential patterns of expression between malignant and non-malignant 
colorectal tissues. Nonetheless, the intensity of protein expression within 
each sample group, particularly in malignant tissues, exhibited wide 
variations, thus highlighting the heterogeneity of biomarker expression. 
Similar findings were observed in the assessment of both the tissue 
transcriptomic and blood proteomic expression of these candidate markers 
(Chapters 4 and 5). If the expression of these genes is related to malignant 
characteristics (as suggested by the mechanistic studies also described in 
Chapter 4), it is intuitive to consider that this heterogeneous expression might 
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result in different biological behaviour. Thus, the content and/or localisation of 
these proteins in tumour tissues might be potentially useful prognostic 
markers.   
Proteomic methods are promising strategies for biomarker discovery 
and validation (Li and Chan, 2014, Tjalsma, 2010, Alvarez-Chaver et al., 
2014, de Wit et al., 2013). Amongst the several methods for assessing 
protein expression, IHC is relatively inexpensive, reproducible, and widely 
available (Lin and Chen, 2014). Other advantages and issues related to IHC 
have been described in Chapter 3. Despite some pitfalls, the method is 
currently used for the assessment of diagnostic, prognostic and predictive 
biomarkers in several types of cancers (Chamberlain et al., 2015, Zaha, 
2014, Toffart et al., 2014, Varma and Jasani, 2005). 
We therefore performed an assessment of the relationship between 
the IHC expression of our candidate proteins and clinicopathologic variables 
(age, gender, tumour grade and stage). Additionally, we also analysed 
whether the expression of these biomarkers correlated with overall survival in 
CRC patients. 
 
6.2. Samples and immunohistochemistry procedures 
 
For this assessment, the main inclusion criteria were: 1. diagnosis of 
CRC and; 2. four or more years of follow-up. This time frame was selected 
because most CRC recurrences occur within 2 to 3 years of follow-up (Buie 
and Attard, 2005). Exclusion criteria were: 1) death occurring within 30 days 
of surgery, as this variable identifies deaths that are related to surgical 
complications, not to the cancer (Jacobs et al., 2006); 2) administration of 
chemotherapy or radiotherapy prior to surgery; 3) absence of tumour tissue 
in the paraffin block. We therefore initially retrieved 95 paraffin blocks from 
two pathology labs in Cuiaba/Brazil. Patients had been diagnosed with CRC 
between 2004 and 2012. By using the selection criteria above, we excluded 
20 of these cases mainly due to early death or absence of tumour tissue. 
Consequently, the final prognostic cohort was made up of 75 CRC cases. 
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Median follow-up time was 84.7 months (ranging from 48 to 153 months). 
Information regarding pathological diagnosis (date of diagnosis, stage and 
grade) and clinical characteristics (age and gender) were obtained from the 
original pathology report and from the records of the pathology labs. The 
main clinical event studied in this analysis was overall survival. Whenever 
possible, records from the cancer clinics where the patients had been 
followed up were assessed in order to obtain additional information about 
mortality. This strategy was complemented by assessing the Mortality 
Information System (“Sistema de Informação de Mortalidade” – SIM), the 
Brazilian nationwide electronic death registry. A WHO report published in 
2005 has classified this database as of “medium quality” (70-90% coverage), 
ranked in the same category as several high-income European countries 
(Mathers et al., 2005). A more recent report has shown that this system has 
improved considerably since then, and now covers more than 95% of deaths 
(Figueiroa Bde et al., 2013). Therefore, we assume that the use of this 
database to confirm the occurrence of death makes our analysis robust. 
Overall survival was recorded as the interval between diagnosis and death 
from any cause or the date when the registry was last checked (when death 
had not occurred). Given the relatively small number of cases included, 
cancer stages were grouped into two groups: early-stage (stages I and II) 
and late-stage (stages III and IV). Table 6.1 describes the clinicopathologic 
characteristics of the patients included in this analysis. 
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Table 6.1. Characteristics of the patients included in the prognostic analysis. 
 
 Characteristics 
Patients 
(n=75) 
 
Mean age (range) 59.7 (33-84) 
 
Gender   
Male 43 (57.3%) 
Female 32 (42.7%) 
 
Stage  
I-II 28 (37.3%) 
III-IV 47 (62.7%) 
 
Grade 
well differentiated 
moderately differentiated 
poorly differentiated 
. 
23 (30.6%) 
50 (66.6%) 
2 (2.6%) 
 
The same antibodies used in the initial IHC assessment of the 
candidate biomarkers were employed in this aspect of the research. The 
same antibody concentrations were also used. However, the procedures 
performed in this section were carried out according to the routine practices 
of the Sao Nicolau pathology lab - Cuiaba/Brazil (Chapter 2). Most clinical 
pathology labs currently use pre-optimised solutions for the various steps 
involved in IHC staining in order to save time and increase productivity. 
Therefore, it would be interesting to assess the validity of our candidate 
biomarkers in this “real-world” setting. For this purpose, we first assessed the 
pattern of staining produced by this technique compared with the pattern 
obtained during our initial IHC study (Chapter 3) using a few samples. 
Fortunately, the staining pattern observed was very similar using both 
methods for the majority of the candidate proteins tested, thus permitting us 
to continue with this method assessment. Differences in image background 
and colour shade (as a result of the use of different cameras in different time 
points) were compensated by the “threshold setting” and the “background 
correction” functions of the scoring plugins. These functions permit 
adjustments that counterbalance differences caused by different equipment 
being used for photographing the slides (Tuominen et al., 2010).  
281 
 
For assessment of the stained IHC slides, we again used the 
electronic scoring tools incorporated in ImageJ: IHC Profiler for cytoplasmic 
staining and ImmunoRatio for nuclear staining. Both methods have been 
thoroughly explained in Chapter 3. Examples of nuclear and cytoplasmic 
scores are depicted in figure 6.1. After scoring the slides, Receiver Operating 
Characteristics (ROC) curves with nuclear and cytoplasmic results were 
plotted for each marker. Scores exhibiting the best trade-off between 
sensitivity and specificity considering the binary endpoint mortality 
(dead/alive) were identified. These cut-offs were used for classifying samples 
as having low or high protein expression. Once samples had been split into 
these two groups, correlations between biomarker expression and 
clinicopathologic variables were assessed. Furthermore, a survival analysis 
was also performed to assess whether the expression of these proteins could 
predict survival.  
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Figure 6.1. Examples of scoring results produced by IHC Profiler and ImmunoRatio 
in NAP1L1-stained colorectal tissues. The electronic tools were capable of 
discriminating samples with different patterns of staining. (A) low nuclear and low 
cytoplasmic staining; (B) low nuclear and high cytoplasmic staining; (C) high nuclear 
and high cytoplasmic staining (see cut-off values below). Magnification: 200x.  
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6.3. NAP1L1 as a prognostic marker in CRC 
 
 
The immuno-expression of NAP1L1 was similar using both staining 
protocols tested in this research project (figure 6.2). Protein content was 
scored using IHC Profiler and ImmunoRatio plugins for cytoplasmic and 
nuclear staining, respectively. Initially, using mortality status as the binary 
event of interest, ROC curves were plotted. The area under the curve (AUC), 
representing the accuracy of the test for predicting the status, was 0.58 for 
the nuclear score and 0.60 for the cytoplasmic score, denoting that these two 
variables were not very accurate tools for discriminating mortality status. This 
is probably the result of many patients still being alive by the end of the study 
in both the low and high expression groups (see figures below). However, the 
assessment of the ROC curves permitted the selection of a cut-off value with 
adequate balance between sensitivity and specificity. The NAP1L1 IHC cut-
off for nuclear staining was 32% (of positive nuclei). The use of this threshold 
resulted in a sensitivity of 61% and a specificity of 67.5% for discriminating 
mortality status. For cytoplasmic staining, a cut-off of 135 (in a range from 0 
to 300) yielded a sensitivity of 57% and a specificity of 54%. As the primary 
aim of this study was predicting survival as measured by the time from 
diagnosis until death or the end of follow-up and not solely the binary 
mortality status, these parameters were deemed adequate.   
 
Figure 6.2. Comparison of NAP1L1 staining patterns observed with the IHC 
protocols used in the initial validation study (A) and in the prognostic study (B). 
Similar staining intensity and localisation are observed. Differences in colour shade 
and background are due to the use of different cameras for recording the images. 
Magnification: 600x. 
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For the evaluation of nuclear staining, the use of a 32% cut-off 
resulted in the separation of the sample cohort into low and high-expression 
groups. In order to assess whether the resulting groups were well balanced 
in terms of known prognostic factors, we produced a table displaying the 
main variables (table 6.2) and statistical tests were performed. As can be 
noted, no significant difference in the distribution of clinicopathologic 
variables was observed, indicating that no associations exist between 
NAP1L1 nuclear expression and the variables age, gender, grade and stage. 
Therefore, any prognostic association eventually found could only be 
attributed to the biomarker expression pattern. Similar analyses were also 
performed for the cytoplasmic scoring results and, once more, no significant 
differences were found (data not shown to avoid unnecessary repetition). 
 
Table 6.2. Clinicopathologic characteristics according to NAP1L1 nuclear 
expression. 
 
 Characteristics 
Low nuclear 
expression 
(n=34) 
High nuclear 
expression 
(n=41) 
(2-sided  
p values) 
Mean age  61.9 57.8 
 
0.157 
Gender    0.648 
Male 17 24  
Female 16 18 
 
 
Stage   0.338 
I-II 10 18  
III-IV 23 24  
 
Grade 
well differentiated 
moderately differentiated 
poorly differentiated 
. 
9 
24 
0 
14 
14 
26 
2 
 
0.351 
No significant difference between groups was observed. Mean age was compared 
by t-test. Categorical variables were compared by Chi-square test or Fisher´s exact 
test.  
 
Using the Kaplan-Meier method, cumulative survivals for the two 
groups (high and low nuclear expression) were compared. Initially, groups 
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were assessed as a whole, i.e. combining all cases regardless of disease 
stage. Results are depicted in figure 6.3. A clear difference in cumulative 
survival was observed when analysing nuclear NAP1L1 staining (p=0.012, 
log-rank test). In the multivariate analysis including age, gender, stage and 
grade (Cox proportional hazards model), the nuclear score was 
independently associated with cumulative survival. The high nuclear 
expression group exhibited a hazard ratio (HR): 0.39 ([95%CI: 0.17 – 0.87]; 
p=0.02), denoting a 61% reduction in cumulative mortality in this group. As a 
result, the estimated 5-year survival was 44.4% in the low expression group 
and 75% in the high expression group. Median duration of survival was 32 
months in the low expression group, whilst it has not been reached for the 
high expression cohort. The only additional variable also associated with 
survival was tumour stage (HR: 2.55 [95%CI: 1.01 – 6.43]; p=0.047), an 
expected finding since stage is a known prognostic factor in CRC. These 
findings strongly suggest an association between NAP1L1 nuclear staining 
and survival in CRC patients. 
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Figure 6.3. Cumulative survival according to NAP1L1 expression (all stages 
combined). In the superior graph, nuclear staining is assessed. A highly significant 
(p=0.012) and clinically relevant (HR=0.39 [95%CI: 0.17 – 0.87]) difference in 
survival between groups was observed favouring the high expression group. In 
terms of cytoplasmic staining (inferior graph), no significant difference was observed 
between the low and high expression groups. Vertical marks=censored cases. HR: 
hazard ratio. CI: confidence interval. 
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Cytoplasmic NAP1L1 staining was not associated with survival or any 
other clinicopathologic variable. Kaplan-Meier curves exhibited similar 
shapes and actually crossed over each other (p=0.759, log-rank test). No 
further statistical tests were performed given these negative results.  
Although a positive association between NAP1L1 nuclear staining and 
survival was already evident from this initial analysis, we recognise that the 
patient groups encompassed a quite heterogeneous population in terms of 
tumour stage. Patients with cancers from stage I (tumours limited to the inner 
portions of the intestinal wall) to stage IV (metastatic disease) were assessed 
together. Given the prominent differences in survival between these different 
stage groups (see figures 1.15 and 1.16 in Chapter 1), we decided to analyse 
patients with early stage (stages I and II) and late stage (stages III and IV) 
disease separately. This strategy could validate NAP1L1 as a prognostic 
biomarker for all cancer stages or identify a subgroup more likely to benefit 
from its application.  
In figure 6.4, the results of the analysis of NAP1L1 nuclear staining in 
either early or late stage tumour groups are shown. For early stage disease, 
no significant difference in survival was noticed when comparing low and 
high expression groups (top graph). Conversely, a highly significant 
(p=0.012, log-rank) difference in survival was observed for the groups 
involving stages III and IV tumours. Multivariate analysis once again 
demonstrated that NAP1L1 nuclear score was an independent prognostic 
factor in CRC patients. The calculated HR (0.28 [95%CI: 0.11 – 0.71]; 
p=0.008) was even more notable than that observed for the entire cohort, 
now suggesting a 72% reduction in cumulative mortality. The 5-year survival 
advantage for high expression tumours was also greater: 70%, versus 34% 
for low expression cancers. Median survival was only 23 months in the low 
expression group and, again, has not been reached in the high expression 
cohort.  
 
 
 
 
288 
 
 
Figure 6.4. Cumulative survival according to nuclear NAP1L1 staining in different 
stage groups. Top graph shows the results for early stage disease (stages I and II). 
No difference in survival between low and high expression groups was observed. 
Bottom graph shows the results for late stage disease (stages III and IV). A 
statistically significant difference was observed favouring the high expression group 
(HR: 0.28 [95%CI: 0.11 – 0.71]). Vertical marks=censored cases. HR: hazard ratio. 
CI: confidence interval. 
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These findings are not surprising. As the prognosis of late stage 
cancers is intrinsically worse, more deaths are expected to occur in this 
group. Survival analyses such as the Kaplan-Meier method are largely 
dependent upon the occurrence of the event of interest (death, in this case). 
In fact, the power of the analysis is more related to the number of events than 
the number of individuals participating in the study (Bradburn et al., 2003). 
Consequently, subgroups with more events are more likely to produce 
different survival curves when a prognostic association really exists. A longer 
follow up or a much larger cohort might increase the number of events and 
identify a prognostic association even in early stage disease. However, our 
results do not allow us to make such an assumption. Nonetheless, the role of 
nuclear NAP1L1 staining as a prognostic CRC biomarker, at least for late 
stage disease, has been clearly demonstrated in a robust and adequate 
manner. The uncomplicated nature and wide availability of the technique 
employed (IHC) makes this novel marker an attractive tool for assessing 
prognosis in CRC patients in clinical settings. However, validation studies to 
test the reproducibility of these findings in independent cohorts of patients 
are required in the first instance.  
 
6.4. RPL6 as a prognostic marker in CRC 
 
The same procedures described for NAP1L1 were adopted for the 
assessment of RPL6 as a potential prognostic marker. A comparison of the 
staining pattern obtained using the IHC techniques adopted in the Sao 
Nicolau lab with the staining observed in the initial validation phase of this 
study indicated different results to those expected. The Sao Nicolau IHC 
demonstrated a weaker staining pattern than that observed in the validation 
study (example in figure 6.5). The use of a higher antibody concentration 
(1:100) did not improve the results. The samples used in this initial 
comparison were collected approximately 3 years before performing this 
experiment. To have a better assessment of the staining pattern produced 
using these conditions, we performed IHC reactions in the entire prognostic 
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cohort. Surprisingly, almost all (except three) of the 75 samples tested 
exhibited totally negative RPL6 staining. Even the fragments of normal 
adjacent mucosa (a type of tissue universally positive in the initial 
assessment, Chapter 3) showed no protein content. We considered the 
possibility that the commercial solutions used in this experiment were not 
compatible with the RPL6 antibody tested. Another possible explanation was 
the different lengths of storage of the FFPE blocks. The sample set used in 
the initial IHC validation was 1-3 years old, whilst the samples used in this 
prognostic study had been stored for 4 to 12 years. To test both hypotheses, 
we re-tested six samples from the prognostic cohort along with six relatively 
new samples from the initial validation study using the protocol planned for 
the prognostic study. All cases from the prognostic cohort (between 10-12 
years of storage) were negative for RPL6, whilst all cases from the initial 
sample set (2 years of storage) demonstrated various degrees of positive 
results (examples depicted in figure 6.6). Notably, samples with fragments of 
adjacent mucosa (that could be regarded as internal “positive controls” based 
on our initial results) also demonstrated the same patterns, thus confirming 
that the absence of immunostaining was limited to the oldest samples.  
 
 
Figure 6.5. Comparison of RPL6 staining patterns observed with the IHC protocols 
used in the initial validation study (A) and in the prognostic study (B). Weaker 
staining was observed in the experiment performed in the prognostic cohort. An 
increase in antibody concentration did not produce different results (data not 
shown). Noteworthy, these two staining procedures were performed two years apart. 
Therefore, the sample had been stored for 1 year in A and for 3 years in B. 
Magnification: 600x. 
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Figure 6.6. Examples of RPL6 immunostaining in samples stored for different 
lengths of time. The IHC protocol from the Sao Nicolau lab was used. Images A and 
B show the staining pattern in a CRC case stored for 12 years (adjacent and cancer 
tissues, respectively). No immuno-reaction is observed either in epithelial or stromal 
cells. Images C (adjacent) and D (tumour) show a clearly positive nuclear staining in 
epithelial cells in a sample stored for two years. Magnification: 200x. 
 
These results suggest that the protocol used is adequate for detecting 
RPL6 immunohistochemical expression in samples that are less than two 
years old, but not in those that have been stored for longer periods of time, 
e.g. the patient samples from the prognostic cohort. The fact that NAP1L1 
and PHB (next section) were easily identified in this collection of older 
samples suggests that only RPL6 immuno-expression is affected by this 
degree of sample storage.  
The most obvious differential characteristic between these two sample 
cohorts is the length of storage. However, stable antigenicity in FFPE blocks 
has been documented up to 68 years after sample collection (Bass et al., 
2014). A few proteins have however been proven to show unstable 
antigenicity during prolonged storage, such as PCNA (Malmstrom et al., 
1992). Antigen degradation is much more common in slides that have been 
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cut months to years prior to IHC experiments (Grillo et al., 2015). This was 
not the case in our investigations since we only used slides that had been cut 
from the paraffin block days to weeks prior to the experiments. In the specific 
case of the experiments shown in figure 6.6 above, we used slides that had 
been prepared the previous day. RPL6 stability in stored slides or FFPE 
blocks has not been previously examined. The samples used in the staining 
comparison had been stored for only one year when the initial validation 
experiments took place (figure 6.5A), whilst they were 3 years-old when the 
prognostic study was performed (figure 6.5B). Therefore, an effect of the 
length of storage on RPL6 immune-reaction, although unlikely, cannot be 
excluded from our data.  
Other ambient conditions (such as temperature and humidity) have 
also been linked to decreased immunogenicity in archival slides (Xie et al., 
2011). Again, the effect of these parameters on paraffin blocks is less clear. 
Given that the blocks used in the prognostic study were retrieved from 
pathology services which did not have standardised protocols to control 
storage conditions, it is possible that these factors may have influenced the 
preservation of the samples. Of note, temperatures in Cuiaba, the Brazilian 
city were this collection took place, can reach daily averages above 30°C 
during the warmest months of the year. Additionally, standard operational 
procedures may have changed over time in terms of pre-analytical factors 
such as pre-fixation, fixation and processing conditions. Therefore, it was not 
possible to fully explain the precise cause of the negative results observed. 
Nonetheless, it is clear that the lack of reaction was restricted to RPL6. 
Issues related to antibody affinity especially in long term stored samples were 
also a possible cause for the negative staining, as the other antibodies tested 
showed adequate results. The use of different RPL6 antibodies could 
potentially clarify this point. Unfortunately such additional experiments could 
not be carried out due to time constraints.  
As the samples that yielded adequate immune reactions all had limited 
follow up times (less than three years), a survival study could therefore not 
be performed. Additionally, clinical information for these cases was not 
available, as this was not the intended cohort for the prognostic study. 
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Therefore, we could not adequately assess the prognostic role of RPL6 
immuno-expression in CRC patients. Further studies to assess RPL6 
expression in samples that have been stored under controlled conditions 
could unveil its prognostic value or any possible effect of storage conditions 
on protein degradation. 
 
6.5. PHB as a prognostic marker in CRC 
 
The same stepwise approach described for NAP1L1 was adopted for 
the assessment of PHB as a prognostic marker in CRC. PHB 
immunostaining was similar using both staining methods (figure 6.7). Nuclear 
and cytoplasmic scores were analysed using ROC curves (AUCs 0.59 and 
0.57, respectively). Scoring cut-offs were set at 18 (percent) for nuclear 
scoring (sensitivity: 61.5%; specificity: 57%) and at 110 for cytoplasmic 
scoring (sensitivity: 54%; specificity: 50%). After splitting the samples into low 
and high expression groups, the first analysis was the comparison between 
groups in relation to clinicopathologic variables in the same way as described 
for NAP1L1 (see table 6.2 for reference). As was the case for NAP1L1, the 
groups were well balanced. Neither the nuclear nor the cytoplasmic 
expression of PHB was associated with age, gender, grade or stage (table 
not shown).  
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Figure 6.7. Comparison of PHB staining patterns observed with the IHC protocols 
used in the initial validation study (A) and in the prognostic study (B). Similar 
staining intensity and localisation were observed. Differences in staining shade and 
background were due to the use of different cameras for recording the images 
(magnification: 400x).  
 
A survival analysis using the same method employed for NAP1L1 is 
shown in figure 6.8. Considering all stages combined, survival was very 
similar until around 2 years of follow-up. After this time point, an apparent 
separation of the survival curves was observed. However, this difference was 
not statistically significant (p=0.286, log-rank test). Estimated 5-year survival 
was 67% for the low expression group and 57% for the high expression 
group; this was also non-significant. For the cytoplasmic staining, survival 
curves were similar during the entire follow up period. The same was 
observed in terms of 5-year survival estimates: 60% and 65% for the low 
expression and the high expression cohorts, respectively (p=0.769, log-rank).  
Analyses were also carried out for early and late stage disease 
separately and, similarly, no significant differences were observed, thus 
confirming the initial findings (figure 6.9). Therefore, no significant impact of 
PHB protein expression on prognosis was found. This finding is partially 
concordant with the results from Cheng et al. who reported no association 
between PHB expression and survival in CRC patients, although a 
correlation with tumour grade was observed in that study (Chen et al., 
2010a). We are unaware of any other report that has assessed the role of 
PHB immunostaining in affecting the prognosis of CRC patients.  
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Figure 6.8. Cumulative survival according to PHB expression (all stages combined). 
The analyses of both nuclear and cytoplasmic immunostaining patterns did not 
reveal significant differences in survival when comparing low and high expression 
groups. However, a trend towards improved survival was observed in the low 
nuclear expression group. Vertical marks=censored cases.  
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Figure 6.9. Cumulative survival according to PHB staining in different stage groups. 
No significant difference between low and high expression groups was observed 
regardless of the tumour stage. Of note, a trend of improved survival was observed 
in the low nuclear expression group, for early stage tumours only. 
 
 
6.6. Discussion 
 
Prognostic markers are helpful for treatment decision-making. 
Individuals with a higher risk of recurrence or death caused by CRC may 
benefit from more aggressive therapeutic approaches or from more intensive 
surveillance programmes after treatment. Conversely, low-risk patients could 
potentially be spared from more radical surgery or toxic adjuvant therapies. 
Cancer stage is the most extensively studied and validated prognostic factor 
in CRC. Several other histopathological and molecular markers also seem to 
have prognostic significance, although none is as consistent as tumour stage 
(Sagaert, 2014). Nonetheless, it has long been recognised that TNM 
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(tumour-node-metastasis) and other similar staging systems (such as the 
Dukes’) are not perfect prognostic indicators, since diseases within similar 
stage groups may exhibit different long-term outcomes (Burke, 2004). 
Advanced stage may be the consequence of worse tumour biology rather 
than the cause of higher mortality per se. This discussion is particularly 
relevant for stage II tumours, which are deemed low-risk disease and, as 
such, patients are usually not offered post-surgical adjuvant chemotherapy 
(Benson et al., 2004). However, 5-year survival among stage II patients is not 
optimal – usually between 70-80% (Morris et al., 2006, Petersen et al., 2002), 
with some studies reporting survival as low as approximately 50% depending 
on tumour depth, number of lymph nodes resected, presence of vascular 
invasion or peritoneal involvement and postoperative CEA levels (Peeples et 
al., 2010, Quirke and Morris, 2007, Petersen et al., 2002). A systematic 
review has suggested that some stage II patients might actually benefit from 
additional treatments (Wu et al., 2012b). Although this controversy (whether 
or not to offer adjuvant chemotherapy) is valid for stage II tumours, all stage 
groups exhibit diverse long-term outcomes and might also benefit from better 
prognostic determination.   
Based on the idea that biology might be more relevant than 
morphology (Burke, 2004), molecular prognostic biomarkers derived from 
pathways associated with colorectal carcinogenesis have been extensively 
pursued. Mutations or methylation of several oncogenes and tumour 
suppressors are associated with prognosis in CRC patients (Yiu and Yiu, 
2016, Erstad et al., 2015). Several non-coding RNAs have also been linked 
to disease progression and survival (Yiu and Yiu, 2016, Saus et al., 2016). 
Proteomics has also been used for biomarker discovery in CRC (Alvarez-
Chaver et al., 2014). Although a plethora of candidate biomarkers has been 
suggested, no protein has been adopted as a prognostic biomarker mostly 
due to inconsistencies in reproducibility and lack of proper validation studies 
(Alvarez-Chaver et al., 2014, Coghlin and Murray, 2015).  
The immunohistochemical expression of β-catenin has been widely 
studied, but with inconsistent results. A meta-analysis involving 3665 cases 
from 18 studies has demonstrated that the nuclear expression of β-catenin is 
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associated with a worse prognosis in CRC patients (Chen et al., 2013). 
Therefore, we decided not to assess the prognostic value of this protein in 
our research. Instead, we concentrated our efforts on the analysis of the 
novel potential biomarkers that had been suggested in our previous studies. 
Using a cohort of 75 Brazilian CRC cases who had a relatively long follow up, 
we assessed NAP1L1, RPL6 and PHB expression and correlated these 
markers with clinicopathologic variables. Furthermore, survival correlations 
were performed in order to define their prognostic significance. 
The importance of NAP1L1 immunohistochemical expression in 
relation to prognosis has not been previously reported either in CRC or in any 
other cancer type. Therefore, our study provides the first evidence for a role 
of this biomarker in predicting clinical outcome in CRC patients. The 
experiments described in this chapter clearly suggest that the nuclear 
expression of NAP1L1 is related to overall prognosis. High nuclear 
expression was independently associated with a marked increase in survival 
duration and 5-year survival estimates. Mortality in this group was 61 - 72% 
lower when compared with the low-expression group. Subgroup analyses 
showed that the survival correlation was however limited to late stage 
tumours (stages III and IV). No association between NAP1L1 nuclear 
expression and clinicopathologic variables (age, gender, stage and grade) 
was observed. As a result, we conclude that NAP1L1 nuclear 
immunostaining is a strong survival predictor in CRC patients. However, 
NAP1L1 cytoplasmic expression did not correlate with overall survival or any 
other clinicopathologic feature.  
RPL6 prognostic importance has not previously been studied in 
human cancers. Our attempt to assess the immuno-expression of this protein 
as a prognostic factor in CRC was unsuccessful mainly due to inadequate 
immune reaction in samples which had been stored for long periods of time. 
The IHC procedures performed were deemed suitable for this assessment, 
as cases which had shorter follow up times produced positive 
immunostaining. The reason for the absence of immune reaction using the 
older samples was not clear and requires further investigation.   
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The prognostic significance of PHB immuno-expression has previously 
been studied in various cancer types. The expression of this protein is 
reduced in poorly differentiated ovarian cancers when compared with more 
differentiated tumours (Jia et al., 2014). A decrease in PHB immunostaining 
has also been correlated with worse prognosis in nasopharyngeal tumours 
(Liao et al., 2013). Conversely, increased PHB immunostaining has been 
associated with adverse prognostic features in lung (Jiang et al., 2013, Guo 
et al., 2012), breast (Najm et al., 2013), gastric (Kang et al., 2008), thyroid 
(Franzoni et al., 2009), prostate (Ummanni et al., 2008) and bladder cancers 
(Wu et al., 2007, Cao et al., 2016). The only study that we found assessing 
the role of PHB immuno-expression in CRC reported no correlation with 
overall survival (Chen et al., 2010a). In the present study, we did not observe 
a significant association between PHB expression and overall survival in 
CRC patients. Neither nuclear nor cytoplasmic PHB immunostaining was 
associated with the clinicopathologic characteristics aforementioned. 
Similarly, no significant survival association was found, a finding concordant 
with the results of Chen et al., 2010a. Only a non-significant trend towards 
improved survival in the low nuclear expression group was noticed and this 
trend was limited to early stage cancers. Therefore, our data do not support 
the hypothesis that PHB immunohistochemical expression is a prognostic 
biomarker in CRC.  
We recognise that this study has several limitations. The limited 
sample size did not allow us to fully assess the prognostic importance of the 
biomarkers for early stage cancers, especially stage II tumours. This was 
caused by the low number of events (deaths) in these groups. Therefore, it 
would be highly desirable to replicate this study in a larger cohort of early 
stage cancers in order to definitively assess whether or not this biomarker 
could be used for the identification of high-risk early stage disease. 
Additionally, for a number of cases, we could not determine precisely 
whether the deaths that occurred were caused by CRC (CRC-specific 
mortality) due to the fact that the Mortality Information System lists only the 
direct cause of death, regardless of the underlying condition. For example, a 
patient who died from pneumonia as a result of cancer progression would 
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have been registered as “dying from pneumonia” even when this outcome 
was clearly related to cancer progression. However, overall survival is the 
“gold standard” clinical endpoint in cancer studies (Sherrill et al., 2012) and 
this reinforces the importance of our findings. Another outcome we would like 
to have explored in this study was CRC recurrence. Unfortunately, this was 
not possible due to the lack of information about this for most patients, but 
this is certainly a point to consider if further studies are undertaken. Tumour 
recurrence is an earlier event requiring a shorter follow up period to be 
properly assessed and is thought to be an adequate surrogate endpoint for 
overall survival in CRC (Giessen et al., 2013). If available, this information 
could also unveil a prognostic impact in stage I and II tumours. Additionally, 
we were not able to obtain accurate information regarding the adjuvant 
treatments that patients had received. Hence, the presence of a treatment 
misbalance between groups could not be assessed. In terms of the technical 
procedures performed, although objective scoring methods were used, 
manual and inter-observer agreement was not assessed. Most pathology 
labs use manual rather than electronic scoring and agreement between 
professionals, especially less experienced ones, may be an issue (Ali et al., 
2016, Jaraj et al., 2009). Despite these caveats, the magnitude of the impact 
of NAP1L1 nuclear immunostaining on the prognosis of CRC patients 
strongly suggests that there is a real correlation. This might therefore be a 
valuable tool to define patients who have a poorer prognosis and may in 
future help guide treatment or follow up decisions. Comprehensive studies 
involving larger populations and other prognostic endpoints are however 
necessary to definitely confirm the clinical utility of this novel CRC biomarker 
before its use can be routinely recommended. 
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7. CHAPTER 7 – GENERAL DISCUSSION 
 
The importance of finding CRC biomarkers for early diagnosis, 
prognostic determination and prediction of response to treatment cannot be 
underestimated. CRC is the third leading cause of cancer mortality in men 
and the second in women worldwide (Ferlay et al., 2015) and most deaths 
result from late diagnosis. A better understanding of disease biology and the 
discovery of accurate biomarkers may permit the use of therapies that are 
tailored for individual patients – personalised medicine. Despite the multitude 
of potential candidates, very few CRC biomarkers have yet been adopted 
into routine clinical practice (Coghlin and Murray, 2015). Therefore, further 
intensive translational research is still necessary in order to transfer 
innovative tools from the laboratory bench to the hospital bedside.  
The use of prospection strategies based on solid biological rationale is 
more likely to yield useful biomarkers than non-targeted approaches such as 
the simple comparison of the whole “omics” profiles of normal versus 
malignant tissues. Effective forms of biomarker discovery rely on the 
exploration of molecular pathways that are associated with carcinogenesis. 
The Wnt signalling pathway is up-regulated in the majority of sporadic CRC 
cases. APC mutation (leading to Wnt activation) is the most common genetic 
event in the early steps of the normal-adenoma-carcinoma transformation 
sequence (Cancer Genome Atlas Network, 2012). Previously in our group, 
Hammoudi (Hammoudi et al., 2013) and Ibrahim (Ibrahim, 2014) 
demonstrated that the analysis of animal models of acute and chronic Apc 
inactivation led to the selection of potential candidate biomarkers of human 
colorectal carcinogenesis. In the research described in this thesis, we have 
performed a comprehensive analysis of these candidate biomarkers using 
scientific techniques that are widely available in clinical and research 
laboratories. Whenever possible, we have assessed the expression of these 
potential biomarkers in different patient populations in order to investigate the 
potential effect of regional differences (ethnic variation, collection and storage 
conditions) on the results. Using this strategy, we have proven the validity of 
some candidate biomarkers and have confirmed that the use of animal 
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models of CRC based on Apc inactivation is a useful approach for biomarker 
prospection. Individual results have been comprehensively discussed in each 
dedicated chapter. A general discussion of the main findings is provided 
below.    
 
7.1. Confirmation of differential immuno-expression of the biomarkers 
 
Immunohistochemistry is an inexpensive, widely available technique 
and is routinely used to assess cancer biomarkers in several tumour types 
(Chamberlain et al., 2015, Zaha, 2014, Toffart et al., 2014, Varma and 
Jasani, 2005). In CRC patients, IHC has been used for assessing MMR 
proteins for the diagnosis of HNPCC and for prognostic determination in 
sporadic tumours (Steinhagen et al., 2012, Yoon et al., 2011). No 
immunohistochemical marker has however yet been routinely adopted for 
clinical use in CRC. Using electronic scoring methods, Wnt activation was 
initially confirmed in all neoplastic tissues, as nuclear and cytoplasmic over-
expression of β-catenin was observed in low-grade adenomas, high-grade 
adenomas and cancer tissues. These results concur with the published 
literature (Wong et al., 2004, Wong et al., 2003, Chen et al., 2013). We then 
proceeded with the evaluation of our novel candidate biomarkers. A clear 
differential expression was observed for NAP1L1, RPL6 and PHB when 
comparing tumours and non-malignant tissues. This confirmed the findings 
from the animal work that has previously been conducted in our research 
group. HMGB1, SFRS2 and CDC5L did not exhibit different immunostaining 
patterns. As a result, these proteins were not further assessed in this thesis.  
NAP1L1 and RPL6 demonstrated similar staining patterns in all 
sample groups analysed. Both proteins exhibited a clear decrease in nuclear 
expression in neoplastic tissues compared to the adjacent normal colonic 
mucosa. A similar, although less pronounced, difference was also observed 
for NAP1L1 cytoplasmic expression. Additionally, the expression of NAP1L1 
and RPL6 in low-grade adenomas was comparable to that observed in 
adjacent normal mucosa and normal control samples, whilst adenomas with 
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high-grade dysplasia exhibited a staining pattern more similar to cancer 
tissues. This latter finding provides a rationale for studying NAP1L1 and 
RPL6 expression to better discriminate between high-risk and low-risk 
adenomas, a possibility that still requires further research. To the best of our 
knowledge, no study of the immuno-expression of these candidate 
biomarkers in CRC has previously been published.  
PHB nuclear expression was also decreased in malignant colorectal 
tissues. However, the cytoplasmic expression of this protein exhibited a slight 
increase in cancer samples. This finding suggests that the protein might have 
been displaced from the nucleus towards the cytoplasm during malignant 
transformation. An increase in PHB cytoplasmic content has already been 
reported in CRC (Chen et al., 2010a), but this study did not assess its 
nuclear expression. Taken together, these findings confirm the potential of 
NAP1L1, RPL6 and PHB immuno-expression as biomarkers for CRC 
development. Validation studies involving larger populations may unveil the 
roles of these proteins for cancer screening and diagnosis. 
 
7.2. Gene expression studies suggest a role for NAP1L1 and RPL6 in 
field cancerisation 
 
Messenger RNA expression analysis using qPCR has been widely 
used to study the expression of genes involved in colorectal carcinogenesis, 
although methodological rigour has frequently been poor (Dijkstra et al., 
2014). Despite this, commercial tests using gene expression panels have 
been developed such as Oncotype Dx Colon™ (Clark-Langone et al., 2010) 
and ColoPrint™ (Kopetz et al., 2015). Both tests aim to assess the risk of 
recurrence in localised tumours. Prognostic tests such as these have not 
gained much acceptance by clinicians, mainly due to the lack of proper 
validation in large population settings (Webber et al., 2010). Robust 
transcriptomic biomarkers are therefore still lacking in this disease. 
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We performed a qPCR-based analysis of the expression of NAP1L1, 
RPL6 and PHB in order to further validate them as potential biomarkers in 
CRC. Additionally, we tested CTNNB1 alongside to assess the function of 
this gene in this biological scenario. We analysed cancer samples, adjacent 
unaffected mucosa and normal control mucosa (from individuals who did not 
have colorectal cancer or polyps).  
The expression of CTNNB1 was only slightly increased in cancer 
tissues compared to both the adjacent and the normal control mucosa. The 
literature reports on the expression of this gene in CRC are conflicting 
(Anwar et al., 2015, Qin et al., 2006, Truant et al., 2008). Our finding was 
therefore not unexpected. Activation of the Wnt pathway in CRC is more 
commonly a result of Apc mutations resulting in accumulation of β-catenin via 
decreased degradation than as a consequence of increased CTNNB1 mRNA 
expression. Even when CTNNB1 is the genetic driver of carcinogenesis, 
mutations, rather than increased expression, appear to be the relevant 
alteration (Cancer Genome Atlas Network, 2012).  
Regarding our candidate biomarkers, we again observed a strikingly 
similar pattern of expression for NAP1L1 and RPL6. Both genes were shown 
to be highly expressed in the tumour and the adjacent mucosa from patients 
with CRC when compared to normal controls. “Field cancerisation” or “field 
effect”, may explain these findings. It has been well described in cancer 
development mostly as a result of genetic and epigenetic modifications 
leading to altered gene expression (Baba et al., 2016), making tissues 
adjacent to tumours prone to developing new primary cancers. It has been 
shown to occur up to several centimetres from the primary colorectal tumour 
(Park et al., 2016). Therefore, even taking into account that the “adjacent” 
samples were collected 10cm from the primary tumour in our study, this 
event could still have taken place.  
On the other hand, differences in patient populations or sample 
collection procedures might have affected these results. There were more 
men in the cancer group (who provided both tumours and adjacent tissues) 
than in the normal control group. However, no influence of gender or sex 
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hormones on the expression of NAP1L1 or RPL6 that could explain the 
difference in gene expression has previously been reported. Additionally, 
factors related to the procedures performed for sample collection might 
explain the findings. Bowel preparation and type of anaesthesia are different 
for colonoscopy and for surgical colectomy and this difference may have had 
an effect on the general gene expression profile. Nonetheless, the fact that 
the expression of CTNNB1 was similar between adjacent and normal 
controls weakens this explanation as the cause of the observed difference. 
PHB gene expression results were not statistically significant, although 
a trend pointing towards increased transcript levels in adjacent normal and 
tumour tissues was observed. The results from Hammoudi et al. showed only 
a 1.32-fold increase in PHB expression in tumour versus adjacent samples 
(Hammoudi et al., 2013). Along with our findings, this suggests that PHB 
mRNA over-expression might not be as important in CRC as it has been 
demonstrated in other cancer types (Franzoni et al., 2009, Jiang et al., 2013, 
Kang et al., 2008, Ummanni et al., 2008). We could not find any other study 
that has assessed PHB gene expression in CRC. 
 
7.3. RPL6 siRNA silencing results in inhibition of proliferation and 
altered expression of cancer-associated genes in CRC cells 
 
After observing a differential expression of NAP1L1 and RPL6 in 
cancer and adjacent tissues, we decided to explore the mechanisms by 
which these genes affect cancer cell biology. For this purpose, we carried out 
siRNA experiments aiming to knockdown the expression of these genes in 
TP53 wild-type and null HCT116 colorectal cancer cells. After successful 
transfection of these cells, a proliferation assay (SRB) was performed. Cells 
without a functioning TP53 gene exhibited severe toxicity probably caused by 
the transfection reagents and/or by nutrient deprivation during the 
proliferation assay. Therefore, the results observed with these cells were not 
deemed sufficiently accurate to draw any meaningful conclusions. 
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In TP53 competent cells, NAP1L1 silencing did not cause any 
alteration in cell proliferation. The literature suggests that NAP1L1 regulates 
the differentiation and proliferation of stem cells (Li et al., 2012, Gong et al., 
2014, Yan et al., 2016) and pancreatic neuroendocrine tumours (Schimmack 
et al., 2014). However, no such suggestion has been made regarding other 
cancer cells. Therefore, disturbed NAP1L1 expression in CRC might not be 
associated with proliferation but, rather, be essential for the maintenance of 
an undifferentiated status.  
Differently, RPL6 silencing resulted in strong inhibition of cell growth in 
HCT116 cells. Proliferation inhibition upon RPL6 silencing has already been 
demonstrated in gastric cancer cell lines (Wu et al., 2011, Du et al., 2005). 
Here, we provide the first evidence that this gene also affects the proliferation 
of a CRC cell line. As the mechanistic functions of RPL6 in the regulation of 
cell proliferation have been poorly described, we decided to assess whether 
other genes related to colorectal carcinogenesis would be affected by RPL6 
knockdown. For this, we analysed the expression of a panel of 28 CRC-
associated genes using RNA extracted from cells transfected with RPL6 
siRNA or scrambled siRNA. Using this strategy, we demonstrated that RPL6 
silencing resulted in the up-regulation of BAX and MSH2 (apoptosis and 
mismatch repair regulators, respectively) and down-regulation of MMP-12 
and MMP-13 (metalloproteinases involved in invasion, angiogenesis and 
metastasis). Collectively, these results strongly support the hypothesis that 
RPL6 is associated with the development of malignant hallmarks in CRC. 
Further research is necessary to confirm and clarify these findings.   
 
7.4. Biomarker concentrations are not consistently increased in blood 
from individuals with CRC or adenoma  
 
Blood tests are favoured as minimally-invasive and widely accepted 
forms of obtaining biological samples (Rifai et al., 2006). In CRC screening, a 
study has suggested that a blood test would result in higher acceptance by 
the population than colonoscopy (Adler et al., 2014). Protein biomarker 
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discovery usually involves the initial use of non-targeted approaches (such as 
LC-MS/MS) exploring the whole proteomic profile of samples, followed by a 
more targeted confirmatory phase usually based on enzyme immunoassays 
such as ELISA (Rifai et al., 2006).  
In this part of the research, immunoassays assessing NAP1L1, RPL6 
and PHB as potential CRC blood biomarkers were performed. Sample 
cohorts from Brazil and from the UK were used in order to generate robust 
and valid results. Plasma and serum were tested, as neither of these fluids 
had been suggested as the optimal matrix for the measurement of those 
proteins. No ELISA kit had previously been confirmed as the gold standard 
for any of the candidate proteins. Therefore, we initially tested kits from 
different manufacturers in order to assess whether they produced uniform 
and concordant results.   
NAP1L1 proved to be the most problematic protein in the 
immunoassays. All three NAP1L1 ELISA kits tested (from Cloud Clone Corp, 
DL Develop and Abbexa) exhibited poor performances and produced 
unreliable results. The only consistent finding was the observation that 
plasma NAP1L1 concentrations were usually higher than serum 
concentrations. As a result of these unsatisfactory findings, we developed an 
in-house immunoassay based on the Meso Scale Discovery® 
electrochemiluminescence (ECL) platform, a method which has results 
generally superior to ELISAs (Chaturvedi et al., 2015, Sloan et al., 2012, 
Postelnek et al., 2016). Quality control tests confirmed that this novel ECL 
assay was more consistent and sensitive than the ELISAs previously used. 
This assay confirmed that plasma was the more adequate matrix for NAP1L1 
assessment. Analyses of the Brazilian and UK cohorts using this in-house 
immunoassay however did not demonstrate significant differences in 
NAP1L1 concentrations between normal controls, adenoma-bearing 
individuals and CRC patients. A trend towards increased plasma NAP1L1 
concentrations in high-grade dysplastic adenomas and cancer samples was 
observed, but statistical significance was not reached.  
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RPL6 and PHB ELISA kits demonstrated better performances than 
NAP1L1 kits in terms of accuracy and consistency. Plasma was again the 
chosen matrix due to the higher protein concentrations observed. Similarly, 
for both candidate markers, the assessment of protein concentrations did not 
show any significant differences between clinical groups. These results are 
different from the initial findings observed by our research group. The very 
limited sample size used in the preliminary phase may however have been 
the cause of this difference. Our final tests were performed using larger and 
more diverse sample cohorts. The consistent results exhibited by plasma 
samples allowed us to conclude that both RPL6 and PHB are not 
differentially expressed in the blood of individuals with CRC or adenomas 
when compared with normal individuals. 
Although we fulfilled the objective of developing an adequate 
immunoassay for NAP1L1, this work did not succeed in identifying any of 
these proteins as potential CRC blood biomarkers. However, important new 
insights related to the study of these proteins in blood-derived fluids were 
generated. Furthermore, a possible effect of sample collection procedures or 
storage conditions on protein levels was unveiled, as we found differences in 
results between similar groups from Brazil and the UK. These findings may 
have important implications for any future research assessing the 
concentrations of NAP1L1, RPL6 or PHB in biological fluids. 
 
7.5. NAP1L1 nuclear expression is a strong predictor of survival in 
late stage CRC 
 
Prognostic biomarkers are defined as clinical or laboratory 
characteristics that are capable of predicting clinical outcome such as tumour 
recurrence and, most importantly, survival (Pritzker, 2015, Atkinson et al., 
2001, Sherrill et al., 2012). Despite the comprehensive search for CRC 
prognostic biomarkers and the several candidates suggested in the literature, 
very few of these have been incorporated into routine clinical practice 
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(Bianchi et al., 2011, Watson and Søreide, 2016, Sagaert, 2014). Here, we 
performed an assessment of the relationship between the 
immunohistochemical expression of our candidate proteins, prognostic 
variables and patient survival.  
The experiments carried out clearly demonstrated that the nuclear 
expression of NAP1L1 was related to prognosis in patients with CRC. High 
nuclear expression was independently associated with a marked increase in 
survival duration and 5-year survival estimates. Mortality in this group was 61 
to 72% lower when compared with the low-expression group. Subgroup 
analyses suggested that the survival correlation was limited to late stage 
tumours (stages III and IV). However, the limited number of events (deaths) 
may have prevented us from finding a correlation for early stage, particularly 
stage II, tumours. No association between NAP1L1 nuclear expression and 
age, gender, grade or stage was observed. The prognostic importance of 
NAP1L1 has not been previously reported in CRC or other cancer types. 
Thus, the present study provides the first evidence for an association 
between the expression of this protein and clinical outcomes in cancer 
patients. Noteworthy, the cytoplasmic expression of NAP1L1 was not 
associated with any prognostic factor in this study.  
We did not observe a significant relationship between PHB expression 
and prognostic factors in CRC patients. Neither nuclear nor cytoplasmic PHB 
immunostaining was associated with clinicopathologic characteristics or 
survival. This finding is concordant with the results from Chen et al. who also 
assessed PHB immuno-expression in CRC patients. Consequently, it is our 
conclusion that PHB immunohistochemical expression is not a prognostic 
biomarker in CRC.  
RPL6 assessment was impaired by the absence of immune reaction in 
the IHC experiments performed using the prognostic cohort of samples. This 
negative reaction seemed to be specifically associated with this group of 
samples, since cases with shorter storage times exhibited adequate 
immunostaining. It is not clear whether this difference was caused by the 
length of storage per se or by any other pre-analytical factor.  
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7.6. Study limitations and suggestions for future research  
 
The use of human clinical samples for research is intrinsically 
problematic. Different from animal models or cell lines, it is difficult to obtain 
tissue or blood from cancer patients in large quantities unless a high-volume 
cancer hospital is committed to the work or a multi-centric effort is 
assembled. Even in those situations, the prospective collection of samples 
still requires a reasonably long time. In this work, samples were collected in 
small cancer centres in Brazil and in a single district general hospital in the 
UK. Additionally, problems with sample transportation from Brazil to the UK 
caused the loss of large amounts of biological materials. As a result of these 
issues, sample sizes used in several parts of this research were suboptimal. 
Although several positive and relevant findings were made, the use of small 
sample sizes may have impeded the observation of more positive results in 
particular sample cohorts. Another consequence of the limited number of 
samples was the necessity of analysing cancer stages as groups and not 
individually. It would in future be interesting to assess the stages separately. 
Better prognostic stratification in stage II disease is desperately needed to 
improve the treatment decision-making process. Besides, splitting stage III 
and stage IV diseases would also be desirable, as these stages result in 
markedly different clinical outcomes.  
Regarding the IHC scoring method, objective electronic systems were 
used in this study. These methods have the advantage of improving result 
consistency especially for non-pathologists. However, most pathology 
services do not use electronic scoring tools, but manual scoring methods 
instead. Therefore, it would be important to assess the reproducibility of our 
findings via manual scoring performed by trained pathologists, ideally by 
more than one professional. 
In the immunoassay experiments, an unanswered question is the 
influence of sample storage conditions upon protein levels. Thus, the 
assessment of sample stability by testing different lengths and temperatures 
of storage, and several freeze-thaw cycles would provide guidance for future 
studies assessing the concentration of the proteins in biological fluids.  
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In the prognostic study, apart from the sample size issue already 
mentioned, another drawback was the lack of data about treatments that had 
been performed and tumour recurrence. This information would provide more 
insights into the significance of the biomarkers in the management of CRC 
patients.     
 
7.7. Conclusions 
 
Despite the issues discussed above, this study has produced several 
interesting and consistent findings. It confirmed that NAP1L1, RPL6 and PHB 
are proteins that are differentially expressed in human colorectal neoplasms, 
as suggested by the initial animal work performed by previous members of 
our research group. It also demonstrated that the gene expression of 
NAP1L1 and RPL6 is increased in tumours and in the adjacent mucosa from 
CRC patients, suggesting that these biomarkers may be involved in 
tumourigenesis and field cancerisation. Mechanistic studies showed an effect 
of RPL6 expression on the proliferation of CRC cells. Additionally, the 
silencing of this gene caused an alteration in the expression of other cancer-
associated genes, reinforcing its importance in colorectal carcinogenesis. 
The assessment of the prognostic impact of the expression of the candidates 
demonstrated a strong effect of NAP1L1 nuclear immunostaining on the 
survival of patients with late stage disease, a finding which has potential 
clinical applications. The analysis of protein levels in blood samples, 
however, did not show increased concentrations of any of the postulated 
biomarkers in patients with either adenomas or colorectal cancer.  
In summary, this research has confirmed the validity of the study of 
animal models of Apc inactivation for the prospection of CRC biomarkers. It 
has suggested that NAP1L1, RPL6 and PHB are involved in colorectal 
carcinogenesis and may be useful biomarkers for the diagnosis of high-risk 
adenomas and CRCs. In addition, it has unveiled a possible role of NAP1L1 
as a prognostic marker in this disease. To avoid these candidates being 
placed in the long list of promising, but non-validated biomarkers of CRC, 
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further prospective research assessing larger sample cohorts is highly 
recommended. 
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